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Abstract 
Dementia occurs in ~30% of Parkinson’s disease (PD) patients, but few studies have 
examined gene expression in the brains of these individuals.  In this thesis, 
quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and 
microarray were used to investigate gene expression in the dorsolateral prefrontal 
cortex (DLPFC), comparing idiopathic Parkinson’s disease (IPD) patients with and 
without dementia against each other and controls.  Expression of the Extracellular-
signal regulated kinase 1/2 (ERK1/2) inhibitor Dual specificity phosphatase 6 
(DUSP6) and the tyrosine kinase Ephrin receptor A2 (EPHA2) was significantly 
decreased and increased, respectively, in IPD versus controls, however these 
phenotypes were unaffected by dementia status.  Expression of the PD gene  
α-Synuclein (SNCA) was unaltered in the DLPFC.  Further qRT-PCR analyses 
demonstrated that DUSP6, EPHA2, and SNCA are not differentially-expressed in 
seven other regions of the IPD brain.  Association and imaging analyses indicated 
that variation at the DUSP6 single nucleotide polymorphism (SNP) rs1689408 
marginally alters IPD risk and profoundly influences grey matter density, possibly 
through an effect on DUSP6 splicing.  Moreover, variation at the EPHA2 SNP 
rs11260822 significantly modified IPD susceptibility.  However, variation at these 
SNPs did not influence the overall expression of DUSP6 or EPHA2, respectively.  In 
addition, a rare haplotype composed of the SNCA SNPs rs11931074 and rs3822086 
significantly increased IPD risk.  Detailed examination of the microarray data 
suggested that pathways involving inflammation, cell adhesion, the cytoskeleton, 
synaptic transmission, lipoprotein metabolism, metal binding, and mitochondria are 
dysregulated in the DLPFC of IPD dementia patients.  Furthermore, in silico mining 
of the microarray data suggested that a positive feedback loop involving EPHA2 and 
ERK1/2 signaling is constitutively-activated in the IPD neurodegeneration DLPFC.  
Notwithstanding the observed changes, the parkinsonian DLPFC was characterised 
by an overall lack of gene dysregulation.  These findings extend our knowledge of 
gene expression in IPD dementia and neurodegeneration.  Moreover, they suggest 
that DUSP6 and EPHA2 are novel genes involved in IPD pathogenesis. 
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HPRT1 Hypoxanthine phosphoribosyltransferase 1 
HD Huntington’s disease 
ID Identity 
IPD Idiopathic Parkinson’s disease (also the combined 
group of IPDD and IPDND) 
IPDD IPD dementia 
IPDND IPD no dementia 
IHC Immunohistochemistry 
IPC Inferior parietal cortex 
IKB Inhibitor of κ light polypeptide gene enhancer in  
B-cells 
IKBKE Inhibitor of κ light polypeptide gene enhancer in  
B-cells, kinase ε 
IFI27 Interferon, α-inducible protein 27 
ITGAL Integrin, alpha L 
IUBMB International Union of Biochemistry and  
Molecular Biology 
IREB2    Iron responsive element binding protein 2 
KRT9    Keratin 9 
kb    Kilobase pairs 
kDa    Kilodaltons 
KRAS    Kirsten rat sarcoma viral oncogene homologue 
KRS    Kufor-Rakeb syndrome 
KEGG    Kyoto Encyclopaedia of Genes and Genomes 
LCM    Laser capture microdissection 
LRRK2   Leucine-rich repeat kinase 2 
LB    Lewy body 
LBD    Lewy body disease 
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LN    Lewy neurite 
LP    Lewy pathology 
LIMMA   Linear Modelling for Microarray Analysis 
LD    Linkage disequilibrium 
LREC    Local Research Ethics Committee 
LOESS   Locally weighted scatter plot smoothing 
LC    Locus coeruleus 
LTP    Long term potentiation 
LY6K    Lymphocyte antigen 6 complex, locus K 
LCK    Lymphocyte-specific protein tyrosine kinase 
M    A measure of reference gene stability (qRT-PCR) 
MRI    Magnetic resonance imaging 
fMRI    Functional MRI 
MHC    Major histocompatibility complex 
MAN1B1   Mannosidase, α, class 1B, member 1 
MED    Medulla 
MARCH7   Membrane-associated ring finger(C3HC4) 7 
MBTPS1   Membrane-bound transcription factor peptidase, site 1 
MPTP    1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MPP+    1-Methyl-4-phenylpyridinium 
MSP    Methyl-specific PCR 
MAPT    Microtubule-associated protein tau 
MID1    Midline 1 
MID1IP1   Midline 1 interacting protein 1 
MLL5-L   Mixed-lineage leukaemia 5-lysine 
MAF    Minor allele frequency 
MMSE   Mini mental state examination 
MAPK    Mitogen-activated protein kinase 
MKP    Mitogen-activated protein kinase phosphatase 
MAO    Monoamine oxidase 
MNI    Montreal Neurological Institute 
NCBI    National Center for Biotechnology Information 
NHNN    National Hospital for Neurology and Neurosurgery 
NP    Neuritic plaque 
NFT    Neurofibrillary tangle 
NLC    Neuronal loss-corrected 
NF    Normalisation factor 
NTC    Nontemplate control 
NA    Not applicable 
ND    Not determined 
NS    Not significant 
NFKB Nuclear factor κ light polypeptide gene enhancer in  
B-cells 
NURR1 Nuclear receptor related 1 
NR3C1   Nuclear receptor subfamily 3, group C, member 1 
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NR4A2 Nuclear receptor subfamily 4, group A, member 2 
(aka NURR1) 
NUP98 Nucleoporin 98 kDa 
dNTP Deoxynucleotide triphosphate 
NbM    Nucleus basalis of Meynert 
OGT    O-linked N-acetylglucosamine transferase 
OR    Odds ratio 
OR2M4   Olfactory receptor, family 2, subfamily M, member 4 
OMIM    Online Mendelian Inheritance in Man 
OFC    Orbitofrontal cortex 
ODF2    Outer dense fibre of sperm tails 2 
PB    Pale body 
PARK2   Parkin 
PD    Parkinson’s disease 
PDD    PD dementia 
PARK7   Parkinson’s disease 7 (aka DJ1) 
PCNX Pecanex homologue 
PINK1 Phosphatase and tensin homologue-induced putative 
kinase 1 
PE    Phosphatidylethanolamine 
PISD    Phosphatidylserine decarboxylase 
PLA2    Phospholipase A2 
PLA2G   Phospholipase A2, group 
PCR    Polymerase chain reaction 
RT-PCR   Reverse transcriptase-PCR 
qRT-PCR   Quantitative RT-PCR 
PET    Positron emission tomography 
PMD    Post mortem delay 
PTM    Post translational modification 
PCC    Posterior cingulate cortex 
POU4F3   POU class 4 homeobox 3 
PFC    Prefrontal cortex 
PSEN1    Presenilin 1 
PCA    Principal components analysis 
PSP    Progressive supranuclear palsy 
PTGDS   Prostaglandin D2 synthase 
PSMB8   Proteasome (prosome, macropain) subunit, β type, 8 
PPP1R16A   Protein phosphatase 1, regulatory subunit 16A 
PTP    Protein tyrosine phosphatase 
PTPN11   Protein tyrosine phosphatase, non-receptor type 11 
PTPRR   Protein tyrosine phosphatase, receptor type, R 
PUM1    Pumilio homologue 1 
QKI    Quaking homologue, KH domain RNA binding 
QC    Quality control 
QTL    Quantitative trait locus 
eQTL    Expression QTL 
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QSBBND   Queen Square Brain Bank for Neurological Disorders 
RN    Raphe nuclei 
REM    Rapid eye movement 
Ras    Rat sarcoma 
RasGAP Ras GTPase activating protein 
RASA1    Ras p21 protein activator 1 
ROS    Reactive oxygen species 
ROC    Receiver operator curve 
ROI    Region of interest 
RRAS    Related Ras viral oncogene homologue 
3R    3-Repeat MAPT 
4R    4-Repeat MAPT 
RARRES2 Retinoic acid receptor responder 2 
RICH2 Rho-type GTPase-activating protein RICH2 
RNA    Ribonucleic acid 
cRNA    Complementary RNA 
mRNA    Messenger RNA 
miRNA   Micro RNA 
rRNA    Ribosomal RNA 
tRNA    Transfer RNA 
RNAi    RNA interference 
RNAse   Ribonuclease 
RPL13A   Ribosomal protein L13A 
RPL35A   Ribosomal protein L35A 
RPS6KA   Ribosomal protein S6 kinase, 90 kDa, polypeptide 
RSK    Ribosomal S6 kinase 
RMA    Robust multi-chip average 
RUSC1   RUN and SH3 domain containing 1 
SEPW1   Selenoprotein W, 1 
SNP    Single nucleotide polymorphism 
htSNP    Haplotype-tagging SNP 
mSNP    Marker SNP 
rSNP    Regulatory SNP 
Src    Sarcoma 
SH2    Src homology 2 
SH3    Src homology 3 
ST    Sense target 
STAT4    Signal transducer and activator of transcription 4 
SPECT   Single photon emission computerised tomography 
SDS    Sodium dodecyl sulphate 
SD    Standard deviation 
SPM    Statistical parametrical mapping 
STAU1    Staufen homologue 1 
STR    Striatum 
SN    Substantia nigra 
SNpc    SN pars compacta 
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STN    Subthalamic nucleus 
SNCAIP   Synuclein, α interacting protein (aka Synphilin 1) 
SNCA    α-Synuclein 
SNCB    β-Synuclein 
TCF/LEF   T-cell factor/lymphoid enhancer binding factor 
TBP    TATA box binding protein 
TC    Temporal cortex 
TdT    Terminal deoxynucleotidyl transferase 
TEX2    Testis expressed 2 
TOL    Tower of London 
TMS    Transcranial magnetic stimulation 
rTMS    Repetitive TMS 
TF    Transcription factor 
TCF7    Transcription factor 7 
TCF7L    Transcription factor 7-like 
TFBS    Transcription factor binding site 
TSS    Transcriptional start site 
TRPM Transient receptor potential cation channel, subfamily 
M, member 
TMC3    Transmembrane channel-like 3 
TBE    Tris-borate-EDTA 
TFIP11   Tuftelin interacting protein 11 
TP53 Tumour protein 53 
UQCRFS1 Ubiquinol-cytochrome c reductase, Rieske iron-sulphur 
polypeptide 1 
UCHL1   Ubiquitin carboxy-terminal hydrolase L1 
UPS    Ubiquitin-proteasome system 
UCSC    University of California Santa Cruz 
UCL    University College London 
UCLH    University College London Hospital 
UPR    Unfolded protein response 
UTR    Untranslated region 
UDG Uracil DNA glycosylase 
dUTP Deoxyuridine triphosphate 
V25 A measure of whether patients presented with cognitive 
impairment or altered personality (two years or more 
after PD diagnosis) 
RELB V-rel reticuloendotheliosis viral oncogene 
homologue B 
VTA Ventral tegmental area 
VLN Ventrolateral nucleus 
vs Versus 
WT Wild type 
WCST Wisconsin Card Sorting Task 
VBM Voxel-based morphometry 
WM Working memory 
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H2O Water 
mqH2O MilliQ H2O 
rfH2O RNAse-free H2O 
tH2O Tap H2O 
XBP1 X-box binding protein 1 
YY1 Yin Yang 1 
ZNF407 Zinc finger protein 407 
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Chapter 1: Introduction 
1.1. Parkinson’s disease 
1.1.1. Clinical and neuropathological characteristics 
of Lewy body disease 
1.1.1.1. Parkinson’s disease: introduction and clinical 
overview 
Parkinson’s disease (PD) was first identified by James Parkinson, and christened the 
“shaking palsy” (Parkinson 1817).  It is the most common neurodegenerative 
movement disorder, affecting roughly 1% of people over the age of 60, rising to 4-5% 
in those 85 or above, and has a higher prevalence in men than in women (Fahn 2003).  
PD typically has an insidious (it presents during mid to late adulthood) and 
asymmetrical onset, with a progressive course eventually resulting in death.  It is 
characterised clinically by the presence of four cardinal motor symptoms, collectively 
known as parkinsonism: bradykinesia (slowed initiation and execution of voluntary 
movement), resting tremor, muscular rigidity, and postural instability.  Bradykinesia 
and at least one other parkinsonian symptom must be present to ensure clinical 
diagnosis of PD [reviewed in (Lees et al. 2009)]. 
 
It is widely accepted that PD motor symptoms are for the most part caused by the 
death and/or dysfunction of neuromelanin-containing dopaminergic neurons in the 
pars compacta of the substantia nigra (SN).  This leads to a severe reduction of 
dopamine (DA) levels in the striatum, a vital structure in the basal ganglia whose 
function is to initiate and coordinate voluntary movement, resulting in parkinsonism 
(see 1.1.1.2) (Farrer 2006).  5-10% of cases are the result of monogenic mutations 
that follow a Mendelian inheritance pattern, and as such are termed familial 
Parkinson’s disease (FPD).  The vast remainder is known as idiopathic Parkinson’s 
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disease (IPD) (see 1.1.2).  Its exact aetiology still escapes elucidation, but most 
commentators believe it arises from a complex interplay of genetic, epigenetic, and 
environmental factors (Lesage and Brice 2009). 
 
Confirmation of PD diagnosis requires clinical parkinsonism and the subsequent 
detection of two essential neuropathological hallmarks post mortem.  These are loss 
of the aforementioned substantia nigra pars compacta (SNpc) dopaminergic neurons 
with concomitant depigmentation, and the presence of proteinaceous cytoplasmic 
inclusions called Lewy bodies (LBs) and/or dystrophic Lewy neurites (LNs) 
(collectively known as Lewy pathology [LP]) in the brain stem (see 1.1.1.2) (Lees et 
al. 2009).  Several other forms of parkinsonism exist, and these conditions are 
distinguished from PD by their lack of the diagnostic triad: parkinsonian motor 
dysfunction, SNpc neuronal loss, and brain stem LP (Farrer 2006).  These atypical 
parkinsonian syndromes are beyond the scope of this chapter, which will concentrate 
on PD and two very closely related diseases: Parkinson’s disease dementia (PDD) 
and dementia with Lewy bodies (DLB).  These conditions are collectively known as 
Lewy body disease (LBD), and together with multiple system atrophy (MSA), form a 
group of neurological disorders termed synucleinopathies (Farrer 2006). 
 
In the past, PD was primarily considered as a movement disorder.  However this view 
is increasingly seen as overly simplistic and a plethora of nonmotor symptoms have 
been described.  Moreover, many of these are thought to arise from dysfunction in 
extranigral structures, highlighting the growing understanding of the role played by 
nondopaminergic systems in PD (see 1.1.1.2) [reviewed in (Adler 2005; Lim et al. 
2009)].  Some of these symptoms can present well before the onset of classical motor 
features, even by decades.  Examples include: cognitive impairment (see 1.1.1.3), 
depression, anxiety, rapid eye movement (REM) behaviour disorder, excessive 
daytime somnolence (sleepiness), insomnia, pain, hyposmia (olfactory impairment), 
and autonomic problems e.g. constipation, incontinence, impotence, and orthostatic 
hypotension (sudden dizziness on standing).  Other nonmotor symptoms tend to be 
associated with more advanced PD.  These include: dementia (see 1.1.1.3), psychosis 
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e.g. visual hallucinations and delusions, dysarthria (speech disorder), and dysphagia 
(swallowing difficulties) [reviewed in (Adler 2005; Lim et al. 2009)]. 
 
PD remains incurable, and the primary therapeutic approach is replacement of 
depleted nigrostriatal DA.  Levodopa, the metabolic precursor of DA, alleviates the 
motor symptoms at first.  But after five years of levodopa therapy, ~60% of patients 
develop a reduced response and/or dyskinesias (involuntary movements) (Fahn 
2003).  More advanced cases undergo surgery.  Stereotactic deep brain stimulation 
(DBS) is the most popular and successful option.  Generally the subthalamic nucleus 
(STN) is targeted, resulting in reduced bradykinesia severity, however stimulation of 
the globus pallidus (GP) is also employed to control levodopa-induced dyskinesia 
(Fahn 2003).  Several methodologies are employed to treat the spectrum of nonmotor 
symptoms, notably acetylcholinesterase inhibitors which can ameliorate the cognitive 
dysfunction associated with this condition (see 1.1.1.4) (Caballol et al. 2007). 
 
 
1.1.1.2. Parkinson’s disease: synaptic pathways and 
neuropathology 
Parkinson’s disease is characterised by severe neuronal loss in the ventrolateral tier of 
the SNpc, which causes marked degeneration of nigrostriatal fibres that project to DA 
receptors in the putamen (Fearnley and Lees 1991).  Under normal circumstances 
these fibres innervate two synaptic systems, known as the “direct” and “indirect” 
pathways, both of which result in excitation of cortical motor areas.  The direct 
pathway begins with excitatory signaling of nigrostriatal fibres to DA D1 receptors in 
the putamen.  Inhibitory γ-aminobutyric acid (GABA) pathways then link the 
putamen to the medial GP, and in turn connect this structure to the thalamic 
ventrolateral nucleus (VLN).  Excitatory glutamergic pathways link the VLN to the 
cortex (Crossman and Neary 2005).  The indirect pathway starts with inhibitory 
signaling of nigrostriatal fibres to DA D2 receptors in the putamen.  GABAergic 
pathways then signal from the putamen to the lateral GP, and in turn connect this 
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structure to the subthalamic nucleus (STN).  Glutamergic pathways link the STN to 
the medial GP, which is itself connected to the VLN and cortex, as per the direct 
pathway.  Hence, the akinetic symptoms observed in PD can be accounted for by 
reduced striatal DA and resultant cortical inhibition via the direct and indirect 
pathways (Crossman and Neary 2005). 
 
However, cell death and concomitant LP (see below) is not restricted to either the 
SNpc or dopaminergic neurons.  Indeed, extensive noradrenergic and serotonergic 
neuronal loss can be detected in the locus coeruleus (LC) and raphe nuclei (RN), 
respectively.  Cholinergic neurons in the dorsal motor nuclei of the medulla 
oblongata, the pons, and the nucleus basalis of Meynert (NbM) are damaged.  To a 
lesser extent, dopaminergic neuronal loss is also observed in the ventral tegmental 
area (VTA).  Moreover, even cells outside the central nervous system (CNS) are 
affected, such as those in the olfactory bulb and mesenteric system [reviewed in (Lees 
2009)].  Neurodegeneration in many of these extranigral regions and the resultant 
neurotransmitter deficiency at postsynaptic cortical targets is believed to contribute to 
some of the nonmotor features seen in PD (see 1.1.1.4) (Scatton et al. 1983; Perry et 
al. 1985). 
 
Neuronal cell loss in PD is generally accompanied by three types of intracellular 
inclusion: LBs, LNs, and pale bodies (PBs).  LBs, the classical pathological hallmark, 
exist as two distinct types.  Brain stem LBs are easily seen under light microscopy 
with haematoxylin and eosin staining.  They are spherical or elongated cytoplasmic 
aggregates possessing a dense eosinophilic core and a paler peripheral halo.  Cortical 
LBs tend to be more irregular in shape, often lack a conspicuous halo, and can be 
difficult to detect with haematoxylin.  Both types of LB possess a filamentous 
ultrastructure and stain positive for α-Synuclein (SNCA).  Aggregated SNCA is a 
major component of LBs and LNs, and its detection is the immunohistochemical 
marker used to evaluate the severity and extent of LP (see below).  Aggregates of this 
protein are also abundant in PBs, which are large rounded eosinophilic filamentous 
structures.  In the early stages of PD, SNCA can be detected in neurons as punctuate 
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cytoplasmic staining.  It is believed that during pathogenesis, cytoplasmic SNCA 
aggregation progresses from punctuate staining to PBs to LBs.  In addition to SNCA, 
LBs contain over 70 other molecules whose functions include signal transduction, 
protein folding, oxidative stress, and protein degradation [reviewed in (Wakabayashi 
et al. 2007)].  The terms incidental Lewy body disease (ILBD) and diffuse Lewy 
body disease (DLBD) are diagnostic definitions used by neuropathologists to indicate 
low levels of brain stem LP or widespread cortical LP, respectively. 
 
An influential publication retrospectively studied groups of PD patients and 
individuals with ILBD at various pathological stages, documenting the spread of 
accumulated SNCA in the form of LBs and LNs i.e. LP.  This has resulted in the 
development of a system known as Braak staging (Braak et al. 2003).  The findings 
indicate that LP begins in the medullary dorsal motor nuclei and the anterior olfactory 
nucleus (stage 1).  As PD progresses, LP ascends rostrally up the brain stem to the 
pons, affecting the reticular formation, particularly the RN and LC (stage 2), and then 
to the midbrain and basal forebrain, notably involving the SNpc and the 
magnocellular nuclei (e.g. the NbM), respectively (stage 3) (Braak et al. 2003).  Next, 
LP expands through the basal forebrain, affecting the amygdala and certain thalamic 
nuclei, and into the temporal mesocortex and the allocortex, involving the perirhinal 
cortex and hippocampus respectively (stage 4).  LP then spreads into the neocortex.  
Initially, the higher order sensory association areas, insula, anterior cingulate cortex 
(ACC), and prefrontal cortex (PFC) are affected (stage 5).  Subsequently, almost the 
entire neocortex is involved, including to some extent the first order sensory 
association areas, primary sensory areas, and premotor and primary motor cortices 
(stage 6).  Note that LNs are generally inferred to precede LBs (Braak et al. 2003). 
 
Notwithstanding its apparent success at charting the spread of LP (see below), 
specific criticisms have been levelled at the Braak system (Kalaitzakis et al. 2008c).  
These have brought an unresolved issue about PD pathophysiology into sharp relief, 
that being whether LBs themselves are neurotoxic, neuroprotective or simply a 
marker of excessive protein load with no direct influence on disease progression.  The 
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first issue with the Braak scheme is that the authors introduced a confounding bias, 
by only selecting individuals demonstrating SNCA positivity in the dorsal motor 
nuclei, thereby undermining their contention that LP at this site is an obligate trigger 
for PD (Kalaitzakis et al. 2008c).  Indeed, two studies have shown that ~7-8% of PD 
cases do not possess LP at this location, despite exhibiting extensive lesions in the 
SNpc and neocortex (Kalaitzakis et al. 2008b; Attems and Jellinger 2008).  The 
second criticism is that the Braak system fails to correlate the spread of LP with the 
severity of either neuronal loss or clinical symptoms, and so does not accurately chart 
PD pathogenesis (Kalaitzakis et al. 2008c).  In PD, bradykinesia and rigidity correlate 
with SNpc neuronal loss, but not with SNpc SNCA accumulation (Greffard et al. 
2006; Greffard et al. 2010).  Prospective and retrospective studies have shown that 
~50-60% of PD brains follow the hierarchical LP pattern proposed by Braak 
(Halliday et al. 2008; Kalaitzakis et al. 2008b).  Moreover, it was found that amongst 
226 SNCA-positive subjects selected regardless of clinical presentation, 83% 
demonstrated SNCA accumulation broadly compatible with the Braak scheme.  
However, 55% of individuals with widespread SNCA pathology (stage 5 or 6) lacked 
parkinsonism or dementia (Parkkinen et al. 2008).  It has been proposed that transient 
SNCA oligomers, not LBs, are the toxic species in PD (see 1.1.2.2) (Volles and 
Lansbury, Jr. 2003).  Furthermore, foetal mesencephalic neurons grafted into the 
striatum of PD patients can develop LBs, suggesting the possibility that the internal 
milieu of the recipient striatum might facilitate host-to-graft propagation of SNCA 
pathology (Li et al. 2008; Kordower et al. 2008), potentially via a prion-like 
mechanism of permissive templating (Hardy 2005).  The recent demonstration that 
SNCA forms inclusion bodies in neuronal stem cells transplanted into the brains of 
mice overexpressing human SNCA supports this hypothesis (Desplats et al. 2009). 
 
Taken together, these findings indicate that Braak staging only applies to a proportion 
of PD cases, and suggest that SNCA accumulation is probably one of several 
pathogenic factors that synergise to generate this disorder.  Moreover, they also 
indicate that PD may in fact encompass several disease entities which have been 
brought together under the same clinical umbrella (see 1.1.1.4) (Lees 2009). 
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1.1.1.3. Parkinson’s disease dementia: clinical overview 
Cognitive impairment and dementia are common in PD.  Estimates of point 
prevalence for the latter range from 24 to 31% (Aarsland et al. 2005b), and its near 
inevitability has been demonstrated in two prospective studies, with over 80% of 
patients developing dementia during the course of their illness (Buter et al. 2008; 
Hely et al. 2008).  Other reports have shown that the risk of dementia amongst PD 
patients is approximately four to six times that of age-matched controls (Levy et al. 
2002b; Aarsland et al. 2001a; Hobson and Meara 2004).  Several longitudinal studies 
indicate that older age at baseline, more severe and protracted motor symptoms, 
akinetic-dominant PD, lower mini mental state examination (MMSE) score at 
baseline, the presence of hallucinations, and male gender are all risk factors that 
increase the incidence of dementia in PD (Aarsland et al. 2001a; Hughes et al. 2000; 
Levy et al. 2000; Aarsland et al. 2003a; Hobson and Meara 2004).  Moreover, age at 
baseline and motor impairment act synergistically to increase the risk of this 
phenotype (Levy et al. 2002b).  The literature is conflicted with regard to the effect of 
parkinsonian symptom age of onset, and evidence has been presented both supporting 
(Hely et al. 1995; Mahieux et al. 1998; Hobson and Meara 2004) and undermining 
(Aarsland et al. 2001a; Hughes et al. 2000; Aarsland et al. 2007) the assertion that 
this factor significantly influences the development of dementia in PD. 
 
Cognitive impairment has been described in nondemented PD patients encompassing 
a variety of domains, including executive, memory, visuospatial, and language 
abilities.  These deficits are often detected early in the disease course and symptom 
presentation is heterogeneous [reviewed in (Caballol et al. 2007; Goetz et al. 2008)].  
Executive dysfunction has been demonstrated by impaired performance on tests 
assessing attentional set shifting (the Wisconsin Card Sorting Task [WCST]), 
cognitive sequencing (digit ordering tasks), and planning (the Tower of London 
[TOL] task) (Lees and Smith 1983; Cooper et al. 1991; Foltynie et al. 2004a).  Note 
that the executive domain is associated with the frontal lobes and relies on several 
cognitive functions, including attention, working memory (WM), and visual 
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processing.  It controls processes required for goal-directed and adaptive mental 
behaviour, such as the generation of new concepts, problem solving, organisation, 
and planning (Dubois and Pillon 1997; Emre 2003).  Deficits in numerical, spatial, 
and verbal WM have been described (Cooper et al. 1991; Bradley et al. 1989; Owen 
et al. 1992; Cooper and Sagar 1993).  Results of word learning and recall trials have 
demonstrated that early stage PD patients also display impairments in declarative 
memory with relatively preserved recognition, suggesting that the disability is one of 
encoding or retrieval but not storage (Taylor et al. 1986; Sagar et al. 1991; Weintraub 
et al. 2004).  Deficits in visuospatial (e.g. facial recognition and visuomotor 
construction) and language (e.g. verbal fluency) skills have both been reported (Levin 
et al. 1991; Auriacombe et al. 1993).  Longitudinal studies demonstrate that 
dysfunction in several of these neuropsychological variables successfully predicts the 
subsequent development of dementia in PD.  Examples include declarative memory 
impairment, executive dysfunction, deficits in verbal fluency, and visuospatial 
impairment.  These correlations highlight the progression from cognitive dysfunction 
to full-blown dementia that is a common feature of PD pathogenesis (Hobson and 
Meara 2004; Levy et al. 2002a; Mahieux et al. 1998; Williams-Gray et al. 2007a). 
 
Parkinson’s disease dementia (PDD) has been defined as an insidious progressive 
dysexecutive-visuospatial syndrome accompanied by declarative memory, language, 
and behavioural symptoms which together impede daily life (Dubois and Pillon 1997; 
Goetz et al. 2008).  These disabilities tend to be qualitatively similar to, but more 
severe than, those found in nondemented PD patients (Girotti et al. 1988).  Moreover, 
symptom presentation is heterogeneous.  One study indicates that while a 
“frontosubcortical” pattern of impairment (i.e. affecting executive abilities) is found 
in over half of PDD cases, almost a third display the “cortical” pattern (i.e. affecting 
declarative memory) typically associated with Alzheimer’s disease (AD) (Janvin et 
al. 2006).  PDD has even been described as cortical dysfunction superimposed on 
frontosubcortical impairment (Pagonabarraga et al. 2008).  Executive dysfunction is 
the core neuropsychological feature of PDD (Emre 2003).  Deficits in attention and 
conceptualisation have been observed when comparing to both controls and AD 
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patients matched for dementia severity (Litvan et al. 1991; Noe et al. 2004).  
Although classically associated with DLB (see 1.1.1.5), fluctuating attention is found 
in almost one third of PDD cases (Ballard et al. 2002).  Furthermore, impairments in 
numerical and verbal WM tasks are seen in this disorder when contrasted against 
controls and dementia-matched AD patients, respectively (Litvan et al. 1991; Bohnen 
et al. 2006; Jefferson et al. 2002).  Marked visuospatial deficits have been described.  
Compared to nondemented PD and controls, PDD patients are impaired with regard 
to visuospatial orientation and reasoning, respectively (Girotti et al. 1988; Huber et 
al. 1989).  Moreover, one publication demonstrated visuoperceptive deficits in PDD 
when contrasted against either nondemented PD or controls (Mosimann et al. 2004). 
 
Impairments in declarative memory have been identified, yet these tend to be less 
severe than those found in AD.  Verbal free recall trials demonstrate that episodic and 
semantic memory are both deficient in PDD patients compared to controls, but not to 
the extent observed in dementia-matched AD patients (Helkala et al. 1989; Litvan et 
al. 1991; Noe et al. 2004).  Subsequent semantic cueing dramatically enhances recall, 
indicating that storage is intact but retrieval is impaired.  Moreover, memory scores 
significantly correlate with executive abilities in PDD patients, suggesting that frontal 
dysfunction underlies the defective activation of memory processes (Pillon et al. 
1993).  Language deficits have been reported.  Verbal fluency, the most commonly 
affected ability, is impaired in PDD patients compared to nondemented PD patients, 
AD patients, and controls (Girotti et al. 1988; Huber et al. 1989).  Behavioural and 
neuropsychiatric symptoms are frequently found in PDD, and include psychosis e.g. 
hallucinations (both visual and auditory) and delusions, and mood disturbances e.g. 
depression, anxiety, and apathy (Aarsland et al. 2001b; Aarsland et al. 2001c). 
 
Collectively, these results indicate that cognitive impairment and dementia are 
relatively common in PD, and are characterised by similar neuropsychological 
symptoms.  These symptoms tend to predict progression from one to the other, and 
are generally more severe in demented compared to nondemented PD patients.  
Furthermore, PDD is viewed primarily as a dysexecutive-visuospatial syndrome. 
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1.1.1.4. Parkinson’s disease dementia: neurochemistry and 
neuropathology 
Efforts to elucidate the mechanistic principles underlying PDD have employed a 
variety of approaches drawing on several neuroscientific disciplines.  The findings 
can be broadly subdivided into two areas: neurochemistry and neuropathology.  The 
data generated in each area are not mutually exclusive and there is crossover between 
them, but unification into an overarching scheme that fully explains PDD 
aetiopathogenesis remains elusive.  This pathophysiological heterogeneity reflects the 
clinical heterogeneity (see 1.1.1.3).  Indeed, attempts to correlate neurochemical and 
neuropathological states with cognitive symptoms have been relatively successful. 
 
Several lines of evidence suggest that DA deficiency might underlie cognitive 
impairment in PD.  Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) causes selective dopaminergic cell death and parkinsonism in humans, and 
impaired executive and visuospatial abilities have been described in these individuals 
(Stern et al. 1990).  In nondemented PD patients, WM is significantly inhibited and 
enhanced by levodopa withdrawal and treatment, respectively (Lange et al. 1992; 
Lewis et al. 2005).  Interestingly, positron emission tomography (PET) analysis of 
brain perfusion suggests that this levodopa effect could be mediated by altered 
cerebral blood flow (CBF) in the dorsolateral prefrontal cortex (DLPFC) (Cools et al. 
2002).  This is consistent with PET experiments quantifying 6-[18F]fluoro-levodopa 
uptake showing that verbal fluency and WM abilities positively correlate with DA 
synthesis in the PD frontal cortex (FC) (Rinne et al. 2000).  However, excessive 
cortical DA can inhibit executive ability in PD, consistent with the “inverted U” 
relationship between DA signaling and PFC function (see 1.1.2.8) (Cools 2006). 
 
The relevance of DA signaling to PD dementia is less clear.  Post mortem findings 
demonstrate that VTA neuronal loss significantly associates with dementia in PD 
(Zweig et al. 1993).  This dopaminergic nucleus projects to the PFC via the 
mesocortical circuit (Van den Heuvel and Pasterkamp 2008).  Moreover, neuronal 
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loss in the medial SNpc significantly correlates with dementia severity in this 
condition (Rinne et al. 1989).  The medial SNpc innervates the caudate, which itself 
receives input from the DLPFC as part of the “dorsolateral prefrontal loop”, believed 
to be important for the manipulation of information in WM [reviewed in (Alexander 
et al. 1986; Owen 2004)].  Single photon emission computerised tomography 
(SPECT) analysis indicates that dopamine transporter (DAT) activities in the caudate 
and putamen are both significantly lower in PDD patients compared to nondemented 
PD or controls (O'Brien et al. 2004).  However, levodopa use does not predict 
dementia incidence in this condition (Levy et al. 2000), and three months of chronic 
levodopa treatment does not significantly improve WM ability or MMSE score in 
PDD patients (Molloy et al. 2006).  Furthermore, PET data indicate no differences in 
striatal or cortical DA synthesis between demented and nondemented PD (Hilker et 
al. 2005).  These findings suggest that impaired DA signaling resulting from cell 
death in the ventral mesencephalon fails to account for all aspects of PDD cognitive 
impairment, but may be involved in the dysexecutive syndrome. 
 
The role of acetylcholine (ACh) in PDD cognitive dysfunction is less controversial.  
Significantly greater neuronal loss in the NbM and significantly lower frontal, 
entorhinal, temporal, and parietal choline acetyltransferase (ChAT) activities are 
observed in demented PD patients when contrasted against their nondemented 
counterparts post mortem (Whitehouse et al. 1983; Perry et al. 1985).  PET studies 
comparing these two groups have found significantly reduced acetylcholinesterase 
(AChE) activity in the PDD inferior parietal and temporal cortices, premotor cortex, 
and posterior cingulate cortex (PCC) (Hilker et al. 2005; Shimada et al. 2009).  These 
findings are generally consistent with SPECT CBF analyses demonstrating 
hypoperfusion in the PDD inferior parietal cortex, precuneus, and PCC (Firbank et al. 
2003; Osaki et al. 2009).  Moreover, cortical AChE activity significantly correlates 
with WM ability and MMSE score in combined groups of PD patients with and 
without dementia (Bohnen et al. 2006; Shimada et al. 2009), and clinical trials 
demonstrate that AChE inhibitors modestly but significantly improve cognitive 
symptoms in PDD, including WM and attention deficits (Emre et al. 2004; Ravina et 
 35 
al. 2005).  Taken together, these results support the hypothesis that NbM neuronal 
death resulting in cortical cholinergic denervation could account for executive, 
memory, visuospatial, and attentional dysfunction in PDD. 
 
Similar research has examined the role of noradrenergic and serotonergic signaling.  
LC noradrenalin levels and neuronal counts are lower in demented compared to 
nondemented PD patients post mortem (Cash et al. 1987; Zweig et al. 1993), and 
cerebrospinal fluid levels of a noradrenalin metabolite significantly correlate with 
attention in this disorder (Stern et al. 1984).  Furthermore, when PDD patients are 
grouped by depression status, significantly greater levels of RN cell death and 
temporal cortex inhibitory serotonin receptor expression are observed post mortem in 
those that experienced depressive behaviour during the course of their illness (Paulus 
and Jellinger 1991; Sharp et al. 2008).  These data suggest that in PDD, loss of LC 
noradrenergic cells and RN serotonergic neurons might underlie attentional 
impairment and depression, respectively.  Collectively, the neurochemical studies 
detailed above have resulted in the hypothesis that deficits in each of these 
neurotransmitters contributes to various aspects of PDD, and that their relative 
influences partially explains the heterogeneity of cognitive and behavioural 
symptoms.  The contention is that DA is to some extent responsible for executive 
dysfunction, ACh is involved in executive, memory, attentional, and visuospatial 
impairment, noradrenalin contributes to attentional dysfunction, and serotonin plays a 
role in depression [reviewed in (Emre 2003)]. 
 
Neuropathological correlates of PDD have been investigated using magnetic 
resonance imaging (MRI) to quantify gross cortical grey matter atrophy.  These 
studies indicate significantly greater atrophy in the PFC, ACC, superior temporal 
gyrus, occipital cortex, caudate, thalamus, and hippocampus of demented PD 
compared to nondemented PD patients (Burton et al. 2004; Nagano-Saito et al. 
2005).  At the cellular level, PDD neuropathology is characterised by Lewy 
pathology, and many post mortem clinicopathological studies have examined LB 
loads in relation to dementia severity (see below).  However, coexistent Alzheimer 
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pathology is frequently detected post mortem, albeit at levels below the diagnostic 
threshold for AD (see below).  This pathological class is characterised by β-amyloid-
positive neuritic plaques (NPs) and Microtubule-associated protein tau (MAPT)-
positive neurofibrillary tangles (NFTs).  There has been considerable debate about the 
nature of the primary pathogenic substrate driving dementia in PD, and disagreement 
over the relative importance of cortical or subcortical regions. 
 
Several reports have concluded that cortical and/or limbic LBs constitute the primary 
pathological mechanism underlying PDD.  Significantly higher LB counts, but not 
NFT and NP densities, have been observed in the neocortex and limbic cortex of 
demented compared to nondemented PD patients (Apaydin et al. 2002).  Moreover, 
LB load in several cortical regions significantly correlates with the degree of 
cognitive impairment, and this is more pronounced after removing cases fulfilling the 
pathological criteria for AD.  Regression analyses in these studies demonstrated that 
cognitive dysfunction is significantly predicted by LB density in the frontal gyrus, 
entorhinal cortex (EC), and ACC, but not by the severity of Alzheimer pathology in 
any region (Mattila et al. 2000; Kovari et al. 2003).  These retrospective data are 
supported by prospective findings showing that LB counts and Braak stage correlate 
with MMSE in this condition, whereas AD pathological stage does not (Aarsland et 
al. 2005a; Braak et al. 2005).  However, some investigators have argued against 
placing LBs at the forefront of PDD pathogenesis.  Indeed, at least two groups have 
indentified subsets of patients that lack dementia despite extensive neocortical and/or 
limbic LB infiltration (Colosimo et al. 2003; Parkkinen et al. 2008). 
 
There is evidence indicating that cortical Alzheimer pathology is the main substrate 
driving PDD.  Overall cortical AD pathological staging has been significantly 
correlated with MMSE score in prospectively-studied PD (Bancher et al. 1993).  PD 
dementia severity significantly correlates with levels of hyperphosphorylated MAPT 
protein in the prefrontal, entorhinal, and temporal cortices (Vermersch et al. 1993).  
Furthermore, another retrospective report examined the cortices of 200 PD patients 
and found that of those with Lewy pathology but lacking Alzheimer pathology, only 
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3% had been demented (Jellinger et al. 2002).  Recent studies have called this 
hypothesis into doubt.  PET analysis showed that cortical β-amyloid load is unaltered 
in demented contrasted against nondemented PD (Edison et al. 2008).  Moreover, no 
difference in MMSE score is seen when prospectively comparing PDD patients with 
and without concomitant cortical Alzheimer pathology (Sabbagh et al. 2009). 
 
Despite the undoubted conflict over these two interpretations of the primary 
mechanism underlying PDD pathogenesis, there is evidence to suggest that this 
dichotomy can be transcended.  Several studies demonstrate that in PD with and 
without dementia, levels of Lewy and Alzheimer pathology significantly and 
positively intercorrelate in a variety of cortical regions, notably the ACC (Apaydin et 
al. 2002; Mattila et al. 2000; Pletnikova et al. 2005; Lashley et al. 2008).  
Furthermore, mice transgenic for human SNCA and Amyloid precursor protein (APP) 
possess more SNCA-reactive neuronal inclusions and learning deficiencies than those 
transgenic for SNCA alone (Masliah et al. 2001).  These results suggest that β-
amyloid and SNCA can synergise to promote dementia progression in PD.  This 
interpretation is consistent with a recent prospective study which found that the LBD 
course is heterogeneous and divided patients into three clinicopathological 
phenotypes.  All individuals that qualified for an end stage diagnosis of PDD were 
found to have both cortical/limbic LBs and NPs post mortem (Halliday et al. 2008). 
 
The third hypothesis proposes that subcortical pathology is the main correlate of 
PDD.  Early studies demonstrated that neuronal loss in the medial SNpc, VTA, NbM, 
and LC significantly associates with dementia in PD (Rinne et al. 1989; Whitehouse 
et al. 1983; Zweig et al. 1993).  In addition, demented PD patients have significantly 
more striatal deposition of β-amyloid than their nondemented counterparts, with no 
difference observed for SNCA or MAPT (Kalaitzakis et al. 2008a).  However, the 
focus of this theory has shifted to subcortical and cortical components of the limbic 
system.  In the ACC, amygdala, and claustrum, both SNCA and β-amyloid 
pathologies significantly associate with dementia and/or cognitive impairment in PD 
patients (Apaydin et al. 2002; Mattila et al. 2000; Kalaitzakis et al. 2009a; 
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Kalaitzakis et al. 2009b).  This relationship also holds true for SNCA and MAPT 
pathologies in the hippocampus (Apaydin et al. 2002; Mattila et al. 2000; Kalaitzakis 
et al. 2009a; Churchyard and Lees 1997). 
 
The pathophysiology of PDD is not fully understood.  Studies have successfully 
identified neurochemical, cellular, and anatomical correlates for this disorder, 
including dysregulated neurotransmission, protein aggregation, and neuronal loss in 
subcortical, limbic, and cortical regions.  Some of these are found to a lesser extent in 
nondemented PD, highlighting the clinicopathological overlap between these two 
conditions, and suggesting that PDD can be viewed as one extreme on a spectrum of 
LBD pathogenesis.  There is some conflict in the literature regarding the exact nature 
and location(s) of the cellular lesion(s) that drive(s) dementia in PD.  Nevertheless, 
the growing appreciation of PDD as a multisystem and heterogeneous illness will 
probably reconcile these differences.  The eventual outcome is likely to be an 
individualistic approach, whereby the clinical course of each patient is explained in 
terms of specific combinations of anatomopathological changes. 
 
 
1.1.1.5. Dementia with Lewy bodies: clinical and 
neuropathological overview 
Lewy body dementias are subdivided into two conditions: PDD and DLB.  Clinicians 
employ the “one year rule” to distinguish between these nosological entities.  This 
states that a diagnosis of DLB is made if dementia is recognised either before or less 
than one year after the onset of parkinsonism.  Otherwise, the patient is classified as 
having PDD.  In clinical and neuropathological terms, PDD and DLB are very 
similar, yet subtle differences do exist [reviewed in (McKeith et al. 2005)].  What 
follows is a brief overview of DLB, highlighting some of these disparities. 
 
Dementia with Lewy bodies shares numerous clinical features with PDD, including 
an insidious onset and a generally idiopathic aetiology.  However, parkinsonism 
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seems to be less severe and more symmetrical in DLB compared to PDD (Burn et al. 
2003).  The type of dementia observed in DLB tends to be very comparable with that 
found in PDD, in that most cases are characterised by a dysexecutive-visuospatial 
syndrome with fluctuating attention and relatively intact memory capabilities, and 
that similar levels of cognitive heterogeneity (i.e. deviation from this pattern of 
frontosubcortical impairment) are observed (Ballard et al. 2002; Janvin et al. 2006).  
However when compared to PDD, DLB patients are impaired in executive abilities, 
such as attention, verbal fluency, and conceptualisation (Downes et al. 1998; 
Aarsland et al. 2003b).  Moreover, hallucinations and delusions are significantly 
more frequent in DLB than in PDD (Aarsland et al. 2001b). 
 
There is much neuropathological overlap between DLB and PDD, in that both 
diseases are characterised by Lewy and Alzheimer pathology post mortem.  In many 
cortical areas, LB densities are similar in PDD and DLB.  However in the temporal 
cortex, significantly more LBs are found in DLB compared to PDD (Harding and 
Halliday 2001; Harding et al. 2002).  Moreover, LB loads in this region significantly 
correlate with visual hallucinations early in the DLB disease course.  Much greater 
cortical Alzheimer pathology is seen in DLB compared to PDD (Harding et al. 2002). 
The coexistence of Alzheimer and Lewy pathologies significantly associates with 
memory impairment and cognitive decline in DLB (Kraybill et al. 2005).  Striatal 
SNCA pathology is thought to be greater in DLB than in PDD, whereas the reverse is 
true for SN neuronal loss (Duda et al. 2002a; Tsuboi and Dickson 2005). 
 
So many similarities exist between PDD and DLB that it has been proposed they 
represent different extremes on a spectrum of LBD (Aarsland et al. 2004).  Indeed, 
this assertion is supported by a study demonstrating that the duration of parkinsonism 
prior to dementia in both PDD and DLB correlates with the severity of Lewy and 
Alzheimer pathology i.e. the one year rule might not distinguish meaningful 
biological entities (Ballard et al. 2006).  However, close examination reveals subtle 
differences, which suggest that the two disorders could be driven by overlapping but 
distinct biological processes operating within the context of this disease spectrum. 
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1.1.2. Molecular genetics and pathogenesis of 
Parkinson’s disease with and without dementia 
1.1.2.1. Introduction 
Familial parkinsonism has been reported in the literature for over a century, yet 
research into the aetiology of PD historically focused on environmental factors and 
played down the influence of genetics.  This was because of strong epidemiological 
evidence linking it to neurotoxic compounds and viruses, implying that familial 
clustering was due to shared environmental exposure (see 1.1.2.10).  Underpowered 
twin studies in the 1980s which indicated similar concordance rates in monozygotic 
and dizygotic twins further strengthened this conclusion [reviewed in (Nussbaum and 
Polymeropoulos 1997)]. 
 
In the last decade, it has emerged that genetic factors play a critical role in the 
aetiology of this disorder.  Linkage and sequencing analyses have identified 
numerous pathogenic coding mutations that cause FPD, together accounting for  
5-10% of all PD.  Such studies have been vital in elucidating the pathways that 
regulate PD pathophysiology, not only in these monogenic forms but also the 
majority of cases, which are termed IPD [reviewed in (Lesage and Brice 2009)].  The 
exact cause(s) of IPD is/are still unknown, but it is believed to arise due to the 
complex interaction of genetic, epigenetic, and environmental factors.  Genetic 
association studies have been employed to uncover alleles that alter IPD 
susceptibility, but insufficient statistical power has hampered replication in many 
instances [reviewed in (Lesage and Brice 2009)].  However, large carefully-designed 
experiments are beginning to identify genetic variants that unequivocally influence 
IPD aetiopathogenesis (Maraganore et al. 2006; Healy et al. 2008; Satake et al. 2009; 
Simon-Sanchez et al. 2009). 
 
There is considerable overlap between the various forms of FPD and IPD, both in 
terms of clinical manifestation and the underlying neuropathology [reviewed in 
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(Schiesling et al. 2008)].  This commonality extends to the genetic level.  
Polymorphisms residing in and around some of the FPD-causing genes demonstrate 
association with IPD (Healy et al. 2008; Kay et al. 2008; Simon-Sanchez et al. 2009).  
Furthermore, microarray studies indicate that the majority of known familial genes 
are differentially-expressed in the IPD SN (Moran et al. 2007; Simunovic et al. 
2009).  It is believed that regulatory variants significantly alter susceptibility to 
complex disease via their effect on gene expression (see 1.2) [reviewed in (Buckland 
2004)].  Estimates suggest that single nucleotide polymorphisms (SNPs) might 
influence the expression of ~20% of cortical transcripts (Myers et al. 2007a), so it is 
interesting that some of the most compelling IPD-associated variants have regulatory 
ability or reside in noncoding regions (Chiba-Falek and Nussbaum 2001; Maraganore 
et al. 2006; Satake et al. 2009). 
 
Investigation into the molecular pathophysiology of Lewy body dementia is still in its 
infancy.  Due to their prominent role in Lewy body disease pathogenesis, most 
studies have concentrated on the synucleins.  Examples include genetic alterations 
that result in familial forms of PDD and DLB, and transgenic mice that model their 
phenotypes in vivo (Ross et al. 2008a; Ohtake et al. 2004; Freichel et al. 2007; Fujita 
et al. 2009).  However, inherent limitations in these model systems can complicate 
interpretation and undermine the relevance to cognitive dysfunction in humans.  
Tentative association with idiopathic Parkinson’s disease dementia (IPDD) has been 
shown for a handful of genetic variants [for example (Williams-Gray et al. 2009a; de 
Lau et al. 2005)], but these findings are still controversial [for example (Ezquerra et 
al. 2008; Kurz et al. 2009)].  Moreover, expression microarray analysis has identified 
genetic pathways that demonstrate dysregulation in IPDD (see 4.1), yet these findings 
await confirmation (Stamper et al. 2008).  In summary, our understanding of the 
molecular processes which generate the emergent property we recognise as dementia 
is still patchy at best. 
 
Given the focus of this thesis, the aim of section 1.1.2 is not to summarise all 
molecular aspects of PD, but to concentrate on what is known about the molecular 
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genetics and pathogenesis of PDD and DLB, with particular emphasis on gene 
expression.  As such, those genes relevant to familial and idiopathic Lewy body 
disease accompanied by a significant degree of dementia and/or cognitive impairment 
will be discussed first.  Genes underlying FPD without cognitive dysfunction will 
then be considered, followed by the role played by environmental factors. 
 
 
1.1.2.2. α-Synuclein (PARK1 and PARK4) 
α-Synuclein (SNCA) was the first gene demonstrated to cause familial PD, and it 
remains an important focus of research into FPD and IPD.  Three rare heterozygous 
missense mutations have been described in SNCA: Ala53Thr, Ala30Pro, and 
Glu46Lys.  These all result in a heterogeneous clinical phenotype of variably 
penetrant autosomal dominant parkinsonism that tends to be early onset (21-40 
years), and diagnoses include PD, PDD, and DLB (PARK1).  A spectrum of cognitive 
impairment, dementia, and hallucinations is observed in the majority of these 
individuals, notably the Spanish Glu46Lys kindred who were diagnosed with DLB 
based on neuropathological criteria (Polymeropoulos et al. 1997; Kruger et al. 1998; 
Kruger et al. 2001; Zarranz et al. 2004).  Extensive LP is found in all of the Ala53Thr 
and Glu46Lys patients, although this exists primarily as LNs and perikaryal 
inclusions in the former, and LBs and LNs in the latter.  Critically, SNCA protein is a 
major component of LBs and LNs found in IPD, DLB, and the aforementioned 
familial cases (Spillantini et al. 1997; Spillantini et al. 1998a; Duda et al. 2002b; 
Yamaguchi et al. 2005; Zarranz et al. 2004).  Taken together, these findings indicate 
that SNCA plays a central role in both familial and idiopathic LBD pathogenesis, and 
suggest that its mutation tends to precipitate cognitive dysfunction. 
 
Rare multiplications of SNCA are also known to cause early onset autosomal 
dominant parkinsonism with concomitant spectra of cognitive dysfunction and LBD 
diagnosis (PARK4).  Several duplication and triplication families have been 
identified, and one prevailing theme is that patients possessing more copies of SNCA 
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are at increased risk of cognitive impairment, dementia, and hallucinations, and tend 
to present these symptoms and parkinsonism at an earlier stage (Chartier-Harlin et al. 
2004; Ibanez et al. 2004; Nishioka et al. 2006; Singleton et al. 2003; Farrer et al. 
2004).  This effect is highlighted by two kindreds where intrafamily variation in the 
cognitive phenotype clearly correlates with the degree of SNCA ploidy (Fuchs et al. 
2007; Ikeuchi et al. 2008).  Moreover, FC SNCA expression is increased in 
triplication patients compared to controls (Farrer et al. 2004; Miller et al. 2004).  
Interestingly, sparse data suggest that SNCA triplication cases exhibit more cortical 
LBs than their duplication counterparts [reviewed in (Ross et al. 2008a)].  These 
results imply that increased SNCA copy number causes parkinsonism and cognitive 
dysfunction by directly affecting the expression of this gene. 
 
α-Synuclein genetic variation has been shown to significantly alter IPD risk in 
Caucasians and Asians.  Key polymorphisms include the upstream promoter 
microsatellite Rep1; SNPs residing in the 5’ promoter, the large ~93 kb intron, the 3’ 
untranslated region (UTR), the 3’ flanking region; and haplotypes constructed thereof 
(see 5.1) (Maraganore et al. 2006; Kay et al. 2008; Mueller et al. 2005; Mizuta et al. 
2006; Sutherland et al. 2009a; Pals et al. 2004; Tan et al. 2004; Farrer et al. 2001; 
Simon-Sanchez et al. 2009; Satake et al. 2009).  Interestingly, common variation at 
Rep1 and five 5’ promoter SNPs does not associate with dementia status in Caucasian 
IPD patients, but the relatively small size of this study may have generated a false 
negative (De Marco et al. 2008).  SNCA multiplication seems incredibly rare in IPD, 
as three reports discovered only two examples of duplication in a combined total of 
1431 cases (Johnson et al. 2004; Nishioka et al. 2006; Ahn et al. 2008).  There is 
evidence to suggest that common variation at Rep1 and the 3’ flanking SNP rs356219 
might influence SNCA expression in the human brain (see 5.1) (Chiba-Falek and 
Nussbaum 2001; Fuchs et al. 2008).  The literature is conflicted concerning SNCA 
expression in IPD.  Some studies have observed increases in the SN of IPD patients 
(Chiba-Falek et al. 2006; Grundemann et al. 2008), whereas several others have 
detected reduced expression in this region (see 5.1) (Kingsbury et al. 2004; Zhang et 
al. 2005b; Dachsel et al. 2007; Moran et al. 2007; Simunovic et al. 2009).  
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Contradictory results are also seen in the IPD FC, but one report found that all four 
spliceforms display increased expression (Kingsbury et al. 2004; Zhang et al. 2005b; 
Chiba-Falek et al. 2006; Beyer et al. 2008).  On the other hand, SNCA is 
alternatively-spliced in DLB, with underexpression observed for the full length (FL) 
isoform (Beyer et al. 2008).  These data demonstrate that SNCA genetic variation 
influences IPD susceptibility, and suggest that it might affect SNCA expression in this 
disorder.  However, variation in this gene appears not to associate with IPDD. 
 
The function of SNCA is not fully understood.  The full length 140 amino acid protein 
is expressed throughout the human brain and localises to the cytosol and presynaptic 
vesicles.  In dopaminergic cells it regulates vesicular trafficking, DA release, and 
synaptic plasticity (Irizarry et al. 1996; Abeliovich et al. 2000; Murphy et al. 2000; 
Cooper et al. 2006).  SNCA can aggregate into oligomers (or protofibrils) and fibrils 
in vitro, and this sequence of events is believed to precede LB and LN formation 
during LBD.  The Ala53Thr and Ala30Pro mutations both promote its conversion 
into pore-like soluble oligomers in vitro, whereas only the former promotes its 
fibrillisation.  Moreover, DA stabilises SNCA oligomers and inhibits fibril formation 
in vitro (Conway et al. 1998; Conway et al. 2000; Conway et al. 2001; Lashuel et al. 
2002).  Importantly, SNCA aggregates are detected in the brains of SNCA triplication 
patients (Miller et al. 2004).  These findings suggest that SNCA oligomers might be 
the pathogenic species that mediate dopaminergic cell death in LBD, potentially by 
permeabilising presynaptic vesicles thereby releasing excess DA into the cytosol, 
resulting in oxidative stress (see below).  The recent discovery that SNCA oligomers 
concentrate at presynaptic terminals in the FC of DLB patients supports this 
hypothesis and implicates these species in dementia pathophysiology (Kramer and 
Schulz-Schaeffer 2007; Paleologou et al. 2009).  SNCA is phosphorylated at Ser129 
and this species forms part of LBs and LNs in LBD brains, yet its pathogenic 
relevance is unclear (Fujiwara et al. 2002; Anderson et al. 2006).  Ser129 
phosphorylation correlates with SNCA oligomerisation and enhanced neuronal 
toxicity in Drosophila melanogaster and mice overexpressing human SNCA (see 
below) (Chen and Feany 2005; Chen et al. 2009; Ihara et al. 2007).  In rats however, 
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SN injection with virus encoding a nonphosphorylateable human SNCA mutant either 
promotes cell death or is as efficient as the wild type (WT) (Gorbatyuk et al. 2008; 
Azeredo da Silveira et al. 2009; McFarland et al. 2009).  Nonetheless, these results 
are consistent with the notion of SNCA oligomers as the key pathogenic species 
driving LBD. 
 
The function of SNCA has been studied in vivo using several model organisms, such 
as Caenorhabditis elegans, Drosophila, mice, and marmosets, successfully 
recapitulating some of the molecular pathophysiology fundamental to LBD.  
Overexpression of WT or Ala53Thr human SNCA in these systems elicits some of the 
phenotypes which characterise PD, including loss of dopaminergic cells (Ala53Thr 
only) or terminals, SNCA-positive neuronal inclusions, and motor dysfunction 
(Lakso et al. 2003; Feany and Bender 2000; Masliah et al. 2000; Giasson et al. 2002; 
Eslamboli et al. 2007).  Interestingly, aged mice transgenic for WT, Ala30Pro, or 
Tyr39Cys human SNCA exhibit significant spatial memory impairment (Freichel et 
al. 2007; Nuber et al. 2008; Zhou et al. 2008). 
 
SNpc ubiquitin-proteasome system (UPS) activity and 20S α subunit levels are 
significantly reduced in IPD (McNaught et al. 2003).  Decreased 20S α subunit 
expression is also seen in the DLB ACC, and its levels significantly correlate with 
MMSE score in these patients (MacInnes et al. 2008).  UPS inhibition and reduction 
of 19S subunits are observed in the midbrain and striatum of aged mice transgenic for 
doubly mutant (Ala53Thr and Ala30Pro) human SNCA (Chen et al. 2006).  The 
chaperone-mediated autophagy (CMA) pathway is significantly inhibited in nigral 
and striatal IPD neurons (Chu et al. 2009; Yang et al. 2009).  Neuronal cell models 
show that CMA degrades WT SNCA, but not the Ala53Thr or Ala30Pro mutants or 
DA-modified WT, which actually impair this system for other substrates (Cuervo et 
al. 2004; Martinez-Vicente et al. 2008).  Importantly, mice transgenic for human WT 
SNCA demonstrate neuronal autophagy dysfunction, but limbic injection with virus 
encoding the proautophagic gene Beclin1 ameliorates this phenotype and significantly 
reduces SNCA immunoreactivity (Spencer et al. 2009). 
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In the IPD SN, mitochondrial complex I activity is reduced, and oxidative damage to 
lipids and proteins is increased (Schapira et al. 1989; Dexter et al. 1989; Alam et al. 
1997).  DA stabilises SNCA oligomers in vitro, and transfection of dopaminergic 
cells with SNCA induces apoptosis dependent on endogenous DA synthesis (Conway 
et al. 2001; Xu et al. 2002).  Snca-null mice are resistant to dopaminergic cell death 
after treatment with the oxidative mitochondrial toxin MPTP (see 1.1.2.10) (Dauer et 
al. 2002).  Furthermore, aged mice transgenic for human Ala53Thr SNCA develop 
neuronal mitochondrial abnormalities and degeneration (Martin et al. 2006).  
Collectively, these findings demonstrate that impaired protein degradation, oxidative 
stress, and mitochondrial dysfunction are central facets of LBD pathophysiology, and 
suggest that they could be involved in the tendency of overexpressed SNCA to 
promote cognitive deficiency in these disorders. 
 
 
1.1.2.3. β-Synuclein 
β-Synuclein (SNCB) belongs to the same genetic family as SNCA (Lavedan 1998).  
Two rare heterozygous missense SNCB mutations, Val70Met and Pro123His, have 
been described in unrelated DLB patients.  Val70Met was found in a seemingly 
idiopathic case, whereas the Pro123His proband belonged to a DLB kindred (Ohtake 
et al. 2004).  Further investigation revealed that the Pro123His clinical phenotype is 
late onset (> 40 years) dementia and parkinsonism inherited in an autosomal 
dominant fashion with incomplete penetrance.  Its neuropathological phenotype is 
extensive Lewy and Alzheimer pathology, with high LB levels in the hippocampus 
and the amygdala.  Notably, no SNCB-positive inclusions are observed (see below), 
but diffuse soluble SNCB immunoreactivity is detected (Ohtake et al. 2004). 
 
Two studies have examined variation at a total of four common SNCB SNPs for 
genetic association with IPD, and none were found to influence overall susceptibility 
in Caucasians.  However, variation at the common upstream polymorphism 
rs1352303 associates with age of onset in females only (Fung et al. 2006; Brighina et 
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al. 2007).  SNCB is significantly underexpressed in the SN and temporal cortex of 
DLB patients, as well as in the DLPFC [Brodmann area 9 (BA9)] of IPD patients 
(Rockenstein et al. 2001; Zhang et al. 2005b).  It seems to be unaltered in the IPD SN 
(Zhang et al. 2005b; Moran et al. 2006).  SNCB is not a component of IPD or DLB 
LBs (Spillantini et al. 1997; Spillantini et al. 1998a), however in both diseases, 
SNCB aggregates are detected within accumulated vesicles localised to degenerating 
hippocampal axons (Galvin et al. 1999). 
 
β-Synuclein is expressed in the cortex, SN, caudate, hippocampus, amygdala, and 
thalamus, and its encoded protein predominately associates with presynaptic vesicles 
(Lavedan 1998).  SNCB can oligomerise, but these species do not bind and 
permeabilise synthetic vesicles in vitro.  SNCB inhibits the oligomerisation and 
fibrillisation of WT and Ala53Thr SNCA in vitro, as well as binding WT SNCA in 
vivo and ameliorating its aggregation in cell models (Park and Lansbury, Jr. 2003; 
Hashimoto et al. 2001).  Moreover, overexpression of human SNCB in aged mice 
transgenic for human WT and Ala53Thr SNCA significantly improves neuronal 
SNCA accumulation, loss of dopaminergic terminals (only WT transgenics were 
assessed), and motor dysfunction (Hashimoto et al. 2001; Fan et al. 2006).  
Interestingly, neuronal cells stably transfected with Val70Met or Pro123His SNCB 
develop lysosomal SNCB-positive inclusion bodies, resulting in significantly 
upregulated lysosomal activity.  Treating these cells with autophagy inhibitors 
significantly reduces inclusion body formation and increases SNCB oligomerisation 
and apoptosis (Wei et al. 2007). 
 
Taken together, these data demonstrate that SNCB mutations can cause DLB, and 
suggest that lysosomal dysfunction might underlie neurodegeneration in these cases.  
Furthermore, they indicate that SNCB might regulate SNCA aggregation under normal 
circumstances, and are consistent with the hypothesis that altered SNCB expression 
affects SNCA accumulation in idiopathic LBD.  However, the paucity of reported 
human DLB cases with mutated SNCB and the failure to detect SNCB in LBs or LNs 
casts doubt on these conclusions. 
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1.1.2.4. Leucine-rich repeat kinase 2 (PARK8) 
Mutations in Leucine-rich repeat kinase 2 (LRRK2) were first demonstrated to cause 
FPD in 2004 (Paisan-Ruiz et al. 2004; Zimprich et al. 2004).  Since then, over 40 
mutations have been described, most of which are missense.  The few that are 
definitely pathogenic result in a fairly uniform clinical phenotype of late onset 
autosomal dominant parkinsonism with variable penetrance (Lesage and Brice 2009).  
Screening has discovered LRRK2 mutation(s) in ~5% of IPD cases worldwide, 
making alteration of this gene the most common single risk factor for IPD (Santpere 
and Ferrer 2009).  One global study of over 10 000 cases demonstrated that the 
Gly2019Ser mutation significantly increases IPD susceptibility in Caucasians (Healy 
et al. 2008).  Cognitive impairment and/or dementia is/are observed in PD patients 
with mutated LRRK2, although at a reduced frequency when compared to PD in 
general.  One report showed that 23% of 162 Gly2019Ser PD cases had evidence of 
cognitive impairment (Healy et al. 2008).  These results are consistent with a smaller 
but more detailed neuropsychological study, which detected frontal lobe dysfunction 
in 35% of 24 Gly2019Ser PD patients (Goldwurm et al. 2006).  The 
neuropathological phenotype of LRRK2 mutation is quite heterogeneous.  SN 
dopaminergic neuronal loss is seen in all PD cases, but LBs can be either present or 
absent [reviewed in (Santpere and Ferrer 2009)]. 
 
Two recent and well-powered genome wide association studies (GWAS) performed 
in Caucasians and Asians both identified several LRRK2 SNPs that might influence 
IPD risk, although none of these survived the stringent Bonferroni threshold for 
multiple testing (Simon-Sanchez et al. 2009; Satake et al. 2009).  LRRK2 is 
significantly underexpressed in IPD SNpc neurons (Simunovic et al. 2009).  
However, neuronal LRRK2 can aggregate in enlarged granules or vacuoles that stain 
positive for endosomal markers, and these are more frequent in the SN and EC of IPD 
and DLB patients compared to controls (Higashi et al. 2009).  The presence of 
LRRK2 in IPD and DLB LBs is controversial, potentially resulting from the use of 
several different antibodies [reviewed in (Santpere and Ferrer 2009)]. 
 49 
Leucine-rich repeat kinase 2 is expressed in neurons and glia, and can be detected in 
the SNpc, striatum, hippocampus, and cortex (Miklossy et al. 2006; Higashi et al. 
2007; Galter et al. 2006).  LRRK2 localises primarily to mitochondria, lysosomes, 
and endosomes (Biskup et al. 2006).  LRRK2 pathogenic mutations increase its kinase 
activity in vitro, and inactivation of its kinase domain inhibits the toxicity of mutant 
LRRK2 in neuronal cell models (West et al. 2005; Smith et al. 2006b).  Moreover, 
injecting the SNpc of rats with virus encoding the kinase domain of Gly2019Ser 
human LRRK2 promotes MAPT-positive inclusion formation, neurite length 
reduction, and apoptosis in dopaminergic neurons (MacLeod et al. 2006).  
Interestingly, LRRK2 binds SNCA in the FC of DLB patients but not controls, and 
Gly2019Ser LRRK2 phosphorylates SNCA at Ser129 in vitro more effectively than 
the wild type (Qing et al. 2009b; Qing et al. 2009a). 
 
Collectively, these results suggest that LRRK2 sequence variation can cause and/or 
increase the risk of both PD and cognitive dysfunction therein, and are consistent 
with the hypothesis that enhanced LRRK2 kinase activity and its resultant effect on 
and MAPT and/or SNCA aggregation might be involved in these phenotypes. 
 
 
1.1.2.5. β-Glucocerebrosidase 
β-Glucocerebrosidase (GBA) encodes a lysosomal enzyme which catalyses the 
breakdown of glucocerebroside (also known as glucosylceramide) in neurons and 
macrophages.  Homozygous GBA mutations cause the lipid storage disorder 
Gaucher’s disease, and a small subgroup of these individuals develop parkinsonism 
[reviewed in (DePaolo et al. 2009)].  GBA mutations, notably Asn370Ser, are 
relatively common in Ashkenazi Jews, and early findings demonstrated that 
Asn370Ser carrier status significantly increases IPD risk in this population (Aharon-
Peretz et al. 2004).  Larger studies have confirmed that GBA mutation significantly 
increases IPD susceptibility in Ashkenazi Jews, non-Ashkenazi Caucasians, and 
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Asians, and indicate that Leu444Pro and Asn370Ser are the most frequent alterations 
in non-Ashkenazi cases (Neumann et al. 2009; Sidransky et al. 2009). 
 
Cognitive impairment, dementia, and hallucinations are seen in IPD patients with 
GBA mutations (Aharon-Peretz et al. 2005; Goker-Alpan et al. 2008).  One group 
observed cognitive dysfunction and/or dementia in 52% of 21 IPD cases with mutant 
GBA (Neumann et al. 2009).  A much larger study reporting data for 1948 individuals 
found some evidence of cognitive change in 26% of mutated and 19% of nonmutated 
patients.  This difference is significant and implies that cognitive impairment is more 
common in patients with GBA mutations than amongst IPD in general (Sidransky et 
al. 2009).  Therefore, it is perhaps unsurprising that GBA mutation also significantly 
increases DLB risk (Goker-Alpan et al. 2006; Mata et al. 2008).  IPD cases with GBA 
mutations display similar patterns of neuropathology as IPD in general, with SNCA-
positive LP in subcortical and cortical regions, however there is a trend for higher 
levels of neocortical involvement (Neumann et al. 2009). 
 
These results demonstrate that GBA mutations significantly enhance susceptibility to 
IPD, IPDD, and DLB.  Moreover, they suggest that lysosomal dysfunction might play 
a role in cognitive impairment in these disorders. 
 
 
1.1.2.6. Microtubule-associated protein tau 
Microtubule-associated protein tau (MAPT) is primarily expressed in neurons where 
it stabilises microtubules by promoting their polymerisation.  Pathological neuronal 
aggregates of hyperphosphorylated MAPT characterises a group of 
neurodegenerative disorders known as tauopathies, which includes AD, progressive 
supranuclear palsy (PSP), and frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP17) [reviewed in (Iqbal et al. 2009)].  Moreover, heterozygous 
missense (e.g. Pro301Leu) and splice site MAPT mutations have been identified in 
autosomal dominant FTDP17 patients (Hutton et al. 1998; Spillantini et al. 1998b).  
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Analysis of MAPT polymorphisms uncovered the existence of two major 
nonrecombining haplotype blocks in Caucasians, called H1 and H2, which originated 
from an ancestral inversion involving ~900 kb of chromosome 17 (Baker et al. 1999; 
Stefansson et al. 2005).  Variation within the common H1 clade is significantly 
associated with idiopathic tauopathies, and further investigation has defined several 
subhaplotypes that appear to be largely driving these associations, notably H1c 
(Baker et al. 1999; Pastor et al. 2004; Pittman et al. 2005; Myers et al. 2005). 
 
Meta-analysis of older studies shows that amongst Caucasians, MAPT H1/H1 
homozygotes are significantly more susceptible to IPD, and several publications have 
replicated this finding (Healy et al. 2004b; Zabetian et al. 2007; Tobin et al. 2008; 
Vandrovcova et al. 2009).  Well-powered GWAS analysis demonstrates that variation 
at three MAPT SNPs significantly associates with IPD in Caucasians, and these 
polymorphisms appear to be tagging the H1 haplotype (Simon-Sanchez et al. 2009).  
Furthermore, MAPT haplotype interacts synergistically with the SNCA SNP rs356219 
to modify IPD risk in this population (Goris et al. 2007).  There is debate regarding 
the influence of variation within common H1 subhaplotypes on IPD risk in 
Caucasians, and at least two reports do not observe association with H1c (Skipper et 
al. 2004; Tobin et al. 2008; Vandrovcova et al. 2009; Zabetian et al. 2007).  Amongst 
Caucasians, MAPT H1/H1 homozygous IPD patients have significantly greater rates 
of cognitive decline, and multivariate analysis demonstrates an age/genotype 
interaction for this effect (Goris et al. 2007).  Critically, a recent follow up study of 
the same longitudinal cohort showed that IPD dementia incidence is significantly 
higher in MAPT H1/H1 homozygotes, and found that the combination of this 
diplotype, older age, and impaired semantic fluency makes IPD patients 88-fold more 
likely to develop dementia (Williams-Gray et al. 2009a).  On the other hand, cross-
sectional data indicates that H1 homozygosity is not associated with IPDD (Ezquerra 
et al. 2008). 
 
Microtubule-associated protein tau is expressed as six isoforms which are generated 
by alternative splicing.  These transcripts differ by the presence of either three or four 
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microtubule-binding domains (3-repeat [3R] and 4-repeat [4R] isoforms) (Iqbal et al. 
2009)  The 4R:3R ratio is significantly increased in the IPD cerebellum, whereas total 
MAPT expression is significantly reduced in PCC neurons of demented compared 
with nondemented IPD or controls (Tobin et al. 2008; Stamper et al. 2008).  Several 
groups have investigated the relative expression of MAPT H1 and H2 haplotypes in 
the human brain.  In the DLPFC, H1:H2 transcript ratio is significantly increased in 
IPD patients but not controls, however only when 4R isoforms are specifically 
quantified (Williams-Gray et al. 2009a).  This isoform-specific effect has also been 
shown for H1c:H2a transcript ratio in the frontal and temporal cortices of controls 
(Myers et al. 2007b).  The demonstration by another report that H1c status does not 
influence total MAPT H1:H2 transcript ratio in controls is consistent with these 
results.  This study also discovered that age significantly and negatively correlates 
with H1:H2 transcript ratio (Hayesmoore et al. 2009).  MAPT can co-localise with 
SNCA in IPD and DLB LBs (Arima et al. 1999; Ishizawa et al. 2003).  Moreover, 
MAPT and SNCA promote each other’s aggregation in vitro and in vivo (Giasson et 
al. 2003).  Interestingly, suppressing MAPT expression ameliorates neuronal loss and 
spatial memory impairment in mice transgenic for human Pro301Leu MAPT 
(Santacruz et al. 2005). 
 
Taken together, these findings indicate that MAPT H1 homozygosity most likely 
enhances IPD susceptibility and progression to dementia, and suggest that these 
effects might be caused by alternative splicing resulting in increased production of 
MAPT 4R isoforms with greater ability to induce SNCA aggregation. 
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1.1.2.7. Apolipoprotein E 
Apolipoprotein E (APOE) is expressed in glia throughout the brain, and it regulates 
lipid transport, synaptic plasticity, and neuronal repair.  Variation at two common 
nonsynonymous SNPs differentiates three transcript isoforms, known as ε2, ε3, and 
ε4 [reviewed in (Bu 2009)].  The APOE ε4 allele significantly increases AD risk in 
Caucasian and Asian populations in a dose-dependent manner (Farrer et al. 1997), 
whereas amongst Caucasians, the ε2 allele is significantly overrepresented in IPD 
cases (Huang et al. 2004; Williams-Gray et al. 2009b). 
 
The relationship between APOE genotype and IPDD is highly contentious.  Meta-
analyses indicate that the ε4 allele significantly associates with an increased 
prevalence of dementia amongst Caucasian IPD patients, however issues over sample 
sizes, publication bias, and ascertainment bias (diagnostic criteria with regard to 
PDD, DLB, and AD) have cast doubt on these results (Huang et al. 2006; Williams-
Gray et al. 2009b).  Nevertheless, longitudinal and post mortem cross-sectional 
studies corroborate the findings of these meta-analyses, although one observed an 
even stronger effect for the ε2 allele (de Lau et al. 2005; Papapetropoulos et al. 
2007).  On the other hand, several relatively well-powered cross-sectional studies 
employing good selection criteria indicate no association between the ε4 allele and 
the prevalence of IPD dementia in Caucasians (Blazquez et al. 2006; Jasinska-Myga 
et al. 2007; Ezquerra et al. 2008), and this conclusion is supported by longitudinal 
and post mortem cross-sectional data (Camicioli et al. 2005; Kurz et al. 2009; 
Williams-Gray et al. 2009b). 
 
The APOE ε4 allele is significantly more expressed than either ε3 or ε2 in control 
brains (Bray et al. 2004).  Moreover, ε4-positive IPD patients possess significantly 
higher cortical LB counts and levels of Alzheimer pathology (Mattila et al. 2000; 
Mattila et al. 1998; Lashley et al. 2008).  Interestingly, mice transgenic for human 
Ala53Thr or Ala30Pro SNCA exhibit increased levels of endogenous Apoe and β-
amyloid in their CNS.  Deletion of Apoe in these mice reduces levels of SNCA 
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oligomers and β-amyloid aggregates, concomitant with delayed onset of motor 
symptoms and improved survival (Gallardo et al. 2008). 
 
Collectively, these results indicate that the APOE ε4 allele might increase dementia 
incidence in IPD, although longitudinal studies with thousands of participants will 
probably be required to confirm or refute this.  They also suggest that APOE may 
regulate SNCA and β-amyloid accumulation in LBD, potentially contributing to 
cognitive dysfunction in these disorders. 
 
 
1.1.2.8. Catechol-O-methyltransferase 
Catechol-O-methyltransferase (COMT) is predominately expressed in neurons and 
catalyses DA breakdown in the PFC but not in the caudate (Matsumoto et al. 2003; 
Yavich et al. 2007).  Variation at the common nonsynonymous COMT SNP 
Val158Met influences this process.  Compared to Val/Val homozygotes, Met/Met 
homozygotes have significantly lower levels of COMT protein and enzymatic activity 
in the DLPFC (Chen et al. 2004).  Association between variation at this 
polymorphism and schizophrenia has been reported in Caucasian and Asian 
populations, although meta-analysis casts doubt on this (Egan et al. 2001; Ohmori et 
al. 1998; Munafo et al. 2005).  Met/Met normal controls appear to score significantly 
better than their Val/Val counterparts on the WCST attentional set shifting task, but 
this is also a matter of debate (Barnett et al. 2007; Barnett et al. 2008). 
 
Studies using the TOL task to assess planning ability in nondemented Caucasian IPD 
patients demonstrate that Met/Met homozygotes perform significantly worse than 
Val/Val homozygotes.  Moreover, functional magnetic resonance imaging (fMRI) 
shows these Val/Val patients have significantly greater task-related activity increases 
in the DLPFC, the posterior parietal cortex, and the frontopolar region (Foltynie et al. 
2004b; Williams-Gray et al. 2007b).  Investigation of attentional set shifting aptitude 
in nondemented Caucasian IPD patients reveals similar effects, with significantly 
 55 
stronger performance and frontoparietal activation in Val/Val homozygotes 
(Williams-Gray et al. 2008).  These data can be interpreted in the context of the 
inverted U model which posits a complex nonlinear relationship between 
dopaminergic signaling and PFC function.  Val/Val homozygotes with higher COMT 
activity cope better with the inhibitory hyperdopaminergic state characteristic of the 
PFC in early IPD, resulting in higher prefrontal-dependent task scores (Kaasinen et 
al. 2001; Williams-Gray et al. 2008). 
 
Longitudinal examination of the same community-based incident cohort, the largest 
of its kind, shows that while Val/Val homozygotes score better in early IPD, the 
reverse is true for later disease.  Given that prefrontal DA levels fall in late IPD, this 
is in keeping with the inverted U model (Williams-Gray et al. 2009a).  Moreover, 
Val158Met genotype and prefrontal-dependent TOL ability do not predict dementia 
incidence in these individuals, whereas MAPT haplotype and temporal-dependent 
semantic fluency aptitude do (see 1.1.2.6).  This recent and intriguing finding 
indicates a dissociation between frontosubcortical and temporal cognitive syndromes 
in IPD, and contrary to accepted wisdom, suggests a startling conclusion about this 
disorder: prefrontal executive dysfunction does not develop into dementia (Williams-
Gray et al. 2009a). 
 
These data demonstrate that COMT Val158Met genotype significantly influences 
executive ability in IPD patients, and that there is a complex nonlinear relationship 
between this cognitive domain and PFC DA levels in IPD.  Furthermore, they suggest 
that the primary pathogenic substrate driving IPD dementia is more likely to be 
cortical rather than subcortical. 
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1.1.2.9. Genes causing familial Parkinson’s disease without 
significant dementia 
Juvenile (< 21 years) or early onset highly penetrant autosomal recessive FPD can be 
caused by missense, nonsense, exonic deletion, and exonic multiplication 
homozygous and compound heterozygous mutations in Parkin (PARK2).  Cognitive 
impairment and dementia are almost unheard of in these individuals, although 
behavioural symptoms (e.g. psychosis and depression) have been described (Kitada et 
al. 1998; Lucking et al. 2000; Khan et al. 2003; Lohmann et al. 2009).  All patients 
with mutant PARK2 display SN neuronal loss, but the majority lack LBs (Pramstaller 
et al. 2005).  Variation at the common PARK2 promoter SNP -258 T/G significantly 
alters IPD risk in Caucasians and influences its expression in neuronal cell models 
but this association is disputed (West et al. 2002; Ross et al. 2007b).  One relatively 
large study demonstrated that rare heterozygous PARK2 mutations do not influence 
IPD susceptibility in Caucasians (Kay et al. 2007).  PARK2 is differentially-spliced in 
the IPD FC, and its protein product can be detected in IPD and DLB LBs (Beyer et 
al. 2008; Schlossmacher et al. 2002). 
 
Parkin is an E3 ligase which adds ubiquitin molecules to substrates thereby targeting 
them for degradation by the UPS.  In this regard, FPD-causing mutants are deficient 
in vitro (Shimura et al. 2000).  Park2-null Drosophila mutants display muscle 
mitochondrial pathology, muscle degeneration, and motor defects (Greene et al. 
2003).  However, deleting Park2 in mice does not cause SN neuronal loss.  Instead, 
the result is a phenotypic spectrum including LC noradrenergic cell death, 
dysregulated nigrostriatal dopaminergic signaling, and reduction in neuronal electron 
transport chain (ETC) component expression, concomitant with decreased 
mitochondrial respiration and increased oxidative damage to lipids and proteins (von 
Coelln et al. 2004; Palacino et al. 2004).  Interestingly, PARK2 can ubiquitinate 
glycosylated SNCA in vitro and Park2 ameliorates human Ala30Pro SNCA-induced 
SN dopaminergic neuronal loss in vivo (Shimura et al. 2001; Lo Bianco et al. 2004). 
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The literature describes one rare missense mutation (Ile93Met) of Ubiquitin carboxy-
terminal hydrolase L1 (UCHL1) that is known to cause late onset autosomal 
dominant FPD with incomplete penetrance (PARK5).  Only one kindred has been 
identified and these patients do not display cognitive dysfunction (Leroy et al. 1998).  
This lack of genetic evidence questions whether UCHL1 should be classified as FPD-
causing at all.  There is also debate regarding the effect of common UCHL1 genetic 
variation on IPD susceptibility.  Some studies indicate that Ser18Tyr significantly 
reduces IPD risk in Caucasians and Asians (Maraganore et al. 2004a; Ragland et al. 
2009), whereas others find no such association (Healy et al. 2006; Sutherland et al. 
2009a).  UCHL1 is significantly underexpressed in the SN and FC of IPD and DLB 
cases (Zhang et al. 2005b; Moran et al. 2007; Barrachina et al. 2006).  UCHL1 
colocalises with SNCA in IPD LBs (Yasuda et al. 2009). 
 
The protein product of UCHL1 can free reusable ubiquitin monomers via its ubiquitin 
hydrolase activity, and the Ile93Met mutation inhibits this process in vitro (Leroy et 
al. 1998).  Mice transgenic for human Ile93Met UCHL1 develop neuronal inclusions, 
SN dopaminergic cell loss, and locomotor dysfunction (Setsuie et al. 2007).  
Overexpression of human SNCA enhances dopaminergic cell death in these mice, but 
not in those transgenic for human WT UCHL1 (Yasuda et al. 2009).  Moreover, 
Ile93Met, but not WT, UCHL1 inhibits CMA and SNCA degradation in cell models 
(Kabuta et al. 2008). 
 
Moderately frequent homozygous and compound heterozygous missense, nonsense, 
and frameshift mutations in Phosphatase and tensin homologue-induced putative 
kinase 1 (PINK1) can cause early onset autosomal recessive FPD with variable 
penetrance (PARK6).  Cognitive impairment is extremely infrequent in these cases 
(Valente et al. 2004; Rogaeva et al. 2004; Bonifati et al. 2005).  However, executive 
dysfunction and/or dementia have been described in a handful of patients with PINK1 
exonic deletion and nonsense mutations.  Nevertheless, PINK1 mutation failed to 
segregate with this phenotype in one of two sib pairs (Li et al. 2005; Ephraty et al. 
2007; Savettieri et al. 2008).  Although the Ala340Thr polymorphism is significantly 
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overrepresented in Asian IPD patients, variation at common PINK1 SNPs and 
haplotypes does not influence IPD susceptibility in Caucasians (Wang et al. 2006; 
Healy et al. 2004a; Sutherland et al. 2009a).  Rare heterozygous PINK1 mutations 
appear to marginally increase IPD risk in Caucasians but this is debated (Abou-
Sleiman et al. 2006a; Marongiu et al. 2008).  Data are conflicted in terms of PINK1 
expression in IPD dopaminergic SN neurons, with both no difference and significant 
reduction reported (Blackinton et al. 2007; Simunovic et al. 2009).  PINK1 is 
detected in a subset of IPD LBs (Gandhi et al. 2006). 
 
The protein product of PINK1 is a putative Ser/Thr kinase that localises to the 
mitochondrial membrane and WT PINK1, but not FPD-causing mutants, protects 
neuronal cells against mitochondrial dysfunction and apoptosis induced by UPS 
inhibition (see 1.1.2.10) (Gandhi et al. 2006; Valente et al. 2004; Abou-Sleiman et al. 
2006a).  Aged Drosophila Pink1 mutants exhibit dopaminergic cell death, muscle 
atrophy, and impaired locomotion resulting from mitochondrial dysfunction.  These 
effects are similar to those observed in Park2-null flies, and expression of Park2 can 
ameliorate the mutant Pink1 phenotype but not vice-a-versa (Park et al. 2006; Clark 
et al. 2006).  Pink1-/- mice display impaired synaptic plasticity, progressive reduction 
of spontaneous movement, and progressive neuronal mitochondrial pathology, 
concomitant with respiratory inhibition and enhanced sensitivity to oxidative stress.  
However, they do not develop SN dopaminergic cell loss (Kitada et al. 2007; Gautier 
et al. 2008; Gispert et al. 2009).  Interestingly, ribonucleic acid interference (RNAi) 
directed against PINK1 in differentiated human midbrain neurons results in lysosomal 
vesicular aggregation and enhanced cell death over the long term (Wood-Kaczmar et 
al. 2008).  Moreover, these cells exhibit mitochondrial Calcium accumulation, which 
stimulates reactive oxygen species (ROS) production and respiratory impairment 
(Gandhi et al. 2009). 
 
Early onset highly penetrant autosomal recessive FPD can be caused by rare missense 
and exonic deletion mutations in Parkinson’s disease 7 (PARK7) (also known as 
DJ1), but these patients do not develop cognitive dysfunction (Bonifati et al. 2003).  
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Variation at common PARK7 SNPs and haplotypes does not significantly influence 
IPD susceptibility in Caucasians, however borderline associations have been 
observed for two polymorphisms in females only (Maraganore et al. 2004b; 
Sutherland et al. 2009a).  PARK7 is significantly underexpressed in the IPD putamen, 
cortex, and cerebellum.  However, results in IPD SN dopaminergic neurons are 
contradictory, with both significant reduction and no difference reported (Kumaran et 
al. 2009; Simunovic et al. 2009; Galter et al. 2007).  PARK7 is generally not found in 
IPD and DLB LBs, although it is detected in nigral, striatal, and cortical DLB NFTs 
(Bandopadhyay et al. 2004; Rizzu et al. 2004). 
 
The protein encoded by PARK7 localises to the mitochondrial matrix and 
intermembrane space and is involved in protecting neurons against oxidative stress 
(Zhang et al. 2005a; Canet-Aviles et al. 2004).  RNAi knockdown of Park7 in 
Drosophila causes dopaminergic cell death, elevated neuronal ROS accumulation, 
and hypersensitivity to hydrogen peroxide (H2O2)-induced oxidative stress (Yang et 
al. 2005).  Park7-null Drosophila do not exhibit neuronal loss, but still display 
enhanced sensitivity to UPS inhibition and agents that promote oxidative stress, such 
as H2O2, paraquat, and rotenone (see 1.1.2.10) (Meulener et al. 2005).  Park7
-/- mice 
develop impaired synaptic plasticity and motor dysfunction, but do not suffer from 
neuronal loss (Goldberg et al. 2005; Chen et al. 2005).  However, treating these 
animals with MPTP or paraquat elicits a range of phenotypes including striatal DA 
deficiency, SNpc dopaminergic cell death, and UPS inhibition (Kim et al. 2005; 
Yang et al. 2007). 
 
Rare Adenosine triphosphatase type 13A2 (ATP13A2) homozygous and compound 
heterozygous frameshift and splice site mutations can cause highly penetrant juvenile 
onset autosomal recessive Kufor-Rakeb syndrome (KRS) (PARK9), and heterozygous 
missense ATP13A2 alterations have been detected in early and late onset autosomal 
recessive FPD cases.  KRS is characterised by parkinsonism, dementia, and 
supranuclear gaze palsy (the inability to look in a particular direction), whereas some 
of the FPD patients in question experienced visual hallucinations but none were 
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demented (Ramirez et al. 2006; Di Fonzo A. et al. 2007; Lin et al. 2008).  Variation 
at common ATP13A2 SNPs and haplotypes does not significantly alter IPD risk in 
North Africans and Caucasians (Vilarino-Guell et al. 2009; Rakovic et al. 2009).  
Analysis of ATP13A2 expression in IPD SN dopaminergic neurons has yielded 
conflicting results, with reports of significant increases and decreases (Ramirez et al. 
2006; Simunovic et al. 2009). 
 
The protein product of ATP13A2 is a lysosomal P-type adenosine triphosphatase 
(ATPase).  ATP13A2 is degraded via the proteasome, and KRS-derived mutants are 
destroyed more rapidly than the WT in cell models (Ramirez et al. 2006).  Expressing 
the relevant WT ATP13A2 orthologues inhibits human SNCA-mediated toxicity in 
yeast cells, Caenorhabditis dopaminergic neurons in vivo, and rat primary 
dopaminergic neurons.  KRS-equivalent or ATPase mutants are deficient in this 
regard.  Further experiments in yeast and Caenorhabditis indicate that WT ATP13A2 
enhances SNCA folding and protects cells from Manganese toxicity (see 1.1.2.10) 
(Gitler et al. 2009). 
 
The genetic evidence for High temperature requirement A2 (HTRA2) (also known as 
Omi) is not as strong.  The initial study detected heterozygous Gly399Ser mutations 
in four late onset apparently idiopathic PD patients but not in 370 normal controls.  
The authors indicated that this suggests an autosomal dominant mode of inheritance 
(PARK13).  They also demonstrated that the heterozygous Ala141Ser mutation is 
marginally but significantly overrepresented in German IPD cases.  The subsequent 
identification of nine heterozygous substitutions and insertions (one of which is 
missense) in late onset familial and apparently idiopathic patients but not in 359 
controls provided further support for the role of HTRA2 in autosomal dominant PD.  
Note that three of the four upstream mutations significantly influence reporter gene 
expression in neuronal cell models.  Cognitive impairment is almost unheard of in 
these patients (Strauss et al. 2005; Bogaerts et al. 2008).  However, association 
between IPD and the Gly399Ser and Ala141Ser mutations was not replicated in 
American Caucasians.  Moreover, analyses in combined groups of IPD and late onset 
 61 
FPD cases indicates that variation at common HTRA2 SNPs and haplotypes does not 
significantly influence disease susceptibility in several Caucasian populations 
(Simon-Sanchez and Singleton 2008; Ross et al. 2008b; Bogaerts et al. 2008).  These 
conflicting results do not exclude the possibility that rare HTRA2 mutations can cause 
FPD in specific populations.  In addition, HTRA2 is detected in a significant 
proportion of IPD and DLB LBs (Strauss et al. 2005; Kawamoto et al. 2008). 
 
The protein encoded by HTRA2 is a mitochondrial serine protease.  During apoptosis, 
it is released into the cytosol and regulates caspase activation, partially via its 
proteolytic function (Suzuki et al. 2001; Yang et al. 2003).  Htra2-/- mice or those 
homozygous for the Ser276Cys Htra2 mutation (the motor neuron disease 2 strain) 
display neuronal mitochondrial pathology, selective death of striatal neurons, 
enhanced cellular sensitivity to oxidative stress, motor dysfunction, and juvenile 
mortality (Jones et al. 2003; Martins et al. 2004).  Furthermore, deletion of Htra2 
induces mitochondrial protein accumulation, respiratory dysfunction, increased ROS 
levels, and a transcriptional stress response that contributes to neuronal cell death 
(Moisoi et al. 2009).  The Ser276Cys, Gly399Ser, and Ala141Ser mutations inhibit 
the protease activity of Htra2 in vitro, and the latter two elicit mitochondrial 
pathology and stress-induced mitochondrial dysfunction in neuronal cell models 
(Jones et al. 2003; Strauss et al. 2005).  PINK1 promotes HTRA2 phosphorylation in 
neuronal cells and the IPD caudate, and phosphorylation of HTRA2 appears to 
enhance its proteolytic activity.  Importantly, PINK1 and HTRA2 cooperate to protect 
primary fibroblasts from apoptosis induced by rotenone and UPS inhibition, and this 
appears to be dependent on HTRA2 phosphorylation (Plun-Favreau et al. 2007). 
 
Taken together, these findings indicate that common variation in genes known to 
cause FPD without dementia tends not to associate with IPD.  Nevertheless, 
heterozygosity for mutations underlying recessive FPD might increase IPD 
susceptibility in certain instances.  In addition, FPD animal models develop a range 
of phenotypes including mitochondrial dysfunction, oxidative stress, UPS 
impairment, lysosomal dysfunction, protein accumulation, deregulated 
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neurotransmission, and motor dysfunction.  However, many of these do not exhibit 
dopaminergic cell death. 
 
 
1.1.2.10. Environmental factors and Parkinson’s disease 
Parkinson’s disease with and without dementia are characterised by considerable 
molecular, neuropathological, and clinical heterogeneity.  This suggests that 
environmental factors play a significant role in the aetiopathogenesis of these 
conditions.  Indeed, various environmental influences can alter PD risk.  Studies 
demonstrate that occupational exposure to herbicides, pesticides, or metals (i.e. 
Manganese, Copper, and Lead); regular well-water consumption; and being knocked 
unconscious significantly increase PD susceptibility.  To put this in context, these 
factors each confer slightly less risk than having a positive history of PD in a first 
degree relative.  On the other hand, smoking; coffee and tea consumption; and 
exposure to general anaesthetic significantly protect against PD (Gorell et al. 2004; 
Dick et al. 2007; Hu et al. 2007). 
 
The discovery that exposure to MPTP causes parkinsonism and executive dysfunction 
in humans markedly advanced our understanding of PD and cognitive impairment 
therein (Langston et al. 1983; Stern et al. 1990).  The active metabolite of MPTP is 
the 1-methyl-4-phenylpyridinium ion (MPP+).  This species is a substrate for the 
dopamine transporter and inhibits mitochondrial ETC complex I.  Therefore, it 
accumulates specifically in dopaminergic neurons, leading to oxidative stress and 
death (Javitch et al. 1985; Nicklas et al. 1985).  MPTP-treated mice exhibit Snca-
positive neuronal accumulations, SNpc dopaminergic cell death, and locomotor 
dysfunction (Heikkila et al. 1984; Vila et al. 2000; Tillerson et al. 2002).  Similar 
effects are observed in rats injected with the pesticide rotenone, a highly selective 
complex I inhibitor (Betarbet et al. 2000).  Interestingly, macaques exposed to 
chronic low dose MPTP display attention and planning deficits (Decamp and 
Schneider 2004). 
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The ability of environmental agents to recapitulate essential aspects of PD is not 
solely restricted to those that directly promote oxidative stress.  In one seminal study, 
the authors injected rats with the proteasome inhibitors epoxomicin and PSI.  After 
several weeks, animals developed a parkinsonian-like syndrome and reduced 
nigrostriatal DA signaling.  Post mortem analyses demonstrated loss of dopaminergic 
cells in the SNpc and LC, noradrenergic neurons in the LC, cholinergic cells in the 
NbM, and neurons in the dorsal motor nucleus.  In the majority of the degenerating 
regions, these changes were accompanied by Snca-positive neuronal inclusions 
(McNaught et al. 2004).  These remarkable findings represent what is probably the 
most comprehensive and accurate animal model of PD neuropathology and motor 
dysfunction in existence. 
 
Collectively, these results indicate that environmental factors are intimately involved 
in PD, and potentially, in PD-associated cognitive impairment.  Further, they echo the 
genetic data, by demonstrating that mitochondrial dysfunction, oxidative stress, and 
UPS inhibition are central components of the molecular pathogenesis driving this 
condition. 
 
 
1.1.2.11. Molecular aetiopathogenesis of Parkinson’s 
disease: a modern synthesis 
The various manifestations of IPD and FPD exhibit a certain degree of molecular 
heterogeneity, both within themselves and compared to each other.  This is most 
likely the result of complex gene-gene and gene-environment interactions.  Despite 
this variability, it is striking that similar insults are consistently observed.  In essence, 
the building blocks of disease are more or less the same, but their specific number 
and combination varies from case to case.  This conclusion is based on a large body 
of work identifying mitochondria, oxidative stress, the UPS, and lysosomal 
degradation as pathways which regulate the molecular aetiopathogenesis of PD.  
Moreover, there is strong evidence from various systems that some of the key players 
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and pathways can interact with each other, converging at the molecular level to drive 
disease (see also below) [reviewed in (Abou-Sleiman et al. 2006b; Lesage and Brice 
2009)].  Research in this area has largely concentrated on intergenetic relationships.  
However, forays are being made into the territory of gene-environment interactions 
[for example (McCulloch et al. 2008)].  This important and necessary direction holds 
much promise of bringing all the pieces together, enabling us to grasp the complex 
mechanics of IPD and develop novel forms of effective therapy. 
 
Amongst the various pathway interactions described in the PD brain and model 
systems, those influencing SNCA accumulation may be particularly relevant to Lewy 
body dementia pathogenesis.  Many of the genes implicated in IPDD or DLB regulate 
SNCA accumulation in vivo, notably MAPT, SNCB, LRRK2, APOE (Hashimoto et al. 
2001; Giasson et al. 2003; Gallardo et al. 2008; Lin et al. 2009b).  Moreover, SNCA 
aggregates are concentrated at presynaptic terminals in DLB, and proteasomal subunit 
levels significantly correlate with MMSE scores in this disorder (Kramer and Schulz-
Schaeffer 2007; MacInnes et al. 2008).  Snca-null mice are resistant to oxidative 
stress-induced dopaminergic cell death (Dauer et al. 2002).  Finally, SNCA ploidy 
and cortical SNCA pathology correlate with the severity of cognitive dysfunction in 
FPD and IPD, respectively (Kovari et al. 2003; Aarsland et al. 2005a; Braak et al. 
2005; Ross et al. 2008a).  Taken together, these findings suggest that pathway 
interactions influencing SNCA accumulation could be critically-involved in the 
processes driving cognitive impairment and/or dementia in Lewy body disease. 
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1.2. Genetic regulation of gene expression 
1.2.1. Genetic variation and gene expression 
Marked differences exist between the human transcriptome and those of our primate 
cousins, particularly in the CNS, and natural selection has driven the evolution of 
gene expression in the human lineage (Enard et al. 2002; Gilad et al. 2006).  Together 
with the unexpectedly small number of protein-coding genes in the human genome, 
these observations have generated the hypothesis that heritable differences in the 
regulation of gene expression account for a large proportion of common human 
phenotypic variation [reviewed in (Buckland 2004)]. 
 
Genetic influences that regulate expression can be subdivided into two classes: cis-
acting and trans-acting.  Cis-acting factors function in an allele-specific manner.  Cis-
acting variants are situated at the target gene locus itself, residing in regulatory 
regions, such as promoters or enhancers, exons, or introns.  They alter transcription, 
splicing, translation, RNA stability, or protein stability (Bray and O'Donovan 2006).  
Trans-acting factors act on both gene copies.  Trans-acting polymorphisms are by 
definition located far from their target gene (generally on a different chromosome), 
and tend to influence expression via transcription factors or hormones (Bray and 
O'Donovan 2006).  Since transcription results in a quantitative phenotype, cis- and 
trans-acting variants are collectively known as expression quantitative trait loci 
(eQTLs) (Pastinen and Hudson 2004). 
 
The identification of polymorphisms that influence expression is complicated by our 
incomplete knowledge of regulatory regions.  The positions of all the DNA elements 
controlling the expression of any specific gene are generally unknown, and may lie in 
promoters, introns, exons, or at distant locations tens or hundreds of kb from the 
transcribed sequence (Buckland 2004).  However, the human genome possesses 
extensive linkage disequilibrium (LD), making it possible to screen for these effects 
indirectly.  This involves genotyping marker variants (e.g. marker SNPs [mSNPs]) 
 66 
and using that information to tag unknown or unidentified regulatory polymorphisms 
(e.g. regulatory SNPs [rSNPs]) (Bray and O'Donovan 2006). 
 
Early small scale estimates suggested that cis-acting variants explain a sizeable 
proportion of interindividual differences in gene expression (Yan et al. 2002; Lo et 
al. 2003).  Large scale genome wide studies indicate that cis-acting variation 
significantly affects the expression of 25-50% of all human transcripts.  They have 
also identified polymorphisms that act as master regulators or “hotspots”; which 
influence the expression of many targets in trans (Morley et al. 2004; Cheung et al. 
2005; Dixon et al. 2007; Goring et al. 2007; Ge et al. 2009).  These data have 
generally been obtained in cultured lymphoblastoid cells.  However, it has been 
demonstrated that eQTLs operate in the human brain.  One genome wide study 
indicates that SNP variation significantly influences the expression of ~20% of 
cortical transcripts, with trans-acting mechanisms accounting for the bulk of this 
(Bray et al. 2003; Buckland et al. 2004; Myers et al. 2007a) 
 
Whole genome studies generate the greatest amount of information for identifying 
regulatory variants.  However, the effect of cis-acting variation can be detected by 
quantifying the relative abundance of messenger ribonucleic acid (mRNA) transcripts 
containing each allele [reviewed in (Bray and O'Donovan 2006)].  This approach 
relies on the marker polymorphism being located on the transcript, and measures 
expression exclusively in heterozygotes.  Relative quantification is performed in the 
same sample, with each allele acting as internal control for the other.  Cis-acting 
variation is detected as a significant departure from the 1:1 ratio of expressed alleles, 
which is known as differential allelic expression (DAE) [reviewed in (Bray and 
O'Donovan 2006)].  This method is sensitive to subtle cis-acting factors, as it controls 
for interindividual differences in trans-acting effects caused by sample preparation, 
mRNA quality, or the environment.  It is limited in that strong LD is required 
between the marker variant and any putative regulatory polymorphisms [reviewed in 
(Bray and O'Donovan 2006)].  Relative allelic expression has been investigated using 
a variety of technologies including single base extension, oligo arrays, haplotype 
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chromatin immunoprecipitation, and reverse transcriptase-coupled 5’ nuclease assays 
(Yan et al. 2002; Lo et al. 2003; Knight et al. 2003; Zhu et al. 2004). 
 
 
1.2.2. Cis-acting variation and complex disease 
Genetic variation affects the aetiopathogenesis of many complex disorders.  It is now 
widely accepted that many polymorphisms each of small to moderate effect act in 
concert with environmental factors to generate disease phenotypes [reviewed in 
(Buckland 2006)].  Many commentators believe that a substantial proportion of these 
variants are likely to be eQTLs that influence risk via the regulation of gene 
expression.  Moreover, a variety of relatively simple techniques can detect their 
effects on gene expression as quantitative endophenotypes (see 1.2.1), making them 
attractive to laboratory researchers [reviewed in (Buckland 2006)]. 
 
Cis-acting variation has been demonstrated post mortem in the brains of neurological 
disease cases.  Examples include AD, where the ε4 and H1c alleles associate with 
significant overexpression of APOE and 4R MAPT, respectively (Bray et al. 2004; 
Myers et al. 2007b), and schizophrenia, in which variation at the SNP rs1047631 
significantly influences Dystrobrevin binding protein 1 (DTNBP1) expression (Bray 
et al. 2005).  Notably, the APOE ε4 allele increases AD risk (Farrer et al. 1997).  Cis-
acting variation has also been shown in IPD brains.  Variation at the polymorphism 
rs356219 significantly influences SNCA expression and IPD susceptibility (Fuchs et 
al. 2008; Mueller et al. 2005), and the H1 haplotype significantly increases 4R MAPT 
expression and IPD risk (Williams-Gray et al. 2009a; Healy et al. 2004b). 
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1.3. Concluding remarks 
Idiopathic Parkinson’s disease is a complex, multifactorial disorder: genes and 
environment are both involved in its genesis.  The extent of these factors’ individual 
roles and the specific interactions between them most likely vary from patient to 
patient.  This is exemplified by the considerable clinicopathological and molecular 
heterogeneity observed in IPD cases, which supports the hypothesis that IPDD and 
DLB are situated at opposing ends of a Lewy body disease spectrum.  Much has been 
learned about the molecular aetiopathogenesis of PD in general, primarily from the 
identification of genes that cause familial forms of this condition.  However, at this 
point very little is known about the molecular determinants that drive cognitive 
impairment and dementia in PD.  Monogenic mutation in SNCA, SNCB, and LRRK2 
can result in familial Lewy body dementia, and alleles in GBA, MAPT, and APOE are 
believed to alter the susceptibility to cognitive dysfunction in IPD.  Nevertheless, if 
we wish to elucidate the processes underlying these complex phenotypes, significant 
inroads must still be made.  Listed below are three broad questions that highlight 
current gaps in our knowledge of the molecular aetiopathogenesis of IPDD: 
 
1. Which genes and genetic pathways demonstrate dysregulated expression in 
the brains of demented compared with nondemented IPD patients? 
2. Can eQTLs be identified that influence the expression of these genes? 
3. Does variation at these polymorphisms associate with IPD dementia and/or 
neurodegeneration? 
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Chapter 2: Materials and Methods 
2.1. Chemicals and prepared solutions 
Unless stated otherwise, all chemicals were obtained from Sigma, UK, all primers 
were obtained from Sigma-Genosys, UK, all 1.5 ml microfuge tubes were obtained 
from Axygen, USA, all falcon tubes were obtained from VWR, UK, and all 96-well 
plates and adhesive covers were obtained from ABgene, UK. 
 
The following solutions were prepared in milliQ H2O (mqH2O): 
 
2x Orange G gel loading dye 
Glycerol 50% by volume 
Orange G dye to colour 
 
10x Tris-Borate-Ethylendiaminetetraacetate (TBE) 
1 M Trizma base 
1 M Boric acid (anhydrous) 
20 mM Ethylendiaminetetraacetate (EDTA) 
pH to 8.3 
 
 
2.2. Agarose gel electrophoresis 
DNA was resolved on agarose gels.  Agarose (Roche Diagnostics GmbH, Germany) 
was dissolved in 1x TBE and ethidium bromide added (to 0.5 µg/ml) before 
polymerisation.  DNA in solution was mixed 1:1 with 2x Orange G dye before 
loading.  Hyperladder II or V DNA ladder (Bioline, UK) was run on each gel.  Gels 
were visualised and photographed using the Gene Genius digital camera system and 
GeneSnap v4.0.0 (both from SynGene, UK). 
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2.3. Quantitative reverse transcriptase-
polymerase chain reaction 
2.3.1. Case and control sample selection 
Flash-frozen post mortem brain samples from unrelated individuals were obtained 
from the Queen Square Brain Bank for Neurological Disorders (QSBBND).  Ethical 
approval was gained from both the National Hospital for Neurology and 
Neurosurgery (NHNN) Local Research Ethics Committee (LREC) (reference: 
06/Q0512/11), and the Research and Development Department of University College 
London Hospital (UCLH) (reference: 06L 306).  All QSBBND samples had been 
previously been acquired with informed consent, and almost exclusively from people 
of European ancestry.  Idiopathic Parkinson’s disease (IPD) cases had been diagnosed 
both clinically and neuropathologically.  Controls had been confirmed by 
neuropathological exam as free of any neurological condition. 
 
Two distinct tissue sets were collected, each from a different group of individuals.  
The first, called the IPD cognitive series, enabled the comparison the gene expression 
between three groups: idiopathic Parkinson’s disease dementia (IPDD), idiopathic 
Parkinson’s disease no dementia (IPDND), and controls.  This series was employed 
for the IPD cognitive expression analysis (see 2.10.2.2), the cis-acting variation 
analysis (see 2.10.5), and validation of IPD cognitive expression microarray hits (see 
2.10.6.2).  IPD cases were segregated into IPDD and IPDND according to two 
measures, both based upon a report of cognitive impairment or change in personality 
by a family member or General Practitioner.  The first measure (termed “COG”) was 
scored as 1 if the patient had presented with such symptoms within two years of IPD 
diagnosis.  The second (termed “V25”) was scored as 1 if such symptoms presented 
at any time after that point.  Cases scoring either 1 in V25 or 1 in both COG and V25 
were placed into the IPDD group.  Cases scoring 0 in both COG and V25 were placed 
into the IPDND group.  Where possible, cases were selected upon whom a mini 
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mental state examination (MMSE) had been performed, and whose results agreed 
with the COG and V25 scores (or in cases where the result did not agree, had been 
performed at least 5 years before death).  Two exclusion criteria were employed: 
cases were to have no family history of Parkinson’s disease (PD); cases were to have 
no pathology indicative of any neurological condition except PD.  Tissue from two 
brain regions obtained from the same individuals was collected for this series: the 
dorsolateral prefrontal cortex (DLPFC) (Brodmann area 46 [BA46]) and the angular 
gyrus (AG) in the inferior parietal cortex (IPC) (BA39).  AG tissue was unavailable 
for two individuals (C19/93 and P12/95).  Cerebellum tissue was also collected for 
each individual in order to extract genomic DNA (gDNA) (see 2.6.2) for single 
nucleotide polymorphism (SNP) genotyping (see 2.6.3) as part of the cis-acting 
variation analysis (see 2.10.5), as well as from two other individuals so as to generate 
quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) standard and 
calibrator complementary DNA (cDNA) (see 2.3.3).  Individual clinicopathological 
data for the cognitive series samples can be seen in table 2.1. 
 
The second tissue set, called the IPD mapping series, facilitated the comparison of 
gene expression between IPD cases and controls.  This was used for the IPD 
expression mapping analyses (see 2.10.2.2).  Note that IPD cases were not segregated 
according to dementia status.  Tissue samples were collected for the mapping series 
from the following seven brain regions obtained from the same individuals: medulla, 
putamen, amygdala, entorhinal cortex (EC) (BA28), anterior cingulate cortex (ACC) 
(BA24), AG (BA39), and frontal cortex (FC) (BA8).  Not all regions were available 
for all individuals.  Due to low availability of medulla tissue, several individuals were 
replaced for this brain region.  The mapping series samples were extracted and 
quantified (see 2.3.2) in collaboration with Simone Sharma from our laboratory.  
Table 2.2 shows individual clinicopathological data for the mapping series samples. 
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2.3.2. Ribonucleic acid extraction and quantification 
Total ribonucleic acid (RNA) was extracted from human brain samples using TRIzol 
(Invitrogen, UK), according to the manufacturer’s instructions.  Before starting the 
protocol, all surfaces and pipettes were cleaned with Ribonuclease (RNase) AWAY 
(Invitrogen, UK).  All centrifugation steps were performed at 4ºC.  Between 
extractions, homogenisation glass tubes were scrubbed with detergent and thoroughly 
washed with tap H2O (tH2O) to remove any brain material, then rinsed with 70% 
ethanol followed by mqH2O. 
 
For each extraction, a frozen piece of brain approximately 1 cm3 in size was 
homogenised in a clean glass tube containing 1 ml of ice-cold TRIzol using a dounce 
homogeniser.  The homogenate was transferred to a 2 ml phase-lock tube (Eppendorf, 
UK).  200 µl chloroform was added and the tube was shaken vigorously by hand 
before being centrifuged at 12 000 g for 15 minutes.  The upper aqueous phase 
(above the phase lock gel barrier) was then transferred to a sterile 2 ml screw cap O-
ring tube (Starstedt, UK).  RNA was precipitated by adding 500 µl propan-2-ol 
(molecular biology grade).  The tube was mixed by inversion and incubated at room 
temperature for 10 minutes.  The tube was centrifuged at 12 000 g for 10 minutes and 
the supernatant aspirated.  The pellet was then washed by adding 1 ml 70% ethanol 
(molecular biology grade) and inverting.  The tube was centrifuged at 7 500 g for  
5 minutes and the supernatant aspirated.  The pellet was air-dried (sealed over with 
perforated Parafilm to avoid contamination) and resuspended in 100-200 µl H2O pre-
treated with diethyl pyrocarbonate (DEPC) (Ambion, UK).  Sample RNAs were 
stored at –80ºC.  RNA concentration and quality was assessed using the NanoDrop 
ND-1000 (NanoDrop Technologies, USA), enabling the identification of samples 
contaminated with protein or other organic compounds. 
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2.3.3. Complementary DNA synthesis 
Complementary DNA was generated from total RNA using the SuperScript II 
Reverse Transcriptase system (Invitrogen, UK), according to the manufacturer’s 
instructions.  All pipettes and surfaces were cleaned with RNAse AWAY.  Sample 
cDNA synthesis batches were carried out on a region-by-region basis, each batch 
comprising all of the IPD and control RNA samples extracted for that region. 
Standard curve and calibrator cDNA were produced in multiple simultaneous 
reactions using RNA extracted from one of four different IPD cases (see 2.3.4).  
Individual RNAs were diluted to 500 ng/µl and plated out onto 96-well plates for ease 
of manipulation. 
 
First strand cDNA synthesis reactions were performed in a total volume of 40 µl.  For 
each reaction, 2 µg total RNA was mixed with DEPC-treated H2O, 6 µg random 
hexamer primers, and deoxynucleotide triphosphates (dNTPs) (to 0.5 mM for each 
dNTP) and added to a 96-well plate.  The plate was sealed and heated to 65ºC for  
5 minutes, before being briefly chilled on ice and centrifuged.  10x first strand buffer, 
dithiothreitol (DTT) (to 10 mM), and 80 U RNaseOUT were added.  The reaction 
was mixed by pipetting and incubated at 25ºC for 2 minutes.  400 U SuperScript II 
enzyme was added and mixed in by gentle pipetting.  The plate was incubated as 
follows: 25ºC for 10 minutes; 42ºC for 50 minutes; 70ºC for 15 minutes.  It was then 
stored at 4ºC until further processing.  Sample cDNA reactions were diluted 10-fold 
with mqH2O, and stored in deep-well 96-well plates at –80ºC or 4ºC, avoiding 
multiple freeze/thaw cycles.  For standard curve/calibrator cDNA, multiple reactions 
were pooled and diluted 2-fold with mqH2O (to generate the neat standard curve) and 
then diluted a further 10-fold with mqH2O (to generate the calibrator), all of which 
were aliquotted and stored at –20ºC or 4ºC, avoiding multiple freeze/thaw cycles. 
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2.3.4. Quantitative reverse transcriptase-polymerase 
chain reaction procedure 
Quantitative RT-PCR was carried out in real time using the Power Sybr Green system 
on an Applied Biosystems 7500 machine running the absolute quantification protocol 
in 9600 emulation mode (both from Applied Biosystems, UK), according to the 
manufacturer’s instructions.  All plates comprised a six-point cDNA standard curve 
(to enable quantification), a nontemplate control (NTC), a calibrator (to ensure 
similar Ct [cycle threshold] values between multiple plates quantifying the same 
gene), and IPD/control cDNA samples.  All reactions were performed in triplicate 
(technical replicates).  Multiple plates analysing expression of the same gene in each 
brain region (termed qRT-PCR runs) were all measured on the same day using the 
same Power Sybr Green/mqH2O/primer mix.  Reference genes were treated as 
independent target genes i.e. their expression was quantified using a separate mix in a 
separate run.  Complementary DNA generated from the same individual was used as 
the standard curve and calibrator samples for each run.  Runs quantifying cognitive 
series cDNA samples used one of three IPD cases as standards/calibrators: P27/00 
cerebellum cDNA, P01/02 BA46 cDNA, or P45/94 BA46 cDNA (the latter solely for 
Dual specificity phosphatase 6 [DUSP6] 1:3 splice form runs).  Runs quantifying 
mapping series cDNA samples used as standards/calibrators IPD case P27/00 
cerebellum cDNA for DUSP6, and P35/00 cerebellum cDNA for Ephrin receptor A2 
(EPHA2) and α-Synuclein (SNCA).  Six-point standard curves were freshly generated 
for each run, by making serial dilutions of standard cDNA in mqH2O, producing the 
following dilutions: neat; 1:5; 1:25; 1:125; 1:250; 1:500. 
 
Amplification was performed in 25 µl reaction volumes.  For each reaction, Power 
Sybr Green Master Mix was mixed with forward and reverse primers (each to  
900 nM).  The mixture was then made up to 20 µl with mqH2O and pipetted into a 
96-well Optical Reaction polymerase chain reaction (PCR) plate (Applied 
Biosystems, UK).  5 µl of standard curve cDNA, calibrator cDNA, IPD/control 
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cDNA sample, or NTC (mqH2O) was added to the relevant wells.  The plate was 
sealed with an Optical Adhesive Cover (Applied Biosystems, UK).  Runs for both 
target genes and reference genes utilised one of five different sets of conditions 
(based on the annealing temperatures of the relevant primer pairs).  All types of 
conditions were immediately followed by a dissociation curve stage, in order to 
confirm that only one amplicon was being generated.  This consisted of bringing the 
plate up to 95ºC for 15 seconds, down to 60ºC for 1 minute, and then up to 99ºC, 
ramping 1ºC at a time, and remaining at each temperature for 15 seconds.  The five 
sets of cycling conditions are listed as follows (data acquisition steps in bold): 
 
55ºC 
50ºC for 2 minutes 
95ºC for 10 minutes 
95ºC for 15 seconds 
55ºC for 30 seconds 
72ºC for 45 seconds 
 
60ºC      64ºC 
50ºC for 2 minutes    50ºC for 2 minutes 
95ºC for 10 minutes    95ºC for 10 minutes 
95ºC for 15 seconds    95ºC for 15 seconds 
60ºC for 45 seconds    64ºC for 45 seconds 
 
62ºC      66ºC 
50ºC for 2 minutes    50ºC for 2 minutes 
95ºC for 10 minutes    95ºC for 10 minutes 
95ºC for 15 seconds    95ºC for 15 seconds 
62ºC for 45 seconds    66ºC for 45 seconds 
 
40 cycles 40 cycles 
40 cycles 
40 cycles 40 cycles 
40 cycles 
40 cycles 
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Tables 2.3 and 2.4 show the qRT-PCR annealing temperatures and primer sequences 
used to amplify each target and reference gene.  As an added check to ensure that 
only one amplicon was being produced in each qRT-PCR run, amplified DNA from 
one well was resolved on 4% agarose gels. 
 
 
 
 
Gene Class 
Annealing 
temperature 
(ºC) 
Gene Class 
Annealing 
temperature 
(ºC) 
ALAS2 Target 66 PTGDS Target 60 
APOA5 FL Target 60 PUM1 Target 60 
APOA5 1:3 Target 62 SNCA Target 62 
ARC Target 60 STAT4 Target 60 
BDNF Target 55 STAU1 Target 60 
CHI3L1 Target 55 UQCRFS1 Target 62 
DUSP6 FL Target 60 ZNF407 FL Target 60 
DUSP6 1:3 Target 62 ZNF407 4:6 Target 62 
EIF2AK4 Target 55 G6PD Reference 62 
EPHA2 Target 64 HPRT1 Reference 55 
ETS1 Target 64 NEFH Reference 62 
PISD Target 60 RPL13A Reference 55 
POU4F3 Target 62 TBP Reference 60 
 
Table 2.3. qRT-PCR annealing temperatures. 
The annealing temperatures used for the 26 genes assayed by qRT-PCR.  Class columns indicate 
whether the gene was a target or a reference gene.  Annealing temperatures indicate which of the five 
different sets of conditions apply (see text for details).  In cases where qRT-PCR was employed to 
distinguish specific splice forms, the gene name is followed either by FL, or by the exons flanking the 
skipped exon (separated by a colon).  See list of abbreviations for gene symbol definitions.  1:3 = 
splice form 1:3; 4:6 = splice form 4:6; FL = full length; qRT-PCR = quantitative reverse transcriptase-
polymerase chain reaction. 
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Table 2.4. qRT-PCR primer sequences. 
The qRT-PCR primer sequences and generated amplicon sizes (in bp) (below and following pages).  
Sense and antisense are in terms of the direction of transcription (except for POU4F3).  Primers 
annealing across an exon-exon boundary are indicated by naming the two relevant exons (separated by 
a dash).  Primers were designed based on information available from Ensembl (releases 36, 44, and 48 
from December 2005, April 2007, and December 2007 respectively), and BLASTed in Ensembl to 
ensure the production of a single predicted amplicon.  In cases where qRT-PCR was employed to 
distinguish specific splice forms, the gene name is followed either by FL, or by the exons flanking the 
skipped exon (separated by a colon).  See list of abbreviations for gene symbol definitions.  1:3 = 
splice form 1:3; 4:6 = splice form 4:6; bp = base pairs; FL = full length; qRT-PCR = quantitative 
reverse transcriptase-polymerase chain reaction. 
 
Gene 
(amplicon 
size in bp) 
Primer 
Annealing 
location 
Primer sequence (5’ to 3’) 
Sense Exon 9-10 TGTGGAGAAGCTGCTGCTGG ALAS2 
(117) Antisense Exon 10 TCCCACTCACTCATGAGCTC 
Sense Exon 1-2 CTTCTTTCAGCGTTTTCGGC APOA5 FL 
(109) Antisense Exon 2 CCATCTTCTGCTGATGGATC 
Sense Exon 1 TAATGGCAAGCATGGCTGCC APOA5 1:3 
(57) Antisense Exon 1-3 AGGGTCCTGAAAGAAGAGCC 
Sense Exon 2 CCCGCCTGGAGAAGAATCA ARC 
(137) Antisense Exon 2-3 TTGAGACCTGTTGTCACTCT 
Sense Exon 4 AATATGTAAGGAATGCTTGG BDNF 
(130) Antisense Exon 4 CACTTAACAGATCTGGCC 
Sense Exon 6 GAAGGCCGAATTTATAAAGG CHI3L1 
(122) Antisense Exon 6-7 GGTGTTGGGATATCTTGGC 
Sense Exon 1-2 TACCTGGAAGGTGGCTTCAG DUSP6 FL 
(162) Antisense Exon 2 AAGGTCAGACTCGATGTCCG 
Sense Exon 1 ACACAGTGGTGCTCTACGAC DUSP6 1:3 
(132) Antisense Exon 1-3 GGGCTTCATCTTCCAGGTAG 
Sense Exon 26-27 GAGGAATCTGTTACAATAAG EIF2AK4 
(148) Antisense Exon 27-28 CCTCTTGGGACTGTGAC 
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Gene 
(amplicon 
size in bp) 
Primer 
Annealing 
location 
Primer sequence (5’ to 3’) 
Sense Exon 15-16 TTGACCCCCGCGTGTCTATC EPHA2 
(144) Antisense Exon 16 TCTCGATGGCAGTGTAGCCG 
Sense Exon 2-3 CTGGGGATCCCAAAAGACCC ETS1 
(132) Antisense Exon 3 GCAGAGGGCTGCTCCATTCA 
Sense Exon 6 CCGCGTCGTGTGACTCCTTC PISD 
(157) Antisense Exon 6-7 ATCAGGGAGCCTGGGAAGTG 
Sense Exon 1-2 CCGCAGCTGCAGGGTAATAT POU4F3 
(109) Antisense Exon 1 TGAACGGATGGTTCTTGCCG 
Sense Exon 2-3 CCTTCCTCAGGAAAAACCAG PTGDS 
(86) Antisense Exon 3 GGGACTCCGGTAGCTGTAG 
Sense Exon 10 CAGCTGTGGTCCCTCACCAG PUM1 
(158) Antisense Exon 10-11 ACGGAGAACCTGCTGCTGTC 
Sense Exon 3-4 TGGCAACAGTGGCTGAGAAG SNCA 
(134) Antisense Exon 4 TTTGACAAAGCCAGTGGCTG 
Sense Exon 20-21 TCTGAAAGTGGGGAAGTGAG STAT4 
(105) Antisense Exon 21 TTGTAGTCTCGCAGGATGTC 
Sense Exon 4-5 TATCCCCCGAGGTACTTTTA STAU1 
(157) Antisense Exon 5 TCTGCAGGATCCTCAACGC 
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Gene 
(amplicon 
size in bp) 
Primer 
Annealing 
location 
Primer sequence (5’ to 3’) 
Sense Exon 1 TGTCGCCATGTTGTCGGTAG UQCRFS1 
(233) Antisense Exon 1-2 CAGAAGCAGGGACATTGAGG 
Sense Exon 5 CGAGAAGTCGTTTCTGTGTG ZNF407 FL 
(89) Antisense Exon 5-6 TTTCTCCTGTGTGCTGTCTG 
Sense Exon 4 AAATGTACCTGGCCCACGTG ZNF407 4:6 
(82) Antisense Exon 4-6 TTTCTCCTGTGTGCGTCCTG 
Sense Exon 3-4 CCACCATCTGGTGGCTGTTC G6PD 
(113) Antisense Exon 4 GAAGGGCTCACTCTGTTTGC 
Sense Exon 3 TGAACGTCTTGCTCGAGAT HPRT1 
(188) Antisense Exon 3-4 GGTCATTACAATAGCTCTTC 
Sense Exon 4 GATAACTGAGTACCGGCGTC NEFH 
(146) Antisense Exon 4-5 GCTGAATGGCTTCCTGGTAG 
Sense Exon 6 GATATAATTGACACTGGCAA RPL13A 
(89) Antisense Exon 6-7 AGCAAGCTTGCGACCTTGA 
Sense Exon 4-5 TAATCCCAAGCGGTTTGCTG TBP 
(112) Antisense Exon 5-6 CTGTTCTTCACTCTTGGCTC 
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2.4. Splicing reverse transcriptase-polymerase 
chain reaction 
Splicing RT-PCR was used to identify alternative splice forms in cognitive series 
DLPFC (BA46) cDNA (see 2.3.1).  RNA extraction, RNA quantification, and cDNA 
synthesis were performed as for qRT-PCR (see 2.3.2 and 2.3.3).  Amplification was 
carried out in 25 µl reaction volumes using MolTaq polymerase (Molzym, Germany), 
according the manufacturer’s instructions.  For each reaction, 10x Taq buffer was 
mixed with enhancer solution, dNTPs (to 0.2 mM for each dNTP), forward and 
reverse primers (each to 600 nM), and 1U Taq polymerase.  This mixture was then 
made up to 23 µl with mqH2O and pipetted into a 96-well plate.  2 µl of IPD/control 
BA46 cDNA sample, positive control (P27/00 cerebellum cDNA), or negative control 
(mqH2O) was added to the relevant wells.  The plate was cycled as follows and then  
6 µl of each reaction resolved on 3% agarose gels: 
 
94ºC for 2 minutes 
94ºC for 1 minute 
62ºC for 1 minute 
72ºC for 1 minute 
72ºC for 7 minutes 
 
Splicing RT-PCR Primers were designed based on information available from 
Ensembl (release 41 from October 2006), and BLASTed in Ensembl to ensure the 
production of a single predicted amplicon.  Splicing RT-PCR primer sequences were 
as follows (predicted amplicon size in brackets after gene name; sense and antisense 
opposite to direction of transcription; annealing location in brackets after primer 
sequence): 
 
DUSP6 (193 bp): 
Sense  5’- TACCTGGAAGATGAAGCCCG -3’ (exon 1-3) 
Antisense 5’- GCAGCTGACCCATGAAGTTG -3’ (exon 1) 
30 cycles 
 88 
2.5. Deoxyribonucleic acid sequencing 
2.5.1. Case and control samples 
Deoxyribonucleic acid sequencing was employed to identify mutations in familial 
Parkinson’s disease (FPD) cases.  Blood samples from FPD patients (n = 82) and 
control individuals (n = 83) were used for this purpose.  All samples had been 
obtained previously with informed consent from individuals almost exclusively of 
European ancestry.  FPD patients had been diagnosed clinically with PD and 
possessed at least one first-degree relative also diagnosed clinically with PD.  Control 
individuals had been confirmed clinically as free of any neurological condition.  No 
further clinicopathological information was available for these individuals.  Where 
available, blood samples acquired from first-degree relatives were used to ascertain 
whether novel mutations segregated with FPD.  Genomic DNA extraction and 
quantification had been performed by members of the NHNN Neurogenetics Service 
team using a similar protocol as that employed for SNP genotyping (see 2.6.2). 
 
 
2.5.2. Sequencing polymerase chain reaction and 
cleanup 
Sequencing PCR was carried out in 25 µl reaction volumes using MolTaq polymerase 
(Molzym, Germany), according the manufacturer’s instructions.  For each reaction, 
10x Taq buffer was mixed with enhancer solution, dNTPs (to 0.2 mM for each 
dNTP), forward and reverse primers (each to 600 nM), and 1U Taq polymerase.  This 
mixture was then made up to 24 µl with mqH2O and pipetted into a 96-well plate.   
50 ng PD/control gDNA sample or 1 µl of negative control (mqH2O) was added to 
the relevant wells.  The plate was cycled as follows: 
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61.5ºC 
94ºC for 2 minutes 
94ºC for 30 seconds 
61.5ºC for 45 seconds 
72ºC for 45 seconds 
72ºC for 7 minutes 
 
Table 2.5 show the sequencing PCR primer sequences.  In order to demonstrate that 
PCR had occurred successfully, 5 µl of each reaction was resolved on 3% agarose 
gels.  PCR reaction cleanup was performed using 96-well MultiScreen PCR Cleanup 
Filter plates (Millipore, UK), according to the manufacturer’s instructions.  For each 
reaction, the remaining 20 µl was mixed with 80 µl mqH2O and added to a PCR 
Cleanup Filter plate.  The mixture was then pulled through the filter using a vacuum 
manifold.  The cleaned PCR product was resuspended in 30 µl mqH2O by shaking at 
room temperature for 15 minutes and stored at –20ºC. 
30 cycles 
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Amplicon 
(size 
in bp) 
Primer Primer sequence (5’ to 3’) 
Sense TGTAAAACGACGGCCAGTGGGAGGGGAGGGTTAAGG Upstream 
(531) Antisense CAGGAAACAGCTATGACCGCGAGGCAGCTCCTCAAT 
Sense TGTAAAACGACGGCCAGTTCATCAACACAACCTGTTCCA 
1A (504) 
Antisense CAGGAAACAGCTATGACCTAATTCCGCCTCGCCTTAC 
Sense TGTAAAACGACGGCCAGTGAGAGAGATTCATTGACACTAAGAGC 
1B (432) 
Antisense CAGGAAACAGCTATGACCCACGTTGATGGCCGACTC 
Sense TGTAAAACGACGGCCAGTGAAATGGCGATCAGCAAGAC 
1C (493) 
Antisense CAGGAAACAGCTATGACCTGAGCGGAGCAGAGGTATTT 
Sense TGTAAAACGACGGCCAGTAGATGATTGCTTTTCTCGTTCT 
2 (535) 
Antisense CAGGAAACAGCTATGACCAAATGTCAGAGCGACGACTATTA 
Sense TGTAAAACGACGGCCAGTGGGTGGTTTTCAGTCTGCTG 
3A (514) 
Antisense CAGGAAACAGCTATGACCCAGACAGCTGGTGTCATTTTG 
Sense TGTAAAACGACGGCCAGTGTCTGGCCCTTCAGCAGTT 
3B (533) 
Antisense CAGGAAACAGCTATGACCCACTGTCAAGTGATTCAAGATCAA 
Sense TGTAAAACGACGGCCAGTGAGGAGCCAAAGAGAGATTTCA 
3C (500) 
Antisense CAGGAAACAGCTATGACCGAGCCCATGATTTGGTGTCT 
 
Table 2.5. DUSP6 DNA sequencing PCR primer sequences. 
Dual specificity phosphatase 6 DNA sequencing PCR primer sequences and generated amplicon sizes 
(in bp).  Amplicon numbers correspond to exon numbers (in the direction of transcription).  Generally 
only exons (including both coding regions, UTRs, and some flanking intronic sequence) were 
amplified.  The last ~330 bp of the 3’UTR was not amplified.  Where exons were too large to allow 
successful dideoxy sequencing in one reaction, multiple overlapping amplicons were generated 
separately (labelled “1A”, “1B”, etc.).  The “Upstream” amplicon covers ~420 bp immediately 
upstream of the transcription start site.  Sense and antisense are in terms of the direction of 
transcription.  Bold text indicates the portion of primer sequences that are M13 tag (see 2.5.3).  Primers 
were designed using Primer3 (Rozen and Skaletsky 2000) based on information available from 
Ensembl (release 45 from June 2007), and BLASTed in Ensembl to ensure the production of a single 
predicted amplicon.  bp = base pairs; DUSP6 = Dual specificity phosphatase 6; PCR = polymerase 
chain reaction; UTR = untranslated region. 
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2.5.3. Dideoxy sequencing 
Dideoxy sequencing was carried out in 10 µl reaction volumes using BigDye 
Terminator v1.1 (Applied Biosystems, UK), according to the manufacturer’s 
instructions.  For each reaction, 1 µl BigDye Terminator v1.1 reagent was mixed with 
10x BigDye buffer and either the M13 sense or antisense primer (to 350 nM) (see 
below).  This mixture was then made up to 6.5 µl with mqH2O and pipetted into a 96-
well plate.  3.5 µl of PD/control clean sequencing PCR product was added to the 
relevant wells.  The plate was cycled as follows and stored at –20ºC wrapped in 
aluminium foil: 
 
96ºC for 10 seconds 
50ºC for 5 seconds 
60ºC for 4 minutes 
 
In order to simplify the dideoxy reaction protocol, all sequencing primers possessed 
the relevant M13 tag sequence (sense or antisense as appropriate) at their 5’.  The 
M13 sense primer was initially used to perform dideoxy sequencing for all DUSP6 
amplicons.  Due to unclear sequencing data, the M13 antisense primer was initially 
utilised to sequence DUSP6 amplicon 2.  Deviations from the human reference 
sequence were confirmed by bidirectional resequencing in those specific samples, 
bringing the total coverage to 2x in the sense direction and 2x in the antisense 
direction.  The M13 primer sequences were as follows: 
 
Sense  5’- TGTAAAACGACGGCCAGT -3’ 
Antisense 5’- CAGGAAACAGCTATGACC -3’ 
25 cycles 
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2.5.4. Dideoxy cleanup and capillary electrophoresis 
Dideoxy reaction cleanup was carried out using 96-well Dye Terminator Removal 
plates (Abgene, UK), according to the manufacturer’s instructions.  Dye Terminator 
Removal plates were cleared of storage buffer by centrifugation at 950 g at room 
temperature for 3 minutes.  For each reaction, 10 µl dideoxy reaction was mixed with 
10 µl mqH2O and added to a pre-cleared Dye Terminator Removal plate.  The 
mixture was pulled through the plate filter into a 96-well plate by centrifugation at 
950 g at room temperature for 3 minutes.  Cleaned dideoxy reactions were then 
sequenced by capillary electrophoresis using a 3730XL DNA Analyzer running the 
BigDye v1.1 protocol (Applied Biosystems, UK).  Sequencing data was imported into 
SeqScape v2.5 (Applied Biosystems, UK) for analysis.  Reference sequence was 
obtained from Ensembl (release 45 from June 2007). 
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2.6. Single nucleotide polymorphism genotyping 
2.6.1. Case and control samples 
Four different sample series were used for SNP genotyping: the two IPD association 
series for the purpose of SNP association analysis (see 2.10.3.2), the imaging series 
for the purpose of genotypic voxel-based morphometry (VBM) analysis (see 2.10.4), 
and the IPD cognitive series for the purpose of cis-acting variation analysis (see 
2.10.5).  All samples had been obtained previously with informed consent from 
individuals almost exclusively of European ancestry. 
 
For all association studies, the IPD case groups were combinations of pathologically-
diagnosed QSBBND cerebellum samples and clinically-diagnosed blood samples.  
These had been extracted previously by members of the NHNN Neurogenetics 
Service team.  For the DUSP6 and EPHA2 association studies, the control groups 
were blood samples obtained from individuals who were confirmed clinically as free 
of any neurological condition, but who had been diagnosed with familial 
hypercholesterolaemia.  These controls were a kind gift of Prof. Steve Humphries 
(Rayne Institute, University College London [UCL]), and had been extracted 
previously by members of Prof. Humphries’ laboratory.  For the SNCA association 
study, the control group was a combination of cerebellum samples confirmed 
neuropathologically as free of any neurological condition and blood samples obtained 
from individuals who were confirmed clinically as free of any neurological condition.  
These controls were a kind gift of Dr. Jana Vandrovcova (Rita Lila Weston Institute, 
UCL), and had been extracted previously Dr. Vandrovcova.  Table 2.6 shows group 
clinical data for the IPD association study series samples. 
 
The imaging series comprised normal control blood samples obtained from 
individuals who had been confirmed clinically as free of any neurological condition.  
These samples had been collected and extracted previously by Dr. Geoffrey Tan in 
our laboratory.  Group demographic data for the imaging series is shown in table 2.7.  
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QSBBND cerebellum tissue obtained from the cognitive series was used for the cis-
acting variation analysis (see 2.3.1).  These samples had been extracted previously by 
members of the NHNN Neurogenetics Service team. 
 
 
 
Table 2.6. IPD association study series clinical data. 
a. DUSP6 and EPHA2 association series group clinical data (below).  In the IPD group, 319 were brain 
samples and 295 were blood samples.  Disease duration values for IPD blood samples were measured 
at a cut-off date in 2003.  All of the controls were blood samples.  Measures of time are in years.  CON 
= control; IPD = idiopathic Parkinson’s disease; NA = not applicable; SD = standard deviation. 
 
Group (n) % males Statistic 
Age of 
onset 
Age of 
donation 
Disease 
duration 
Mean NA 47.6 NA CON (619) 49.6 
SD NA 15.1 NA 
Mean 60.1 75.1 13.9 
IPD (614) 58.3 
SD 11.1 8.3 8.3 
 
b. SNCA association series group clinical data (below).  In the IPD group, 319 were brain samples and 
386 were blood samples; in the CON group these counts were 94 and 478, respectively.  Disease 
duration values for IPD blood samples were measured at a cut-off date in 2003.  Measures of time are 
in years.  CON = control; IPD = idiopathic Parkinson’s disease; NA = not applicable; SD = standard 
deviation. 
 
Group (n) % males Statistic 
Age of 
onset 
Age of 
donation 
Disease 
duration 
Mean NA 38.7 NA CON (572) 50.7 
SD NA 8.2 NA 
Mean 57.4 72.0 14.1 
IPD (705) 58.1 
SD 12.9 11.5 8.8 
 
 
 
Group (n) 
% 
males 
Statistic Age of scan 
Mean 31.6 CON (302) 45.4 
SD 12.2 
 
Table 2.7. Imaging series demographic data. 
Group demographic data for the imaging series.  Age of donation is measured in years.  CON = 
control; SD = standard deviation. 
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2.6.2. Genomic DNA extraction and quantification 
Genomic DNA was extracted from human cerebellum samples using the Wizard 
Genomic DNA Purification Kit (Promega, UK), according to the manufacturer’s 
instructions.  All centrifugation steps were performed at room temperature.  For each 
extraction, 960 µl 0.5 M EDTA was added to 4 ml Nuclei Lysis Solution and chilled 
on ice until cloudy.  4.8 ml of this mixture was added to a frozen piece of brain 
approximately 1 cm3 in size in a 15 ml falcon tube.  140 µl proteinase K (at  
20 mg/ml) was added and the tube incubated at 55ºC for 16 hours until the brain was 
completely digested.  24 µl RNAse Solution was added to the nuclear lysate and 
mixed in by inversion.  The tube was incubated at 37ºC for 30 minutes and then 
allowed to cool to room temperature for 5 minutes.  200 µl Protein Precipitation 
Solution was added and the tube vortexed vigorously for 20 seconds.  The tube was 
chilled on ice for 5 minutes and centrifuged at 12 000 g for 4 minutes.  The 
supernatant was carefully transferred to a new 15 ml falcon containing 4.8 ml propan-
2-ol (molecular biology grade).  The tube was gently mixed by inversion to 
precipitate the DNA and then centrifuged at 12 000 g for 1 minute.  The supernatant 
was carefully decanted and the pellet was washed by adding 4.8 ml 70% ethanol 
(molecular biology grade).  The tube was centrifuged at 12 000 g for 1 minute.  The 
ethanol was carefully aspirated and the pellet air-dried (sealed over with perforated 
Parafilm avoid contamination).  The pellet was resuspended in 800 µl DNA 
Rehydration Solution and incubated at room temperature for 16 hours.  The DNA 
solution was transferred to a sterile 2 ml screw cap O-ring tube and stored at 4ºC until 
further processing.  DNA concentration and quality were assessed using the 
NanoDrop ND-1000, enabling the identification of samples contaminated with 
protein or other organic compounds.  Sample gDNAs were diluted to 50 ng/µl and 
stored in 96-well plates at –20ºC or 4ºC, avoiding multiple freeze/thaw cycles.  Blood 
gDNA extraction and quantification were carried out using a similar protocol. 
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2.6.3. TaqMan allelic discrimination genotyping 
Allelic discrimination genotyping was carried out in 5 µl reaction volumes in 384- or 
96-well Optical Reaction PCR plates using the TaqMan system (all from Applied 
Biosystems, UK), according to the manufacturer’s instructions.  IPD/control gDNA 
samples and negative controls (mqH2O) were plated out and left to evaporate 
overnight.  2.5 ng gDNA was used for EPHA2 SNPs; 5 ng gDNA was used for all 
other SNPs.  For each reaction, 2.5 µl TaqMan Genotyping Master Mix was mixed 
with 0.125 µl of the relevant TaqMan SNP Genotyping Assay and 2.375 µl mqH2O 
and pipetted into the plate, which was sealed with an Optical Adhesive Cover 
(Applied Biosystems, UK).  The plate was cycled as follows and stored at –20ºC 
wrapped in aluminium foil: 
 
95ºC for 10 minutes 
92ºC for 15 seconds 
60ºC for 60 seconds 
 
Alleles were subsequently called using allelic discrimination protocols run on an 
Applied Biosystems 7900HT machine (384-well plates) or an Applied Biosystems 
7500 machine (96-well plates) (both from Applied Biosystems, UK).  Table 2.8 
shows information about the SNPs interrogated by TaqMan genotyping. 
40 cycles 
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Gene 
(chromosome) 
SNP identity 
[DNA base 
ambiguity] 
Chromosomal 
location 
HapMap 
CEPH 
MAF 
rs11105262 [C/G] 88263586 0.068 
rs770087 [A/C]* 88268904 0.150 
rs2279574 [A/C]* 88269608 0.388 
DUSP6 (12) 
rs1689408 [C/T] 88278032 0.076 
rs3754334 [G/A] 16324354 0.292 
rs10907223 [G/A] 16332332 0.067 
rs6603855 [T/C] 16333128 0.102 
rs2230597 [G/A] 16337260 0.412 
rs11260822 [T/C] 16358398 0.356 
EPHA2 (1) 
rs4661717 [T/G] 16368501 0.093 
rs11931074 [G/T] 90858538 0.100 
SNCA (4) 
rs3822086 [C/T] 90883817 NA 
 
Table 2.8. TaqMan allelic discrimination SNP assays. 
SNPs genotyped by TaqMan allelic discrimination.  SNP identities, CEPH DNA base ambiguities 
(positive strand), and CEPH MAFs were obtained from HapMap phase II (release 23a from March 
2008).  DNA base ambiguity shows the major allele first (single letter codes in accordance with the 
International Union of Biochemistry and Molecular Biology).  Chromosomal locations are according 
to NCBI assembly build 36.  All SNPs were genotyped using predesigned TaqMan assays, except 
those marked with a *, for which custom assays were designed using File Builder v3.1 (software 
downloaded from Applied Biosystems, UK).  The rs11931074 assay was a kind gift of Dr. Anna 
Melchers in our laboratory.  CEPH = Centre d’Étude du Polymorphisme Humain; DUSP6 = Dual 
specificity phosphatase 6; EPHA2 = Ephrin receptor A2; MAF = minor allele frequency; NCBI = 
National Center for Biotechnology Information; SNP = single nucleotide polymorphism; NA = not 
applicable; SNCA = α-Synuclein. 
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2.7. Structural magnetic resonance imaging 
T1-weighted anatomical brain images were obtained using a Siemens 1.5 Tesla 
magnetic resonance imaging (MRI) scanner.  Images had been acquired previously 
from the imaging series (see table 2.7) with informed consent.  All scans were 
performed by Dr. Geoffrey Tan. 
 
 
2.8. Expression microarray 
2.8.1. Case and control sample selection 
The aim of the expression microarray was to compare genome wide gene expression 
and alternative splicing between three groups: IPDD, IPDND, and controls.  
Therefore, post mortem QSBBND tissue obtained from cognitive series individuals 
was used for this purpose (see 2.3.1).  However, financial constraints restricted the 
analysis to only a subset of the original series in only one brain region (the DLPFC 
[BA46]).  Members of the IPD microarray series were selected based on RNA 
quality.  Previously-extracted RNA (see 2.3.2) was assessed by capillary 
electrophoresis using the RNA 6000 Nano LabChip Kit on an Agilent 2100 
Bioanalyzer (both from Agilent, UK).  Those samples demonstrating clean 18S and 
28S ribosomal RNA (rRNA) peaks and a minimum of low molecular weight 
degraded RNA were selected.  Individual clinicopathological data and RNA quality 
graphs for the microarray series can be seen in table 2.9 and the Appendix, 
respectively.  All RNA quality assessments and microarray procedures were 
performed by members of the Gene Microarray Centre (Institute of Child Health, 
UCL). 
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2.8.2. Microarray procedure 
Genome wide expression and splicing were examined using GeneChip Human Exon 
1.0 Sense Target (ST) oligonucleotide microarrays (Affymetrix, UK), according to 
the manufacturer’s instructions.  Independent probe sets span each annotated exon, 
enabling investigation of both differential gene expression and alternative exon 
splicing.  Unless stated otherwise, all kits and equipment were obtained from 
Affymetrix, UK and tubes were kept on ice at all times.  All procedures refer to the 
processing of one RNA sample. 
 
Poly(A) RNA Controls were generated with the GeneChip Poly(A) RNA Control Kit 
and added to 2 µg total RNA, producing the Total RNA/Poly(A) RNA Controls Mix.  
Ribosomal RNA was reduced from the Total RNA/Poly(A) RNA Controls Mix by 
hybridisation and magnetic isolation using the RiboMinus Concentration Module Kit 
(Invitrogen, UK).  Ribosomal RNA-Reduced Total RNA/Poly(A) RNA Controls Mix 
was cleaned and concentrated by spin column with the GeneChip In Vitro Translation 
(IVT) complementary RNA (cRNA) Cleanup Kit, and then eluted in ~9.8 µl RNAse-
free H2O (rfH2O).  RNA quality and rRNA reduction were assessed using the Agilent 
2100 Bioanalyzer (see 2.8.1). 
 
T7-(N)6 Primers were generated with the GeneChip Whole Transcript cDNA 
Synthesis Kit and 500 ng added to 4 µl rRNA-Reduced Total RNA/Poly(A) RNA 
Controls Mix, producing the Total RNA/Poly(A) RNA Controls/T7-(N)6 Primers 
Mix.  First cycle cDNA synthesis was performed using the GeneChip Whole 
Transcript cDNA Synthesis Kit.  First strand synthesis was carried out by mixing all 
of the Total RNA/Poly(A) RNA Controls/T7-(N)6 Primers Mix with first strand 
buffer, DTT (to 10 mM), dNTPs (to 0.5 mM each dNTP), 0.5 µl RNase Inhibitor, 1 µl 
SuperScript II enzyme, and incubating as follows: 25ºC for 10 minutes; 42ºC for  
60 minutes; 70ºC for 10 minutes; 4ºC for not more than 10 minutes.  Second strand 
synthesis was performed by mixing all of the first strand synthesis reaction with 
MgCl2 (to 3.5 mM), dNTPs (to 0.2 mM for each dNTP), 0.6 µl DNA Polymerase I, 
 100 
0.2 µl RNase H, rfH2O, and incubating as follows: 16ºC for 120 minutes; 75ºC for  
10 minutes; 4ºC for not more than 10 minutes. 
 
cRNA was synthesised at 37ºC for 16 hours using the GeneChip Whole Transcript 
cDNA Amplification Kit, cleaned and concentrated by spin column with the 
GeneChip Sample Cleanup Module, and then eluted in ~13.5 µl rfH2O.  RNA 
concentration was assessed using the NanoDrop ND-1000.  Second cycle cDNA 
synthesis (first strand only) was carried out using the GeneChip Whole Transcript 
cDNA Synthesis Kit by mixing 10 µg cRNA with 4.5 µg Random Primers and rfH2O 
and incubating as follows: 70ºC for 5 minutes; 25ºC for 5 minutes; 4ºC for at least  
2 minutes.  First strand buffer, DTT (to 10 mM), deoxyuridine triphosphate (dUTP) 
and dNTPs (each dNTP and dUTP to 0.625 mM), and 4.75 µl SuperScript II enzyme 
were mixed with the reaction and incubated as follows: 25ºC for 10 minutes; 42ºC for 
90 minutes; 70ºC for 10 minutes; 4ºC for at least 2 minutes.  cRNA was hydrolysed at 
37ºC for 45 minutes with RNase H enzyme using the GeneChip Whole Transcript 
cDNA Synthesis Kit.  The remaining single-stranded DNA (ssDNA) was cleaned by 
spin column with the GeneChip Sample Cleanup Module and eluted in ~28 µl cDNA 
Elution Buffer.  DNA concentration was assessed using the NanoDrop ND-1000. 
 
ssDNA fragmentation and biotin-labelling were performed using the GeneChip 
Whole Transcript Terminal Labeling Kit.  5.5 µg ssDNA was fragmented at 37ºC for 
60 minutes with 1000 U Apurinic/Apyrimidinic endonuclease 1 (APE1) and 10 U 
Uracil DNA glycosylase (UDG).  DNA fragmentation was assessed using the Agilent 
2100 Bioanalyzer (see 2.8.1).  Fragmented ssDNA was biotin-labelled at 37ºC for 60 
minutes with 60 U Terminal deoxynucleotidyl transferase (TdT) and DNA Labeling 
Reagent (to 83 µM).  Hybridisation and microarray washing and staining were carried 
out using the GeneChip Hybridization, Wash and Stain Kit.  Fragmented and labelled 
ssDNA was injected into a microarray and incubated in a hybridisation oven at  
60 rpm and 45ºC for 16 hours.  Several cycles of washing and streptavidin-staining 
were performed, before scanning the microarray with a GeneChip Scanner 3000 7G. 
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2.9. Methyl-specific polymerase chain reaction 
2.9.1. Case and control sample selection 
The aim of the methyl-specific PCR (MSP) was to compare levels of relative CpG 
methylation in the DUSP6 putative promoter (DPP) between IPD patients and control 
individuals.  Therefore, post mortem DLPFC (BA46) QSBBND tissue obtained from 
cognitive series individuals was used for this purpose (see 2.3.1).  Six IPD cases 
(three IPDD and three IPDND) and six control individuals were selected.  This choice 
was based on the qRT-PCR results for DUSP6 in the DLPFC, whereby the IPD cases 
had relatively high expression and the control individuals had relatively low 
expression.  Previously-extracted blood gDNA from one hereditary motor and 
sensory neuropathy (HMSN) patient was used as a positive control.  Table 2.10 
shows individual clinicopathological data for the IPD MSP series samples. 
 
 
2.9.2. Genomic deoxyribonucleic acid extraction and 
quantification 
Genomic DNA was extracted from brain tissue using the QIAamp DNA Mini Kit 
(Qiagen, UK), according to the manufacturer’s instructions.  All centrifugation steps 
were performed at room temperature.  Buffers AW1 and AW2 were prepared by 
resuspending the concentrate in 25 ml and 30 ml ethanol (molecular biology grade) 
respectively.  For each extraction, 25 mg frozen brain was homogenised by hand in a 
1.5 ml microfuge tube containing 80 µl 1x phosphate-buffered saline (PBS).  100 µl 
Buffer ATL and 20 µl proteinase K were added and the tube was mixed by vortexing.  
The tube was incubated at 56ºC for 2 hours (vortexing occasionally to disperse the 
sample) until the brain was completely digested.  The tube was then briefly 
centrifuged.  200 µl Buffer AL was added and the tube was mixed by vortexing for  
15 seconds.  The tube was incubated at 70ºC for 10 minutes and briefly centrifuged.  
 104 
200 µl ethanol (molecular biology grade) was added.  The tube was mixed by 
vortexing for 15 seconds and briefly centrifuged.  The contents of the tube (including 
any precipitate) were carefully applied to a QIAamp Mini spin column (in a 2 ml 
collection tube), which was then centrifuged at 6000 g for 1 minute.  The collection 
tube was discarded and replaced with a fresh collection tube.  The column was 
washed by adding 500 µl Buffer AW1, before being centrifuged at 6000 g for  
1 minute.  The flow-through was discarded.  500 µl Buffer AW2 was added to the 
column, which was centrifuged at 20 000 g for 3 minutes.  The collection tube was 
emptied and returned to the column, which was then cleared of residual wash buffer 
by centrifugation at 20 000 g for 1 minute.  The column was placed in a clean 1.5 ml 
microfuge tube.  100 µl Buffer AE was added to the column, which was incubated at 
room temperature for 5 minutes.  DNA in solution was eluted by centrifugation at 
6000 g for 1 minute.  The addition of Buffer AE and subsequent centrifugation were 
repeated twice to increase DNA yield.  DNA concentration and quality were assayed 
using the NanoDrop ND-1000, enabling the identification of samples contaminated 
with protein or other organic compounds.  Sample gDNAs were stored at –20ºC or 
4ºC, avoiding multiple freeze/thaw cycles. 
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2.9.3. Bisulphite conversion and cleanup 
Sample gDNA was bisulphite-converted and cleaned using the EpiTect Bisulphite Kit 
(Qiagen, UK), according to the manufacturer’s instructions.  All centrifugation steps 
were performed at room temperature.  Buffers BW and BD were prepared by adding 
30 ml and 27 ml ethanol (molecular biology grade) respectively.  Bisulphite Mix was 
prepared by resuspending the concentrate in 800 µl rfH2O and vortexing vigorously 
until completely dissolved.  For each conversion, 500 ng sample gDNA was pipetted 
into a 96-well plate and made up to 20 µl with rfH2O.  85 µl Bisulphite Mix was 
added, followed by 25 µl DNA Protect Buffer.  The plate was sealed and vortexed 
vigorously, before being briefly centrifuged.  The plate was then incubated as 
follows: 99ºC for 5 minutes; 60ºC for 25 minutes; 99ºC for 5 minutes; 60ºC for  
85 minutes; 99ºC for 5 minutes; 60ºC for 175 minutes; 20ºC overnight.  The plate 
was centrifuged briefly and the reaction transferred to a 1.5 ml microfuge tube.   
560 µl Buffer BL was added and the mixture was vortexed and briefly centrifuged, 
before being carefully applied to an EpiTect spin column (with collection tube).  The 
column was centrifuged at 20 000 g for 1 minute and the flow-through discarded.  
Converted DNA was washed by adding 500 µl Buffer BW and centrifuging at  
20 000 g for 1 minute.  The flow-through was discarded.  DNA desulphonation was 
achieved by adding 500 µl Buffer BD and incubating at room temperature for  
15 minutes, followed by centrifugation at 20 000 g for 1 minute.  The flow-through 
was discarded.  DNA was washed a further two times by adding 500 µl Buffer BW, 
centrifuging at 20 000 g for 1 minute, and discarding the flow-through.  The column 
was cleared of residual wash buffer by centrifugation at 20 000 g for 5 minutes.  The 
column was placed in a clean 1.5 ml microfuge tube.  20 µl Buffer EB was added to 
the column and DNA in solution was eluted by centrifugation at 15 000 g for  
1 minute.  DNA yield was increased by adding a further 20 µl Buffer EB to the 
column and centrifuging it at 20 000 g for 1 minute.  DNA concentration and quality 
were assayed using the NanoDrop ND-1000, enabling the identification of samples 
contaminated with protein or other organic compounds.  Clean bisulphite-converted 
sample gDNA was stored at –20ºC. 
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2.9.4. Methyl-specific polymerase chain reaction 
procedure 
Reactions was carried out in 15 µl volumes using HotStarTaq Plus polymerase 
(Qiagen, UK), according the manufacturer’s instructions with guidance from a 
published protocol (Herman et al. 1996).  Two different E Twenty-Six (ETS) family 
binding sites in the DPP were interrogated with regard to their CpG methylation 
status.  Bisulphite-converted gDNA from each individual was subjected to two 
separate amplification reactions at each site, achieved using different combinations of 
primers.  One reaction was specific for methylated alleles, while the other was 
specific for unmethylated alleles.  For each reaction, 10x Taq buffer was mixed with 
Q solution, dNTPs (to 1.25 mM for each dNTP), forward and reverse primers (each 
to 1 µM), and 1U HotStarTaq Plus polymerase.  This mixture was then made up to 11 
µl with mqH2O and pipetted into a 96-well plate.  4 µl of IPD/control bisulphite-
converted BA46 gDNA sample, positive control (bisulphite-converted HMSN blood 
gDNA), or negative control (mqH2O) was added to the relevant wells.  The plate was 
cycled as follows: 
 
ETS1-binding site A    ETS1-binding site B 
95ºC for 5 minutes    95ºC for 5 minutes 
94ºC for 30 seconds    94ºC for 30 seconds 
48ºC for 30 seconds    51ºC for 30 seconds 
72ºC for 45 seconds    72ºC for 45 seconds 
72ºC for 10 minutes    72ºC for 10 minutes 
 
Table 2.11 shows the primer sequences for each MSP reaction at each location in the 
DPP.  13 µl of each reaction was resolved on 3% agarose gels. 
 
40 cycles 40 cycles 35 cycles 
 
10
8 
  
E
T
S
 b
in
d
in
g
 s
it
e 
(d
is
ta
n
ce
 r
el
a
ti
v
e 
to
 
D
U
S
P
6
 T
S
S
 i
n
 b
p
) 
A
m
p
li
co
n
 
si
ze
 (
b
p
) 
P
ri
m
e
r 
(M
/U
 a
ll
el
e 
sp
ec
if
ic
it
y
) 
P
ri
m
e
r 
se
q
u
en
ce
 (
5
’ 
to
 3
’)
 
S
en
se
 (
M
) 
C
T
A
A
A
A
T
A
C
C
C
T
A
A
T
T
T
A
T
A
T
A
C
C
C
T
A
C
T
C
 
95
 
A
nt
is
en
se
 (
M
) 
A
A
A
T
A
A
G
T
T
G
T
A
A
T
A
G
C
G
G
G
T
T
C
G
G
C
 
S
en
se
 (
U
) 
C
T
A
A
A
A
T
A
C
C
C
T
A
A
T
T
T
A
T
A
T
A
C
C
C
T
A
C
T
C
 
A
 (
-1
92
) 
99
 
A
nt
is
en
se
 (
U
) 
G
T
G
T
A
A
A
T
A
A
G
T
T
G
T
A
A
T
A
G
T
G
G
G
T
T
T
G
G
 
S
en
se
 (
M
) 
G
T
A
T
T
G
G
G
G
T
T
T
A
T
T
C
G
G
A
G
C
 
19
4 
A
nt
is
en
se
 (
M
) 
A
A
A
C
A
A
C
T
C
C
T
C
A
A
T
A
A
A
T
A
C
A
A
A
C
A
A
 
S
en
se
 (
U
) 
T
T
T
G
T
A
T
T
G
G
G
G
T
T
T
A
T
T
T
G
G
A
G
T
 
B
 (
-1
36
) 
19
7 
A
nt
is
en
se
 (
U
) 
A
A
A
C
A
A
C
T
C
C
T
C
A
A
T
A
A
A
T
A
C
A
A
A
C
A
A
 
 T
a
b
le
 2
.1
1
. 
M
S
P
 p
ri
m
er
 s
eq
u
en
ce
s.
 
M
S
P
 p
ri
m
er
s 
se
qu
en
ce
s 
an
d 
ge
ne
ra
te
d 
am
pl
ic
on
s 
si
ze
s 
(i
n 
bp
).
  
T
he
 n
um
be
rs
 i
n 
th
e 
fi
rs
t 
co
lu
m
n 
re
pr
es
en
t 
th
e 
di
st
an
ce
 b
et
w
ee
n 
th
e 
re
le
va
nt
 D
P
P
 E
T
S
 b
in
di
ng
 
si
te
 a
nd
 t
he
 T
S
S
 o
f 
D
U
S
P
6
 (
ne
ga
ti
ve
 v
al
ue
s 
in
di
ca
te
 t
ha
t 
th
e 
si
te
s 
ar
e 
up
st
re
am
 i
n 
th
e 
di
re
ct
io
n 
of
 t
ra
ns
cr
ip
ti
on
) 
(s
ee
 a
ls
o 
fi
gu
re
 4
.1
1)
. 
 P
ri
m
er
s 
w
er
e 
de
si
gn
ed
 
us
in
g 
M
et
hP
ri
m
er
 (
L
i 
an
d 
D
ah
iy
a 
20
02
) 
ba
se
d 
on
 i
nf
or
m
at
io
n 
av
ai
la
bl
e 
fr
om
 E
ns
em
bl
 (
re
le
as
e 
48
 f
ro
m
 D
ec
em
be
r 
20
07
).
  
F
or
 s
it
e 
B
, s
en
se
 a
nd
 a
nt
is
en
se
 a
re
 i
n 
te
rm
s 
of
 t
he
 d
ir
ec
ti
on
 o
f 
tr
an
sc
ri
pt
io
n,
 w
he
re
as
 f
or
 s
it
e 
A
, t
he
 o
pp
os
it
e 
is
 t
ru
e 
(n
ot
e 
th
at
 D
U
S
P
6
 i
s 
tr
an
sc
ri
be
d 
fr
om
 t
he
 n
eg
at
iv
e 
st
ra
nd
).
  
T
o 
re
du
ce
 v
ar
ia
bi
li
ty
, 
on
e 
pr
im
er
 w
as
 c
om
m
on
 t
o 
th
e 
m
et
hy
la
te
d 
al
le
le
-s
pe
ci
fi
c 
an
d 
un
m
et
hy
la
te
d 
al
le
le
-s
pe
ci
fi
c 
re
ac
ti
on
 f
or
 e
ac
h 
E
T
S
 b
in
di
ng
 s
it
e:
 t
hi
s 
w
as
 t
he
 s
en
se
 p
ri
m
er
 f
or
 s
it
e 
A
, a
nd
 t
he
 a
nt
is
en
se
 p
ri
m
er
 f
or
 s
it
e 
B
.  
bp
 =
 b
as
e 
pa
ir
s;
 D
U
S
P
6
 =
 D
u
a
l 
sp
ec
if
ic
it
y 
p
h
o
sp
h
a
ta
se
 6
; 
D
P
P
 =
 D
U
S
P
6
 p
ut
at
iv
e 
pr
om
ot
er
; 
E
T
S
 =
 E
 T
w
en
ty
-S
ix
; 
M
S
P
 
=
 m
et
hy
l-
sp
ec
if
ic
 p
ol
ym
er
as
e 
ch
ai
n 
re
ac
ti
on
; M
 =
 m
et
hy
la
te
d;
 T
S
S
 =
 tr
an
sc
ri
pt
io
na
l s
ta
rt
 s
it
e;
 U
 =
 u
nm
et
hy
la
te
d.
 
 
 109 
2.10. Data analysis 
2.10.1. Multiple testing correction methodology 
In order to reduce the chance of statistical false positives, correction for multiple 
testing was employed throughout this thesis.  The Bonferroni approach was mostly 
used, although family-wise error (FWE) and the less severe false discovery rate 
(FDR) were selected for the genotypic VBM (see 2.10.4) and expression microarray 
analyses (see 2.10.6.1), respectively [reviewed in (Shaffer 1995)].  In addition, the in 
silico microarray mining results (see 2.10.6.3) were uncorrected due to prior 
hypothesis (Rothman 1990).  The overall Bonferroni strategy was to correct within 
each experimental type on a chapter-by-chapter basis e.g. correcting across all the 
qRT-PCR statistical tests in chapter 3 (i.e. cognitive expression analysis, DUSP6 full 
length [FL] and 1:3 expression analysis, DUSP6 expression mapping analysis, 
DUSP6 cis-acting variation analysis) generated a correction factor of 45. 
 
 
2.10.2. Quantitative reverse transcriptase-polymerase 
chain reaction 
2.10.2.1. Raw data processing and normalisation 
Quantitative RT-PCR (see 2.3.4) raw expression data were generated with Applied 
Biosystems 7500 System Software v1.4 (Applied Biosystems, UK).  The standard 
curve method was employed, which entails the use of said curves to generate raw 
expression values from Ct values (Giulietti et al. 2001).  If the standard curve  
r
2 < 0.95, outlying standard curve data points were removed before reanalysis.  
Dissociation curves were checked to ensure the existence of only one PCR product 
above the data acquisition temperature, or the relevant data points were excluded 
from the analysis.  Triplicates were examined to ensure that the Ct standard deviation 
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(SD) < 0.5 (or that the Ct of two replicates differed by < 0.5) for each sample, or the 
relevant sample was excluded from the analysis.  The arithmetic mean of the raw 
expression values for each triplicate was calculated and used as the raw expression 
value for that sample. 
 
Potential reference genes were selected based upon statistical modelling performed 
on experimental gene expression data (Szabo et al. 2004).  For each brain region, the 
expression of multiple reference genes was quantified and raw data processed as 
above.  The geometric mean of the raw expression values for these reference genes 
was calculated on a sample-by-sample basis; this value was termed the normalisation 
factor (NF) (Vandesompele et al. 2002).  In certain instances, geNorm v3.5 was used 
to generate optimal sets of reference genes.  It achieves this by calculating the 
average pairwise variation of a particular reference gene with all other reference 
genes (the stability measure, M).  The optimal set contains those reference genes that 
are most stable across all samples i.e. that have the lowest M values (Vandesompele 
et al. 2002).  Expression data was normalised on a sample-by-sample basis, by 
dividing the raw target gene expression value by the NF.  As each qRT-PCR run 
comprised two plates, the mean of this normalised dataset was calculated, and each 
value divided by the mean in order to distribute the values around 1, producing a set 
of final relative expression data for each target gene in each brain region.  NF group 
mean and 95% confidence interval (CI) values were calculated and examined to 
ensure comparability of final relative target gene expression between disease groups. 
 
 
2.10.2.2. Idiopathic Parkinson’s disease cognitive and 
mapping expression analyses 
Final relative expression data were imported into SPSS v12.0.1 (SPSS Inc., USA) for 
statistical analysis.  Data were grouped according to sample type (IPDD, IPDND, 
IPD, or control) and analysed on a gene-by-gene and region-by-region basis.  
Clustered boxplots were drawn, and extreme outliers (datapoints further than three 
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SD from the group mean) were removed from the analysis.  Shapiro-Wik and 
Kolmogorov-Smirnov tests were used to check the data for normality.  Given that the 
data for almost all genes were found not to exhibit normal distribution, two-tailed 
Mann-Whitney tests were used to analyse qRT-PCR expression data throughout this 
thesis.  Bonferroni-corrected p values ≤ 0.05 were taken as significantly different.  
Mean expression with 95% CI was plotted in Excel (Microsoft, USA), as appropriate. 
 
Groups were also compared with regard to age of onset, age of death, disease 
duration, post mortem delay (PMD), brain pH, and MMSE, as appropriate.  This was 
performed according to the method outlined above, except that three group 
comparisons were carried out by two-tailed Kruskal-Wallis test.  Bonferroni-
corrected p values ≤ 0.05 were taken as significantly different.  Post hoc statistical 
power calculations were carried out using an online tool, as appropriate 
(www.stat.ubc.ca/~rollin/stats/ssize/n2.html).  In one instance, clinicopathological 
data were correlated using the two-tailed Spearman’s rho coefficient, and scatter plots 
were generated.  Bonferroni-corrected p values ≤ 0.05 were taken as significantly 
different. 
 
 
2.10.3. Idiopathic Parkinson’s disease single 
nucleotide polymorphism association 
2.10.3.1. Haplotype tagging 
Haplotype tagging SNPs (htSNPs) were generated as follows.  Genotypes of common 
(minor allele frequency [MAF] ≥ 0.05) polymorphic SNPs were downloaded for 
Centre d’Étude du Polymorphisme Humain (CEPH) trios (Utah residents with 
ancestry from northern and western Europe) from HapMap phase II (release 23a from 
March 2008) (Frazer et al. 2007).  Pairwise tagging was performed using Tagger (de 
Bakker et al. 2005) in Haploview v4.0 (Barrett et al.
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locus haplotype r2 ≥ 0.8.  Linkage disequilibrium (LD) plots were generated using 
Haploview. 
 
 
2.10.3.2. Single nucleotide polymorphism association 
analysis 
Single nucleotide polymorphisms were genotyped by TaqMan allelic discrimination 
(see 2.6.3).  Genotypic data were grouped according to disease status (IPD or control) 
and imported into Haploview v4.0 for statistical analysis on a gene-by-gene basis.  
Two-tailed exact tests were employed to identify deviations from the Hardy-
Weinberg equilibrium (HWE) (Wigginton et al. 2005).  Uncorrected p values ≤ 0.05 
were taken as significant deviation from HWE.  Haplotypes were inferred using an 
accelerated expectation-maximisation (EM) algorithm similar to the partition-ligation 
method (Qin et al. 2002), as appropriate.  Statistical assessments of allelic and 
haplotypic association were carried out by two-tailed χ2 test under a multiplicative 
model.  This states that the genotype relative risk of one homozygote is the square of 
genotype relative risk of the heterozygote, if the other homozygote is taken as 
reference (Lewis 2002).  Bonferroni-corrected p values ≤ 0.05 were taken as 
significantly different.  Odds ratios (ORs) with 95% confidence interval (CI) were 
estimated based on the null hypothesis (also known as the Peto OR) using an online 
calculator (Bland and Altman 2000).  Post hoc statistical power calculations were 
carried out using the CaTS software, as appropriate (Skol et al. 2006). 
 
 
2.10.4. Genotypic voxel-based morphometry 
Single nucleotide polymorphisms were genotyped by TaqMan allelic discrimination 
(see 2.6.3).  Deviation from HWE was assessed in Haploview (see 2.10.3.2).  
Genotypic VBM analysis (Ashburner and Friston 2000) was carried out using the 
statistical parametrical mapping 5 (SPM5) software package (Functional Imaging 
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Laboratory, Institute of Cognitive Neuroscience, UCL) on Matlab 7 (The Mathworks, 
USA) by Dr. Geoffrey Tan.  MRI images were segmented using a unified 
segmentation procedure (Ashburner and Friston 2005) to obtain grey matter 
probability maps, spatially normalised into Montreal Neurological Institute (MNI) 
space with a fast diffeomorphic algorithm (Ashburner 2007), and modulated and 
smoothed with a 12 mm full width at half maximum (FWHM) isotropic Gaussian 
kernel.  Individuals were grouped by SNP genotype, and the groups subjected to 
voxel-wise comparisons of grey matter density, based on a generalised linear model.  
Brain regions of interest (ROIs) were selected based on differential expression in the 
expression analyses (see 2.10.2.2), expression in the mouse brain according to the 
Allen Mouse Brain Atlas (Lein et al. 2007), or a well-established role in IPD 
[reviewed in (Lees et al. 2009)].  Brain ROIs were used to generate a mask, which 
was applied to the data, producing the ROI analysis.  The global analysis was 
subsequently generated by examining changes in grey matter density across the entire 
brain unconstrained by prior hypothesis.  Statistical comparisons were performed by 
two-tailed t test, with significance set at corrected p < 0.05.  The FWE approach was 
employed in accordance with random field theory to correct for multiple testing 
across the brain [reviewed in (Shaffer 1995)].  Associated regions were located based 
on their MNI coordinates using the WFU PickAtlas tool (Lancaster et al. 2000; 
Maldjian et al. 2003) in Matlab 7. 
 
 
2.10.5. Cis-acting variation analysis 
Single nucleotide polymorphisms were genotyped by TaqMan allelic discrimination 
(see 2.6.3).  Deviation from HWE was assessed in Haploview (see 2.10.3.2).  Final 
relative expression data (see 2.10.2.1) were grouped by genotype and imported into 
SPSS v12.0.1 for statistical analysis.  Extreme outliers were removed as in the 
cognitive and mapping expression analyses (see 2.10.2.2).  If the SNP MAF was so 
low that the minor allele homozygote group only comprised a few individuals, this 
group was removed from the analysis.  Groups were compared by two-tailed Mann-
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Whitney or Kruskal-Wallis test.  Bonferroni-corrected p values ≤ 0.05 were taken as 
significantly different. 
 
 
2.10.6. Idiopathic Parkinson’s disease cognitive 
expression microarray analysis 
2.10.6.1. Data preprocessing, quality control, and analysis 
Expression microarray data was analysed in R v2.5.0 using the Bioconductor v2.0 
package Linear Modelling for Microarray Analysis (LIMMA) (Gentleman et al. 
2004).  Analysis was performed at both the exon and gene levels.  Data preprocessing 
was conducted using the robust multichip average (RMA) algorithm (Irizarry et al. 
2003), which consisted of three steps: background correction, summarisation, and 
normalisation.  In background correction, probes were adjusted (array by array) using 
a global model of probe intensity distribution.  This removed cross-hybridising 
probesets.  Summarisation used the median polish algorithm to combine data from 
several probes and generate exon and gene expression values.  In the case of exon 
level analysis, summarisation combined the multiple probe intensities for each 
probeset to produce a single expression value for each exon.  In the case of gene level 
analysis, multiple probeset (exon) intensities were combined to produce a single 
expression value for each transcript cluster (gene).  Mapping between probesets and 
transcript clusters was based on 17817 “core” RefSeq and full length Genbank 
mRNAs (obtained previously from the National Center for Biotechnology 
Information).  Quantile normalisation was employed to adjust the probeset intensity 
distributions, thus making microarrays comparable with each other. 
 
Microarray data quality control (QC) analysis was carried out to evaluate the extent to 
which valid conclusions could be drawn from the data.  Receiver operator curves 
were plotted to assess how well the summarisation method separated exonic 
(positive) and intronic (negative) controls present on each array.  Pairwise microarray 
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total fluorescence correlations were calculated, in order to identify chips outlying the 
others and evaluate overall array performance.  RNA and technique quality were 
assessed by plotting intensity distribution histograms.  MvA scatter plots were 
generated to gauge variation between biological replicates (i.e. samples in the same 
group). 
 
Log2 exon and gene expression were compared between the various groups (IPDD, 
IPDND, and controls) by modified t test incorporating Bayesian statistics.  For the 
exon level analysis, log2 probeset intensities were first normalised by log2 transcript 
cluster intensities to control for differential expression at the gene level.  For both 
levels, low expressing probesets and transcripts were then filtered out, and intergroup 
fold change and p values were calculated.  The FDR approach was used for multiple 
testing correction, with p < 0.05 taken as significantly different (Benjamini and 
Hochberg 1995).  Given the high levels of biological variation, uncorrected p < 0.01 
was employed as the significance threshold for identifying microarray hits (see 4.3.2).  
For the gene level analysis, principal components analysis plots were generated.  All 
microarray data analyses up to this point were performed by Dr. Sonia Shah at the 
Bloomsbury Centre for Bioinformatics (UCL).  Groups were also compared with 
regard to age of onset, age of death, disease duration, PMD, brain pH, and MMSE (as 
appropriate), according to the procedure outlined for the cognitive and mapping 
expression analyses (see 2.10.2.2).  Bonferroni-corrected p values ≤ 0.05 were taken 
as significantly different. 
 
 
2.10.6.2. Confirmation and validation 
Differential gene expression and alternative exon splicing events detected by the 
microarray were confirmed using the NetAffx (Liu et al. 2003) and X:Map (Yates et 
al. 2008) databases.  Dysregulation events involving expression below the signal-
noise cut-off point (5 units on the log2 fluorescence scale) were excluded from further 
analysis.  Gene ontology (GO) terms (release 24th January 2010) associated with 
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confirmed microarray hits were collected (Ashburner et al. 2000).  Validation by 
qRT-PCR was then attempted (see 2.3.4 and 2.10.2). 
 
 
2.10.6.3. In silico data mining 
The following bioinformatic resources were consulted to obtain lists of candidate 
genes: BioGRID, Kyoto Encyclopaedia of Genes and Genomes (KEGG), Online 
Mendelian Inheritance in Man (OMIM), PROMO (set to a maximum dissimilarity 
rate of 1%), Ensembl (release 48 from December 2007), and University of California 
Santa Cruz (UCSC) PhyloP (assembly hg18) (Kanehisa and Goto 2000; Messeguer et 
al. 2002; Siepel et al. 2006; Stark et al. 2006; Hubbard et al. 2007).  NetAffx was 
used to obtain transcript cluster identities for these candidates, and log2 microarray 
data were mined in silico.  Groups were then compared for candidate gene expression 
according to the procedure outlined for the cognitive and mapping expression 
analyses (see 2.10.2.2), except that statistical comparisons were carried out by t test 
or Mann-Whitney test (depending on distribution normality), and p values were not 
corrected for multiple testing because of prior hypothesis (Rothman 1990).  
Uncorrected p values ≤ 0.05 were taken as significantly different.  Selected hits 
arising from the microarray data mining were validated by qRT-PCR (see 2.3.4 and 
2.10.2). 
 
 
2.10.7. Identification of putative functional variants 
2.10.7.1. Elucidation of linkage disequilibrium 
Haploview was used to elucidate and plot fine scale pairwise r2 LD relationships in 
the SNCA locus.  This was based on SNP genotype data obtained for the SNCA IPD 
association study (see 2.10.3.2) and SNP genotype data obtained previously by Dr. 
Coro Paisán-Ruíz, from the laboratory of Dr. Andrew Singleton. 
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2.10.7.2. In silico data mining 
Single nucleotide polymorphisms putatively driving genetic association were 
identified as follows.  CEPH trio LD data for all the polymorphic SNPs in a defined 
ROI was downloaded from HapMap phase II (release 23a from March 2008).  The 
UCSC (assembly hg18 from March 2006) PhyloP database was mined for predicted 
interspecies DNA sequence conservation across 32 placental mammals at these SNP 
positions.  PhyloP computes predicted conservation based on a phylogenetic hidden 
Markov model.  Sites predicted to be conserved are assigned positive scores, whereas 
sites predicted to be fast-evolving are assigned negative scores.  The absolute values 
represent –log p values under a null hypothesis of neutral evolution.  The literature 
was mined for Caucasian and Asian IPD genetic association data pertaining to SNPs 
residing at positions assigned a positive score by PhyloP (Mueller et al. 2005; Mizuta 
et al. 2006; Ross et al. 2007a; Westerlund et al. 2008; Winkler et al. 2007), and SNPs 
displaying association with IPD were considered as putative functional variants. 
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Chapter 3: Idiopathic Parkinson’s disease 
cognitive expression analysis and genetic 
characterisation of Dual specificity 
phosphatase 6 
3.1. Introduction 
Parkinson’s disease (PD) is an incurable neurodegenerative disorder characterised 
clinically by bradykinesia, rigidity, resting tremor, and postural instability.  Its 
neuropathological hallmarks are dopaminergic cell death in the substantia nigra (SN) 
and cytoplasmic protein aggregates called Lewy bodies (LBs), of which accumulated 
α-synuclein is a major component [reviewed in (Lees et al. 2009)].  PD is frequently 
accompanied by dementia, and point prevalence is estimated to be 24-31% (Aarsland 
et al. 2005b).  Parkinson’s disease dementia (PDD) is defined as a progressive 
dysexecutive syndrome that impedes daily life.  Its neuropsychological features are 
marked deficits in working memory (WM), attention, verbal fluency, and visuospatial 
ability.  These symptoms are often accompanied by declarative memory impairment 
and behavioural disturbances [reviewed in (Goetz et al. 2008)].  There is much 
controversy over the neuropathological basis of PDD.  For example, dementia in PD 
has been significantly correlated with cortical LB load, cortical Alzheimer pathology 
severity, subcortical neuronal loss, and the degree of limbic system pathology 
(Aarsland et al. 2005a; Zweig et al. 1993; Bancher et al. 1993; Kalaitzakis et al. 
2009a). 
 
Monogenic mutation accounts for 5-10% of PD.  Similarities between these familial 
Parkinson’s disease (FPD) patients and the majority of cases, which are known as 
idiopathic Parkinson’s disease (IPD), suggest that they involve common molecular 
mechanisms [reviewed in (Schiesling et al. 2008)].  Mutations or multiplications in  
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α-Synuclein (SNCA), β-Synuclein (SNCB), and Leucine-rich repeat kinase 2 (LRRK2) 
can cause familial forms of PDD and the related condition dementia with Lewy 
bodies (DLB) (Zarranz et al. 2004; Ross et al. 2008a; Ohtake et al. 2004; Healy et al. 
2008).  Moreover, genetic variation in β-Glucocerebrosidase (GBA), Microtubule-
associated protein tau (MAPT), and Apolipoprotein E (APOE) can significantly alter 
the susceptibility to cognitive impairment and/or dementia in IPD (Sidransky et al. 
2009; Williams-Gray et al. 2009a; de Lau et al. 2005).  Importantly, several of these 
mutations and polymorphisms appear to influence gene expression in the human 
brain (Farrer et al. 2004; Williams-Gray et al. 2009a; Bray et al. 2004). 
 
In the current literature, only two reports specifically compare gene expression in IPD 
with and without dementia.  Genes encoding G-protein-coupled receptor kinases 
(GRKs) and arrestins are significantly overexpressed in the striatum of demented IPD 
patients contrasted against their nondemented counterparts (Bychkov et al. 2008).  
This is relevant to IPD as GRK-induced phosphorylation of SNCA at Ser129 may 
promote its accumulation and neurotoxicity in vivo (Chen and Feany 2005; Ihara et 
al. 2007).  The only published microarray study comparing IPD with and without 
dementia demonstrated that numerous genes are differentially-expressed in posterior 
cingulate cortex (PCC) neurons.  The findings indicate that idiopathic Parkinson’s 
disease dementia (IPDD) is associated with dysregulation of molecular pathways 
encompassing mitochondrial function, inflammation, cell adhesion, ribonucleic acid 
(RNA) splicing, and axonal transport (see 4.1 for more details) (Stamper et al. 2008). 
 
Working memory impairment is a central facet of the IPDD dysexecutive syndrome.  
Two brain regions involved in WM amongst normal controls have also been 
implicated in IPD cognitive dysfunction: Brodmann area 46 (BA46) in the 
dorsolateral prefrontal cortex (DLPFC), and the angular gyrus (AG [BA39]) in the 
inferior parietal cortex (IPC).  The DLPFC plays a role in the monitoring and 
manipulation of items held in WM (Petrides 2000).  Targeting the DLPFC with either 
repetitive transcranial magnetic stimulation (rTMS) or transcranial direct current 
stimulation (tDCS) significantly improves WM ability in nondemented IPD patients 
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(Boggio et al. 2005; Boggio et al. 2006).  Moreover, significantly greater atrophy of 
BA46 is observed in demented compared to nondemented IPD cases (Nagano-Saito 
et al. 2005).  The AG is involved in numerical and verbal WM (Gruber et al. 2001; 
Dronkers et al. 2004).  Cerebral blood flow (CBF) is significantly reduced in the AG 
of IPDD patients contrasted against controls (Firbank et al. 2003).  As yet, no studies 
have investigated IPDD gene expression in these two brain regions. 
 
In summary, PDD is characterised by executive dysfunction, including deficits in 
WM.  Some of the mutations and polymorphisms implicated in familial and 
idiopathic PDD appear to influence gene expression in the human brain.  Very few 
studies have investigated gene expression in IPDD, and to date none have examined 
the DLPFC and AG, two areas known to play a role in WM. 
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3.2. Aims and methodology 
Based on the background literature, it was hypothesised that there might be a 
relationship between IPD dementia status and target gene expression in the DLPFC 
and/or AG, and that target gene single nucleotide polymorphism (SNP) variation 
might influence IPD risk and gene expression.  Therefore, the aims and methodology 
of this chapter were as follows: 
 
1. Identify genes implicated in IPD dementia and/or neurodegeneration.   
Sybr Green quantitative reverse transcriptase-polymerase chain reaction (qRT-
PCR) (see 2.3.4) was employed to compare the messenger RNA (mRNA) 
expression of 10 target genes in complementary DNA (cDNA) generated (see 
2.3.3) from the IPD cognitive series (idiopathic Parkinson’s disease dementia 
[IPDD]; idiopathic Parkinson’s disease no dementia [IPDND]; controls) DLPFC 
(BA46) and AG (BA39) (see 2.3.1).  This was called the IPD cognitive 
expression analysis (see 2.10.2.2).  The three group study design enabled the 
discrimination of expression signatures associated with specific IPD subtypes i.e. 
IPD dementia, IPD neurodegeneration, or both (see figure 3.1).  Membership in 
the IPDD or IPDND group was assigned based on reported cognitive impairment 
and/or change in personality.  This was backed up by mini mental state 
examination (MMSE) scores where available; MMSE ≤ 27 was taken as 
indicative of dementia (see 2.3.1).  The DLPFC and AG were selected because of 
their involvement in WM and IPDD (see 3.1).  Target genes were selected based 
on a connection to working or long term memory (see 3.3.1).  In order to control 
for neuronal cell death and/or gliosis in IPD samples and for technical variation, 
target gene expression data were normalised with a normalisation factor (NF) 
calculated as the geometric mean of two reference genes: Ribosomal protein L13A 
(RPL13A) and TATA box binding protein (TBP) (see 2.10.2.1).  Only those targets 
exhibiting significant differential expression underwent further characterisation.  
For confirmatory purposes, a second batch of DLPFC cDNA (batch 2) was 
generated from the same RNA samples.  For batch 2, target gene expression data 
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were normalised with a NF calculated from the reference genes Glucose-6-
phosphate dehydrogenase (G6PD), RPL13A, and TBP.  This was termed “total” 
expression.  As an alternative approach to correct for neuronal cell death, 
“neuronal loss-corrected” (NLC) target gene expression data were normalised 
with a neuronal marker acting as the reference gene (Fuchs et al. 2008).  
Neurofilament H (NEFH) was selected for this purpose (Goldstein et al. 1983; 
Schulz et al. 2003; Lariviere and Julien 2004; Cahoy et al. 2008).  Where 
appropriate, splicing reverse RT-PCR was undertaken (with the products resolved 
on agarose gels) (see 2.4) and splice form-specific qRT-PCR reactions were 
performed (see 2.3.4).  Statistical comparisons were carried out by Mann-Whitney 
test, with significance set at corrected p ≤ 0.05 (see 2.10.2.2).  DLPFC and AG 
expression data were not compared with each other statistically. 
2. Examine target gene mRNA expression in multiple brain regions.  In an effort 
to provide a more extensive picture of expression, Sybr Green qRT-PCR was 
employed to compare total and NLC target gene mRNA expression in cDNA 
generated from seven subcortical and cortical brain regions obtained from the IPD 
mapping series (IPD; controls) (see 2.3.1).  The medulla, putamen, amygdala, 
entorhinal cortex (EC [BA28]), anterior cingulate cortex (ACC [BA24]), AG 
(BA39), and frontal cortex (FC [BA8]) were examined.  These brain areas were 
selected based on their susceptibility to Lewy pathology (LP) during the disease 
process (Braak et al. 2003).  Figure 3.2 shows the brain regions examined in the 
cognitive and mapping series.  Total expression data were normalised with a NF 
calculated from the most stable set of the following reference genes: G6PD, 
Hypoxanthine phosphoribosyltransferase 1 (HPRT1), RPL13A, and TBP.  These 
sets were determined on a region-by-region basis using geNorm (see 2.10.2.1).  
NLC expression data were normalised with the neuronal marker NEFH.  
Statistical comparisons were carried out by Mann-Whitney test, with significance 
set at corrected p ≤ 0.05 (see 2.10.2.2).  Brain area expression data were not 
compared with each other statistically. 
3. Investigate target gene involvement in FPD, IPD, and normal brain 
structure.  This aim consisted of three parts.  In order to identify target gene 
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mutations that segregate with FPD, patient, control, and first-degree patient 
relative (where available) genomic DNA (gDNA) was amplified by polymerase 
chain reaction (PCR) and dideoxy sequencing undertaken (see 2.5).  Where 
appropriate, Ensembl (release 45 from June 2007) and the PROMO online 
resource were employed for in silico transcription factor binding site (TFBS) 
prediction (see 2.10.6.3).  So as to ascertain whether target gene SNP variation 
influences IPD risk, a case-control genetic association study (see 2.10.3) was 
performed, by using HapMap phase II Centre d’Étude du Polymorphisme Humain 
(CEPH) trio genotypic data (release 23a from March 2008) and Tagger (see 
2.10.3.1) to generate haplotype-tagging single nucleotide polymorphisms 
(htSNPs), and TaqMan-genotyping (see 2.6.3) gDNA samples obtained from the 
IPD association series (IPD; controls) (see 2.6.1).  Statistical assessment of allelic 
association under a multiplicative model was carried out by χ2 test in Haploview 
with significance set at corrected p ≤ 0.05 (see 2.10.3.2).  In order to evaluate 
whether IPD-associated SNPs affect brain structure, genotypic voxel-based 
morphometry (VBM) analysis was performed.  This involved using structural 
magnetic resonance imaging (MRI) to acquire T1-weighted anatomical brain 
images (see 2.7) of the imaging series controls (see 2.6.1), TaqMan-genotyping 
their gDNA, and then employing statistical parametrical mapping (SPM) to carry 
out voxel-wise comparisons of grey matter density.  Statistical comparisons were 
performed by t test, with significance set at corrected p < 0.05 (see 2.10.4). The 
family-wise error (FWE) approach was used for multiple testing correction 
[reviewed in (Shaffer 1995)]. 
4. Investigate the effect of cis-acting SNP variation on target gene mRNA 
expression.  In order to ascertain whether SNP variation influences target gene 
expression, cis-acting variation analysis was carried out, by TaqMan-genotyping 
gDNA samples obtained from the cognitive series, and regrouping total and NLC 
DLPFC target gene mRNA expression data (batch 2) by genotype.  Statistical 
comparisons were performed by Mann-Whitney test, with significance set at 
corrected p ≤ 0.05 (see 2.10.5). 
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Figure 3.1. IPD cognitive expression analysis design. 
Diagrammatic representation of the three group IPD cognitive expression analysis design.  
Significantly different expression is required in two of the three intergroup comparisons (A, B, and C) 
to qualify target gene expression signature for association with an IPD subtype.  The associated 
subtype (IPD dementia, IPD neurodegeneration, or both) depends on the specific combination of said 
comparisons (see table for details).  CON = control; IPD = idiopathic Parkinson’s disease; IPDD = 
idiopathic Parkinson’s disease dementia; IPDND = idiopathic Parkinson’s disease no dementia. 
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Figure 3.2. Brain regions and structures of interest. 
(a) Sagittal aspect of and (b) coronal section through the human brain.  Regions and structures of 
interest are labelled, including those in which gene expression was quantified in the cognitive and 
mapping series (in red text).  Figure adapted from (Crossman and Neary 2005) with permission from 
the publisher.  BA = Brodmann area. 
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3.3. Results 
3.3.1. Idiopathic Parkinson’s disease cognitive 
expression analysis target gene selection 
Target selection was founded on the premise that genes involved in working or long 
term memory function might be differentially-expressed in IPDD individuals.  This 
idea stems from the “generalist brain” hypothesis, which proposes that variation in a 
specific set of genes affects many cognitive abilities and disabilities (Kovas and 
Plomin 2006).  Target genes were selected using a two step process.  The first step 
consisted of choosing numerous candidate targets from four sources (human 
orthologues of animal genes were used where appropriate): 
 
1. Genes that display altered expression in the murine hippocampus after 
contextual fear conditioning, as detected by expression microarray (Levenson 
et al. 2004). 
2. Genes that are mutated in Drosophila and mice impaired with regard to 
olfactory conditioning and spatial memory, respectively (Dubnau et al. 2003; 
Costa-Mattioli et al. 2005). 
3. Genes that exhibit differential expression in the hippocampus of mice doubly 
transgenic for human Lys670Asn, Met671Leu Amyloid precursor protein 
(APP) and Met146Leu Presenilin 1 (PSEN1), as detected by expression 
microarray and qRT-PCR (Dickey et al. 2003).  These mice display spatial 
WM impairment (Morgan et al. 2000). 
4. Genes that display altered expression in the hippocampus of individuals 
diagnosed with neurocognitive disorders characterised by WM dysfunction 
i.e. DLB and schizophrenia, as detected by qRT-PCR (Imamura et al. 2005; 
Chung et al. 2003). 
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In the next step, HapMap phase II CEPH data (release 19 from October 2005) was 
utilised to assess candidate targets for SNP content and haplotype structure.  This was 
performed to facilitate subsequent genetic analyses.  The final list of 10 target genes 
was generated by selecting candidates of interest that possess several common SNPs 
(minor allele frequency [MAF] ≥ 0.05) and an adequate r2 linkage disequilibrium 
(LD) structure (see table 3.1). 
 
 
 
 
Gene 
name 
Gene 
symbol 
Source 
Chromosomal 
location 
Protein function 
Activity-regulated 
cytoskeleton-
associated protein 
ARC 3 8q24.3 Synaptic plasticity 
Brain-derived 
neurotrophic factor 
BDNF 4 11p13 Synaptic plasticity 
Chitinase 3-like 1 CHI3L1 4 1q32.1 Inflammation 
Dual specificity 
phosphatase 6 
DUSP6 1 12q22-q23 
Cytoplasmic ERK-
directed phosphatase 
Eukaryotic translation 
initiation factor 2 α 
kinase 4 
EIF2AK4 2 15q15.1 Synaptic plasticity 
Membrane-associated 
ring finger(C3HC4) 7 
MARCH7 1 2q24.2 E3 ubiquitin ligase 
Phosphatidylserine 
decarboxylase 
PISD 1 22q12.2 
Mitochondrial 
PE synthesis 
Prostaglandin D2 
synthase 
PTGDS 1 9q34.2-q34.3 Neuromodulation 
Pumilio homologue 1 PUM1 2 1p35.2 Synaptic plasticity 
Staufen homologue 1 STAU1 2 20q13.1 Synaptic plasticity 
 
Table 3.1. IPD cognitive expression analysis target genes. 
The 10 target genes selected for the IPD cognitive expression analysis.  Their sources (see text for 
details), chromosomal locations, and encoded protein functions are listed.  All information was 
obtained from the NCBI Gene database.  ERK = Extracellular-signal regulated kinase; IPD = 
idiopathic Parkinson’s disease; NCBI = National Center for Biotechnology Information; PE = 
phosphatidylethanolamine. 
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3.3.2. Mini mental state examination score correlates 
with cerebellar post mortem brain pH 
Before quantifying gene expression in the cognitive series samples, it was necessary 
to ensure that the three groups (IPDD [n = 15]; IPDND [n = 16]; control [n = 16]) 
were comparable based on the relevant clinicopathological characteristics (see 
2.10.2.2).  To this end, group data for age of onset, age of death, disease duration, 
post mortem delay (PMD), post mortem brain pH, and MMSE were analysed.  After 
correction for multiple testing, the groups were not significantly different with regard 
to any of the first five metrics, indicating that they are comparable (see table 3.2).  
However, group MMSE scores for IPDD were significantly lower than those for 
IPDND (corrected p = 0.048).  This indicates that based on carer report and the 
available MMSE data, these two groups can be considered as IPD patients with and 
without dementia, respectively.  Individual clinicopathological data for each member 
of the cognitive series is shown in table 2.1. 
 
Hypoperfusion has been demonstrated in several regions of the IPDD brain (Firbank 
et al. 2003; Osaki et al. 2009).  Given that CBF would be expected to influence pH, it 
was hypothesised that there might be a relationship between IPD dementia severity 
and brain pH.  Therefore, correlation between MMSE score and cerebellar post 
mortem brain pH was evaluated using the Spearman’s rho coefficient (see 2.10.2.2).  
All of the IPDD and IPDND samples with available data for both metrics (n = 16) 
were analysed.  Significant positive correlation between these two variables was 
observed (r = 0.557; corrected p = 0.038) (see figure 3.3a).  Because of the relatively 
low number of samples in this analysis, the Queen Square Brain Bank for 
Neurological Disorders (QSBBND) database was mined for more IPD cases with 
available pH and MMSE data.  The resultant IPD correlation series (n = 37) (see table 
3.3) included the 16 cognitive series cases mentioned above.  The previous 
correlation was repeated in the larger series.  As with the cognitive series, the 
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correlation series data demonstrated significant positive correlation between MMSE 
score and post mortem brain pH (r = 0.412; corrected p = 0.022) (see figure 3.3b). 
 
 
 
Group 
(n) 
Statistic 
Age of 
onset 
Age of 
death 
Disease 
duration 
PMD 
Brain 
pH 
MMSE 
Mean NA 78.2 NA 42.4 6.55 ND CON 
(16) SD NA 8.8 NA 28.2 0.22 ND 
Mean 57.6 74.7 17.1 40.8 6.29 22.3 IPDD 
(15) SD 10.0 5.5 9.0 19.3 0.29 5.1 
Mean 60.3 76.4 16.1 39.8 6.41 29.6 IPDND 
(16) SD 11.4 7.3 5.7 26.3 0.27 0.5 
Uncorrected 0.514 0.206 0.859 0.873 0.034 0.004 
p value 
Corrected NS NS NS NS 0.408 0.048 
 
Table 3.2. IPD cognitive series clinicopathological data. 
Group clinicopathological metrics and statistical results for the IPD cognitive series.  After correction 
for multiple testing, the first five metrics were not significantly different, indicating that the groups are 
comparable.  However, MMSE was significantly lower in the demented patients.  Together with carer 
reports regarding cognitive impairment and/or change in personality (see table 2.1), this result 
indicates that the IPDD and IPDND groups are correctly labelled as such.  Measures of time are in 
years, except for PMD, which is measured in hours.  Groups were compared by Mann-Whitney or 
Kruskal-Wallis test as appropriate.  p values were corrected x12.  CON = control; IPD = idiopathic 
Parkinson’s disease; IPDD = idiopathic Parkinson’s disease dementia; IPDND = idiopathic 
Parkinson’s disease no dementia; MMSE = mini mental state examination; NA = not applicable; ND = 
not determined; NS = not significant; PMD = post mortem delay; SD = standard deviation. 
 
 
 
Group (n) Statistic 
Age of 
death 
PMD Brain pH MMSE 
Mean 76.2 35.4 6.35 25.6 IPD (37) 
SD 6.5 20.0 0.29 4.9 
 
Table 3.3. IPD correlation series clinicopathological data. 
Group clinicopathological metrics for the IPD correlation series.  Age of death is measured in years, 
and PMD in hours.  IPD = idiopathic Parkinson’s disease; MMSE = mini mental state examination; 
PMD = post mortem delay; SD = standard deviation. 
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Figure 3.3. MMSE score correlates with cerebellar post mortem brain pH. 
Scatter plots with linear best fit lines displaying Spearman’s rho correlations between cerebellar post 
mortem brain pH and MMSE score in the (a) IPD cognitive and (b) IPD correlation series.  Moderate 
but significant correlations were observed in both series.  Spearman’s r coefficients, corrected p 
values, and n values are shown on each plot.  p values were corrected x2.  IPD = idiopathic 
Parkinson’s disease; MMSE = mini mental state examination. 
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3.3.3. Variation in dorsolateral prefrontal cortex 
Dual specificity phosphatase 6 expression is associated 
with idiopathic Parkinson’s disease 
Dorsolateral prefrontal cortex and angular gyrus target gene expression were 
measured in the cognitive series using qRT-PCR.  In order to correct for variation in 
tissue composition and experimental procedure, target expression data were 
normalised with a NF calculated from the reference genes RPL13A and TBP.  Table 
3.4, figure 3.4, and figure 3.5 show the findings of the IPD cognitive expression 
analysis.  Examination of the data indicated high levels of intragroup variation in 
several instances and an overall lack of intergroup differential expression.  Thus only 
the IPDD and IPDND groups were compared statistically.  Clear trends of IPDD vs 
IPDND overexpression and underexpression were seen for MARCH7 in the DLPFC 
and DUSP6 in the AG, respectively.  Both observations were accompanied by altered 
IPDD expression compared to controls, suggesting that these genes might exhibit IPD 
dementia expression signatures (see figure 3.1).  However, the magnitude of the 
IPDD vs control differences and relevant levels of intragroup variation indicated that 
these changes were nonsignificant.  After correction for multiple testing, all 10 target 
genes failed to demonstrate significant IPDD vs IPDND differential expression in 
either region.  Therefore, there is no evidence to support the hypothesis that there is a 
relationship between IPD dementia status and DLPFC or AG target gene expression. 
 
The data suggested that when contrasted against controls, DLPFC DUSP6 expression 
was reduced in both IPDD and IPDND (see figure 3.4).  To further investigate this 
finding, IPDD and IPDND were combined to generate the IPD group.  IPD (n = 31) 
and control (n = 16) DUSP6 expression in the DLPFC and AG were then compared 
statistically.  Strikingly, IPD DUSP6 expression was significantly lower than that of 
controls in the DLPFC (corrected p = 0.008), but not in the AG (corrected p > 1) (see 
figure 3.6).  This demonstrates that variation in DLPFC DUSP6 expression is 
associated with IPD in the cognitive series. 
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Fold change mean 
expression/CON 
IPDD vs IPDND 
p value 
Brain 
region 
Gene 
IPDD IPDND Uncorrected Corrected 
ARC 0.76 0.63 0.221 NS 
BDNF 0.65 0.76 0.874 NS 
CHI3L1 1.41 0.83 0.262 NS 
DUSP6 0.47 0.60 0.221 NS 
EIF2AK4 0.99 0.92 0.339 NS 
MARCH7 1.31 1.01 0.013 0.585 
PISD 1.03 0.97 0.553 NS 
PTGDS 1.04 0.94 0.548 NS 
PUM1 0.85 0.93 0.527 NS 
DLPFC 
(BA46) 
STAU1 0.97 0.89 0.664 NS 
ARC 1.03 1.45 0.191 NS 
BDNF 0.89 1.46 0.065 NS 
CHI3L1 1.17 1.20 0.447 NS 
DUSP6 0.63 1.25 0.002 0.090 
EIF2AK4 0.91 0.87 0.188 NS 
MARCH7 0.97 0.89 0.419 NS 
PISD 0.88 1.00 0.239 NS 
PTGDS 1.11 1.57 0.395 NS 
PUM1 1.08 1.12 0.190 NS 
AG 
(BA39) 
STAU1 0.99 1.14 0.351 NS 
 
Table 3.4. IPD cognitive expression analysis data. 
Dorsolateral prefrontal cortex (BA46) and angular gyrus (BA39) fold change mean target gene 
expression values (relative to controls) and statistical results for the IPD cognitive expression analysis.  
No significant differences were observed after correction for multiple testing.  Expression data were 
normalised with RPL13A and TBP.  For all targets, IPDD and IPDND groups were compared by 
Mann-Whitney test.  p values were corrected x45.  Gene symbols are defined in table 3.1.  AG = 
angular gyrus; BA = Brodmann area; CON = control; DLPFC = dorsolateral prefrontal cortex; IPD = 
idiopathic Parkinson’s disease; IPDD = idiopathic Parkinson’s disease dementia; IPDND = idiopathic 
Parkinson’s disease no dementia; RPL13A = Ribosomal protein L13A; TBP = TATA box binding 
protein. 
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3.3.4. Dual specificity phosphatase 6 underexpression 
in the idiopathic Parkinson’s disease dorsolateral 
prefrontal cortex is not caused by modulated splicing 
The human DUSP6 gene is composed of three exons.  According to Ensembl, two 
splice forms are transcribed from this gene: the full length (FL) transcript, which 
contains all three exons; and a shorter transcript, comprised of exons 1 and 3 
(hereafter known as “DUSP6 1:3”) (see figure 3.7).  This architecture has an 
important consequence for Sybr Green qRT-PCR, in that it is impossible to design 
exon-exon boundary-spanning primers able to simultaneously detect both splice 
forms.  Consequently, the underexpression of DUSP6 observed in the IPD DLPFC 
could have been an artefact caused by modulated splicing.  In order to confirm that 
DUSP6 1:3 is expressed in the DLPFC, splicing RT-PCR was used to amplify 
cognitive series DLPFC cDNA (batch 1).  The results showed that DUSP6 1:3 is 
expressed in the DLPFC of the entire cognitive series (see figure 3.8). 
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Figure 3.7. DUSP6 FL mRNA and DUSP6 FL protein architecture. 
Human DUSP6 FL mRNA transcript and DUSP6 FL protein architecture.  DUSP6 is transcribed from 
the negative strand.  Alternative splicing generates two transcripts, the FL and 1:3 splice forms, which 
contain and lack exon 2, respectively.  The FL protein isoform contains five phosphatase domains 
(“P1” to “P5”), primary and secondary KIMs (“KIM1” and “KIM2”, respectively, which regulate 
ERK1/2 binding), a NES (which regulates nucleocytoplasmic shuttling), and an AD (which regulates 
enzymatic activation after ERK1/2 binding).  Cys293 is the critical phosphatase active site residue.  
mRNA scale bar indicates locations on chromosome 12 according to NCBI assembly build 36.  mRNA 
information was obtained from Ensembl (release 45 from June 2007).  Protein scale bar indicates 
amino acid locations.  Blue and green protein regions are encoded by blue and green exons, 
respectively, whilst protein domains and critical residues are overlaid in red.  Phosphatase domain 
locations were obtained from the Prints database.  Locations of all other protein domains were 
obtained from (Zhou et al. 2001).  AD = activation domain; Cys = cysteine; DUSP6 = Dual specificity 
phosphatase 6; Ex = exon; ERK 1/2 = Extracellular-signal regulated kinase 1/2; FL = full length; KIM 
= kinase interaction motif; mRNA = messenger ribonucleic acid; NCBI = National Center for 
Biotechnology Information; NES = nuclear export sequence; UTR = untranslated region. 
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Figure 3.8. DUSP6 1:3 is expressed in the DLPFC of the entire IPD cognitive series. 
Splicing RT-PCR amplification of DUSP6 1:3 from IPD cognitive series DLPFC batch 1 cDNA.  This 
splice form is expressed in the DLPFC of the entire series.  RT-PCR products were resolved on 
agarose gels.  Arrows denote the 200 base pair marker on each gel.  -ve = negative control (water); +ve 
= positive control (IPD cerebellum cDNA); 1:3 = splice form 1:3; CON = control; DLPFC = 
dorsolateral prefrontal cortex; cDNA = complementary DNA; DUSP6 = Dual specificity phosphatase 
6; IPD = idiopathic Parkinson’s disease; IPDD = idiopathic Parkinson’s disease dementia; IPDND = 
idiopathic Parkinson’s disease no dementia; M = marker ladder; RT-PCR = reverse transcriptase-
polymerase chain reaction. 
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We wanted to confirm the underexpression of DUSP6 observed in the IPD DLPFC, 
evaluate whether this effect is the result of modulated splicing, and attempt an 
alternative normalisation strategy to correct for neuronal loss in IPD samples.  
Therefore, qRT-PCR was employed to measure the expression of DUSP6 FL and 1:3 
in cognitive series DLPFC cDNA batches 1 and 2 (IPD [n = 31]; controls [n = 16]).  
As before, batch 1 DUSP6 expression data were normalised with a NF calculated 
from RPL13A and TBP (see 3.3.3).  For batch 2, two different normalisation 
approaches were used: the neuronal marker NEFH; and a NF calculated from G6PD, 
RPL13A, and TBP.  The resultant normalised datasets were labelled as NLC and total, 
respectively.  NLC data represents an alternative correction strategy and does not 
equate to neuron-specific expression.  Expression in IPD and controls was compared 
statistically (see table 3.5 and figure 3.9). 
 
In batch 2, total DUSP6 FL expression was significantly reduced in IPD compared to 
controls (corrected p = 0.045), although to a lesser extent than batch 1, in which mean 
IPD expression was 0.54-fold of that in controls (corrected p = 0.008).  Batch-by-
batch, total DUSP6 1:3 expression patterns tended to recapitulate those of total 
DUSP6 FL expression.  For example in batch 2, total DUSP6 1:3 expression was 
significantly decreased in IPD compared with controls (corrected p = 0.045).  
However in batch 1, the IPD underexpression of total DUSP6 1:3 was less 
pronounced than that of total DUSP6 FL, and failed to reach significance after 
correction for multiple testing (corrected p = 0.090).  Trends of lower NLC DUSP6 
FL and 1:3 expression were observed in IPD contrasted against controls, but these 
effects did not survive correction. 
 
Overall, these findings confirm that variation in DLPFC DUSP6 expression is 
associated with IPD in the cognitive series.  Moreover, there is little evidence to 
suggest that this phenomenon is a consequence of alternative DUSP6 splicing.  
Although changes in transcript ratio might play a minor role, the most parsimonious 
interpretation of these data is that DUSP6 underexpression in the cognitive series IPD 
DLPFC is not caused by modulated splicing. 
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IPD vs CON p value 
cDNA 
synthesis 
batch 
Expression 
Splice 
form 
Fold change 
mean DUSP6 
expression 
(IPD/CON) Uncorrected Corrected 
FL 0.54 1.87e-4 0.008 1 Total 
1:3 0.63 0.002 0.090 
FL 0.63 0.001 0.045 
2 Total 
1:3 0.60 0.001 0.045 
FL 0.64 0.016 0.720 
2 NLC 
1:3 0.76 0.037 NS 
 
Table 3.5. IPD cognitive series DLPFC DUSP6 expression data. 
Fold change mean DUSP6 expression values (relative to controls) and statistical results for cognitive 
series DLPFC cDNA batches 1 and 2.  Batch-by-batch, total DUSP6 1:3 expression patterns tended to 
recapitulate those of total DUSP6 FL expression, indicating that DUSP6 underexpression in the 
cognitive series IPD DLPFC is not caused by modulated splicing.  Note that batch 1 total DUSP6 FL 
expression data and statistics were already presented in figure 3.6.  Batch 1 total expression data were 
normalised with RPL13A and TBP, and batch 2 total expression data with G6PD, RPL13A, and TBP.  
NLC expression data were normalised with NEFH.  IPD and CON groups were compared by Mann-
Whitney test.  p values were corrected x45.  1:3 = splice form 1:3; CON = control; cDNA = 
complementary DNA; DLPFC = dorsolateral prefrontal cortex; DUSP6 = Dual specificity phosphatase 
6; FL = full length; G6PD = Glucose-6-phosphate dehydrogenase; IPD = idiopathic Parkinson’s 
disease; NEFH = Neurofilament H; NLC = neuronal-loss corrected; NS = not significant; RPL13A = 
Ribosomal protein L13A; TBP = TATA box binding protein. 
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Figure 3.9. DUSP6 underexpression in the IPD DLPFC is not caused by differential splicing. 
Relative mean DUSP6 expression values with 95% CI and statistical results for cognitive series 
DLPFC cDNA batches 1 and 2.  Batch-by-batch, total DUSP6 1:3 expression patterns tended to 
recapitulate those of total DUSP6 FL expression, indicating that DUSP6 underexpression in the 
cognitive series IPD DLPFC is not caused by modulated splicing.  Note that batch 1 total DUSP6 FL 
expression data and statistics were already presented in figure 3.6.  Batch 1 total expression data were 
normalised with RPL13A and TBP, and batch 2 total expression data with G6PD, RPL13A, and TBP.  
NLC expression data were normalised with NEFH.  IPD and CON groups were compared by Mann-
Whitney test.  Corrected p values are displayed.  p values were corrected x45.  1:3 = splice form 1:3; 
CI = confidence interval; CON = control; cDNA = complementary DNA; DLPFC = dorsolateral 
prefrontal cortex; DUSP6 = Dual specificity phosphatase 6; FL = full length; G6PD = Glucose-6-
phosphate dehydrogenase; IPD = idiopathic Parkinson’s disease; NEFH = Neurofilament H; NLC = 
neuronal-loss corrected; NS = not significant; RPL13A = Ribosomal protein L13A; TBP = TATA box 
binding protein. 
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3.3.5. Dual specificity phosphatase 6 underexpression 
in idiopathic Parkinson’s disease is restricted to the 
dorsolateral prefrontal cortex 
In order to provide a more extensive picture of DUSP6 in IPD, qRT-PCR was used to 
measure expression of the FL isoform in seven subcortical and cortical brain regions 
obtained from the mapping series.  Total expression data were normalised with a NF 
calculated from the most stable set of the following reference genes: G6PD, HPRT1, 
RPL13A, and TBP.  For the medulla, putamen, ACC, AG, and FC, these sets 
comprised all four reference genes.  For the amygdala and EC, these sets consisted of 
HPRT1, RPL13A, and TBP.  All NLC expression data were normalised with NEFH.  
As before, comparability based on clinicopathological characteristics was assessed 
(see 3.3.2).  Group data for age of death, PMD, and post mortem brain pH were 
analysed.  Comparisons were not possible for age of onset, disease duration, and 
MMSE.  After correction for multiple testing, the IPD (n = 20) and control (n = 20) 
groups were not significantly different with regard to any of the metrics, indicating 
that they are comparable (see table 3.6).  This was the case for both the generalised 
and the medulla-specific mapping series.  Individual clinicopathological data for each 
member of the mapping series is shown in table 2.2.  DUSP6 FL expression in IPD 
and controls was then compared statistically. 
 
Table 3.7 and figure 3.10 show the results of this analysis.  Relatively high levels of 
intragroup variation were detected in the majority of regions.  After correction for 
multiple testing, no significant changes were observed for total or NLC DUSP6 FL 
expression in any of the seven regions obtained from the mapping series.  Clear 
trends of reduction in IPD contrasted against controls were seen for total expression 
in the ACC, and NLC expression in the AG and FC.  However, these effects failed to 
reach significance after correction.  Notably, the lack of differential total DUSP6 
expression observed in the mapping series AG corroborates the cognitive series data 
for this area (see figure 3.6).  Taken together, these findings demonstrate that DUSP6 
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FL is not differentially-expressed in the mapping series.  Moreover, they indicate that 
in all eight brain areas examined thus far, IPD DUSP6 underexpression is restricted to 
the DLPFC. 
 
 
 
 
Table 3.6. IPD mapping series clinicopathological data. 
a. Putamen, amygdala, entorhinal cortex, anterior cingulate cortex, angular gyrus, frontal cortex 
(below). 
 
Group 
(n) 
Statistic 
Age of 
onset 
Age of 
death 
Disease 
duration 
PMD 
Brain 
pH 
Mean NA 78.9 NA 49.1 6.38 CON (20) 
SD NA 10.5 NA 24.9 0.29 
Mean 60.6 76.3 15.8 51.0 6.29 
IPD (20) 
SD 11.6 7.7 8.4 31.6 0.27 
Uncorrected NA 0.155 NA 0.935 0.223 
p value 
Corrected NA NS NA NS NS 
 
b. Medulla only (below). 
 
Group 
(n) 
Statistic 
Age of 
onset 
Age of 
death 
Disease 
duration 
PMD 
Brain 
pH 
Mean NA 78.6 NA 46.7 6.41 CON (15) 
SD NA 9.9 NA 24.3 0.33 
Mean 62.3 76.2 13.9 50.6 6.30 
IPD (17) 
SD 10.7 7.9 7.3 26.3 0.28 
Uncorrected NA 0.186 NA 0.461 0.207 
p value 
Corrected NA NS NA NS NS 
 
Group clinicopathological metrics and statistical results for the IPD mapping series.  After correction 
for multiple testing, none of the metrics were significantly different, indicating that the groups are 
comparable.  Due to low availability of medulla tissue, several individuals were replaced solely for this 
region (see table 2.2).  Measures of time are in years, except for PMD, which is measured in hours.  
Groups were compared by Mann-Whitney test.  p values were corrected x12.  CON = control; IPD = 
idiopathic Parkinson’s disease; NS = not significant; PMD = post mortem delay; SD = standard 
deviation. 
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IPD vs CON p value Brain 
region 
Expression 
Fold change mean 
DUSP6 FL expression 
(IPD/CON) Uncorrected Corrected 
Total 1.59 0.043 NS Medulla 
NLC 0.55 0.576 NS 
Total 1.00 0.524 NS 
Putamen 
NLC 0.48 0.200 NS 
Total 1.12 0.748 NS 
Amygdala 
NLC 0.64 0.429 NS 
Total 1.25 0.957 NS EC 
(BA28) NLC 0.59 0.128 NS 
Total 0.77 0.013 0.585 ACC 
(BA24) NLC 0.76 0.204 NS 
Total 1.00 0.267 NS AG 
(BA39) NLC 0.39 0.008 0.360 
Total 0.83 0.116 NS FC 
(BA8) NLC 0.46 0.007 0.315 
 
Table 3.7. IPD mapping series DUSP6 FL expression data. 
Fold change mean DUSP6 FL expression values (relative to controls) and statistical results for the 
mapping series.  No significant differences were observed after correction for multiple testing, 
indicating that DUSP6 underexpression in IPD is restricted to the DLPFC.  Total expression data were 
normalised with G6PD, HPRT1, RPL13A, and TBP, except for amygdala and EC data, which were 
normalised with HPRT1, RPL13A, and TBP.  NLC expression data were normalised with NEFH.  IPD 
and CON groups were compared by Mann-Whitney test.  p values were corrected x45.  AG = angular 
gyrus (BA39); ACC = anterior cingulate cortex (BA24); BA = Brodmann area; CON = control; 
DLPFC = dorsolateral prefrontal cortex (BA46); DUSP6 = Dual specificity phosphatase 6; EC = 
entorhinal cortex (BA28); FC = frontal cortex (BA8); FL = full length; G6PD = Glucose-6-phosphate 
dehydrogenase; HPRT1 = Hypoxanthine phosphoribosyltransferase 1; IPD = idiopathic Parkinson’s 
disease; NEFH = Neurofilament H; NLC = neuronal-loss corrected; NS = not significant; RPL13A = 
Ribosomal protein L13A; TBP = TATA box binding protein. 
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Figure 3.10. DUSP6 FL is not differentially-expressed in the IPD mapping series. 
Relative mean DUSP6 FL expression values with 95% CI for the mapping series.  No significant 
differences were observed after correction for multiple testing, indicating that DUSP6 underexpression 
in IPD is restricted to the DLPFC.  Total expression data were normalised with G6PD, HPRT1, 
RPL13A, and TBP, except for amygdala and EC data, which were normalised with HPRT1, RPL13A, 
and TBP.  NLC expression data were normalised with NEFH.  IPD and CON groups were compared 
by Mann-Whitney test.  p values were corrected x45.  AG = angular gyrus (BA39); ACC = anterior 
cingulate cortex (BA24); BA = Brodmann area; CI = confidence interval; CON = control; DLPFC = 
dorsolateral prefrontal cortex (BA46); DUSP6 = Dual specificity phosphatase 6; EC = entorhinal 
cortex (BA28); FC = frontal cortex (BA8); FL = full length; G6PD = Glucose-6-phosphate 
dehydrogenase; HPRT1 = Hypoxanthine phosphoribosyltransferase 1; IPD = idiopathic Parkinson’s 
disease; NEFH = Neurofilament H; NLC = neuronal-loss corrected; RPL13A = Ribosomal protein 
L13A; TBP = TATA box binding protein. 
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3.3.6. Dual specificity phosphatase 6 sequencing 
identifies one familial Parkinson’s disease-restricted 
mutation and three low frequency polymorphisms 
Pathogenic mutations in several different genes are known to cause FPD [reviewed in 
(Lesage and Brice 2009)].  We wanted to evaluate whether DUSP6 might exhibit 
mutations that segregate with FPD.  Therefore, gDNA samples obtained from FPD 
patients (n = 82) were amplified by PCR and dideoxy sequencing was performed.  
DUSP6 coverage consisted of ~420 bp of upstream sequence, the 5’ untranslated 
region (UTR), the coding portions of exons 1 to 3, and the majority (the first 830 bp) 
of the 3’UTR.  Deviations from the reference sequence and segregation with FPD 
were evaluated by sequencing the relevant amplicons in control individuals (n = 83) 
and in first-degree relatives of known FPD status, respectively. 
 
Four novel heterozygous deviations from the DUSP6 reference sequence were 
identified: two transitions and two transversions (see table 3.8).  Three of these 
changes were found in FPD cases and controls, and hence can be classified as low 
frequency SNPs.  These were as follows: -285A/C in the upstream region, +394C/T 
in the 5’UTR, and +740G/A in exon 1, which is predicted to result in a Thr87Ile 
substitution.  In contrast, the novel +460G>C alteration was detected in only one case 
and none of the controls, and therefore appears to be a point mutation.  Segregation 
with FPD could not be assessed for this mutation, as no relatives were available.  In 
silico TFBS prediction analysis was carried out for +460G>C.  Genomic DNA 
sequence encompassing this position and 60 bp in either direction was downloaded 
from Ensembl and entered into PROMO.  The +460G>C mutation was found to 
abolish a predicted DNA binding site for the transcription factor (TF) glucocorticoid 
receptor α, which is encoded by the nuclear receptor subfamily 3, group C, member 1 
(NR3C1) gene (see figure 3.11). 
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These results establish the existence of one FPD-restricted point mutation and three 
novel low frequency SNPs in the human DUSP6 locus.  They also suggest that 
DUSP6 mutation is unlikely to be a significant cause of FPD. 
 
 
 
 
 
 
 
Sequence 
alteration 
Location 
Amino acid 
substitution 
FPD 
allelic 
frequency 
Control 
allelic 
frequency 
Segregates 
with FPD? 
-285A>C Upstream NA 3/144 8/148 ND 
+394C>T 5’UTR NA 3/130 7/138 No* 
+460G>C 5’UTR NA 1/130 0/140 ND 
+740G>A Exon 1 Thr87Ile 3/108 3/84 ND 
 
Table 3.8. DUSP6 DNA sequencing data. 
Dual specificity phosphatase 6 DNA sequencing data obtained in FPD patients, controls, and first-
degree patient relatives (where available).  All changes were heterozygous.  One FPD-restricted 
5’UTR mutation and three low frequency SNPs were discovered.  Base identities are from the positive 
strand (note that DUSP6 is transcribed from the negative strand).  Base positions are on the negative 
strand in relation to the TSS, where the first transcribed base is +1.  DNA base and amino acid codes 
are in accordance with the International Union of Biochemistry and Molecular Biology.  * = affected 
sibling of one heterozygous FPD patient was homozygous wild type; DUSP6 = Dual specificity 
phosphatase 6; FPD = familial Parkinson’s disease; NA = not applicable; ND = not determined; SNP = 
single nucleotide polymorphism; TSS = transcriptional start site; UTR = untranslated region. 
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Figure 3.11. The +460G>C DUSP6 mutation abolishes a predicted NR3C1 DNA binding site. 
In silico analysis investigating the effect of DUSP6 mutation on predicted TF binding.  The +460G>C 
DUSP6 5’UTR mutation abolishes a predicted DNA binding site for the TF glucocorticoid receptor α 
(also known as NR3C1).  PROMO maximum binding dissimilarity was 1%.  Locations on the negative 
strand of chromosome 12 are according to NCBI assembly build 36.  +460G>C is shown bolded in 
red.  Box indicates predicted NR3C1 binding site.  DNA base codes are in accordance with the 
International Union of Biochemistry and Molecular Biology.  DUSP6 = Dual specificity phosphatase 
6; NCBI = National Center for Biotechnology Information; NR3C1 = nuclear receptor subfamily 3, 
group C, member 1; TF = transcription factor; UTR = untranslated region. 
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3.3.7. Variation at rs1689408 is implicated in 
idiopathic Parkinson’s disease risk 
Genetic association studies have identified polymorphisms that affect IPD 
aetiopathogenesis [for example (Simon-Sanchez et al. 2009)].  In order to assess SNP 
variation in the DUSP6 locus for its potential to influence IPD susceptibility, a case-
control association study was undertaken.  A region encompassing the DUSP6 gene 
(~4.5 kb) and 10 kb upstream and downstream was defined, and HapMap phase II 
CEPH data were used to evaluate LD relationships between common SNPs and 
generate htSNPs (see figure 3.12).  Four htSNPs were produced, with an average 
locus haplotype r2 of 0.994.  Taqman was employed to genotype these markers in 
gDNA extracted from the association series (IPD [n = 614]; controls [n = 619]), and 
they were tested for allelic association with IPD under a multiplicative model.  The 
novel SNPs identified during DUSP6 sequencing (see 3.3.6) were not examined due 
to low MAF.  Group clinical data for the association series can be seen in table 3.9. 
 
Table 3.10 shows the findings of the SNP association study.  The Hardy-Weinberg 
equilibrium (HWE) was not violated for any of the htSNPs in either group, indicating 
that no serious genotyping errors had occurred.  Variation at rs1689408 displayed a 
trend for association with IPD (corrected p = 0.088).  The estimated odds ratio (OR) 
for this effect was 0.747 with a 95% confidence interval (CI) that ranged from 0.582 
to 0.958, suggesting that the observation is not a false positive.  Comparison of the 
IPD (0.102) and control (0.133) MAFs suggested that the minor T allele confers 
reduced susceptibility to IPD.  Therefore, these data indicate that variation at 
rs1689408 is implicated in IPD risk in the association series.  According to HapMap, 
this polymorphism is in perfect LD with three other DUSP6 locus SNPs in 
Caucasians: rs1650342, rs704080, and rs808820.  This implies uncertainty over 
which of these four SNPs (or combination thereof) is/are driving the observed trend. 
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Figure 3.12. DUSP6 genomic locus SNP LD plot. 
Pairwise r2 LD plot for common SNPs (MAF ≥ 0.05) in the DUSP6 genomic locus (~24.5 kb).  CEPH 
trio genotypic data were obtained from HapMap phase II (release 23a from March 2008).  Tagger was 
used to generate four htSNPs capturing 95% the SNP variation in this region (average locus haplotype 
r2 = 0.994).  Pairwise LD values (out of 100) label the relevant squares.  Degree of square shading 
denotes LD magnitude.  Empty black squares indicate LD = 1.  Red boxes denote htSNPs.  Boundaries 
of DUSP6 transcribed sequence (~4.5 kb) in relation to the white bar are indicated.  Locations on 
chromosome 12 are according to NCBI assembly build 36.  CEPH = Centre d’Étude du 
Polymorphisme Humain; DUSP6 = Dual specificity phosphatase 6; LD = linkage disequilibrium; 
MAF = minor allele frequency; NCBI = National Center for Biotechnology Information; SNP = single 
nucleotide polymorphism; htSNP = haplotype-tagging single nucleotide polymorphism. 
 
Group (n) % males Statistic 
Age of 
onset 
Age of 
donation 
Disease 
duration 
Mean NA 47.6 NA CON (619) 49.6 
SD NA 15.1 NA 
Mean 60.1 75.1 13.9 
IPD (614) 58.3 
SD 11.1 8.3 8.3 
 
Table 3.9. IPD association series clinical data. 
Group clinical metrics for the IPD association series.  In the IPD group, 319 were brain samples and 
295 were blood samples.  Disease duration values for IPD blood samples were measured at a cut-off 
date in 2003.  All of the controls were blood samples.  Measures of time are in years.  CON = control; 
IPD = idiopathic Parkinson’s disease; NA = not applicable; SD = standard deviation. 
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3.3.8. Variation at rs1689408 influences grey matter 
density in several brain regions 
The mechanism underlying the effect of rs1689408 variation on IPD risk is unclear.  
Structural MRI has been used to examine grey matter density in asymptomatic Parkin 
heterozygous mutation carriers (Binkofski et al. 2007).  Exploring relationships 
between this endophenotype and rs1689408 variation might shed further light on its 
role in IPD and the human brain.  Therefore, genotypic VBM analysis was carried out 
for this SNP.  MRI scans were generated for the imaging series (n = 302) (see table 
3.11).  These normal controls were then genotyped at rs1689408, split into 
homozygote majors and heterozygotes, and the groups subjected to voxel-wise 
statistical comparisons of grey matter density.  Several regions of interest (ROIs) 
were selected based on evidence of DUSP6 differential expression in the IPD 
expression analyses (see 3.3.3 and 3.3.5), on Dusp6 expression as demonstrated in the 
Allen Mouse Brain Atlas (AMBA), or on a well-established role in IPD.  The AG and 
FC were selected as ROIs based on the magnitude of differential NLC DUSP6 
expression, even though these changes did not survive correction.  The ROIs were 
used to generate a mask which was applied to the data, producing the ROI analysis.  
The global analysis was subsequently generated by examining changes in grey matter 
density across the entire brain unconstrained by prior hypothesis.  This experiment 
was performed in collaboration with Geoffrey Tan from our laboratory.  Dr. Tan 
carried out the MRI scans, gDNA extractions, and statistical analyses. 
 
 
Group (n) 
% 
males 
Heterozygote 
frequency 
Statistic Age of scan 
Mean 31.6 CON (302) 45.4 0.179 
SD 12.2 
 
Table 3.11. Imaging series demographic data. 
Group demographic metrics for the imaging series.  Heterozygote frequency refers to rs1689408 
genotype.  The rs1689408 genotypic data did not violate Hardy-Weinberg equilibrium (uncorrected  
p = 0.148).  Age of donation is measured in years.  CON = control; SD = standard deviation. 
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After FWE correction for multiple testing, the VBM ROI analysis demonstrated 
significant unilateral associations in several cortical and subcortical regions (see table 
3.12 and figure 3.13).  The results indicated that compared to C/C homozygotes, C/T 
heterozygotes possess higher grey matter density in these areas.  Starting with the 
cortex, the right medial EC (corrected p = 9.52e-5), right DLPFC (corrected  
p = 0.001), and left FC (corrected p = 0.001) were of significantly higher density in 
heterozygotes.  In the subcortical limbic system, the same was true of the left 
hippocampus (corrected p = 2.31e-5) and right amygdala (corrected p = 2.62e-4).  
Within the striatum, the left caudate (corrected p = 0.008) was also of significantly 
higher density in heterozygotes.  No significant differences were seen in the AG or 
the SN. 
 
The VBM global analysis showed that rs1689408 heterozygotes possess significantly 
higher grey matter density in several regions, most of which were cortical (see table 
3.13 and figure 3.14).  Significant bilateral effects were observed in the subgenual 
ACC (corrected p = 6.60e-8 and 5.16e-4 in left and right hemispheres, respectively), 
lateral orbitofrontal cortex (OFC) (corrected p = 0.002 and 3.32e-6 in left and right 
hemispheres, respectively), and insular cortex (corrected p = 1.68e-4 and 5.21e-4 in 
left and right hemispheres, respectively).  Significant unilateral differences were seen 
in the right inferior temporal pole (corrected p = 2.51e-4), right superior frontal pole 
(corrected p = 2.63e-4), left superior temporal sulcus (corrected p = 5.46e-4), right 
medial EC (corrected p = 0.001), right precuneus (corrected p = 0.007), and left FC 
(corrected p = 0.008).  Significant effects were also seen in two noncortical areas: the 
left cerebellar vermis (corrected p = 1.27e-5) and left hippocampus (corrected  
p = 3.19e-4). 
 
Taken together, these data demonstrate that normal rs1689408 heterozygotes in the 
imaging series possess significantly higher levels of grey matter density in a variety 
of cortical and subcortical regions. 
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Figure 3.13. Genotypic rs1689408 VBM images: ROI analysis. 
Genotypic rs1689408 VBM ROI analysis T1-weighted MRI images.  Individuals heterozygous at 
rs1689408 exhibited significantly higher grey matter density in the right medial EC, right DLPFC, left 
FC, left hippocampus, right amygdala, and left caudate.  No significant effects were observed in the 
AG or SN.  Groups were compared by t test.  p values were corrected using the FWE approach.  Blue 
crosshairs specify the location of the peak associated voxels (and the first titular region in images 
displaying multiple associations).  Heat map scales indicate T score gradients within the associated 
voxel clusters.  AG = angular gyrus (BA39); BA = Brodmann area; DLPFC = dorsolateral prefrontal 
cortex (BA46); EC = entorhinal cortex (BA28); FWE = family-wise error; FC = frontal cortex (BA8); 
MRI = magnetic resonance imaging; ROI = region of interest; SN = substantia nigra; VBM = voxel-
based morphometry. 
 156 
 
 
 
 
Global Statistics (FWE-corrected) 
Region (BA) Hemisphere 
MNI 
coordinates 
Z score p value 
Cluster 
extent 
Subgenual 
ACC (32) 
Left -10 39 -10 7.12 6.60e-8 1699 
Subgenual 
ACC (32) 
Right 8 33 -11 5.64 5.16e-4 1699 
Lateral 
OFC (11) 
Left -27 39 -14 5.35 0.002 149 
Lateral 
OFC (11) 
Right 34 41 -12 6.52 3.32e-6 819 
Cerebellar vermis Left -15 -34 -45 6.29 1.27e-5 149 
Insular cortex (13) Left -37 -9 7 5.84 1.68e-4 429 
Insular cortex (13) Right 44 -1 -19 5.63 5.21e-4 321 
Insular cortex (13) Right 37 -13 7 4.97 0.013 64 
Inferior temporal 
pole (20) 
Right 47 -3 -43 5.77 2.51e-4 662 
Superior frontal 
pole (10) 
Right 26 58 10 5.76 2.63e-4 436 
Hippocampus Left -23 -17 -19 5.73 3.19e-4 439 
Superior temporal 
sulcus (21) 
Left -45 -9 -14 5.62 5.46e-4 547 
Medial EC (28) Right 24 -17 -24 5.46 0.001 339 
Precuneus Right 10 -40 6 5.10 0.007 57 
FC (8) Left -8 29 46 5.08 0.008 68 
 
Table 3.13. Genotypic rs1689408 VBM data: global analysis. 
Genotypic rs1689408 VBM global analysis data.  Individuals heterozygous at rs1689408 exhibited 
significantly higher grey matter density in the bilateral subgenual ACC, bilateral lateral OFC, left 
cerebellar vermis, bilateral insular cortex (BA13), right inferior temporal pole (BA20), right superior 
frontal pole (BA10), left hippocampus, left superior temporal sulcus (BA21), right medial EC, right 
precuneus, and left FC.  Cluster extent is the number of voxels making up each associated cluster.  
Groups were compared by t test.  p values were corrected using the FWE approach.  ACC = anterior 
cingulate cortex (BA32); BA = Brodmann area; EC = entorhinal cortex (BA28); FWE = family-wise 
error; FC = frontal cortex (BA8); MNI = Montreal Neurological Institute; OFC = orbitofrontal cortex 
(BA11); VBM = voxel-based morphometry. 
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Figure 3.14. Genotypic rs1689408 VBM images: global analysis. 
Genotypic rs1689408 VBM global analysis T1-weighted MRI images.  Individuals heterozygous at 
rs1689408 exhibited significantly higher grey matter density in the bilateral subgenual ACC, bilateral 
lateral OFC, left cerebellar vermis, bilateral insular cortex (BA13), right inferior temporal pole 
(BA20), right superior frontal pole (BA10), left hippocampus, left superior temporal sulcus (BA21), 
right medial EC, right precuneus, and left FC.  Groups were compared by t test.  p values were 
corrected using the FWE approach.  Blue crosshairs specify the location of the peak associated voxels 
(and the first titular region in images displaying multiple associations).  Heat map scales indicate T 
score gradients within the associated voxel clusters.  ACC = anterior cingulate cortex (BA32); BA = 
Brodmann area; EC = entorhinal cortex (BA28); FWE = family-wise error; FC = frontal cortex (BA8); 
MRI = magnetic resonance imaging; OFC = orbitofrontal cortex (BA11); VBM = voxel-based 
morphometry. 
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3.3.9. Variation at rs1689408 is implicated in 
Dual specificity phosphatase 6 splicing in the 
dorsolateral prefrontal cortex 
Variation at rs1689408 could alter brain structure and IPD susceptibility through a 
variety of mechanisms.  This SNP is located ~7.6 kb upstream of the DUSP6 
transcriptional start site (TSS) in an intergenic region of no known regulatory 
function.  One possibility is that rs168408 variation influences DUSP6 expression.  
This could occur directly, for example by altering TF binding, or indirectly, by 
tagging a distant functional polymorphism.  According to HapMap, this variant is in 
perfect LD with rs808820, which resides just 24 bp upstream of the start of DUSP6 
exon 2, and hence might influence DUSP6 splicing.  In order to investigate these 
possibilities, cis-acting variation analysis was performed for rs1689048.  The 
cognitive series individuals were genotyped at this SNP, total and NLC DLPFC 
DUSP6 expression data (cDNA batch 2 only) grouped by genotype, and the groups 
compared statistically (C/C homozygote majors [n = 33]; C/T heterozygotes  
[n = 13]).  Two analyses were carried out on these groups.  Initially, DUSP6 FL 
expression data were analysed.  However to investigate splicing, DUSP6 FL data 
were also divided by DUSP6 1:3 data on an individual-by-individual basis, and 
resultant the DUSP6 FL/1:3 ratios analysed in a similar fashion. 
 
Table 3.14 and figure 3.15 show the results of these analyses.  A trend of increased 
expression in heterozygotes compared to homozygotes was seen for NLC DUSP6 FL 
expression.  Similar trends were observed for total and NLC DUSP6 FL/1:3 ratio.  
For these latter effects, the relative splice form balance was shifted towards DUSP6 
FL in heterozygotes.  After correction for multiple testing, no significant effects were 
observed for variation at rs1689408 on DUSP6 FL expression or DUSP6 FL/1:3 
ratio.  Nevertheless, these data suggest that variation at rs1689408 is implicated in 
DUSP6 splicing in the cognitive series DLPFC. 
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het vs hom p value DUSP6 
splice form 
Expression 
Fold change mean 
expression (het/hom) Uncorrected Corrected 
Total 1.18 0.453 NS FL 
NLC 1.98 0.037 NS 
Total 1.48 0.035 NS 
FL/1:3 ratio 
NLC 1.49 0.035 NS 
 
Table 3.14. DLPFC DUSP6 rs1689408 cis-acting variation analysis data. 
Fold change mean DUSP6 FL expression values and FL/1:3 ratios (rs1689408 hets relative to homs), 
and statistical results for cognitive series DLPFC cDNA batch 2.  No significant differences were 
observed after correction for multiple testing.  However, trends of increased total and NLC DUSP6 
FL/1:3 ratio were observed in hets, suggesting that variation at rs1689048 is implicated in DUSP6 
splicing in the DLPFC.  Total expression data were normalised with G6PD, RPL13A, and TBP.  NLC 
expression data were normalised with NEFH.  FL/1:3 ratios were generated on an individual-by-
individual basis; these are taken to be relative guides and do not necessarily represent the absolute 
ratios of FL to 1:3.  Data were grouped by rs1689408 genotype, and hets and homs compared by 
Mann-Whitney test.  p values were corrected x45.  The rs1689408 genotypic data did not violate 
Hardy-Weinberg equilibrium (uncorrected p = 0.747).  1:3 = splice form 1:3; cDNA = complementary 
DNA; DLPFC = dorsolateral prefrontal cortex; DUSP6 = Dual specificity phosphatase 6; FL = full 
length; G6PD = Glucose-6-phosphate dehydrogenase; het = heterozygote; hom = homozygote major; 
NEFH = Neurofilament H; NLC = neuronal-loss corrected; NS = not significant; RPL13A = Ribosomal 
protein L13A; TBP = TATA box binding protein. 
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Figure 3.15. rs1689408 is implicated in DUSP6 splicing in the DLPFC. 
Relative mean DUSP6 expression values and FL/1:3 ratios with 95% CI and statistical results for 
cognitive series DLPFC cDNA batch 2.  No significant differences were observed after correction for 
multiple testing.  However, trends of increased total and NLC DUSP6 FL/1:3 ratio were observed in 
hets, suggesting that variation at rs1689048 is implicated in DUSP6 splicing in the DLPFC.  Total 
expression data were normalised with G6PD, RPL13A, and TBP.  NLC expression data were 
normalised with NEFH.  FL/1:3 ratios were generated on an individual-by-individual basis; these are 
taken to be relative guides and do not necessarily represent the absolute ratios of FL to 1:3.  Data were 
grouped by rs1689408 genotype, and hets and homs compared by Mann-Whitney test.  p values were 
corrected x45.  The rs1689408 genotypic data did not violate Hardy-Weinberg equilibrium 
(uncorrected p = 0.747).  1:3 = splice form 1:3; CI = confidence interval; cDNA = complementary 
DNA; DLPFC = dorsolateral prefrontal cortex; DUSP6 = Dual specificity phosphatase 6; FL = full 
length; G6PD = Glucose-6-phosphate dehydrogenase; het = heterozygote; hom = homozygote major; 
NEFH = Neurofilament H; NLC = neuronal-loss corrected; RPL13A = Ribosomal protein L13A; TBP = 
TATA box binding protein. 
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3.4. Discussion 
In this chapter it was demonstrated that MMSE score positively correlates with 
cerebellar post mortem brain pH in IPD patients.  We used qRT-PCR to investigate 
10 target genes, selected for their involvement in working or long term memory, and 
found that none were differentially-expressed in the DLPFC or AG of demented 
compared to nondemented IPD patients.  However, variation in DLPFC DUSP6 
expression was shown to significantly associate with IPD.  Moreover, it was 
demonstrated that this association manifests as DUSP6 underexpression in IPD 
contrasted against controls, that this underexpression is not caused by modulated 
splicing, and that variation in DUSP6 expression is not related to disease status in 
seven other subcortical and cortical brain regions.  DUSP6 DNA sequencing 
identified three low frequency SNPs and one 5’UTR point mutation that is restricted 
to FPD and abolishes a predicted NR3C1 TFBS.  SNP allelic association analysis 
indicated that variation at rs1689408 is implicated in IPD susceptibility by trend of 
borderline significance.  Specifically, the rs1689408 minor allele was found to confer 
decreased risk of IPD.  Furthermore, genotypic VBM experiments demonstrated that 
normal rs1689048 heterozygotes possess significantly higher grey matter density in 
several brain regions.  These include cortical (the subgenual ACC, lateral OFC, 
insular cortex, medial EC, DLPFC, and FC) and subcortical (the hippocampus, 
amygdala, and caudate) areas.  Finally, a trend was observed in which rs1689408 
heterozygotes exhibit relatively higher DLPFC DUSP6 FL/1:3 ratios, thus providing 
a putative mechanism through which variation at this polymorphism might exert its 
effects on brain structure and IPD risk. 
 
These findings connect DUSP6 to IPD neurodegenerative processes in general, and 
not to IPD dementia.  Moreover, the experiments detailed in this chapter failed to 
discover any genes specifically implicated in IPDD.  Therefore, our results do not 
support the hypothesis that there is a relationship between IPD dementia status and 
gene expression in the DLPFC or AG.  The expression of these 10 targets has not 
previously been investigated in the IPD BA46 or BA39, and so no direct precedent 
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exists against which we could evaluate the data.  However, two microarray studies 
provide results of some relevance.  One of these examined BA9 whole tissue extracts, 
and observed that IPD DUSP6 expression was ~0.6-fold of that in controls (Zhang et 
al. 2005b).  Given that BA9 and BA46 are DLPFC regions which lie adjacent to one 
another, this result goes some way to corroborating our own findings regarding 
DUSP6 expression in the IPD DLPFC.  The other study quantified gene expression in 
IPDD PCC neurons.  This report showed that in IPD compared to controls, BDNF 
was expressed at ~0.6-fold and PTGDS at ~2-fold.  Interestingly, the results also 
demonstrated that DUSP6 was expressed at ~0.5-fold in IPDD vs IPDND and at 
~0.4-fold in IPDD vs controls.  These data indicate connections between 
BDNF/PTGDS and IPD neurodegeneration, and between DUSP6 and IPD dementia 
(Stamper et al. 2008). 
 
In terms of the relationship between DUSP6 expression and IPD subtype, the 
discrepancy between our results and those of Stamper et al. might be explained by 
differences in brain region.  Indeed, our data suggest that the association between IPD 
and variation in DUSP6 expression is restricted to the DLPFC.  SNCA and/or MAPT 
aggregation in the ACC and EC are the best cortical neuropathological predictors of 
cognitive dysfunction in IPD (Vermersch et al. 1993; Kovari et al. 2003; Pletnikova 
et al. 2005).  Furthermore, a recent groundbreaking study has demonstrated that IPD 
dementia incidence is predicted by temporal-dependent semantic fluency skills, but 
not by prefrontal-dependent planning ability, suggesting that prefrontal executive 
dysfunction does not develop into dementia in this disorder (Williams-Gray et al. 
2009a).  Imaging studies indicate that semantic fluency tasks mainly activate the 
perirhinal cortex, parahippocampal cortex, and hippocampus (Pihlajamaki et al. 
2000).  Consequently, despite the classical neuropsychological rationale (WM-
prefrontal-parietal) behind their selection, the DLPFC and AG may not have been the 
ideal regions in which to perform these experiments. 
 
Apart from the choice of brain area, several other confounds could underlie the 
failure of the cognitive expression analysis to identify genes implicated in IPDD.  
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Firstly, the criteria for IPDD/IPDND group membership were carer reports of 
cognitive impairment and/or change in personality, backed up by MMSE scores 
indicative of dementia.  The retrospective nature of the cognitive series meant that the 
latter was not available for some individuals allocated to the IPDND group, and 
hence they may have been incorrectly assigned.  Moreover, the QSBBND database 
lacks information about other tests of dementia severity (e.g. the Mattis dementia 
rating scale), or of executive function (e.g. the Weschler Adult Intelligence Scale 
digit span, Wisconsin Card Sorting Task, or semantic fluency animal test), the latter 
of which would be most pertinent to the cognitive deficits that characterise IPDD 
(Girotti et al. 1988; Litvan et al. 1991; Bohnen et al. 2006; Williams-Gray et al. 
2009a).  Secondly, the two groups may have differed with regard to date of death, PD 
gene mutation, LB load, or therapeutic drug treatment.  However, no clear disparities 
were observed (see Appendix).  Thirdly, the number of individuals in each group may 
have been too low to robustly demonstrate significant differential expression.  
Nevertheless, post hoc calculations showed that the sample size provided 80% power 
to detect 1.3-fold ± 0.2-fold (SD) expression differences at a significance of corrected 
p ≤ 0.05, suggesting that the numbers were sufficient.  Next, the premise used to 
select targets (i.e. genes with a connection to working or long term memory) may 
have been flawed in the context of this disease.  However, semantic fluency tasks 
recently found to predict dementia incidence in IPD are known to activate the 
perirhinal cortex, parahippocampal cortex, and hippocampus (see above) 
(Pihlajamaki et al. 2000; Williams-Gray et al. 2009a).  The perirhinal cortex and 
hippocampus are both involved in long term and working memory, which therefore 
lends to support to our target selection approach (Squire and Zola-Morgan 1991; 
Cabeza et al. 2002; Lee et al. 2006a).  Finally, the number of target genes could have 
simply been too few. 
 
The positive correlation between cerebellar post mortem brain pH and MMSE score 
in IPD patients is an interesting result.  We were unable to find any published study 
reporting this finding.  One potential explanation might relate to CBF.  This is 
decreased in the IPDD IPC, precuneus, and PCC, suggesting a relationship between 
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hypoperfusion and cognitive impairment in IPD (Firbank et al. 2003; Osaki et al. 
2009).  Reduced CBF would be expected to lower pH in the brain.  Therefore our 
observed correlation between cerebellar pH and MMSE might be indicative of this 
relationship, adding further evidence in support of the published findings, and 
suggesting that they could be relevant to the IPD cerebellum.  Nevertheless, this 
conclusion is potentially weakened by several confounding factors.  Interindividual 
differences in agonal state (the state during the time immediately preceding death), 
notably in cause of death, might have affected post mortem pH via the opposing 
processes of acidosis and alkalosis.  Furthermore, MMSE was not consistently 
measured at the same time before death in these individuals, which could have 
introduced a bias into the correlation. 
 
The underexpression of DUSP6 observed in the IPD DLPFC was robust.  The best 
estimate of this effect is that on average, IPD cases express total DUSP6 FL at ~60% 
of the level found in controls (see 3.3.4).  Expression data for total DUSP6 1:3 
indicate that this phenomenon is not caused by modulated splicing.  Moreover, the 
majority of DUSP6 locus SNP variation did not associate with IPD and the detected 
cis-acting influence was relatively weak (see below), which suggests that DUSP6 
underexpression does not have a primary genetic aetiology.  Neuronal cell death is a 
potential confound.  Indeed, demented IPD patients exhibit greater atrophy in BA46 
than controls or their nondemented counterparts, although no differences are seen 
when comparing IPDND with controls (Burton et al. 2004; Nagano-Saito et al. 
2005).  Furthermore, the detected reductions in NLC DUSP6 FL and 1:3 expression 
were merely nonsignificant trends, suggesting that a proportion of the DUSP6 
underexpression in the IPD DLPFC might be caused by neuronal loss.  However, this 
possibility is unlikely to be the case for three main reasons: the total expression data 
were normalised with multiple reference genes which buffers against variation in 
tissue composition and experimental procedure (and would be expected to so more 
effectively than a single neuronal marker gene); NLC expression displayed changes 
of a similar direction and magnitude as total expression (albeit with more intragroup 
variation); and total DUSP6 FL expression values for the IPDD and IPDND groups 
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were very similar, despite the reported differences in BA46 atrophy.  We cannot 
exclude the possibility that the underexpression of DUSP6 seen in the IPD DLPFC 
results in part from altered glial expression.  Taken together, these results suggest that 
two possible explanations remain: changes in DUSP6 transcriptional activity and/or 
alterations in DUSP6 mRNA stability.  These could be caused by modulation in many 
processes, such as TF binding and/or stability, epigenetic modification, or RNA 
interference.  Whatever the reason behind DUSP6 differential expression, our data 
suggest that this phenomenon is probably a secondary effect of IPD pathogenesis. 
 
The role played by DUSP6 in primary disease aetiology was evaluated using DNA 
sequencing and SNP association analyses.  The sequencing data identified one FPD-
restricted 5’UTR point mutation, +460G>C, which abolishes a predicted binding site 
for the TF NR3C1.  However, the lack of available relatives precluded our ability to 
assess whether +460G>C segregates with FPD.  Despite the limited number of 
samples, these findings suggest that DUSP6 mutation is unlikely to be a significant 
cause of FPD.  In contrast, the results of the SNP association study implied that the 
rs1689048 minor allele confers reduced susceptibility to IPD.  Post hoc calculations 
showed that the sample size provided 80% power to detect an effect of OR ≈ 0.67 
with the observed control MAF at a significance of corrected p ≤ 0.05 (disease 
prevalence = 0.01).  This suggests that the experiment was underpowered to 
confidently demonstrate significance for the observed trend. 
 
Genotypic VBM analysis demonstrated that normal rs1689048 heterozygotes exhibit 
significantly higher grey matter density in several cortical and subcortical regions.  
These findings are not without precedent.  Variation at the nonsynonymous Ile62Met 
polymorphism residing in Dusp6 exon 1 significantly influences murine brain weight 
and anterior and hippocampal commissure size (Liu 2008).  We observed effects in 
areas that acquire LP during IPD pathogenesis, such as the caudate, amygdala, 
hippocampus, medial EC, and subgenual ACC (Braak et al. 2003).  Interestingly, 
several of these are known to display significant associations between LP burden and 
dementia in IPD patients i.e. the medial EC, amygdala, and hippocampus (Kovari et 
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al. 2003; Kalaitzakis et al. 2009a).  Moreover, results were seen in regions that 
mediate critical cognitive and/or affective processes, some of which are relevant to 
IPD dementia.  These include the ACC, OFC, and DLPFC which project to the 
striatum (specifically to the caudate, in the case of the OFC and DLPFC), forming 
part of the anterior cingulate, lateral orbitofrontal, and dorsolateral prefrontal loops, 
respectively (Alexander et al. 1986).  The subgenual ACC is involved in affective 
processing and is activated by emotional attention tasks and depression (Bush et al. 
2000).  The lateral OFC is believed to regulate both executive ability, specifically the 
evaluation of novel stimuli that can result in behavioural change e.g. reversal 
learning, and the extent to which such information is encoded in declarative memory 
(Kringelbach 2005; Petrides 2007).  The DLPFC controls the monitoring and 
manipulation of items held in WM (Petrides 2000).  Other examples include the 
superior frontal pole, which is thought to be involved in executive functioning, 
specifically enabling the interposition of two concurrent mental strategies (Koechlin 
and Hyafil 2007); and the hippocampus and medial EC, which together constitute a 
well-established interconnected network that mediates the storage of information in 
declarative memory (Squire and Zola-Morgan 1991).  Furthermore, rodent lesion 
studies suggest that the medial EC may also be implicated in WM and attention 
(Coutureau and Di Scala 2009).  Given our trends potentially connecting AG DUSP6 
expression to IPD dementia, these data hint at the possibility that the role of DUSP6 
might extend to this disease subtype. 
 
The cis-acting variation analysis results implied that rs1689408 heterozygotes exhibit 
increased DLPFC DUSP6 FL/1:3 ratios.  However, variation at this SNP does not 
seem to influence DLPFC DUSP6 FL expression per se.  We arrived at these 
conclusions because very similar fold change values were detected for total and NLC 
FL/1:3 ratios, whereas the fold change values for total and NLC FL expression were 
markedly different from each other.  Nevertheless, the FL/1:3 ratio results were 
nonsignificant trends after correction, indicating that this finding is both preliminary 
and describing a relatively weak effect.  Post hoc calculations showed that the sample 
size provided 80% power to detect 1.5-fold ± 0.34-fold (SD) differences at a 
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significance of corrected p ≤ 0.05.  This suggests that levels of intragroup variation 
were too large and/or the sample size too small to confidently demonstrate 
significance for the observed trends.  Critically, our combined data suggest that this 
effect of SNP variation on DUSP6 splicing is most likely distinct from the more 
general DUSP6 underexpression effect observed in the IPD DLPFC. 
 
In conclusion, it was shown that DUSP6 expression is significantly decreased in the 
IPD DLPFC, but unaltered in seven other subcortical and cortical regions of the IPD 
brain, and that DUSP6 mutation is unlikely to be a major cause of FPD.  Moreover, 
the results indicated that genetic variation in the DUSP6 locus marginally alters IPD 
risk and profoundly affects the structure of several human brain areas, possibly by 
influencing the splicing of this gene. 
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Chapter 4: Idiopathic Parkinson’s disease 
cognitive expression microarray analysis 
and genetic characterisation of Ephrin 
receptor A2 
4.1. Introduction 
Microarray-based approaches have been used to investigate gene expression in the 
Parkinson’s disease (PD) brain, successfully expanding our understanding of this 
condition.  These findings have strengthened the role of known molecular players and 
pathways, and provided evidence that corroborates emerging research avenues (see 
below).  Most studies have understandably focused on the substantia nigra (SN), 
although these techniques have also been employed to scrutinise other brain areas.  
When one compares publications examining the same region, there is considerable 
overlap of dysregulated pathways, even if the contents of gene lists vary (see below).  
Disparities arise from many interacting factors, including differences in array 
platform, sample quality and preparation (e.g. the use of whole tissues or specific cell 
types), disease stage(s) and course(s) of the patients under study, and data analysis 
methodology.  The necessary constraint of using post mortem tissue usually obtained 
from late stage disorder suggests that a sizeable proportion of the detected changes 
are probably secondary effects arising during the disease process.  At first glance, this 
seems disappointing for researchers interested in primary genetic aetiology.  
However, neuronal cell death in PD is most likely caused by a complex interplay of 
genetic, epigenetic, and environmental factors operating over many years [reviewed 
in (Lesage and Brice 2009)].  Consequently, these secondary effects probably drive 
disease progression at the molecular level and contribute to its clinical manifestation.  
Therefore, expression microarray techniques represent a powerful approach, with the 
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potential to elucidate key events in PD pathogenesis and generate novel therapies for 
this disorder. 
 
One of the first microarray studies investigated gene expression in substantia nigra 
pars compacta (SNpc) whole tissue extracts.  The authors found that in PD, signal 
transduction, protein degradation, energy/glycolysis, and iron transport pathways 
were downregulated, whereas those involved in the extracellular matrix (ECM), 
cytoskeleton/cell adhesion, and inflammation/hypoxia were upregulated (Grunblatt et 
al. 2004).  Another early report also assessed SN whole tissues.  This demonstrated 
PD-associated expression increases amongst heat shock genes, and decreases 
amongst genes mediating mitochondrial function, the ubiquitin-proteasome system 
(UPS), and protein trafficking.  Within the final group, many of the hits regulated 
neurotransmitter secretion (Hauser et al. 2005).  Zhang et al. analysed the SN, 
putamen, and dorsolateral prefrontal cortex (DLPFC) (Brodmann area 9 [BA9]) in 
parallel.  They observed several group-based alterations that occurred across all (or 
two) of the regions tested.  In PD, these included upregulation of heat shock, 
metallothionein, and polypyrimidine tract-binding genes, and downregulation of 
proteasome and mitochondrial electron transport chain (ETC) components, 
specifically constituents of complexes I, III, and IV (Zhang et al. 2005b).  These data 
support the notion of PD as a multisystem disease involving several areas of the 
brain, and fit well with the widespread Lewy pathology (LP) detected in patients post 
mortem (Braak et al. 2003).  This postulate was further bolstered by a study which 
focused on the SN but also examined the superior frontal gyrus, and observed 
significant genetic coregulation across these regions.  The results identified numerous 
pathways that displayed PD-based expression changes in the SN, including those 
involved in metal ion binding, transport, signaling, nucleic acid binding, protein 
synthesis/breakdown, and cell adhesion (Moran et al. 2006). 
 
The microarray experiments discussed so far were all performed using whole tissue 
extracts.  Consequently, reports of dysregulated gene expression might not be “true” 
hits, but instead could represent artefacts arising from neuronal cell death and/or 
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gliosis.  Moreover, it is difficult to ascertain the relative contribution of specific cell 
types (e.g. neurons or glia) to observed differences in expression.  Cantuti-Castelvetri 
et al. circumvented these problems by employing laser capture microdissection 
(LCM) to examine expression exclusively in SNpc dopaminergic neurons.  They 
detected PD-associated alterations of several gene groups, such as those mediating 
metal ion transport, cell-cell signaling, neurotransmitter secretion, and synaptic 
transmission.  Furthermore, this was the first study to investigate gender-specific 
changes in PD.  In females, protein kinase and proteolytic gene groups were 
dysregulated, whereas in males, the notable groups were those involved in protein-
protein interactions and copper binding (Cantuti-Castelvetri et al. 2007).  Simunovic 
et al. also used LCM to analyse SNpc dopaminergic neurons.  In PD, their results 
demonstrated increased expression of pathways regulating apoptosis, inflammation, 
and cell survival, and decreased expression of pathways involved in ion transport, 
synaptic transmission, cytoskeletal maintenance, microtubule function, chaperone 
function, the UPS, and the mitochondrial ETC.  Several PD-linked PARK locus genes 
were also downregulated (Simunovic et al. 2009). 
 
Another recent publication assessing the SN took a slightly different approach to 
control for neuronal loss.  The most intact regions (i.e. the most pigmented due to 
neuromelanin content) were selected for analysis.  Moreover, the percentage 
reduction in neuronal density due to PD was measured, enabling the authors to more 
accurately evaluate changes in gene expression per neuron.  One advantage of this 
methodology is that it still permits the quantification of nonneuronal (e.g. glial) 
expression (Bossers et al. 2009).  The data indicated PD-associated alterations in 
neurotrophin signaling, axonal guidance, and synaptic transmission pathways, and 
demonstrated upregulation of gene groups involved in iron binding, cytoskeletal 
protein binding, and the ECM, as well as downregulation of groups mediating 
microtubule-based movement, oxidative phosphorylation, and the proteasome 
(Bossers et al. 2009).  Consilient themes of dysfunctional pathways emerge from 
these studies, many of which play well-documented roles in PD and/or animal models 
thereof.  Examples include the UPS, the mitochondrial ETC, oxidative stress, metal 
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ion binding/transport, synaptic transmission, axonal guidance, 
cytoskeletal/microtubule function, inflammation, cell adhesion/the ECM, 
chaperone/heat shock function, signal transduction, and apoptosis [reviewed in 
(Abou-Sleiman et al. 2006b; Sulzer 2007; Lin et al. 2009a; Hirsch and Hunot 2009)]. 
 
Until recently, microarrays had not been used to investigate gene expression in 
Parkinson’s disease dementia (PDD).  However, the study published by Stamper et 
al. changed the landscape of PD cognitive genetics.  LCM was employed to isolate 
layer V and VI pyramidal neurons from the posterior cingulate cortex (PCC) of PD 
patients with and without dementia (and controls).  Affymetrix’s Human Genome 
U133 array was subsequently used to compare expression in these groups (Stamper et 
al. 2008).  The results demonstrated that in PD dementia, genes mediating 
mitochondrial function and inflammation were downregulated and upregulated, 
respectively.  In terms of PD neurodegeneration, differential expression was observed 
for genes regulating the proteasome, oxidative stress, axonal transport, axonal 
pathfinding, and synaptic transmission.  Interestingly, the authors identified a subset 
of genes displaying changes of a similar direction in the PD demented vs 
nondemented and PD nondemented vs control comparisons.  These were inferred to 
represent candidate “initiators” of dementia; cell adhesion, ribonucleic acid (RNA) 
splicing, and axonal transport were highlighted as key pathways putatively involved 
in this process (Stamper et al. 2008). 
 
In summary, microarrays can reveal primary and secondary changes in gene 
expression, both of which probably contribute to the molecular pathogenesis of PD.  
These experiments have demonstrated that numerous genetic pathways exhibit 
dysregulation in the PD brain, corroborating evidence obtained using alternative 
genetic and biochemical approaches.  The only published expression microarray 
study of PDD has pinpointed mitochondrial function, inflammation, cell adhesion, 
RNA splicing, and axonal transport as critical pathways implicated in this disease 
subtype. 
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4.2. Aims and methodology 
Based on the background literature discussed in this (see 4.1) and the last chapter  
(see 3.1), it was hypothesised that there might be a relationship between idiopathic 
Parkinson’s disease (IPD) dementia status and gene expression in the DLPFC, and 
that single nucleotide polymorphism (SNP) variation might influence IPD risk and 
gene expression.  Therefore, the aims and methodology of this chapter were as 
follows: 
 
1. Identify genes implicated in IPD dementia and/or neurodegeneration.  
Affymetrix GeneChip Exon 1.0 sense target (ST) oligonucleotide microarrays 
were used to compare genome wide messenger RNA (mRNA) gene expression in 
complementary DNA (cDNA) generated (see 2.8.2) from IPD microarray series 
(idiopathic Parkinson’s disease with dementia [IPDD]; idiopathic Parkinson’s 
disease no dementia [IPDND]; controls) DLPFC (BA46) (see 2.8.1).  This was 
called the IPD cognitive expression microarray analysis (see 2.10.6).  This array 
platform can detect differential gene expression and alternative exon splicing.  
Sample RNA quality was assessed using an Agilent 2100 Bioanalyzer (see 
Appendix) (see 2.8.1).  Analysis was performed at the exon and gene levels.  Data 
preprocessing was conducted using the robust multichip average (RMA) 
algorithm, and microarray quality control (QC) was carried out (see 2.10.6.1).  
The three group study design was identical to that employed for the IPD cognitive 
gene expression analysis (and similar to the approach used by Stamper et al.).  As 
before, it enabled the discrimination of expression signatures related to specific 
IPD subtypes i.e. IPD dementia, IPD neurodegeneration, or both (see figure 3.1).  
Statistical comparisons were performed on log2 data by modified t test, with 
significance set at uncorrected p < 0.01 (see 2.10.6.1).  The false discovery rate 
(FDR) approach was employed for multiple testing correction, but hits were 
identified by uncorrected significance due to biological variation and 
experimental constraints (see 4.3.2).  Gene ontology (GO) terms (release 24th 
January 2010) associated with each microarray hit were collected (see 2.10.6.2).  
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Selected hits were validated using Sybr Green quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR) to measure total and neuronal loss-
corrected (NLC) mRNA expression in IPD cognitive series DLPFC cDNA batch 
2 (see 3.2).  Total expression data were normalised with a normalisation factor 
(NF) calculated from the reference genes Glucose-6-phosphate dehydrogenase 
(G6PD), Ribosomal protein L13A (RPL13A), and TATA box binding protein 
(TBP).  NLC expression data were normalised with the neuronal marker 
Neurofilament H (NEFH) acting as reference gene (see 3.2).  Statistical 
comparisons were carried out by Mann-Whitney test, with significance set at 
corrected p ≤ 0.05 (see 2.10.2.2).  So as to reduce the risk of pursuing false 
positives, only those genes exhibiting significant dysregulation in both the 
microarray and qRT-PCR analyses underwent further characterisation (henceforth 
called target genes). 
2. Examine target gene mRNA expression in multiple brain regions.  In order to 
further investigate target gene expression in IPD, Sybr Green qRT-PCR was 
employed to measure total and NLC target gene mRNA expression in medulla, 
putamen, amygdala, entorhinal cortex (EC [BA28]), anterior cingulate cortex 
(ACC [BA24]), angular gyrus (AG [BA39]), and frontal cortex (FC [BA8]) 
cDNA obtained from the IPD mapping series (see 3.2).  Total expression data 
were normalised with a NF calculated from the most stable set of the following 
reference genes: G6PD, RPL13A, and TBP, and Hypoxanthine 
phosphoribosyltransferase 1 (HPRT1).  NLC expression data were normalised 
with the NEFH (see 3.2).  Statistical comparisons were carried out by Mann-
Whitney test, with significance set at corrected p ≤ 0.05 (see 2.10.2.2).  Brain 
region expression data were not compared with each other statistically. 
3. Investigate the effect of target gene SNP variation on IPD risk and target 
gene mRNA expression.  This aim consisted of two parts.  In order to ascertain 
whether target gene SNP variation influences IPD susceptibility, a case-control 
genetic association study was performed, by using HapMap phase II Centre 
d’Étude du Polymorphisme Humain (CEPH) trio genotypic data (release 23a from 
March 2008) and Tagger to generate haplotype-tagging single nucleotide 
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polymorphisms (htSNPs), and TaqMan-genotyping IPD association series 
genomic DNA (gDNA) samples (see 3.2).  Statistical assessment of allelic 
association under a multiplicative model was carried out by χ2 test in Haploview, 
with significance set at corrected p ≤ 0.05 (see 2.10.3.2).  So as to discover 
whether target gene SNP variation affects target gene expression, cis-acting 
variation analysis was performed using cognitive series total and NLC DLPFC 
target gene mRNA expression data (batch 2) (see 3.2).  Statistical comparisons 
were carried out by Mann-Whitney test, with significance set at corrected p ≤ 0.05 
(see 2.10.5). 
4. Evaluate hypotheses relevant to target gene differential expression and IPD 
pathogenesis.  In order to evaluate hypotheses relevant to target gene differential 
expression and IPD pathogenesis, in silico data mining was performed.  The 
following bioinformatic resources were consulted to obtain lists of candidate 
genes: BioGRID, Kyoto Encyclopaedia of Genes and Genomes (KEGG), Online 
Mendelian Inheritance in Man (OMIM), University of California Santa Cruz 
(UCSC) PhyloP (assembly hg18), Ensembl (release 48 from December 2007), 
and PROMO.  Log2 microarray data were then mined in silico, and groups 
compared for candidate gene expression.  Depending on distribution normality, 
statistical comparisons were carried out by t test or Mann-Whitney test, with 
significance set at uncorrected p ≤ 0.05.  p values were uncorrected due to prior 
hypothesis (see 2.10.6.3).  Selected mining hits were validated using qRT-PCR to 
measure total and NLC expression in cognitive series DLPFC cDNA batch 2 (see 
above).  Statistical comparisons were performed by Mann-Whitney test, with 
significance set at corrected p ≤ 0.05 (see 2.10.2.2). 
5. Investigate the relationship between variation in target gene promoter CpG 
methylation and IPD.  So as to elucidate mechanisms underlying target gene 
differential expression, CpG methylation analysis was carried out (see 2.9).  
Methyl-specific polymerase chain reaction (MSP) (see 2.9.4) was employed to 
compare target gene relative CpG methylation in bisulphite-converted DLPFC 
gDNA (see 2.9.3) obtained from the IPD MSP series (IPD; controls) (see 2.9.1).  
MSP products were then resolved on agarose gels. 
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4.3. Results 
4.3.1. Idiopathic Parkinson’s disease cognitive 
expression microarray analysis: quality control 
Microarrays were used to quantify genome wide exon and gene expression in the 
microarray series DLPFC.  The microarray experiment was performed in 
collaboration with the Gene Microarray Centre (Institute of Child Health, University 
College London [UCL]) and the Bloomsbury Centre for Bioinformatics (UCL).  
Members of the former carried out the RNA quality assessments and microarray 
procedures; Dr. Sonia Shah at the latter performed the microarray preprocessing, QC, 
and statistical analyses.  Before examining the microarray QC data, the microarray 
series was assessed for comparability based on clinicopathological characteristics.  
Group data for age of onset, age of death, disease duration, post mortem delay 
(PMD), post mortem brain pH, and mini mental state examination (MMSE) were 
analysed.  After correction for multiple testing, the three groups (IPDD [n = 7]; 
IPDND [n = 7]; control [n = 7]) were not significantly different with regard to any of 
the first five metrics, indicating that they are comparable (see table 4.1).  However, 
group MMSE scores for IPDD were significantly lower than those for IPDND 
(corrected p = 0.048), indicating that based on carer report and the available MMSE 
data, these two groups can be considered as IPD patients with and without dementia, 
respectively.  Table 2.9 shows individual clinicopathological data for each member of 
the microarray series. 
 
The expression microarray QC data can be seen in figures 4.1 and 4.2.  Receiver 
operator curves (ROCs) evaluate how well the summarisation method separates 
exonic (positive) and intronic (negative) controls present on each array.  The area 
under the curve (AUC) value for each chip fell between 0.8 and 0.9, indicating a low 
likelihood of false positives (data not shown).  Pairwise microarray fluorescence 
correlations identify chips outlying the others in terms of total fluorescence, thereby 
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assessing overall array performance.  For data normalised at both the exon and gene 
levels, most of the coefficients were high (r ≥ 0.95), although the P24/94 and P59/00 
chips were slightly less correlated to the others (data not shown).  The intensity 
distribution histogram (IDH) curves for most arrays overlapped relatively well, 
indicating that microarray technique and RNA quality were of a good standard.  
However, this was less apparent in the gene level-normalised data. 
 
MvA scatter plots were used to evaluate variation between the biological replicates 
comprising each group.  For the most part, variation between the IPDD samples was 
relatively high.  P18/01 exhibited marked differences from several other members of 
this group.  These were visible in the exon level data, but much more pronounced in 
the gene level data.  Similar patterns were observed for P24/94 and P59/00, although 
these were less extreme.  Variation within the IPDND group was notably lower.  One 
exception was P75/00, which also displayed its differences more extensively in the 
gene rather than the exon level data.  Variation between the control samples fell 
somewhere between that seen within the two IPD groups.  C03/00 was clearly 
different from the other controls, with C04/99 only slightly less so.  Again, these 
observations were more pronounced in the gene level data when contrasted against 
the exon level data. 
 
Taken together, these results demonstrate that the expression microarray data is 
generally high quality but possesses marked levels of biological variation, 
particularly in terms of the gene level-normalised data.  Therefore, the expression 
array analysis will possess reduced statistical power.  This is exemplified by the gene 
level principal components analysis (PCA) plot, which showed that the majority of 
samples did not cluster according to group (see figure 4.3). 
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Group 
(n) 
Statistic 
Age of 
onset 
Age of 
death 
Disease 
duration 
PMD 
Brain 
pH 
MMSE 
Mean NA 80.7 NA 27.0 6.52 ND CON 
(7) SD NA 7.0 NA 16.7 0.18 ND 
Mean 54.1 73.3 19.2 38.1 6.15 19.9 IPDD 
(7) SD 9.6 5.0 10.4 13.8 0.23 4.9 
Mean 59.4 75.1 15.7 48.8 6.43 29.5 IPDND 
(7) SD 10.7 8.0 4.5 33.1 0.37 0.6 
Uncorrected 0.338 0.175 0.443 0.318 0.019 0.008 
p value 
Corrected NS NS NS NS 0.114 0.048 
 
Table 4.1. IPD microarray series clinicopathological data. 
Group clinicopathological metrics and statistical results for the IPD microarray series.  After correction 
for multiple testing, the first five metrics were not significantly different, indicating that the groups are 
comparable.  However, MMSE was significantly lower in the demented patients.  Together with carer 
reports regarding cognitive impairment or change in personality (see table 2.9), this result indicates 
that the IPDD and IPDND groups are correctly labelled as such.  Measures of time are in years, except 
for PMD, which is measured in hours.  Groups were compared by Mann-Whitney or Kruskal-Wallis 
test as appropriate.  p values were corrected x6.  CON = control; IPDD = idiopathic Parkinson’s 
disease dementia; IPDND = idiopathic Parkinson’s disease no dementia; MMSE = mini mental state 
examination; NA = not applicable; ND = not determined; NS = not significant; PMD = post mortem 
delay; SD = standard deviation. 
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Figure 4.3. Cognitive expression microarray gene level PCA plot. 
Cognitive expression microarray PCA plot for gene level-normalised data.  PCA mapping identified 
two principal components that together account for 42.7% of the variation in expression.  The majority 
of samples did not cluster according to group, indicating high levels of intragroup variation.  CON = 
control; IPDD = idiopathic Parkinson’s disease dementia; IPDND = idiopathic Parkinson’s disease no 
dementia; L = left hemisphere; PCA = principal components analysis; R = right hemisphere. 
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4.3.2. Idiopathic Parkinson’s disease cognitive 
expression microarray analysis: results overview 
Given the huge number of statistical tests carried out when analysing microarray data, 
it is necessary to perform correction for multiple testing.  Bonferroni correction is 
generally considered too harsh for this kind of analysis, and other methods are 
available.  The FDR approach was selected for the cognitive expression microarray 
analysis.  Table 4.2 shows the number of differentially-expressed exons and genes for 
each of the three intergroup comparisons.  The results demonstrated that no events 
pass the FDR threshold p < 0.05.  The only potential hit was an exon downregulated 
in IPDD vs controls, but this proved to be expressed below the signal-noise cut-off 
point (see 2.10.6.2).  This lack of hits was perhaps unsurprising, when one considers 
the relatively high levels of biological variation observed in the IPDD and control 
groups (see 4.3.1). 
 
Consequently, a more relaxed threshold of uncorrected p < 0.001 was applied, so as 
to gain an overall picture of the extent of dysregulated expression.  Using this 
approach, multiple dysregulation events were observed (see table 4.2).  The analysis 
detected much more alternative splicing than differential expression.  For example in 
the IPDD vs control comparison, 709 exons were alternatively-spliced, whereas only 
68 genes were differentially-expressed.  Over all three comparisons, 945 alternative 
splicing and 73 differential expression events were observed.  Markedly more 
dysregulation events were seen in the IPDD vs control comparison than in either the 
IPDND vs control or IPDD vs IPDND comparisons; similarly low numbers of events 
were observed in these latter two comparisons.  For example, when contrasting IPDD 
vs controls against IPDND vs controls, 68 and 3 genes were differentially-expressed, 
respectively.  This was the case in both the exon and gene level analyses, and 
suggests that when both groups are compared to controls, more genetic dysregulation 
occurs in IPDD than in IPDND. 
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Exon level analysis 
Corrected 
p < 0.05 threshold 
IPDD vs CON IPDND vs CON IPDD vs IPDND 
Upregulated 0 0 0 
No change 175503 175504 175504 
Downregulated 1 0 0 
Uncorrected 
p < 0.001 threshold 
IPDD vs CON IPDND vs CON IPDD vs IPDND 
Upregulated 403 54 52 
No change 174795 175374 175398 
Downregulated 306 76 54 
Gene level analysis 
Corrected 
p < 0.05 threshold 
IPDD vs CON IPDND vs CON IPDD vs IPDND 
Upregulated 0 0 0 
No change 17817 17817 17817 
Downregulated 0 0 0 
Uncorrected 
p < 0.001 threshold 
IPDD vs CON IPDND vs CON IPDD vs IPDND 
Upregulated 39 1 2 
No change 15075 15140 15141 
Downregulated 29 2 0 
 
Table 4.2. IPD cognitive expression microarray analysis summary. 
Summary of dysregulation events observed in the IPD cognitive expression microarray analysis.  
Multiple genes demonstrated differential expression or alternative splicing at the uncorrected p < 0.001 
threshold, but none of these events survived FDR correction.  Exon level counts indicate alternative 
splicing events, and exclude situations where the majority of a gene’s exonic complement is 
dysregulated in the same direction; these are registered as gene level differential expression events.  
All data are displayed at two significance thresholds: FDR-corrected p < 0.05 and uncorrected  
p < 0.001.  CON = control; FDR = false discovery rate; IPD = idiopathic Parkinson’s disease; IPDD = 
idiopathic Parkinson’s disease dementia; IPDND = idiopathic Parkinson’s disease no dementia. 
 185 
Therefore, multiple genes demonstrated differential expression or alternative splicing 
in the expression microarray at the uncorrected p < 0.001 threshold, but none of these 
events survived FDR correction.  Given the high levels of biological variation (see 
figure 4.2) and the requirement for genes/exons to be significantly different in two 
comparisons (see figure 3.1), uncorrected p < 0.01 was employed as the significance 
threshold for identifying microarray hits.  We are aware that this decreases statistical 
confidence in the results.  Nonetheless, it is known that when examining microarray 
data, uncorrected significance is valid as long as certain conditions are met.  These 
conditions are that probes should be expressed above the signal-noise cut-off, group 
interquartile ranges should be sufficiently distant from each other, and hits should fit 
into a sensible biological context (M. Hubank, personal communication).  Thus, as 
long as the reduced statistical confidence is kept in mind, these uncorrected findings 
can be useful for flagging genes of potential importance. 
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4.3.3. Expression microarray: genes implicated in 
idiopathic Parkinson’s disease neurodegeneration 
Genes implicated in IPD neurodegeneration were filtered out of the microarray data, 
by identifying all of the genes/exons exhibiting dysregulation in both the IPDD vs 
control and IPDND vs control comparisons (uncorrected p < 0.01).  Using these 
criteria, six genes were differentially-expressed and 12 were alternatively-spliced (see 
table 4.3). 
 
Examining the National Center for Biotechnology Information (NCBI) Gene 
database, GO term associations, and literature indicates that these hits encompass 
several functional pathways relevant to IPD.  The first of these was synaptic 
transmission/ion transport.  The ion channel subunit-encoding genes FXYD domain 
containing ion transport regulator 2 (FXYD2) and Calcium channel, voltage-
dependent, α2/δ3 subunit (CACNA2D3) were alternatively-spliced.  FXYD2 
modulates the activity of the sodium-potassium adenosine triphosphatase (ATPase) 
which maintains neuronal resting potential (Geering 2006).  CACNA2D3 regulates 
voltage-dependent L-type Cav1.2 and Cav1.3 channels which mediate calcium influx 
during synaptic transmission.  Blocking Cav1.3 protects SNpc dopaminergic neurons 
from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced cell death in 
vivo (Chan et al. 2007).  Dysregulation of these genes could alter potassium and 
calcium ion transport, respectively, affecting neuronal viability in IPD (Sulzer 2007).  
Alternative splicing was also observed for Exocyst complex component 3-like 
(EXOC3L), potentially influencing neurotransmitter secretion.  Adenylate cyclase 
activating polypeptide 1 (ADCYAP1) was underexpressed, which may contribute to 
IPD-associated neuronal loss, as its encoded peptide hormone and neurotransmitter 
protects SNpc dopaminergic cells and improves parkinsonian symptoms in rats 
treated with 6-hydroxydopamine (6-OHDA) (Reglodi et al. 2004).  Given the well-
documented hyposmia that occurs early in IPD, it was interesting to see 
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downregulation of Olfactory receptor, family 2, subfamily M, member 4 (OR2M4) 
(Katzenschlager and Lees 2004). 
 
The next pathway of note was glycosylation/protein degradation.  Genes encoding 
two enzymes that regulate glycosylation, Mannosidase, α, class 1B, member 1 
(MAN1B1) and O-linked N-acetylglucosamine transferase (OGT), were alternatively-
spliced.  MAN1B1 is a member of the mannosidase I family, which controls the entry 
of substrates into the endoplasmic reticulum-associated degradation (ERAD) 
pathway.  This system mediates the retrotranslocation of misfolded proteins from the 
endoplasmic reticulum (ER) to the cytosol, where they are destroyed by the UPS.  
ERAD is thought to play a role in protein aggregation during IPD pathogenesis 
(Yoshida 2007).  OGT catalyses the addition of N-acetylglucosamine onto Ser/Thr 
residues in a wide range of substrates, thereby influencing several neuronal processes, 
including proteasomal degradation, transcription, signaling, and axonal transport.  
Furthermore, there is evidence to suggest that OGT regulates Microtubule-associated 
protein tau (MAPT) phosphorylation and stability (Lazarus et al. 2009).  
Dysregulation of these genes could alter glycosylation and/or protein degradation and 
affect neuronal cell death in IPD. 
 
Inflammation/immune response was the third implicated pathway.  Four genes of 
known or putative immunological function were dysregulated: Interferon, α-inducible 
protein 27 (IFI27); Lymphocyte antigen 6 complex, locus K (LY6K); V-rel 
reticuloendotheliosis viral oncogene homologue B (RELB); and Retinoic acid 
receptor responder 2 (RARRES2).  RELB is a member of the Nuclear factor κ light 
polypeptide gene enhancer in B-cells (NFKB) transcription factor (TF) family.  This 
pathway can be induced by multiple stimuli, including inflammation and stress, and 
influences neuronal cell death outcomes both directly and indirectly, via glial-
mediated proinflammatory cytokine release (see below) (Memet 2006).  Moreover, 
NFKB is activated in IPD SNpc dopaminergic cells, and its inhibition protects SNpc 
dopaminergic neurons and ameliorates locomotor dysfunction in MPTP-treated mice 
(Hunot et al. 1997; Ghosh et al. 2007).  RARRES2 is a chemotactic protein that 
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attracts dendritic cells, macrophages, and natural killer cells to sites of inflammation 
(Moretta et al. 2008).  In our series, the expression of these four genes may well be 
glial-derived, and the observed changes could affect inflammatory and/or immune 
processes and modulate IPD-associated neuronal loss.  Indeed, inflammation 
resulting from reactive gliosis, and possibly even gliodegeneration, are believed to 
contribute to IPD pathogenesis (Croisier and Graeber 2006). 
 
The final dysregulated pathway was transcription/translation, which encompassed 
POU class 4 homeobox 3 (POU4F3), Quaking homologue, KH domain RNA binding 
(QKI), and RELB.  POU4F3 encodes a TF that regulates inner ear hair cell survival 
and migration in mouse models (Xiang et al. 1998).  Mutations in this gene cause 
autosomal dominant deafness in humans (OMIM #602459), apparently through 
inhibition of DNA binding and transcription (Collin et al. 2008).  QKI is an RNA-
binding protein which controls myelination, oligodendrocyte differentiation, and 
apoptosis, via its effects on RNA splicing, stabilisation, and translation (Chenard and 
Richard 2008).  Dysregulation of POU4F3, QKI, and RELB (see above) could alter 
the expression of their target genes and influence neuronal cell death in IPD. 
 
Overall, these results suggest that synaptic transmission/ion transport, 
glycosylation/protein degradation, inflammation/immune response, and 
transcription/translation pathways are dysregulated in IPD neurodegeneration. 
 
 
Table 4.3. Cognitive expression microarray: genes implicated in IPD neurodegeneration. 
Genes exhibiting dysregulated expression or splicing implicating them in IPD neurodegeneration 
(following pages).  The results suggest that synaptic transmission/ion transport, glycosylation/protein 
degradation, inflammation/immune response, and transcription/translation pathways are dysregulated 
in IPD neurodegeneration.  Genes are listed alphabetically, with the differential expression group 
preceding the alternative splicing group.  All p values were uncorrected, except those marked with §, 
which were FDR-corrected.  Uncorrected IPDD vs IPDND p values were nonsignificant for all listed 
genes.  GO term associations were obtained from the GO database (release 24th January 2010); GO 
term identity codes are bolded.  See list of abbreviations for gene symbol definitions.  ATPase = 
adenosine triphosphatase; CON = control; FDR = false discovery rate; GO = gene ontology; IPD = 
idiopathic Parkinson’s disease; IPDD = idiopathic Parkinson’s disease with dementia; IPDND = 
idiopathic Parkinson’s disease no dementia; pwy = pathway; RNA = ribonucleic acid; mRNA = 
messenger RNA; Src = Sarcoma; SH2 = Src homology 2; SH3 = Src homology 3; sig = signaling. 
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4.3.4. Expression microarray: genes implicated in 
idiopathic Parkinson’s disease dementia 
Genes implicated in IPD dementia were filtered out of the microarray data by 
identifying all of the genes/exons exhibiting dysregulation in both the IPDD vs 
control and IPDD vs IPDND comparisons (uncorrected p < 0.01).  Using these 
criteria, six genes were differentially-expressed and 22 were alternatively-spliced (see 
table 4.4). 
 
As before, the NCBI Gene database, GO term associations, and literature were 
examined to identify functional pathways.  The first of these was mitochondria/metal 
binding.  Dysregulation was observed for Arginyl-transfer RNA synthetase 2, 
mitochondrial (RARS2); Aminolevulinate, δ-, synthase 2 (ALAS2); Ubiquinol-
cytochrome c reductase, Rieske iron-sulphur polypeptide 1 (UQCRFS1); Ferritin, 
heavy polypeptide 1 (FTH1); and Selenoprotein W, 1 (SEPW1).  The first three genes 
encode mitochondrial proteins.  The last four are involved in metal binding, 
specifically iron, in the case of ALAS2, UQCRFS1, and FTH1.  Post mortem and 
imaging studies demonstrate increased levels of iron accumulation in the SN of IPD 
patients compared to controls.  Moreover, iron catalyses the Fenton reaction, which 
converts hydrogen peroxide (H2O2) into reactive oxygen species (ROS), thereby 
enhancing oxidative stress (Rhodes and Ritz 2008).  ALAS2 is expressed in the 
mitochondrial matrix where it regulates heme biosynthesis (Napier et al. 2005).  
UQCRFS1 is the iron-sulphur-binding subunit of ubiquinol-cytochrome c reductase 
(also known as complex III), which transfers electrons from ubiquinol to cytochrome 
c and contributes to the proton gradient as part of the mitochondrial ETC (Trumpower 
1990).  UQCRFS1 dephosphorylation may play a role in the mitochondrial 
permeability transition that ultimately results in the cytosolic release of proapoptotic 
proteins during cellular stress (He and Lemasters 2005).  The Ferritin protein, which 
is composed of subunits encoded by FTH1 and Ferritin, light polypeptide (FTL), 
mediates iron storage in glia, and to a lesser extent, neurons (Rhodes and Ritz 2008).  
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Excessive ferritin-bound iron can interfere with microglial inflammatory processes 
(Crichton et al. 2002).  FTL mutation causes a neurodegenerative disease 
characterised by ferritin-positive intracellular bodies detectable throughout the brain; 
its symptoms include parkinsonism and cognitive impairment (Vidal et al. 2004).  
Moreover, Iron responsive element binding protein 2 (Ireb2) knockout mice express 
increased levels of Ferritin and Alas2, and develop a neurodegenerative parkinsonian 
movement disorder (Lavaute et al. 2001; Cooperman et al. 2005).  RARS2 encodes a 
mitochondrial arginyl-transfer RNA (tRNA) synthetase, whose mutation causes 
autosomal recessive mitochondrial ETC impairment and pontocerebellar atrophy 
(OMIM #611523) (Edvardson et al. 2007).  SEPW1 is a selenium-binding 
oxidoreductase that can protect cells from H2O2-mediated toxicity (Chen and Berry 
2003).  Dysregulation of these five genes could affect mitochondrial function and/or 
metal binding, thereby altering oxidative stress and neuronal loss in IPDD. 
 
Axonal guidance/cytoskeleton was the next implicated pathway.  Dysregulation was 
observed for Ephrin receptor A2 (EPHA2) (see also figure 4.4a); Keratin 9 (KRT9); 
Midline 1 interacting protein 1 (MID1IP1); Outer dense fibre of sperm tails 2 
(ODF2); Protein phosphatase 1, regulatory subunit 16A (PPP1R16A); and Rho-type 
guanosine triphosphatase-activating protein RICH2 (RICH2).  EPHA2 is a receptor 
Tyr kinase that regulates axonal guidance and dopaminergic neurogenesis during 
development (Brittis et al. 2002; Aoki et al. 2004).  This protein also seems to play a 
role in inflammatory responses, migration, tumourigenesis, and radiation-induced 
apoptosis, probably through its Rho family-mediated inhibition of cell adhesion 
(Ivanov and Romanovsky 2006; Pasquale 2008; Zhang et al. 2008).  RICH2 promotes 
Rho family guanosine triphosphatase (GTPase) activity and is involved in actin 
cytoskeletal dynamics (Richnau and Aspenstrom 2001; Rollason et al. 2009).  
PPP1R16A regulates Protein phosphatase 1 activity towards the cytoskeletal 
component myosin (Yong et al. 2006).  MID1IP1 cooperates with the protein product 
of Midline 1 (MID1) to stabilise microtubules (Berti et al. 2004).  X-linked Opitz 
syndrome is characterised by corpus callosum dysplasia and mental retardation 
(OMIM #300000).  This condition is caused by MID1 mutation, resulting in 
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stabilisation of Protein phosphatase 2A and hypophosphorylation of microtubule-
associated proteins (Trockenbacher et al. 2001).  ODF2 is necessary for centrosome-
mediated microtubule organisation and normal mitotic progression (Soung et al. 
2006).  This protein is also required for primary cilia formation, and may therefore 
modulate the function of plasma membrane sensory receptors (Ishikawa et al. 2005).  
Dysregulation of these six genes might influence cytoskeletal dynamics and IPDD 
pathogenesis. 
 
The third highlighted pathway was synaptic transmission/ion transport.  Brain 
angiogenesis inhibitor 1-associated protein 3 (BAIAP3); Glutamate receptor, 
ionotrophic, AMPA 4 (GRIA4); and Transient receptor potential cation channel, 
subfamily M, member 4 (TRPM4) were alternatively-spliced.  GRIA4 encodes a 
subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) Glu 
receptor cation channel which regulates postsynaptic membrane depolarisation.  
AMPA receptors containing GRIA4 may mediate some forms of long term 
potentiation (LTP) (Sprengel 2006).  TRPM4 is a monovalent cation-selective ion 
channel that regulates postsynaptic membrane depolarisation and cytosolic calcium 
influx.  It is thought that this protein modulates neuronal action potentials and T-cell-
mediated cytokine release (Perraud et al. 2004; Massullo et al. 2006).  BAIAP3 is 
expressed in the cortex and may be involved in exocytotic neurotransmitter secretion 
(Palmer et al. 2002).  Alternative splicing of these genes could alter synaptic 
transmission and/or ion transport and affect IPDD pathogenesis. 
 
Lipoprotein metabolism was the next pathway of note.  Apolipoprotein A5 (APOA5) 
(see also figure 4.4b) and Coiled-coil domain containing 92 (CCDC92) were 
alternatively-spliced.  APOA5 is involved in triglyceride-rich lipoprotein metabolism; 
it negatively regulates plasma triglyceride levels (Tai and Ordovas 2008).  APOA5 
belongs to the same family as APOE, whose expression appears to promote protein 
aggregation and dementia in IPD patients (Mattila et al. 2000; Bray et al. 2004; de 
Lau et al. 2005).  CCDC92 is an uncharacterised coiled-coil protein.  Genetic 
variation in the CCDC92 locus influences plasma lipoprotein and triglyceride levels 
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(Chasman et al. 2009).  Alternative splicing of APOA5 and CCDC92 might affect 
lipoprotein metabolism and IPDD pathogenesis. 
 
The fifth dysregulated pathway was inflammation/immune response, which 
encompassed EPHA2; FTH1; Inhibitor of κ light polypeptide gene enhancer in B-
cells, kinase ε (IKBKE); Integrin, alpha L (ITGAL); Proteasome (prosome, 
macropain) subunit, β type, 8 (PSMB8); and TRPM4.  IKBKE phosphorylates 
Inhibitor of κ light polypeptide gene enhancer in B-cells (IKB) and promotes its 
degradation, which relaxes the latter’s inhibition of the proinflammatory NFKB 
transcriptional pathway (see 4.3.3) (Clement et al. 2008).  ITGAL regulates cell 
adhesion and is necessary for microglial migration into injured neuronal cultures 
(Ullrich et al. 2001).  Furthermore, this protein is expressed on the surface of 
activated microglia in the IPD putamen (Imamura et al. 2003).  PSMB8 encodes a β 
subunit of the immunoproteasome.  This proteolytic complex is found in cells 
exposed to proinflammatory interferon γ and mature dendritic cells.  It exhibits 
different substrate specificity to the standard proteasome, and is known to regulate the 
processing of antigens for presentation by major histocompatibility complex (MHC) 
class I (Van den Eynde and Morel 2001).  PSMB8 protein expression is increased in 
Huntington’s disease (HD) cortical and striatal neurons compared to controls (Diaz-
Hernandez et al. 2003).  Dysregulation of these three genes, along with EPHA2, 
FTH1, and TRPM4 (see above), could modulate inflammatory and/or immune 
processes and influence IPDD-associated neuronal cell death. 
 
Cell adhesion/ECM was the sixth highlighted pathway.  Dysregulation was observed 
for Collagen, type II, α 1 (COL2A1); Collagen, type XXVII, α 1 (COL27A1); EPHA2; 
and ITGAL.  COL2A1 and COL27A1 homotrimerise to form collagen types II and 
XXVII, respectively.  These ECM fibrillar proteins are found mainly in cartilage 
(Shoulders and Raines 2009).  COL2A1 expression is dysregulated during 
inflammatory conditions such as osteoarthritis (Goldring et al. 2008).  COL27A1 
seems to play a role in the transition of cartilage to bone during skeletogenesis 
(Hjorten et al. 2007).  Dysregulation of these two genes, as well as EPHA2 and 
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ITGAL (see above), might alter cell adhesion and/or the ECM and affect IPDD 
pathogenesis. 
 
The final notable pathway was transcription/splicing.  IKBKE, Tuftelin interacting 
protein 11 (TFIP11), and Zinc finger protein 407 (ZNF407) were alternatively-
spliced.  TFIP11 appears to mediate intron lariat release during late stage RNA 
splicing (Yoshimoto et al. 2009).  ZNF407 resides in the chromosomal region 
generally absent in 18q deletion syndrome, one feature of which is mental retardation 
(OMIM #601808) (Linnankivi et al. 2006).  ZNF407 contains zinc finger and 
homeobox domains, making it a putative transcriptional regulator.  Alternative 
splicing of TFIP11, ZNF407, and IKBKE (see above), could influence transcription 
and/or splicing and modulate IPDD pathogenesis. 
 
Taken together, these results suggest that mitochondrial/metal binding, axonal 
guidance/cytoskeletal, synaptic transmission/ion transport, lipoprotein metabolism, 
inflammation/immune response, cell adhesion/ECM, and transcription/splicing 
pathways are dysregulated in IPD dementia. 
 
 
 
 
Table 4.4. Cognitive expression microarray: genes implicated in IPD dementia. 
Genes exhibiting dysregulated expression or splicing implicating them in IPD dementia (following 
pages).  The results suggest that mitochondrial/metal binding, axonal guidance/cytoskeletal, synaptic 
transmission/ion transport, lipoprotein metabolism, inflammation/immune response, cell 
adhesion/ECM, and transcription/splicing pathways are dysregulated in IPDD.  Genes are listed 
alphabetically, with the differential expression group preceding the alternative splicing group.  All p 
values were uncorrected, except those marked with §, which were FDR-corrected.  Uncorrected 
IPDND vs CON p values were nonsignificant for all listed genes.  GO term associations were obtained 
from the GO database (release 24th January 2010); GO term identity codes are bolded.  See list of 
abbreviations for gene symbol definitions.  ATP = adenosine triphosphate; AMPA = α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid; CON = control; FDR = false discovery rate; GO = gene 
ontology; GTPase = guanosine triphosphatase; IPD = idiopathic Parkinson’s disease; IPDD = 
idiopathic Parkinson’s disease with dementia; IPDND = idiopathic Parkinson’s disease no dementia; 
IKB = Inhibitor of κ light polypeptide gene enhancer in B-cells; MHC = major histocompatibility 
complex; NFKB = nuclear factor κ light polypeptide gene enhancer in B-cells; pwy = pathway; RNA = 
ribonucleic acid; mRNA = messenger RNA. 
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Figure 4.4. Expression microarray plots for EPHA2 and APOA5. 
Gene and exon level expression microarray plots for (a) EPHA2 and (b) APOA5, respectively.  
Differential expression and alternative splicing were observed for EPHA2 and APOA5, respectively, 
implicating these genes in IPDD.  In IPDD vs IPDND or control, EPHA2 gene expression was 
increased and APOA5 exon 2 expression was decreased.  (a) EPHA2 gene level log2 fluorescence 
intensity group median and quartile data are shown as a box and whisker plot, with outliers depicted as 
empty circles.  (b) APOA5 exon level probeset log2 fluorescence intensity group mean and standard 
error data are presented as bar chart.  APOA5 gene level group mean fluorescence values are shown as 
horizontal lines.  Probesets are numbered, and their approximate annealing sites in relation to APOA5 
genetic architecture are indicated.  APOA5 = Apoliprotein A5; CON = control; EPHA2 = Ephrin 
receptor A2; Ex = exon; IPD = idiopathic Parkinson’s disease; IPDD = idiopathic Parkinson’s disease 
with dementia; IPDND = idiopathic Parkinson’s disease no dementia; UTR = untranslated region. 
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4.3.5. Variation in dorsolateral prefrontal cortex 
Ephrin receptor A2 expression is associated with 
idiopathic Parkinson’s disease 
Various microarray hits were selected for validation by qRT-PCR.  Our general 
approach was to concentrate on genes implicated in IPDD.  Given the importance of 
mitochondria and iron metabolism in IPD [reviewed in (Abou-Sleiman et al. 2006b; 
Rhodes and Ritz 2008)], ALAS2, FTH1, and UQCRFS1 were chosen.  APOA5 was 
selected, because this gene belongs to the same family as APOE, whose expression 
appears to promote protein aggregation and dementia in IPD patients (Mattila et al. 
2000; Bray et al. 2004; de Lau et al. 2005).  As it belongs to several of the pathways 
implicated in IPDD (see 4.3.4), EPHA2 was chosen.  The TFs ZNF407 and POU4F3 
were selected, because of their potential for affecting multiple target genes.  Due to 
its neuroprotective ability in IPD models (Reglodi et al. 2004), ADCYAP1 was also 
chosen.  The existence of several FTH1 pseudogenes made this gene refractory to 
qRT-PCR primer design.  Moreover, the qRT-PCR assay for ADCYAP1 could not be 
optimised to ensure the generation of a single amplicon.  For the remaining genes, 
qRT-PCR was employed to measure total and NLC expression in cognitive series 
DLPFC cDNA batch 2 (IPDD [n = 15]; IPDND [n = 16]; control [n = 16]).  Separate 
qRT-PCR assays were used to interrogate full length (FL) and alternatively-spliced 
transcripts of the same gene, as appropriate.  Clinicopathological group comparisons 
and expression data normalisation strategies for this series and cDNA batch have 
been described (see 3.3.2 and 3.3.4).  Expression in IPDD and IPDND was compared 
statistically, and these two groups subsequently combined to generate the IPD group.  
Expression in IPD (n = 31) and controls (n = 16) was then compared statistically. 
 
Table 4.5 and figure 4.5 show the qRT-PCR microarray validation data.  EPHA2 was 
confirmed as differentially-expressed.  Strikingly, total EPHA2 expression was 
significantly higher (2.56-fold) in IPD compared with controls (corrected p = 0.020).  
A similar trend of higher NLC EPHA2 expression was observed in IPD contrasted 
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against controls, but this did not survive correction.  However, total and NLC EPHA2 
expression were unaltered in IPDD compared with IPDND.  On the other hand, 
dysregulation was not validated for ALAS2, APOA5, POU4F3, UQCRFS1, or 
ZNF407.  APOA5 FL and 1:3 displayed trends of underexpression in IPD compared 
to controls.  But these changes were suggestive of differential expression in IPD 
neurodegeneration, whereas the array findings indicated alternative splicing in IPD 
dementia. 
 
These results demonstrate that variation in DLPFC EPHA2 expression is associated 
with IPD in the cognitive series.  However in contrast to the microarray, this variation 
is not associated with IPD dementia.  Undoubtedly there is discord between the 
microarray and qRT-PCR expression datasets with regard to this gene.  Nevertheless, 
when one examines the EPHA2 microarray expression plot (see figure 4.4a), it is 
clear that the IPDND group lies somewhere in between the other two.  Therefore, the 
most parsimonious and conservative interpretation is that variation in EPHA2 
expression is associated with IPD neurodegeneration, not with IPD dementia. 
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4.3.6. Ephrin receptor A2 overexpression in idiopathic 
Parkinson’s disease is restricted to the dorsolateral 
prefrontal cortex 
In order to further investigate EPHA2 in the context of IPD, qRT-PCR was employed 
to quantify total and NLC expression in seven subcortical and cortical brain regions 
obtained from the mapping series.  Clinicopathological group comparisons and 
expression data normalisation strategies for this series have been described (see 
3.3.5).  Expression in IPD (n = 20) and controls (n = 20) was compared statistically. 
 
The results of this analysis can be seen in table 4.6 and figure 4.6.  Relatively high 
levels of intragroup variation were detected in the majority of regions.  After 
correction for multiple testing, no significant changes were observed for total or NLC 
EPHA2 expression in any of the seven areas obtained from the mapping series.  In 
IPD compared to controls, trends of increase and decrease were seen for total 
expression in the medulla and NLC expression in the FC, respectively.  However, 
these effects failed to survive correction.  Taken together, these findings demonstrate 
that EPHA2 is not differentially-expressed in the mapping series.  Furthermore, they 
indicate that in all eight brain areas examined thus far, IPD EPHA2 overexpression is 
restricted to the DLPFC. 
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IPD vs CON p value Brain 
region 
Expression 
Fold change mean EPHA2 
expression (IPD/CON) Uncorrected Corrected 
Total 1.88 0.010 0.520 Medulla 
NLC 0.52 0.600 NS 
Total 1.32 0.730 NS 
Putamen 
NLC 1.03 0.664 NS 
Total 1.33 0.607 NS 
Amygdala 
NLC 0.56 0.520 NS 
Total 1.76 0.595 NS EC 
(BA28) NLC 0.89 0.694 NS 
Total 0.89 0.801 NS ACC 
(BA24) NLC 0.63 0.274 NS 
Total 2.08 0.129 NS AG 
(BA39) NLC 2.88 0.704 NS 
Total 0.93 0.395 NS FC 
(BA8) NLC 0.63 0.064 NS 
 
Table 4.6. IPD mapping series EPHA2 expression data. 
Fold change mean qRT-PCR EPHA2 expression values (relative to controls) and statistical results for 
the mapping series.  No significant differences were observed after correction for multiple testing, 
indicating that EPHA2 overexpression in IPD is restricted to the DLPFC.  Total expression data were 
normalised with G6PD, HPRT1, RPL13A, and TBP, except for amygdala and EC data, which were 
normalised with HPRT1, RPL13A, and TBP.  NLC expression data were normalised with NEFH.  IPD 
and CON groups were compared by Mann-Whitney test.  p values were corrected x52.  AG = angular 
gyrus (BA39); ACC = anterior cingulate cortex (BA24); BA = Brodmann area; CON = control; 
DLPFC = dorsolateral prefrontal cortex (BA46); EC = entorhinal cortex (BA28); EPHA2 = Ephrin 
receptor A2; FC = frontal cortex (BA8); G6PD = Glucose-6-phosphate dehydrogenase; HPRT1 = 
Hypoxanthine phosphoribosyltransferase 1; IPD = idiopathic Parkinson’s disease; NEFH = 
Neurofilament H; NLC = neuronal-loss corrected; NS = not significant; qRT-PCR = quantitative 
reverse transcriptase-polymerase chain reaction; RPL13A = Ribosomal protein L13A; TBP = TATA box 
binding protein. 
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Figure 4.6. EPHA2 is not differentially-expressed in the mapping series. 
Relative mean qRT-PCR EPHA2 expression values with 95% CI for the mapping series.  No 
significant differences were observed after correction for multiple testing, indicating that EPHA2 
overexpression in IPD is restricted to the DLPFC.  Total expression data were normalised with G6PD, 
HPRT1, RPL13A, and TBP, except for amygdala and EC data, which were normalised with HPRT1, 
RPL13A, and TBP.  NLC expression data were normalised with NEFH.  IPD and CON groups were 
compared by Mann-Whitney test.  p values were corrected x52.  AG = angular gyrus (BA39); ACC = 
anterior cingulate cortex (BA24); BA = Brodmann area; CI = confidence interval; CON = control; 
DLPFC = dorsolateral prefrontal cortex (BA46); EC = entorhinal cortex (BA28); EPHA2 = Ephrin 
receptor A2; FC = frontal cortex (BA8); G6PD = Glucose-6-phosphate dehydrogenase; HPRT1 = 
Hypoxanthine phosphoribosyltransferase 1; IPD = idiopathic Parkinson’s disease; NEFH = 
Neurofilament H; NLC = neuronal-loss corrected; qRT-PCR = quantitative reverse transcriptase-
polymerase chain reaction; RPL13A = Ribosomal protein L13A; TBP = TATA box binding protein. 
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4.3.7. Variation at rs11260822 influences idiopathic 
Parkinson’s disease risk 
So as to evaluate SNP variation in the EPHA2 locus for its effect on IPD risk, a case-
control genetic association study was carried out.  A region encompassing the EPHA2 
gene (~31.7 kb) and 15 kb upstream was defined.  HapMap phase II CEPH data were 
then used to assess linkage disequilibrium (LD) relationships between common SNPs 
and generate htSNPs (see figure 4.7).  Six htSNPs were produced, with an average 
locus haplotype r2 of 0.941.  Taqman was employed to genotype these markers in 
gDNA extracted from the association series (IPD [n = 614]; controls [n = 619]), and 
they were tested for allelic association with IPD under a multiplicative model.  Group 
clinical data for this series have been presented (see 3.3.7). 
 
Table 4.7 shows the SNP association study data.  The Hardy-Weinberg equilibrium 
(HWE) was not violated for any of the htSNPs in either group, indicating that no 
serious genotyping errors had occurred.  Variation at rs11260822 displayed 
significant association with IPD (corrected p = 0.018).  The estimated odds ratio (OR) 
for this effect was 1.289 with a 95% confidence interval (CI) that ranged from 1.092 
to 1.521.  The case (0.423) and control (0.362) minor allele frequencies (MAFs) 
showed that the minor C allele confers increased susceptibility to IPD. 
 
Therefore, these findings indicate that variation at rs11260822 influences IPD risk in 
the association series.  HapMap data shows that this polymorphism, which is situated 
~3.2 kb upstream of the EPHA2 transcriptional start site (TSS), resides in a block 
characterised by high levels of LD in Caucasians.  Thus it is unclear which of the 13 
SNPs in this block (or combination thereof) is/are driving the observed association 
with IPD.  Twelve of these variants (including rs11260822) are intronic or upstream 
of the EPHA2 coding sequence, and are not located near to any exons.  Hence they 
would be unlikely to have any effect on EPHA2 splicing or mRNA stability.  
According to HapMap, the r2 LD between the remaining SNP, rs6678616, and 
 212 
rs11260822 is 0.928 in Caucasians.  The rs6678616 polymorphism is a synonymous 
variant situated in exon 3, and its presence on the EPHA2 transcript suggests that it 
might affect the stability of this mRNA. 
 
 
 
 
 
Figure 4.7. EPHA2 genomic locus SNP LD plot. 
Pairwise r2 LD plot for common SNPs (MAF ≥ 0.05) in the EPHA2 genomic locus (~46.7 kb).  CEPH 
trio genotypic data were obtained from HapMap phase II (release 23a from March 2008).  Tagger was 
used to generate six htSNPs capturing 95% the SNP variation in this region (average locus haplotype 
r2 = 0.941).  Pairwise LD values (out of 100) label the relevant squares.  Degree of square shading 
denotes LD magnitude.  Empty black squares indicate LD = 1.  Red boxes denote htSNPs.  Boundaries 
of EPHA2 transcribed sequence (~31.7 kb) in relation to the white bar are indicated.  Locations on 
chromosome 1 are according to NCBI assembly build 36.  CEPH = Centre d’Étude du Polymorphisme 
Humain; EPHA2 = Ephrin receptor A2; LD = linkage disequilibrium; MAF = minor allele frequency; 
NCBI = National Center for Biotechnology Information; SNP = single nucleotide polymorphism; 
htSNP = haplotype-tagging single nucleotide polymorphism. 
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4.3.8. Variation at rs11260822 does not influence 
Ephrin receptor A2 expression in the dorsolateral 
prefrontal cortex 
Variation at rs11260822 could alter IPD susceptibility via an effect on EPHA2 
expression.  In order to investigate this possibility, cis-acting variation analysis was 
performed for rs11260822.  The cognitive series individuals were genotyped at this 
polymorphism, DLPFC cDNA batch 2 EPHA2 expression data grouped by genotype, 
and the groups compared statistically (T/T homozygote majors [n = 12]; T/C 
heterozygotes [n = 21]; C/C homozygote minors [n = 12]). 
 
Variation at rs11260822 did not significantly associate with either total or NLC 
DLPFC EPHA2 expression.  An interesting but weak trend was observed of higher 
NLC expression with increasing C allele ploidy (see figure 4.8).  This fits well with 
the elevated EPHA2 expression seen in IPD compared to controls (see figure 4.5) and 
the increased IPD risk conferred by the C allele (see table 4.7).  However, the 
relationship between rs11260822 genotype and NLC EPHA2 expression was 
nonsignificant even before correction.  Therefore, these results indicate that variation 
at rs11260822 does not influence EPHA2 expression in the cognitive series DLPFC. 
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Figure 4.8. Variation at rs11260822 does not influence EPHA2 expression in the DLPFC. 
Relative mean qRT-PCR EPHA2 expression values with 95% CI for cognitive series DLPFC cDNA 
batch 2.  No significant differences were observed, indicating that variation at rs11260822 does not 
influence DLPFC EPHA2 expression.  Total expression data were normalised with G6PD, RPL13A, 
and TBP, and NLC expression data with NEFH.  Data were grouped by rs11260822 genotype, and 
groups compared by Kruskal-Wallis test.  Uncorrected p values were 0.530 for total expression and 
0.343 for NLC expression.  p values were corrected x52.  The rs11260822 genotypic data did not 
violate Hardy-Weinberg equilibrium (uncorrected p = 0.822).  Single letter codes in accordance with 
the International Union of Biochemistry and Molecular Biology.  CI = confidence interval; cDNA = 
complementary DNA; DLPFC = dorsolateral prefrontal cortex; EPHA2 = Ephrin receptor A2; G6PD = 
Glucose-6-phosphate dehydrogenase; NEFH = Neurofilament H; NLC = neuronal-loss corrected; 
qRT-PCR = quantitative reverse transcriptase-polymerase chain reaction; RPL13A = Ribosomal 
protein L13A; TBP = TATA box binding protein. 
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4.3.9. Expression microarray data mining:  
Ephrin receptor A2-related pathways 
The vast amount of data generated by the expression microarray presents interesting 
opportunities to systematically investigate relationships between IPD pathogenesis 
and DLPFC gene expression at the pathway level.  Previous findings have 
demonstrated that EPHA2 is differentially-expressed in this region (see figure 4.5), so 
we began by examining pathways related to this kinase.  It was hypothesised that 
EPHA2 overexpression might be accompanied by long term changes in the 
expression of EPHA2 pathway genes, potentially resulting in specific patterns of 
signaling activity.  Four groups of candidate genes were selected.  The first was 
EPHA2 interactors; this consisted of the Ephrin A ligand family and other genes 
whose protein products bind EPHA2, identified using BioGRID.  Due to this gene’s 
role in axonal guidance (Brittis et al. 2002), the next group comprised axonal 
guidance pathway genes, chosen using the KEGG database.  This resource was also 
used to select members of the third group: Mitogen-activated protein kinase (MAPK) 
signaling genes.  This group was included because EPHA2 activation has been shown 
to induce Extracellular-signal regulated kinase 1/2 (ERK1/2) phosphorylation 
resulting in enhanced ERK1/2 signaling (Pratt and Kinch 2002).  The final group 
consisted of genes known or predicted to regulate EPHA2 expression.  The T-cell 
factor/lymphoid enhancer binding factor (TCF/LEF) (Katoh and Katoh 2006) and 
Sarcoma (Src) (Baldwin et al. 2006) families were chosen, as well as Tumour protein 
53 (TP53) (Yang et al. 2006).  Microarray data for these 97 candidates were mined in 
silico, and expression in IPD (n = 14) and controls (n = 7) compared statistically. 
 
Table 4.8 shows the results of this analysis.  The first point of note is that the majority 
of evaluated genes were not differentially-expressed.  This is perhaps unsurprising, 
given that most of the candidates belong to the MAPK signaling and axonal guidance 
groups.  These pathways generally operate via sequential cascades of protein-protein 
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binding and post translational modification (PTM), and not via changes in gene 
expression.  However, differential expression was observed for several candidates. 
 
The EPHA2-directed phosphatase Acid phosphatase 1, soluble (ACP1) was 
underexpressed (p = 0.043) (Kikawa et al. 2002), whereas the EPHA2 ligand Ephrin 
A2 (EFNA2) was overexpressed (p = 0.001).  Together with the increase in EPHA2 
expression demonstrated previously, these changes imply enhanced levels of EPHA2 
kinase activity.  The expression of Rat sarcoma (Ras) inhibitor Ras p21 protein 
activator 1 (RASA1) and Related Ras viral oncogene homologue 2 (RRAS2) were 
decreased (p = 0.020) and increased (p = 0.035), respectively.  Notwithstanding the 
reduction in Kirsten rat sarcoma viral oncogene homologue (KRAS) expression  
(p = 0.012), these data suggest increased signaling activity of Ras GTPase family 
members.  Dual specificity phosphatase 4 (DUSP4) (p = 0.024); Dual specificity 
phosphatase 6 (DUSP6) (p = 0.001); and Protein tyrosine phosphatase, receptor type, 
R (PTPRR) (p = 0.023) were all underexpressed.  Decreased expression of these 
enzymes, which are known to dephosphorylate and reduce the activity of ERK1/2 
(Guan and Butch 1995; Muda et al. 1996; Zuniga et al. 1999), imply relaxed ERK1/2 
inhibition.  Notably, IPD DUSP6 expression was ~50% of that in controls (data not 
shown).  This finding validates the DUSP6 qRT-PCR results, both in terms of 
magnitude and direction of effect (see 3.3.4). 
 
Amongst the downstream ERK1/2 effectors, overexpression was observed for 
Phospholipase A2, group IID (PLA2G2D) (p = 0.048); Phospholipase A2, group IIE 
(PLA2G2E) (p = 0.046); Phospholipase A2, group III (PLA2G3) (p = 0.010); and 
E26-like kinase 1 (ELK1) (p = 0.019), whereas the expression of Stathmin 1 (STMN1) 
(p = 0.037); Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 (RPS6KA3)  
(p = 0.006); and Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 (RPS6KA6)  
(p = 0.022) were reduced.  These data suggest increased activity of Phospholipase A2 
(PLA2) and ELK1 pathways, but decreased activity of STMN1 and Ribosomal S6 
kinase (RSK)/Cyclic adenosine monophosphate response element binding protein 
(CREB) pathways.  Overexpression was observed for three putative regulators of 
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EPHA2 transcription: Transcription factor 7 (TCF7) (p = 0.011), Transcription factor 
7-like 1 (TCF7L1) (p = 0.007), and Lymphocyte-specific protein tyrosine kinase 
(LCK) (p = 0.011).  This finding identifies several candidate genes that could be 
involved in mediating EPHA2 differential expression in the IPD DLPFC. 
 
Taken together, these mining data indicate that several EPHA2-related genes exhibit 
dysregulation in the microarray series IPD DLPFC (see figure 4.9).  Moreover, they 
validate the qRT-PCR results with regards to IPD DUSP6 underexpression in this 
brain region (see 3.3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.8. Expression microarray data mining: EPHA2-related pathways. 
Statistical results for the EPHA2-related pathways expression microarray in silico data mining analysis 
(following pages).  Several EPHA2-related genes were differentially-expressed in the microarray series 
IPD DLPFC (in bold text).  IPD and CON log2 group expression was compared by t test, or when the † 
symbol is shown, by Mann-Whitney test.  All p values were uncorrected.  Positive and negative 
symbols indicate the direction of differential expression in IPD vs CON.  See text for details of 
pathways and sources.  KEGG pathway codes are listed when appropriate.  See list of abbreviations for 
definitions of gene symbols and common gene aliases.  BG = BioGRID; CON = control; DLPFC = 
dorsolateral prefrontal cortex; EPHA2 = Ephrin receptor A2; hsa = Homo sapiens; IPD = idiopathic 
Parkinson’s disease; KEGG = Kyoto Encyclopaedia of Genes and Genomes; MAPK = Mitogen-
activated protein kinase; ref 1 = (Katoh and Katoh 2006); ref 2 = (Baldwin et al. 2006); ref 3 = (Yang 
et al. 2006); Src = Sarcoma; TCF/LEF = T-cell factor/lymphoid enhancer binding factor. 
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4.3.10. Expression microarray data mining:  
the unfolded protein response pathway 
The unfolded protein response (UPR) pathway is a collection of cellular stress 
responses activated by the presence of unfolded and/or misfolded proteins.  This 
process counteracts protein burden by attenuating translation, increasing chaperone 
gene expression, and promoting ERAD [reviewed in (Rao and Bredesen 2004)].  UPS 
dysfunction and protein accumulation are thought to induce the UPR pathway in IPD 
(Lindholm et al. 2006).  Indeed, UPR gene upregulation has been described in the 
familial and idiopathic PD brain (Imai et al. 2001; Moisoi et al. 2009).  It was 
hypothesised that the UPR pathway could be chronically-activated in the IPD 
DLPFC.  Therefore, genes involved in the UPR were selected using OMIM.  
Microarray data for these 42 candidates were mined in silico, and expression in IPD 
(n = 14) and controls (n = 7) compared statistically. 
 
The results of this analysis are shown in table 4.9.  Differential expression was 
observed for nine genes.  Of these, eight were underexpressed and one was 
overexpressed in IPD contrasted against controls.  Elastase, neutrophil expressed 
(ELANE) expression was increased (p = 0.004).  Impaired UPR activity has been 
demonstrated in individuals mutated at this gene (Grenda et al. 2007).  However, the 
majority of affected genes exhibited reduced expression.  These included key 
members of the UPR, such as DnaJ homologue, subfamily C, member 10 (DNAJC10) 
(p = 0.008); ER degradation enhanced, mannosidase α-like 1 (EDEM1) (p = 0.033); 
Mitogen-activated protein kinase 8 (MAPK8) (p = 0.010); and Membrane-bound 
transcription factor peptidase, site 1 (MBTPS1) (p = 0.035) (Ushioda et al. 2008; 
Urano et al. 2000; Ye et al. 2000).  Essential regulators of this pathway were not 
differentially-expressed, including Activating transcription factor 6 (ATF6); DNA-
damage-inducible transcript 3 (DDIT3); ER to nucleus signaling 1 (ERN1); G-
protein-coupled receptor 37 (GPR37); Heat shock 70 kDa protein 1A (HSPA1A); 
Heat shock 70 kDa protein 5 (HSPA5); and X-box binding protein 1 (XBP1) (Rao and 
 223 
Bredesen 2004).  Furthermore, the vital UPR initiators Eukaryotic translation 
initiation factor 2 α kinase 3 (EIF2AK3) (p = 0.040) and Eukaryotic translation 
initiation factor 2, subunit 1 α, 35 kDa (EIF2S1) (p = 0.023) were underexpressed 
(Harding et al. 2000). 
 
Overall, these data suggest that the UPR pathway is not chronically-activated in the 
microarray series IPD DLPFC.  In fact, some of the genes essential for initiating and 
executing this process were either underexpressed in IPD or unaffected by disease 
status. 
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4.3.11. Expression microarray data mining: 
Parkinson’s disease and parkinsonism-dementia 
Several studies have investigated the expression of genes linked to familial 
Parkinson’s disease (FPD) (OMIM #168600) in IPD brain samples.  α-Synuclein 
(SNCA) is differentially-expressed in both the SN and FC (Kingsbury et al. 2004; 
Beyer et al. 2008; Grundemann et al. 2008; Simunovic et al. 2009).  Parkin (PARK2) 
is alternatively-spliced in the FC (Beyer et al. 2008).  Ubiquitin carboxy-terminal 
hydrolase L1 (UCHL1) is underexpressed in the SN and FC (Moran et al. 2007; 
Zhang et al. 2005b).  In SN neurons, conflicting results have been observed for 
Phosphatase and tensin homologue-induced putative kinase 1 (PINK1), Parkinson’s 
disease 7 (PARK7), and ATPase type 13A2 (ATP13A2), whereas Leucine-rich repeat 
kinase 2 (LRRK2) is underexpressed (Blackinton et al. 2007; Galter et al. 2006; 
Ramirez et al. 2006; Simunovic et al. 2009).  The expression of genes with proximal 
IPD- and IPDD-associated variants has been examined in this disorder.  Examples 
include β-Glucocerebrosidase (GBA) and Nuclear receptor subfamily 4, group A, 
member 2 (NR4A2) expression, which are decreased in the SN, and Synuclein, α 
interacting protein (SNCAIP), which is overexpressed in the FC (Moran et al. 2007; 
Beyer et al. 2008).  Various diseases exist in which patients manifest both 
parkinsonism and dementia, and several of these are thought to result from 
monogenic mutation.  Expression of the relevant genes has generally not been 
assessed in the IPD brain, however some exceptions do exist.  β-Synuclein (SNCB) 
mutations are implicated in dementia with Lewy bodies (DLB) (OMIM #127750) 
(Ohtake et al. 2004).  In IPD, SNCB expression is reduced in BA9 but unaltered in 
the SN (Zhang et al. 2005b).  MAPT mutations cause frontotemporal dementia and 
parkinsonism linked to chromosome 17 (FTDP17) (OMIM # 600274); this gene is 
underexpressed in IPD SNpc dopaminergic neurons (Hutton et al. 1998; Simunovic et 
al. 2009).  Interestingly, PCC neuronal MAPT expression is reduced in IPDD 
compared to IPDND or controls, implying that it might play a role in IPD dementia 
(Stamper et al. 2008). 
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It was hypothesised that genes implicated in FPD, IPD, or parkinsonism-dementia 
might be differentially-expressed in the IPD DLPFC.  Consequently, known or 
predicted PARK loci genes and those involved in forms of parkinsonism-dementia 
were identified using OMIM.  Other genes with proximal polymorphisms that 
demonstrate association with IPD or IPDD were identified using two publications 
(Sulzer 2007; de Lau et al. 2005).  Microarray data for these 26 candidates were 
mined in silico, and expression in IPD (n = 14) and controls (n = 7) compared 
statistically.  For those genes involved in parkinsonism-dementia, expression in IPDD 
(n = 7) and IPDND (n = 7) was also compared statistically. 
 
Table 4.10 shows the results of this analysis.  The majority of genes were not 
differentially-expressed.  The four exceptions all displayed reduced expression in IPD 
contrasted against controls: Fragile X mental retardation 1 (FMR1) (p = 0.022); GBA 
(p = 0.040); High temperature requirement A2 (HTRA2) (p = 0.035); and Transient 
receptor potential cation channel, subfamily M, member7 (TRPM7) (p = 0.030).  
SNCA exhibited a trend of underexpression in IPD (p = 0.052).  None of the 
parkinsonism-dementia genes displayed differential expression in the IPDD vs 
IPDND comparison.  Taken together, these findings suggest that variation in the 
DLPFC expression of genes implicated in PD and parkinsonism-dementia is not 
associated with IPD in the microarray series. 
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Table 4.10. Expression microarray data mining: PD and parkinsonism-dementia. 
Statistical results for the PD and parkinsonism-dementia expression microarray in silico data mining 
analysis (next page).  Only four genes were differentially-expressed (in bold text), suggesting that 
variation in the DLPFC expression of genes implicated in PD and parkinsonism-dementia is not 
associated with IPD in the microarray series.  Log2 group expression was compared by t test, or when 
the † symbol is shown, by Mann-Whitney test.  All p values were uncorrected.  Positive and negative 
symbols indicate the direction of differential expression in IPDD vs IPDND or IPD vs CON, as 
appropriate.  LRRK2 expression was not quantified in the microarray.  See list of abbreviations for 
definitions of gene symbols and common gene aliases.  AODP = adult onset dystonia parkinsonism 
(OMIM #612953); ALS-PDC = amyotrophic lateral sclerosis-parkinsonism dementia complex (OMIM 
#105500); APSP = atypical progressive supranuclear palsy (OMIM #260540); CON = control; DLB = 
dementia with Lewy bodies (OMIM #127750); DLPFC = dorsolateral prefrontal cortex; FAD3 = 
familial Alzheimer’s disease 3 (OMIM #607822); FPD = familial Parkinson’s disease (OMIM 
#168600); FXTAS = fragile X tremor ataxia syndrome (OMIM #300623); FTDP17 = frontotemporal 
dementia and parkinsonism linked to chromosome 17 (OMIM #600274); FTLDU = frontotemporal 
lobar degeneration with ubiquitin-positive inclusions (OMIM #607485); GSD = Gerstmann-Straussler 
disease (OMIM #137440); IPD = idiopathic Parkinson’s disease; IPDD = idiopathic Parkinson’s 
disease with dementia; IPDND = idiopathic Parkinson’s disease no dementia; ND = not determined; 
OMIM = Online Mendelian Inheritance in Man; PD = Parkinson’s disease. 
 
 
22
8 
 
U
n
co
rr
e
ct
ed
 p
 v
a
lu
e 
C
h
a
n
g
e 
in
 
D
is
ea
se
(s
) 
S
o
u
rc
e 
G
en
e 
(a
li
a
s)
 
IP
D
D
 v
s 
IP
D
N
D
 
IP
D
 v
s 
C
O
N
 
IP
D
D
 v
s 
IP
D
N
D
 
IP
D
 v
s 
C
O
N
 
P
A
R
K
1
 
S
N
C
A
†  
N
D
 
0.
05
2 
N
D
 
- 
P
A
R
K
2
 
P
A
R
K
2
†  
N
D
 
0.
06
3 
N
D
 
- 
P
A
R
K
3
 
S
P
R
 
N
D
 
0.
40
0 
N
D
 
- 
P
A
R
K
5
 
U
C
H
L
1
 
N
D
 
0.
12
8 
N
D
 
- 
P
A
R
K
6
 
P
IN
K
1
 
N
D
 
0.
26
1 
N
D
 
- 
P
A
R
K
7
 
P
A
R
K
7
 (
D
J1
) 
N
D
 
0.
10
5 
N
D
 
- 
P
A
R
K
8
 
L
R
R
K
2
 
N
D
 
N
D
 
N
D
 
N
D
 
P
A
R
K
9
 
A
T
P
1
3
A
2
 
N
D
 
0.
14
5 
N
D
 
- 
P
A
R
K
1
1
 
G
IG
Y
F
2
 
N
D
 
0.
06
3 
N
D
 
- 
P
A
R
K
1
3
 
H
T
R
A
2
 (
O
m
i)
 
N
D
 
0
.0
3
5
 
N
D
 
- 
F
P
D
 
P
A
R
K
1
5
 
F
B
X
O
7
 
N
D
 
0.
11
9 
N
D
 
- 
S
ul
ze
r 
20
07
 
C
Y
P
2
D
6
 
N
D
 
0.
52
4 
N
D
 
+
 
S
ul
ze
r 
20
07
 
F
G
F
2
0
 
N
D
 
0.
06
1 
N
D
 
- 
S
ul
ze
r 
20
07
 
G
B
A
 
N
D
 
0
.0
4
0
 
N
D
 
- 
S
ul
ze
r 
20
07
 
N
R
4
A
2
 (
N
U
R
R
1
)†
 
N
D
 
0.
65
0 
N
D
 
+
 
S
ul
ze
r 
20
07
 
P
O
L
G
 
N
D
 
0.
38
2 
N
D
 
- 
IP
D
 
S
ul
ze
r 
20
07
 
S
N
C
A
IP
 (
S
yn
p
h
il
in
 1
)  
N
D
 
0.
63
1 
N
D
 
+
 
IP
D
D
 
de
 L
au
 e
t 
a
l.
 2
00
5 
A
P
O
E
†  
0.
56
5 
0.
15
6 
+
 
+
 
F
X
T
A
S
 
O
M
IM
 
F
M
R
1
 
0.
66
1 
0
.0
2
2
 
- 
- 
F
T
L
D
U
 
O
M
IM
 
G
R
N
 (
P
ro
g
ra
n
u
li
n
) 
0.
71
2 
0.
74
6 
+
 
- 
F
T
D
P
17
/A
P
S
P
 
O
M
IM
 
M
A
P
T
 
0.
64
2 
0.
13
8 
- 
- 
A
O
D
P
 
O
M
IM
 
P
L
A
2
G
6
†  
0.
19
8 
0.
50
1 
- 
- 
G
S
D
 
O
M
IM
 
P
R
N
P
 
0.
80
1 
0.
27
7 
- 
- 
F
A
D
3 
O
M
IM
 
P
S
E
N
1
 
0.
50
9 
0.
25
7 
- 
- 
D
L
B
 
O
M
IM
 
S
N
C
B
†  
0.
74
9 
0.
45
6 
- 
- 
A
L
S
-P
D
C
 
O
M
IM
 
T
R
P
M
7
 
0.
33
9 
0
.0
3
0
 
- 
- 
  
 229 
4.3.12. Expression microarray data mining:  
putative regulators of dorsolateral prefrontal cortex 
Dual specificity phosphatase 6 expression 
The final mining experiment was an attempt to elucidate the mechanism underlying 
DUSP6 underexpression in the IPD DLPFC (see 3.3.3 and 4.3.9).  This phenomenon 
is unlikely to be caused by cis-acting SNP variation (see 3.3.7).  Furthermore, 
although the low frequency variant rs1689408 is implicated in DUSP6 splicing (see 
3.3.9), there is little evidence to suggest that modulated splicing accounts for the 
majority of the DUSP6 underexpression effect (see 3.3.4).  It was hypothesised that a 
TF which regulates DUSP6 expression could itself be differentially-expressed in the 
IPD DLPFC.  Therefore, the UCSC PhyloP database was consulted to search for 
putative DUSP6 regulatory elements, and an upstream region possessing high levels 
of predicted DNA sequence conservation across 32 placental mammals was 
identified.  This region extends 650 bp upstream from the DUSP6 TSS (henceforth 
called the “DUSP6 putative promoter” [DPP]).  It encompasses those elements found 
to control expression of the murine and human orthologues of this gene (Ekerot et al. 
2008; Zhang et al. 2009).  The DPP gDNA sequence was then downloaded from 
Ensembl, and entered into the PROMO online resource which employs the Transfac 
database to search for predicted transcription factor binding sites (TFBS).  Factors 
possessing at least one predicted binding site in the DPP were identified.  Microarray 
data for these 16 candidates were mined in silico, and expression in IPD (n = 14) and 
controls (n = 7) compared statistically.  Successful candidates were validated using 
qRT-PCR to measure total and NLC expression in cognitive series DLPFC cDNA 
batch 2, and expression in IPD (n = 31) and controls (n = 16) compared statistically. 
 
The results of this analysis are shown in table 4.11 and figure 4.10.  Differential 
expression was observed for six genes: ELK1, Estrogen receptor 1 (ESR1), E Twenty-
Six oncogene homologue 1 (ETS1), Hepatic nuclear factor 1 homeobox A (HNF1A), 
Signal transducer and activator of transcription 4 (STAT4), and Yin Yang 1 (YY1).  It 
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was reasoned that factors displaying reduced expression in IPD compared to controls 
would be most likely to mediate DUSP6 underexpression.  This approach identified 
ETS1 and STAT4 as putative regulators of DLPFC DUSP6 expression.  However, 
underexpression of ETS1 and STAT4 were not validated by qRT-PCR, indicating that 
these genes are not differentially-expressed in the IPD DLPFC. 
 
Overall, these findings suggest that DUSP6 underexpression in the IPD DLPFC is not 
caused by altered expression of a regulatory TF, although the involvement of other 
putative regulatory elements cannot be excluded. 
 
 
Gene (alias) 
Number of 
predicted binding 
sites in the DPP 
Uncorrected 
IPD vs CON 
p value 
Change in IPD 
CEBPB 20 0.322 + 
ELK1 1 0.019 + 
ESR1 (ERα) 1 0.011 + 
ETS1 1 0.021 - 
FOXP3 2 0.111 + 
GTF2I (TFII-I)† 1 0.263 - 
HNF1A 2 0.044 + 
MAZ (PUR1) 1 0.318 - 
NFIC (CTF)† 1 0.156 + 
NR3C1 (GR) 14 0.107 - 
PAX5 3 0.343 + 
PEX5 (PXR1) 1 0.052 - 
RXRA 2 0.148 + 
STAT4 1 0.042 - 
TBP (TFIID) 2 0.166 - 
YY1 2 0.038 + 
 
Table 4.11. Expression microarray data mining: putative DLPFC DUSP6 expression regulators. 
Statistical results for the putative regulators of DLPFC DUSP6 expression microarray in silico data 
mining analysis.  ETS1 and STAT4 were underexpressed in the microarray series IPD DLPFC, and 
hence were designated as putative regulators of DLPFC DUSP6 expression (in bold text).  
Transcription factors possessing one or more predicted binding sites in the DPP were identified using 
PROMO at a maximum binding dissimilarity of 1%.  IPD and CON log2 group expression was 
compared by t test, or when the † symbol is shown, by Mann-Whitney test.  All p values were 
uncorrected.  Positive and negative symbols indicate the direction of differential expression in IPD vs 
CON.  See list of abbreviations for definitions of gene symbols and common gene aliases.  CON = 
control; DLPFC = dorsolateral prefrontal cortex; DUSP6 = Dual specificity phosphatase 6; DPP = 
DUSP6 putative promoter; ETS1 = E Twenty-Six oncogene homologue 1; IPD = idiopathic Parkinson’s 
disease; STAT4 = Signal transducer and activator of transcription 4. 
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Figure 4.10. ETS1 and STAT4 are not differentially-expressed in the IPD DLPFC. 
Relative mean qRT-PCR ETS1 and STAT4 expression values with 95% CI for cognitive series DLPFC 
cDNA batch 2.  No significant differences were observed, indicating that ETS1 and STAT4 are not 
differentially-expressed in the IPD DLPFC.  Total expression data were normalised with G6PD, 
RPL13A, and TBP, and NLC expression data with NEFH.  IPD and CON were compared by Mann-
Whitney test.  Uncorrected ETS1 p values were 0.369 for total expression and 0.841 for NLC 
expression.  Uncorrected STAT4 p values were 0.178 for total expression and 0.575 for NLC 
expression.  p values were corrected x52.  CI = confidence interval; CON = control; cDNA = 
complementary DNA; DLPFC = dorsolateral prefrontal cortex; ETS1 = E Twenty-Six oncogene 
homologue 1; G6PD = Glucose-6-phosphate dehydrogenase; IPD = idiopathic Parkinson’s disease; 
NEFH = Neurofilament H; NLC = neuronal-loss corrected; qRT-PCR = quantitative reverse 
transcriptase-polymerase chain reaction; RPL13A = Ribosomal protein L13A; STAT4 = Signal 
transducer and activator of transcription 4; TBP = TATA box binding protein. 
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4.3.13. Variation in CpG methylation is implicated in 
Dual specificity phosphatase 6 underexpression in the 
idiopathic Parkinson’s disease dorsolateral prefrontal 
cortex 
One possible explanation for DUSP6 underexpression in the IPD DLPFC is 
modulated CpG methylation.  The murine Dusp6 promoter contains one conserved 
Ets family binding site that is necessary for Fgf-induced reporter gene expression 
(Ekerot et al. 2008).  Moreover, the orthologous sequence upstream of human 
DUSP6 regulates reporter gene expression and mediates ETS binding (Zhang et al. 
2009).  Closer inspection of the Ekerot et al. and Zhang et al. publications reveal that 
this ETS target incorporates the predicted STAT4 binding site identified in the DPP 
by PROMO (see 4.3.12).  Due to the laboratory and bioinformatic evidence presented 
in these papers, this site will be considered as an ETS target, henceforth designated as 
ETS binding site B.  The predicted ETS1 target identified by PROMO (see 4.3.12) 
will henceforth be called ETS binding site A.  Thus, ETS factors are known or 
predicted to bind two locations in the DPP (see figure 4.11). 
 
It was hypothesised that DPP ETS binding site CpG methylation might be altered in 
the IPD DLPFC.  Therefore, bisulphite-converted DLPFC gDNA extracted from the 
MSP series (see table 4.12) was amplified using MSP reactions separately 
interrogating CpG methylation at ETS binding sites A and B, and relative CpG 
methylation in IPD (n = 6) and controls (n = 6) compared.  The bisulphite conversion 
protocol uses sulphonation to deaminate unmethylated cytosines, followed by 
desulphonation to convert the deaminated cytosines into uracil.  Methylated cytosines 
are resistant to these modifications and remain as cytosines.  Subsequent PCR 
employs primers specific for converted or unconverted DNA, enabling the specific 
amplification of unmethylated or methylated alleles, respectively (Herman et al. 
1996).  One caveat should be kept in mind.  The constraints of MSP primer design 
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and the existence of additional CpGs within primer annealing sequences can make it 
impossible to solely analyse the desired target CpG.  ETS binding sites A and B each 
contain one CpG, however the relevant MSP reactions necessarily interrogated 
methylation at three and two CpGs, respectively (see figure 4.11).  Consequently, the 
degree of relative methylation at both binding sites was an amalgam of multiple 
CpGs, only one of which might directly influence transcription. 
 
Figure 4.12 shows the MSP results.  Almost all individuals displayed markedly more 
unmethylated than methylated alleles at ETS binding site A, and relative CpG 
methylation was similar in IPD and controls.  However, the data for ETS binding site 
B were somewhat different.  The controls all exhibited more unmethylated than 
methylated alleles, except for one individual who displayed approximately equal 
amounts of the two.  On the other hand, relative CpG methylation was marginally 
higher in the IPD group.  Methylated alleles exceeded their unmethylated 
counterparts in one IPD patient, and these species were roughly equal in two other 
cases.  Nonetheless, the three remaining IPD patients were similar to the controls i.e. 
unmethylated outnumbered methylated alleles.  No clear differences at either binding 
site were observed when comparing the IPDD and IPDND groups. 
 
These results suggest that variation in CpG methylation at DPP ETS binding site B is 
implicated in DUSP6 underexpression in the IPD DLPFC.  However, half of the IPD 
group displayed levels of relative CpG methylation similar to that seen in controls, 
indicating that this mechanism cannot account for the entire DUSP6 underexpression 
effect. 
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Figure 4.11. DUSP6 putative promoter ETS family binding sites and CpG locations. 
E Twenty-Six family binding sites and CpG locations in the 3’ DPP.  The DPP is indicated by blue 
sequence and the DUSP6 5’UTR by black.  Locations on the negative strand of chromosome 12 are 
according to NCBI assembly build 36.  Boxes indicate ETS binding sites A and B, based on PROMO 
and (Zhang et al. 2009) (see text for details).  CpGs are underlined and bolded.  CpGs interrogated by 
MSP reactions are in red.  Arrows indicate MSP primer annealing sites.  DNA base codes are in 
accordance with the International Union of Biochemistry and Molecular Biology.  DUSP6 = Dual 
specificity phosphatase 6; DPP = DUSP6 putative promoter; ETS = E Twenty-Six; MSP = methyl-
specific polymerase chain reaction; NCBI = National Center for Biotechnology Information; UTR = 
untranslated region. 
 
 
Group (n) Statistic 
Age of 
onset 
Age of 
death 
Disease 
duration 
PMD Brain pH 
Mean NA 79.8 NA 27.6 6.51 CON (6) 
SD NA 7.3 NA 18.2 0.20 
Mean 60.3 75.5 15.2 38.8 6.26 
IPD (6) 
SD 12.0 9.3 5.9 18.2 0.16 
 
Table 4.12. IPD MSP series clinicopathological data. 
Group clinicopathological metrics for the IPD MSP series.  The IPD group consists of three IPDD 
patients and three IPDND patients.  Measures of time are in years, except for PMD, which is measured 
in hours.  Table 2.10 shows individual clinicopathological data for each member of the MSP series.  
CON = control; IPD = idiopathic Parkinson’s disease; IPDD = idiopathic Parkinson’s disease with 
dementia; IPDND = idiopathic Parkinson’s disease no dementia; MSP = methyl-specific polymerase 
chain reaction; NA = not applicable; PMD = post mortem delay; SD = standard deviation. 
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Figure 4.12. Variation in CpG methylation at DPP ETS binding site B is implicated in DUSP6 
underexpression in the IPD DLPFC. 
MSP amplification of bisulphite-converted MSP series DLPFC gDNA interrogating CpG methylation 
at DPP ETS binding sites A and B.  Relative CpG methylation at site B was marginally higher in IPD 
compared to controls, suggesting that variation in CpG methylation at this site is implicated in DUSP6 
underexpression in the IPD DLPFC.  MSP products were resolved on agarose gels.  Arrows denote the 
100 and 200 base pair marker on site A and B gels, respectively.  -ve = negative control (water); +ve = 
positive control (HMSN bisulphite-converted blood gDNA); CON = control; gDNA = genomic DNA; 
DLPFC = dorsolateral prefrontal cortex; DUSP6 = dual specificity phosphatase 6; DPP = DUSP6 
putative promoter; ETS = E Twenty-Six; HMSN = Hereditary motor and sensory neuropathy; IPD = 
idiopathic Parkinson’s disease; IPDD = idiopathic Parkinson’s disease dementia; IPDND = idiopathic 
Parkinson’s disease no dementia; L = marker ladder; MSP = methyl-specific polymerase chain 
reaction; M = methylated-specific reaction; U = unmethylated-specific reaction. 
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4.4. Discussion 
In this chapter DLPFC expression microarray analysis was carried out to identify 
genes exhibiting dysregulation in different IPD subtypes.  These data suggested that 
synaptic transmission/ion transport, glycosylation/protein degradation, 
inflammation/immune response, and transcription/translation pathways are 
dysregulated in IPD neurodegeneration.  Moreover, the array findings suggested that 
mitochondrial/metal binding, axonal guidance/cytoskeletal, synaptic transmission/ion 
transport, lipoprotein metabolism, inflammation/immune response, cell 
adhesion/ECM, and transcription/splicing pathways are dysregulated in IPD 
dementia.  We used qRT-PCR to demonstrate that variation in DLPFC EPHA2 
expression is significantly associated with IPD.  This association takes the form of 
increased expression in IPD compared to controls, but variation in EPHA2 expression 
is not related to disease status in seven other cortical and subcortical regions of the 
IPD brain.  SNP allelic association analysis indicated that the rs11260822 minor 
allele significantly increases IPD risk.  However, variation at this SNP does not 
influence DLPFC EPHA2 expression.  In silico mining of the microarray data was 
performed to evaluate several hypotheses.  This approach indicated that several 
EPHA2-related genes exhibit dysregulation in the IPD DLPFC, and validated IPD 
DUSP6 underexpression in this region.  Furthermore, these analyses suggested that 
the UPR pathway is not chronically-activated in the IPD DLPFC, and that variation in 
the DLPFC expression of genes involved in PD and parkinsonism-dementia is not 
associated with IPD.  Array mining also indicated that, of the TFs with predicted 
binding sites in the conserved DPP, only ETS1 and STAT4 exhibit differential 
expression in the IPD DLPFC consistent with DUSP6 underexpression; however 
these observations were not validated by qRT-PCR.  Finally, MSP experiments 
suggested that variation in CpG methylation at DPP ETS binding site B is implicated 
in, but cannot fully explain, DUSP6 underexpression in the IPD DLPFC. 
 
The microarray data suggested that genes belonging to a variety of pathways are 
differentially-expressed in the IPD DLPFC, and that the two IPD subtypes display 
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some degree of overlap in this regard.  Although genome wide gene expression in the 
IPDD DLPFC has not previously been investigated, our results are mirrored by 
similar findings reported in array experiments examining several brain regions.  
Pathways implicated in IPD dementia, such as mitochondria, the cytoskeleton, 
synaptic transmission, ion transport, cell adhesion, and inflammation, are all known 
to exhibit dysregulation in IPDD PCC neurons, IPD BA9 whole tissue, and IPD SNpc 
dopaminergic neurons (Stamper et al. 2008; Zhang et al. 2005b; Simunovic et al. 
2009).  The same is true for other pathways that our dataset implicated in IPD 
dementia, including lipid metabolism and metal binding in both IPD BA9 and SN 
whole tissues (Zhang et al. 2005b; Moran et al. 2006), and axonal guidance in IPD 
PCC neurons, IPD SNpc dopaminergic cells, and IPD SN whole tissue (Stamper et al. 
2008; Simunovic et al. 2009; Bossers et al. 2009).  Pathway-level parallels between 
our IPD neurodegeneration results and the literature can also be found, such as for 
protein degradation and glycosylation pathways in both IPD BA9 whole tissue and 
IPD SNpc dopaminergic neurons (Zhang et al. 2005b; Simunovic et al. 2009). 
 
Overall, these parallels suggest that similar genetic pathways are dysregulated in the 
DLPFC and SN, supporting the hypothesis that IPD is a multisystem disorder (Zhang 
et al. 2005b; Moran et al. 2006).  When viewed collectively with the pathway 
overlaps we observed between IPD dementia and IPD neurodegeneration, they also 
suggest that the two disease subtypes are driven by similar pathogenic processes, 
most likely involving mitochondria, protein degradation, axonal function, synaptic 
transmission, and inflammation.  Moreover, when both groups were compared to 
controls, IPDD displayed much greater levels of dysregulation than IPDND.  Taken 
together, these findings suggest that IPDD can be seen as an “extension” of the 
parkinsonian state.  This conclusion is supported by the spectrum concept of Lewy 
body disease (Aarsland et al. 2004), and by evidence of positive correlations between 
cortical Lewy body pathology/gene dysregulation severity and cognitive dysfunction 
in IPD (Kovari et al. 2003; Aarsland et al. 2005a; Stamper et al. 2008).  Interestingly, 
our IPD dementia data flagged several pleiotropic pathways which mediate neural 
development during embryogenesis, and neural maintenance and plasticity in 
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adulthood.  Examples include axonal guidance, the cytoskeleton, and synaptic 
transmission.  The involvement of axonal guidance fits well with several SNP 
association studies demonstrating that this pathway influences IPD susceptibility, and 
with the detection of misrouted axonal fibres in the IPD brain [reviewed in (Lin et al. 
2009a)]. 
 
Notwithstanding these results, none of the microarray differential expression or 
alternative splicing events passed the FDR threshold.  Furthermore, relatively small 
numbers of genes were differentially-expressed at the more relaxed uncorrected  
p < 0.001 threshold.  Several confounds could have accounted for this situation.  
Examples, such as choice of brain region, lack of cognitive testing specifically 
relevant to IPDD, and insufficient numbers of samples (see below), have been 
discussed (see 3.4).  Among these possibilities, the general lack of differential 
expression observed using microarray and qRT-PCR (see also 3.3.3) suggests that 
choice of brain region may have been critically important.  Indeed, one of the primary 
conclusions of the microarray experiment could be that, when compared to other 
brain areas, genetic dysregulation is relatively uncommon in the IPD DLPFC.  The 
issue is one of significance threshold and confidence in the findings.  The FDR-
corrected data indicated no dysregulation in either IPD subtype, whereas changes 
were observed in the uncorrected p < 0.001 results.  However, reduced confidence in 
these latter findings means that they must be interpreted with caution i.e. as 
suggestive rather than demonstrative.  The conclusion that differential expression is 
rare in the DLPFC may be particularly relevant to the IPD dementia subtype.  
Neuropathological and neuropsychological evidence suggests that the ACC (BA24), 
EC (BA28), perirhinal cortex (BA35), parahippocampal cortex (BA36), or 
hippocampus could be the most promising regions for identifying genetic 
dysregulation that associates with IPDD (see 3.4) (Pletnikova et al. 2005; Vermersch 
et al. 1993; Kovari et al. 2003; Williams-Gray et al. 2009a; Pihlajamaki et al. 2000). 
 
Although region selection and cognitive testing issues probably contributed to the 
low number of hits, another important factor was highlighted by the microarray QC.  
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Relatively high levels of biological variation were detected, particularly in the IPDD 
and control groups.  Moreover, consistently more variation was seen in the gene level 
compared to the exon level data.  This variation may have been a function of the 
sample number in each group and/or caused by problems with RNA quality.  It 
undoubtedly had a negative effect on statistical power and the total number of 
significant hits, and might also explain why alternative splicing was detected much 
more frequently than differential expression.  However, this last observation could 
suggest that alternative splicing is actually of greater biological significance than 
differential expression in the IPD DLPFC.  Furthermore, the high levels of biological 
variation probably contributed to the general lack of qRT-PCR validation, in that the 
chance of detecting false positives was increased.  Validation was attempted for six 
genes, and only EPHA2 was confirmed as differentially-expressed (see below).  
However, it is likely that inherent differences between the two quantification 
techniques were also involved.  Given the reduced confidence in our array results, the 
risk of pursuing false positives was minimised by only selecting those hits validated 
via qRT-PCR for further characterisation. 
 
These findings connect EPHA2 to IPD neurodegenerative processes in general, and 
not to IPD dementia.  Taken together, the microarray and qRT-PCR validation 
experiments detailed here failed to confirm any gene as specifically implicated in 
IPDD.  Therefore, our results do not provide strong support for the hypothesis that 
there is a relationship between IPD dementia status and gene expression in the 
DLPFC.  Notwithstanding the lack of papers investigating gene expression in the 
IPDD DLPFC, the EPHA2 data could be evaluated against the Stamper et al. 
microarray study which quantified expression in IPDD PCC neurons.  The authors 
found that EPHA2 was significantly overexpressed ~2.7-fold in IPDD vs controls, 
and exhibited a strong trend of ~1.6-fold increased expression in IPDD vs IPDND 
(Stamper et al. 2008).  These results are similar to our array findings for EPHA2.  
When viewed together in the context of its axonal guidance function, and despite the 
fact that our qRT-PCR validation connected this gene to IPD neurodegeneration, 
these data suggest that EPHA2 should not be ignored by future attempts to identify 
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IPD cognitive genes.  The mechanism underlying EPHA2 overexpression in the IPD 
DLPFC remains unclear.  Cis-acting SNP variation in the EPHA2 locus is unlikely to 
account for this effect.  Variation at five of the six EPHA2 htSNPs, which together 
capture 95% of the common SNP variation in this region, does not influence IPD 
susceptibility.  Although this relationship was demonstrated for rs11260822, variation 
at this SNP does not associate with DLPFC EPHA2 expression.  Taken together, 
these data imply that EPHA2 overexpression in the IPD DLPFC is not caused by 
local genetic variation, and probably arises as a secondary effect of IPD pathogenesis.  
Two major possible causes remain: alterations in EPHA2 transcriptional activity 
and/or changes in EPHA2 mRNA stability (see below).  We cannot exclude the 
possibility that EPHA2 overexpression results in part from altered glial expression. 
 
In silico mining of the microarray data indicated that several genes belonging to 
EPHA2-related pathways exhibit dysregulation in the IPD DLPFC.  Interestingly, 
these changes could be linked together, enabling us to outline likely patterns of 
signaling activity in the parkinsonian DLPFC, and to infer putative nodes through 
which this activity might be transduced.  We observed differential expression 
suggestive of increased EPHA2, Ras, and ERK1/2 signaling.  Furthermore, similar 
changes were seen in certain ERK1/2 effectors, specifically overexpression of PLA2G 
genes and ELK1, and underexpression of RPS6KA genes and STMN1.  Overall, these 
results suggest that signaling patterns in the IPD DLPFC might be characterised by 
enhanced EPHA2-Ras-ERK1/2 activity, preferentially directed through ELK1 and 
PLA2 pathways, rather than those involving STMN1 and RSK/CREB.  Furthermore, 
these findings could help elucidate the mechanism driving EPHA2 overexpression in 
the IPD DLPFC.  Several TFs known or predicted to regulate EPHA2 expression 
themselves exhibited differential expression in this region.  TCF/LEF family 
members TCF7 and TCF7L1 were overexpressed in IPD.  Bioinformatic evidence 
indicates that the EPHA2 promoter contains one putative TCF/LEF binding site 
(Katoh and Katoh 2006), thus increased expression of these factors might be 
important.  However, further inspection of this region with PROMO suggested that 
the relevant site is bound specifically by LEF1 and TCF7L2 but not by the other 
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family members (data not shown), indicating that TCF/LEF-mediated transcription is 
unlikely to cause EPHA2 overexpression in our series.  ELK1 was also found to be 
overexpressed in IPD.  ERK1/2 phosphorylates ELK1, enhancing its DNA-binding 
and transcriptional activities (Sharrocks 2002).  Interestingly, activation of EPHA2 
increases ELK1-dependent transcription in a pathway mediated through ERK1/2.  In 
the same cell model, EPHA2 activation upregulates EPHA2 expression in an 
ERK1/2-dependent manner (Pratt and Kinch 2002; Pratt and Kinch 2003).  These 
publications indicate the existence of an EPHA2-ERK1/2-ELK1-EPHA2 positive 
feedback loop.  The differential expression of ELK1 and of genes suggesting 
enhanced activity along the EPHA2-Ras-ERK1/2 pathway (see above) implies that 
this loop could be constitutively activated in the IPD DLPFC, thereby providing a 
plausible mechanism to explain the overexpression of EPHA2. 
 
In silico mining of the microarray also generated several other findings of interest.  
This approach suggested that the UPR pathway is not chronically-activated in the IPD 
DLPFC, and that variation in the DLPFC expression of genes implicated in PD and 
parkinsonism-dementia does not associate with IPD.  Both of these results are 
interesting, in that one would expect the opposite based on the literature.  Indeed, 
UPR components are known to be upregulated in IPD (Moisoi et al. 2009), and 
several genes linked to FPD and parkinsonism-dementia are differentially-expressed 
in IPD [for example (Moran et al. 2007; Simunovic et al. 2009)].  However, most of 
these studies have examined gene expression in midbrain regions e.g. the SN.  
Therefore, our DLPFC data are entirely plausible.  In particular, UPR quiescence in 
this region might be because the forebrain is one of the last areas to acquire LP, 
which itself can be thought of as a marker of misfolded protein burden (Braak et al. 
2003). 
 
The final in silico mining, qRT-PCR validation, and MSP experiments were 
undertaken in order to explain DUSP6 underexpression in the IPD DLPFC (see 
3.3.4).  The results indicated that TFs predicted to bind the DPP were not 
underexpressed in the IPD DLPFC, suggesting that DUSP6 underexpression is not 
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caused by differential expression of a regulatory TF.  An ETS family binding site 
located in the DPP is thought to regulate DUSP6 expression (Ekerot et al. 2008; 
Zhang et al. 2009).  MSP analysis suggested that increased ETS site CpG methylation 
in the IPD DLPFC could account for some, but not all, of the DUSP6 
underexpression effect.  Despite the inability of this mechanism to fully explain the 
phenomenon in question, this could be an important finding.  Erk1/2 activity induces 
Dusp6 expression in vivo (Gomez et al. 2005; Tsang et al. 2004; Eblaghie et al. 2003; 
Smith et al. 2006a).  As our microarray and qRT-PCR results implied enhanced 
ERK1/2 activity in the IPD DLPFC, one would also expect increased DUSP6 
expression in this region, especially since ERK1/2 phosphorylates ETS proteins 
augmenting their transcriptional activity (Foulds et al. 2004).  Consequently, 
increased CpG methylation causing reduced ETS binding constitutes an attractive 
mechanism to explain decreased DUSP6 expression under the spectre of chronic 
ERK1/2 activation.  Interestingly, DUSP6 intron 1-2 has recently been shown to 
induce transcriptional activity which is sensitive to mutation of a resident ETS 
binding site (Furukawa et al. 2008).  Therefore, modulated CpG methylation at this 
intronic location might conceivably explain the remainder of the DUSP6 
underexpression effect. 
 
In conclusion, expression microarray data suggested that mitochondrial/metal 
binding, axonal guidance/cytoskeletal, synaptic transmission/ion transport, 
lipoprotein metabolism, inflammation/immune response, cell adhesion/ECM, and 
transcription/splicing pathways are dysregulated in the IPD dementia DLPFC.  It was 
demonstrated that EPHA2 expression is significantly increased in the IPD DLPFC, 
but unaltered in seven other subcortical and cortical regions of the IPD brain.  
Moreover, genetic variation in the EPHA2 locus significantly influences IPD 
susceptibility, but not DLPFC EPHA2 expression.  In silico microarray mining 
suggested that the IPD DLPFC is characterised by enhanced EPHA2-Ras-ERK1/2 
signaling, which might explain EPHA2 overexpression in this region.  Finally, 
epigenetic analysis suggested that increased CpG methylation is implicated in DUSP6 
underexpression in the IPD DLPFC. 
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Chapter 5: Genetic analyses of α-Synuclein 
in idiopathic Parkinson’s disease 
5.1. Introduction 
Of the genes currently known to cause Parkinson’s disease (PD), α-Synuclein (SNCA) 
is probably the most investigated.  Three autosomal dominant missense mutations as 
well as multiplications have been described in familial Parkinson’s disease (FPD) 
kindreds (Polymeropoulos et al. 1997; Kruger et al. 1998; Zarranz et al. 2004; Ross 
et al. 2008a), and its protein product is a major constituent of Lewy bodies (LBs) and 
Lewy neurites (LNs) (Spillantini et al. 1997; Spillantini et al. 1998a).  In pedigrees 
carrying SNCA gene alterations, it is relatively common for parkinsonian symptoms 
to be accompanied by cognitive impairment, dementia, and hallucinations.  This is 
seen in the missense mutation families, notably the Glu46Lys patients 
(Polymeropoulos et al. 1997; Kruger et al. 2001; Zarranz et al. 2004).  Other 
examples are derived from studies of SNCA multiplication kindreds, in which the 
number of genomic copies broadly correlates with the age of onset of parkinsonian 
characteristics and the existence or otherwise of concomitant dementia.  Families 
harbouring SNCA duplications tend to either not exhibit dementia or present it much 
later in the disease course (Chartier-Harlin et al. 2004; Ibanez et al. 2004; Nishioka et 
al. 2006).  Conversely, dementia is a regular feature in pedigrees carrying SNCA 
triplications, and can occur early in the pathogenic process (Singleton et al. 2003; 
Farrer et al. 2004).  This phenomenon is highlighted by two kindreds where 
intrafamily variation in the cognitive phenotype clearly correlates with the degree of 
SNCA ploidy (Fuchs et al. 2007; Ikeuchi et al. 2008).  Commentators have suggested 
that in these multiplication pedigrees, increased SNCA ploidy causes parkinsonism 
and dementia by directly affecting SNCA expression, and this hypothesis is supported 
by analyses of post mortem frontal cortex (FC) tissue obtained from these individuals 
(Singleton et al. 2003; Farrer et al. 2004; Miller et al. 2004). 
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Publications investigating SNCA expression in idiopathic Parkinson’s disease (IPD) 
have arrived at differing and often contradictory conclusions.  This is likely to have 
resulted from heterogeneity in many factors, including sample quality/number, 
methodological approach, disease stage, and brain region.  An early study employing 
in situ hybridisation (ISH) showed that in IPD, SNCA expression is reduced in 
melanised substantia nigra (SN) and FC neurons (Kingsbury et al. 2004).  Similar 
results were obtained using expression microarray and quantitative reverse 
transcriptase-polymerase chain reaction (qRT-PCR) to investigate the SN and 
putamen (Zhang et al. 2005b; Moran et al. 2007; Dachsel et al. 2007), and more 
recently in a microarray analysis of isolated substantia nigra pars compacta (SNpc) 
dopaminergic cells (Simunovic et al. 2009).  On the other hand, qRT-PCR has also 
been employed to demonstrate increased SNCA expression in the IPD SN, both in 
whole tissue and isolated dopaminergic neurons (Chiba-Falek et al. 2006; 
Grundemann et al. 2008).  Moreover, one report used qRT-PCR to specifically 
examine each of the four main SNCA transcript splice forms, which are called 140, 
126, 112, and 98, based on the length of their encoded protein.  This showed that all 
four display overexpression in the IPD FC, although greater increases were observed 
for the 98 and 126 species (Beyer et al. 2008).  The potential importance of SNCA 
expression in idiopathic Parkinson’s disease dementia (IPDD) is highlighted by 
experiments demonstrating that both neocortical LB load and overall 
neuropathological disease stage significantly correlate with dementia severity in IPD 
(Mattila et al. 2000; Kovari et al. 2003; Aarsland et al. 2005a; Braak et al. 2005). 
 
Variation at SNCA genetic polymorphisms can significantly influence IPD risk.  
Many groups have investigated the complex dinucleotide promoter microsatellite 
Rep1, which resides ~10 kb upstream of the translational start.  A host of publications 
have generated conflicting data both in support of and undermining the association of 
variation at Rep1 with IPD [summarised in (Lesage and Brice 2009)].  Nevertheless, 
two well-powered multi centre studies have provided strong evidence supporting this 
relationship in Caucasians.  Both demonstrate that amongst the three common Rep1 
alleles, IPD susceptibility is significantly increased by the largest allele and reduced 
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by the smallest.  The largest allele also marginally but significantly decreases IPD age 
of onset (Maraganore et al. 2006; Kay et al. 2008).  Furthermore, significant 
association has also been shown with haplotypes constructed of Rep1 and 5’ 
promoter single nucleotide polymorphism (SNP) alleles (Farrer et al. 2001; Pals et al. 
2004; Tan et al. 2004; Sutherland et al. 2009a).  In vitro neuronal cell culture reporter 
assays and in vivo quantification of SNCA protein in blood both indicate that 
variation at Rep1 may affect IPD risk by altering the expression of this gene, as the 
latter phenotype appears to positively correlate with Rep1 allele length (Chiba-Falek 
and Nussbaum 2001; Fuchs et al. 2008). 
 
Association studies examining SNPs residing in the SNCA locus have shown that 
variation at several polymorphisms and haplotypes constructed thereof significantly 
alters IPD susceptibility in Caucasian and Asian populations.  These are concentrated 
in the 5’ promoter, the large ~93 kb intron, the 3’ untranslated region (UTR), and the 
3’ flanking region (Pals et al. 2004; Tan et al. 2004; Mueller et al. 2005; Mizuta et al. 
2006; Winkler et al. 2007; Westerlund et al. 2008).  Moreover, one of these variants, 
the 3’ flanking SNP rs356219, interacts synergistically with Microtubule-associated 
protein tau (MAPT) haplotype to modify IPD risk (Goris et al. 2007).  Two well-
powered genome wide association studies (GWAS) performed in Caucasians and 
Asians have recently confirmed that SNCA is central to IPD aetiopathogenesis.  These 
reports demonstrated highly significant associations with variation at one SNP in the 
5’ promoter, two in the ~93 kb intron, and one in the 3’ flanking region.  Two of the 
associations were common to both populations (Simon-Sanchez et al. 2009; Satake et 
al. 2009).  Interestingly, variation at Rep1 and five SNPs located in the 5’ promoter 
or haplotypes constructed thereof does not associate with dementia status in 
Caucasian IPD patients, but the relatively small size of this experiment may have 
generated a false negative (De Marco et al. 2008).  Variation at two IPD-associated 
SNCA SNPs has been correlated with SNCA messenger RNA (mRNA) levels in post 
mortem brain samples.  Significant effects for rs356219 were seen in the SN and 
cerebellum of a combined set of IPD cases and controls, but a different study failed to 
replicate the cerebellum result at the protein level (Fuchs et al. 2008; Westerlund et 
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al. 2008).  Trends were observed for the intronic polymorphism rs7684318 in the IPD 
and control FC (Mizuta et al. 2006).  However, whole genome studies correlating 
SNP genotype with cortical gene expression have not identified any variants 
demonstrating association with SNCA expression, and one of these specifically 
examined IPD-associated SNPs at this locus (Myers et al. 2007a; Simon-Sanchez et 
al. 2009). 
 
In summary, there is evidence to suggest that increasing SNCA copy number 
correlates with a more dementia-prone FPD phenotype, and that this effect could be 
mediated by changes in SNCA expression.  Furthermore, variation at polymorphisms 
situated in the 5’ promoter and 3’ terminus of SNCA significantly associates with IPD 
and may influence the expression of its mRNA. 
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5.2. Aims and methodology 
Based on the background literature, it was hypothesised that there could be a 
relationship between IPD dementia status and SNCA mRNA expression, and that 
SNCA locus SNP variation might influence IPD risk and SNCA mRNA expression.  
Therefore, the aims of this chapter were as follows: 
 
1. Examine SNCA mRNA expression in IPD dementia and neurodegeneration.  
This was accomplished by employing Sybr Green qRT-PCR to compare total and 
neuronal loss-corrected (NLC) SNCA mRNA expression in IPD cognitive series 
(idiopathic Parkinson’s disease with dementia [IPDD]; idiopathic Parkinson’s 
disease no dementia [IPDND]; controls) dorsolateral prefrontal cortex (DLPFC) 
(Brodmann area 46 [BA46]) complementary DNA (cDNA) batch 2 (see 3.2).  The 
qRT-PCR assay was able to detect the SNCA 140 and 112 splice forms.  Total 
expression data were normalised with a normalisation factor (NF) calculated from 
the reference genes Glucose-6-phosphate dehydrogenase (G6PD), Ribosomal 
protein L13A (RPL13A), and TATA box binding protein (TBP).  NLC expression 
data were normalised with the neuronal marker Neurofilament H (NEFH) acting 
as reference gene (see 3.2).  Statistical comparisons were carried out by Mann-
Whitney test, with significance set at corrected p ≤ 0.05 (see 2.10.2.2).  DLPFC 
expression array data obtained from the microarray series were mined in silico to 
corroborate the results (see 4.2).  Statistical comparisons were performed by 
Mann-Whitney test, with significance set at corrected p ≤ 0.05 (see 2.10.6.3). 
2. Examine SNCA mRNA expression in multiple brain regions.  In order to 
further investigate its role in IPD, Sybr Green qRT-PCR was employed to 
measure total and NLC SNCA mRNA expression in medulla, putamen, amygdala, 
entorhinal cortex (EC [BA28]), anterior cingulate cortex (ACC [BA24]), angular 
gyrus (AG [BA39]), and frontal cortex (FC [BA8]) cDNA obtained from the IPD 
mapping series (see 3.2).  The qRT-PCR assay was able to detect the 140 and 112 
splice forms.  Total expression data were normalised with a NF calculated from 
the most stable set of the following reference genes: G6PD, RPL13A, and TBP, 
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and Hypoxanthine phosphoribosyltransferase 1 (HPRT1).  NLC expression data 
were normalised with the neuronal marker NEFH (see 3.2).  Statistical 
comparisons were carried out by Mann-Whitney test, with significance set at 
corrected p ≤ 0.05 (see 2.10.2.2).  Brain region expression data were not 
compared with each other statistically. 
3. Characterise the influence of SNCA SNP variation on IPD risk.  This aim 
consisted of three parts.  Firstly, a case-control study evaluating genetic 
association with IPD was performed, by TaqMan-genotyping SNPs in genomic 
DNA (gDNA) samples acquired from the IPD association series (see 3.2).  
Haplotypes were inferred within Haploview (see 2.10.3.2).  Statistical 
assessments of allelic and haplotypic association under a multiplicative model 
were carried out by χ2 test in Haploview, with significance set at corrected  
p ≤ 0.05 (see 2.10.3.2).  Next, association study genotypic data was used to 
elucidate fine scale pairwise r2 SNP linkage disequilibrium (LD), in order to place 
SNPs in a haplotypic context (see 2.10.7.1).  Finally, in silico mining was 
employed to identify putative functional SNPs which might be driving association 
with disease.  HapMap phase II Centre d’Étude du Polymorphisme Humain 
(CEPH) trio polymorphic SNP LD data was downloaded (release 23a from March 
2008).  The University of California Santa Cruz (UCSC) PhyloP database 
(assembly hg18 from March 2006) was mined for predicted DNA conservation 
across 32 placental mammals, and the literature was then mined for Caucasian 
and Asian IPD genetic association study data (see 2.10.7.2). 
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5.3. Results 
5.3.1. α-Synuclein is not differentially-expressed in 
the idiopathic Parkinson’s disease dorsolateral 
prefrontal cortex 
In order to investigate possible relationships between SNCA and IPD dementia status, 
qRT-PCR was employed to measure total and NLC expression in cognitive series 
DLPFC cDNA batch 2 (IPDD [n = 15]; IPDND [n = 16]; control [n = 16]).  
Clinicopathological group comparisons and expression data normalisation strategies 
for this series and cDNA batch have been described (see 3.3.2 and 3.3.4).  So as to 
corroborate the findings, DLPFC expression array data obtained from the microarray 
series (IPDD [n = 7]; IPDND [n = 7]; control [n = 7]) were mined in silico.  Again, 
clinicopathological comparability of this series has been demonstrated (see 4.3.1).  
Expression in IPDD and IPDND was compared statistically, and these two groups 
subsequently combined to generate the IPD group.  Expression in IPD (qRT-PCR  
n = 31; microarray n = 14) and controls (qRT-PCR n = 16; microarray n = 7) was 
then compared statistically. 
 
Table 5.1 and figure 5.1 show the results of this analysis.  Notable levels of 
intragroup variation were detected in the qRT-PCR NLC and microarray data.  No 
significant changes were observed for qRT-PCR total, qRT-PCR NLC, or microarray 
SNCA expression.  Indeed, the qRT-PCR results indicated nearly identical expression 
across the groups.  The microarray data displayed a trend of SNCA underexpression 
in IPD contrasted against controls, but this only approached significance even before 
correction for multiple testing.  Taken together, these findings demonstrate that SNCA 
is not differentially-expressed in the IPD DLPFC in these series.  Hence, there is no 
evidence to support the hypothesis that there is a relationship between IPD dementia 
status and DLPFC SNCA expression. 
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Figure 5.1. SNCA is not differentially-expressed in the IPD DLPFC. 
Relative mean (a) qRT-PCR and (b) microarray DLPFC SNCA expression values with 95% CI for 
cognitive series cDNA batch 2 and the microarray series, respectively.  No significant differences were 
observed in any comparison, demonstrating that SNCA is not differentially-expressed in the IPD 
DLPFC.  For the qRT-PCR, total expression data were normalised with G6PD, RPL13A, and TBP, and 
NLC expression data with NEFH.  For the microarray, statistical analyses were performed on log2 
data, but raw mean and CI data were generated using antilog functions and plotted to aid comparison.  
Groups were compared by Mann-Whitney test.  p values were corrected x20.  CI = confidence interval; 
CON = control; cDNA = complementary DNA; DLPFC = dorsolateral prefrontal cortex; G6PD = 
Glucose-6-phosphate dehydrogenase; IPD = idiopathic Parkinson’s disease; IPDD = idiopathic 
Parkinson’s disease with dementia; IPDND = idiopathic Parkinson’s disease no dementia; NEFH = 
Neurofilament heavy polypeptide; NLC = neuronal loss-corrected; qRT-PCR = quantitative reverse 
transcriptase-polymerase chain reaction; RPL13A = Ribosomal protein L13A; SNCA = α-Synuclein; 
TBP = TATA box binding protein. 
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5.3.2. α-Synuclein is not differentially-expressed in 
seven other subcortical and cortical regions of the 
idiopathic Parkinson’s disease brain 
So as to further investigate SNCA in the context of IPD, qRT-PCR was used measure 
total and NLC expression in seven subcortical and cortical brain regions obtained 
from the mapping series.  Clinicopathological group comparisons and expression data 
normalisation strategies for this series have been described (see 3.3.5).  Expression in 
IPD (n = 20) and controls (n = 20) was compared statistically. 
 
The results of this analysis can be seen in table 5.2 and figure 5.2.  Relatively high 
levels of intragroup variation were detected in the NLC data for several areas, notably 
the medulla, amygdala, AG, and FC.  No significant changes were observed for total 
or NLC SNCA expression in the majority of mapping series regions.  The one 
exception was the FC, in which NLC expression was significantly reduced in IPD 
contrasted against controls (corrected p = 0.015).  However, total expression was 
unaltered, indicating a general lack of support for SNCA differential expression in this 
area.  A trend of decreased NLC expression was also observed in the amygdala, but 
this was nonsignificant even before correction.  Overall, these findings demonstrate 
that SNCA is not differentially-expressed in the mapping series.  Therefore, there is 
little evidence to support the view that variation in SNCA expression is associated 
with IPD in any of these seven regions. 
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IPD vs CON p value Brain 
region 
Expression 
Fold change mean SNCA 
expression (IPD/CON) Uncorrected Corrected 
Total 0.95 0.558 NS Medulla 
NLC 0.47 0.756 NS 
Total 0.88 0.411 NS 
Putamen 
NLC 0.75 0.214 NS 
Total 1.02 0.346 NS 
Amygdala 
NLC 0.58 0.081 NS 
Total 0.87 0.328 NS EC 
(BA28) NLC 0.96 0.523 NS 
Total 1.06 0.607 NS ACC 
(BA24) NLC 0.97 0.757 NS 
Total 1.02 0.665 NS AG 
(BA39) NLC 1.01 0.673 NS 
Total 0.84 0.116 NS FC 
(BA8) NLC 0.45 7.44e-4 0.015 
 
Table 5.2. IPD mapping series SNCA expression data. 
Fold change mean qRT-PCR SNCA expression values (relative to controls) and statistical results for 
the mapping series.  No significant differences in both total and NLC SNCA expression were observed 
in any region, demonstrating that SNCA is not differentially-expressed in the mapping series.  Total 
expression data were normalised with G6PD, HPRT1, RPL13A, and TBP, except for amygdala and EC 
data, which were normalised with HPRT1, RPL13A, and TBP.  NLC expression data were normalised 
with NEFH.  IPD and CON groups were compared by Mann-Whitney test.  p values were corrected 
x20.  AG = angular gyrus (BA39); ACC = anterior cingulate cortex (BA24); BA = Brodmann area; 
CON = control; DLPFC = dorsolateral prefrontal cortex (BA46); EC = entorhinal cortex (BA28); FC = 
frontal cortex (BA8); G6PD = Glucose-6-phosphate dehydrogenase; HPRT1 = Hypoxanthine 
phosphoribosyltransferase 1; IPD = idiopathic Parkinson’s disease; NEFH = Neurofilament H; NLC = 
neuronal-loss corrected; NS = not significant; qRT-PCR = quantitative reverse transcriptase-
polymerase chain reaction; RPL13A = Ribosomal protein L13A; SNCA = α-Synuclein; TBP = TATA 
box binding protein. 
 
 254 
 
 
 
 
 
 
 
Figure 5.2. SNCA is not differentially-expressed in the mapping series. 
Relative mean qRT-PCR SNCA expression values with 95% CI for the mapping series.  No significant 
differences in both total and NLC SNCA expression were observed in any region, demonstrating that 
SNCA is not differentially-expressed in the mapping series.  Total expression data were normalised 
with G6PD, HPRT1, RPL13A, and TBP, except for amygdala and EC data, which were normalised 
with HPRT1, RPL13A, and TBP.  NLC expression data were normalised with NEFH.  IPD and CON 
groups were compared by Mann-Whitney test.  p values were corrected x20.  AG = angular gyrus 
(BA39); ACC = anterior cingulate cortex (BA24); BA = Brodmann area; CI = confidence interval; 
CON = control; DLPFC = dorsolateral prefrontal cortex (BA46); EC = entorhinal cortex (BA28); FC = 
frontal cortex (BA8); G6PD = Glucose-6-phosphate dehydrogenase; HPRT1 = Hypoxanthine 
phosphoribosyltransferase 1; IPD = idiopathic Parkinson’s disease; NEFH = Neurofilament H; NLC = 
neuronal-loss corrected; qRT-PCR = quantitative reverse transcriptase-polymerase chain reaction; 
RPL13A = Ribosomal protein L13A; SNCA = α-Synuclein; TBP = TATA box binding protein. 
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5.3.3. α-Synuclein haplotypic variation influences 
idiopathic Parkinson’s disease risk 
Multiple system atrophy (MSA) is an adult onset progressive neurological disorder 
characterised in most cases by autonomic dysfunction, striatonigral degeneration, and 
parkinsonism.  Its primary neuropathological hallmark is the presence of misfolded 
protein aggregates within oligodendrocytes.  These glial cytoplasmic inclusions 
(GCIs) are mainly composed of filamentous SNCA.  GCIs are associated with 
demyelination, reactive gliosis, and neuronal loss, all of which occur selectively in 
the brainstem, SNpc, putamen, and cerebellum.  Due to their similarities, MSA and 
IPD are both classified as synucleinopathies [reviewed in (Wenning et al. 2008)]. 
 
Based on this clinicopathological overlap, it was hypothesised that genetic variants 
demonstrating association with both conditions could improve our understanding of 
IPD.  Two recent reports have identified MSA-associated SNPs.  The most significant 
results from each study were rs11931074 and rs3822086, both of which reside in the 
SNCA locus (Scholz et al. 2009; Al-Chalabi et al. 2009).  Notably, variation at these 
polymorphisms also associates with IPD, however the evidence for rs3822086 is less 
strong (Simon-Sanchez et al. 2009; Mueller et al. 2005).  Nonetheless, these two 
markers are amongst the most promising genetic susceptibility factors common to 
MSA and IPD.  Therefore, a case-control genetic association study was performed.  
Taqman was used to genotype rs3822086 and rs11931074 in gDNA extracted from 
the association series (IPD [n = 705]; controls [n = 572]) and haplotypes were 
inferred.  SNP alleles and haplotypes were tested for association with IPD under a 
multiplicative model.  Group clinical data for the association series can be seen in 
table 5.3.  This experiment was carried out in collaboration with Coro Paisán-Ruíz 
from the laboratory of Dr. Andrew Singleton (National Institutes of Health).  Dr. 
Paisán-Ruíz had previously generated the IPD case genotypic data for rs119311074. 
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Group (n) % males Statistic 
Age of 
onset 
Age of 
donation 
Disease 
duration 
Mean NA 38.7 NA CON (572) 50.7 
SD NA 8.2 NA 
Mean 57.4 72.0 14.1 
IPD (705) 58.1 
SD 12.9 11.5 8.8 
 
Table 5.3. IPD association series clinical data. 
Group clinical metrics for the IPD association series.  Due to sample availability, this series differed 
substantially from chapters 3 and 4 (see table 2.6).  In the IPD group, 319 were brain samples and 386 
were blood samples; in the CON group these counts were 94 and 478, respectively.  Disease duration 
values for IPD blood samples were measured at a cut-off date in 2003.  Measures of time are in years.  
CON = control; IPD = idiopathic Parkinson’s disease; NA = not applicable; SD = standard deviation. 
 
Table 5.4 shows the SNP association study results.  The Hardy-Weinberg equilibrium 
(HWE) was not violated in the case or control groups for either polymorphism, 
indicating that no serious genotyping errors had occurred.  Single marker allelic 
association with IPD was not demonstrated for variation at rs3822086 or rs11931074.  
On the other hand, the rare GT haplotype was significantly associated with IPD 
(corrected p = 0.030).  The estimated odds ratio (OR) for this effect was 5.935, with a 
95% confidence interval (CI) that ranged from 1.714 to 20.555.  The case and control 
frequencies showed that this haplotype confers increased susceptibility to IPD. 
 
Therefore, these findings indicate that the GT haplotype increases IPD risk in the 
association series.  Using Alzheimer’s disease (AD) genetic data, it has been 
demonstrated that haplotypes constructed of markers flanking but not including an 
associated variant can themselves display association (Fallin et al. 2001).  Hence, our 
results suggest that one or more IPD-associated variants is/are being tagged by the 
GT haplotype and reside(s) in the sequence flanked by these two SNPs i.e. the ~25.2 
kb between 90858538 and 90883817 on chromosome 4.  SNCA is located between 
90865728 and 90978489 and is transcribed from the negative strand.  Placing this 
region of interest (ROI) in context of the SNCA transcript, rs3822086 lies towards the 
3’ end of the ~93 kb intron, and rs11931074 is situated downstream.  Hence this ROI 
encompasses Ensembl exons 970014 and 1520237 (including the 3’UTR), the 
relevant intronic sequences, and ~7.2 kb of downstream sequence (see figure 5.3). 
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5.3.4. The polymorphisms rs11931074, rs3822086, 
and rs3857059 reside on the same haplotype block 
The polymorphism rs3822086 has not been genotyped as part of the HapMap project.  
As such, little is known about its LD relationships with SNP haplotype structure in 
the SNCA locus, in particular with rs11931074.  Therefore, fine scale pairwise r2 LD 
was elucidated from genotypes obtained for the association study (see 5.3.3).  This 
was carried out using rs3822086 and rs11931074 genotypic data for the 572 controls.  
Subsequently, this was performed using genotypic data for 563 of the IPD cases.  In 
addition to rs3822086 and rs11931074, this second dataset included genotypes at 
eight SNCA locus SNPs.  These other variants were located in and around the SNCA 
transcribed region: one ~38 kb upstream; four in the ~93 kb intron; and three 
downstream, the most distant residing ~94 kb from the 3’UTR (see figure 5.3).  This 
experiment was carried out in collaboration with Coro Paisán-Ruíz from the 
laboratory of Dr. Andrew Singleton.  Dr. Paisán-Ruíz had previously generated the 
IPD case genotypic data for all SNPs except rs3822086. 
 
Figure 5.3 shows the results.  LD between rs11931074 and rs3822086 in controls was 
very high (r2 = 0.96).  In IPD cases, rs3822086 possessed fairly strong LD with 
rs11931074 (r2 = 0.77) and rs3857059 (r2 = 0.78).  However, LD values between 
rs3822086 and the remaining seven SNPs were markedly lower (r2 < 0.55 in all 
comparisons).  These findings, especially the very strong relationship in controls, 
indicate that rs11931074 and rs3822086 are probably located on the same haplotype 
block in Caucasians.  In agreement with HapMap CEPH data, the IPD results also 
suggest that rs3857059 belongs to this block, implying that the ROI suggested to 
contain one or more IPD-associated variant(s) (see 5.3.3) could be extended to 
include the genomic space flanked by rs3857059. 
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Figure 5.3. SNP LD relationships in the SNCA locus. 
Fine scale pairwise r2 LD plots for SNCA locus SNPs based on genotyping (a) 572 controls (brain  
[n = 94]; blood [n = 478]) and (b) 563 IPD cases (brain [n = 318]; blood [n = 245]).  LD between 
rs11931074 and rs3822086 in controls was very high, and in IPD cases, LD between rs3822086 and 
both rs11931074 and rs3857059 was fairly strong, indicating that these three variants are probably 
situated on the same haplotype block in Caucasians (boxed in red).  Pairwise LD values (out of 100) 
label the relevant squares.  Degree of square shading denotes LD magnitude.  (a) Ensembl exon 
identities and their relative positions along the SNCA transcript in relation to the white bar are 
indicated.  (b) Boundaries of SNCA transcript (~113.2 kb) on chromosome 1 according to NCBI 
assembly build 36 in relation to the white bar are indicated.  IPD = idiopathic Parkinson’s disease LD 
= linkage disequilibrium; NCBI = National Center for Biotechnology Information; SNP = single 
nucleotide polymorphism; SNCA = α-Synuclein. 
 260 
5.3.5. Identification of putative functional variants in 
the region flanked by rs11931074 and rs3857059 
Linkage disequilibrium architecture in the human genome has an important 
consequence: it can be difficult to determine exactly which variant(s) within a 
haplotype block is/are driving genetic association with disease.  This can be relatively 
clear if one of the polymorphisms is obviously functional e.g. a nonsynonymous 
SNP.  However, associated variants often reside in introns or intergenic space.  In this 
instance, how can one sift through a list of polymorphisms and identify the functional 
variant?  Assessment of evolutionary DNA sequence conservation provides a 
reasonable handle to grasp this problem.  Therefore, in silico mining was employed to 
identify putative functional variants which could underlie the haplotypic association 
with IPD (see 5.3.3).  The SNPs rs11931074 and rs3857059 are probably situated on 
the same haplotype block in Caucasians (see 5.3.4), hence the aforementioned 
association ROI (see 5.3.3) was redefined as their entire intergenomic space i.e. 
90858538 to 90894261 on chromosome 4.  LD data for all polymorphic SNPs 
residing in this ~35.7 kb ROI was downloaded from HapMap, and UCSC PhyloP was 
mined for predicted mammalian DNA sequence conservation data at these SNP 
positions.  For those variants displaying some degree of predicted conservation, the 
literature was then mined for IPD genetic association data (Mueller et al. 2005; 
Mizuta et al. 2006; Ross et al. 2007a; Westerlund et al. 2008; Winkler et al. 2007). 
 
The results can be seen in table 5.5.  Of the 28 SNPs situated in the ROI, only five are 
located at positions displaying some degree of predicted conservation.  The variants 
rs11931074, rs3822086, and rs3857059 reside at positions predicted by PhyloP to be 
undergoing rapid evolution.  The five aforementioned polymorphisms were: 
rs7436973, rs356165, rs356204, rs3857057, and rs356168.  The SNP rs7436973 is 
situated ~3 kb downstream of the SNCA transcript, rs356165 is located in the 3’UTR, 
and the remaining three polymorphisms reside in the ~93 kb intron.  IPD genetic 
association study data was available for rs356165, rs356204, and rs356168, but not 
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for rs7436973 and rs3857057.  Variation at rs356165 significantly associated with 
IPD in four out of five cohorts examined, and an extremely low p value was observed 
in an Asian population (Mueller et al. 2005; Mizuta et al. 2006; Ross et al. 2007a; 
Westerlund et al. 2008; Winkler et al. 2007).  These findings, together with its 
3’UTR location which hypothetically might affect RNA stability, splicing, or 
microRNA (miRNA) targeting, suggest that rs356165 is an important putative 
functional variant.  The SNP rs356204 exhibited the highest amount of predicted 
conservation.  Furthermore, variation at this polymorphism significantly influenced 
IPD risk in both of the relevant studies (Mueller et al. 2005; Westerlund et al. 2008), 
suggesting that it is also a putative functional variant.  On the other hand, variation at 
rs356168 failed to confidently demonstrate association with IPD (Mueller et al. 
2005), making it unlikely to be a putative functional variant. 
 
Taken together, these data suggest that rs356165 and rs356204 are both putative 
functional variants which could be driving the haplotypic association with IPD.  
However, their status as such is tentative at best, and still requires validation by 
functional assay. 
 
 
Table 5.5. Identification of putative functional variants in the SNCA ROI. 
Predicted DNA sequence conservation and IPD association study literature mining data for SNPs 
located in the SNCA ROI flanked by rs11931074 and rs3857059 (next page).  Five SNPs resided at 
positions exhibiting some degree of predicted conservation (in bold text).  Literature mining suggested 
that two of these variants, rs356165 and rs356204, are putative functional variants.  SNP identities and 
CEPH LD data were obtained from HapMap phase II (release 23a from March 2008), except for 
rs3822086 LD data (marked with a *), which pertains to the IPD association series controls (see 5.3.4).  
Locations on chromosome 4 are according to NCBI assembly build 36.  PhyloP conservation data were 
mined from UCSC (assembly hg18 from March 2006).  Conservation values are –log p values of 
predicted DNA sequence conservation across 32 placental mammals under a null hypothesis of neutral 
evolution.  Conserved sites are assigned positive scores and fast-evolving sites are assigned negative 
scores.  Literature mining Caucasian and Asian IPD association study allelic p values are uncorrected.  
The significance threshold for each cohort is in parentheses under the first author’s name (Mueller et 
al. 2005; Mizuta et al. 2006; Ross et al. 2007a; Westerlund et al. 2008; Winkler et al. 2007).  For 
Mueller et al., I and II signify replication cohorts.  CEPH = Centre d’Étude du Polymorphisme 
Humain; chr = chromosome; IPD = idiopathic Parkinson’s disease; LD = linkage disequilibrium; 
NCBI = National Center for Biotechnology Information; NA = not applicable; ND = not determined; 
ROI = region of interest; SNP = single nucleotide polymorphism; SNCA = α-Synuclein; UCSC = 
University of California Santa Cruz. 
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5.4. Discussion 
In this chapter we employed qRT-PCR and in silico microarray mining to investigate 
SNCA expression, and demonstrated that it is not altered in the IPD DLPFC.  
Moreover, qRT-PCR experiments showed that variation in SNCA expression is not 
related to disease status in seven other subcortical and cortical regions of the IPD 
brain.  IPD association analysis was carried out for two SNCA locus SNPs, 
rs11931074 and rs3822086.  Single marker allelic association was not demonstrated 
for variation at either polymorphism, however the rare GT haplotype composed of 
these two SNPs significantly increased IPD risk, suggesting that this haplotype is 
tagging one or more IPD-associated variant(s).  SNP genotype data was used to 
elucidate fine scale LD relationships in the SNCA locus.  This demonstrated very high 
LD between rs3822086 and rs11931074 in controls, and fairly strong LD between 
rs3822086 and both rs11931074 and rs3857059 in IPD cases, indicating that these 
three polymorphisms are probably situated on the same haplotype block in 
Caucasians.  Predicted DNA conservation and literature mining were employed to 
identify SNPs potentially driving the observed haplotypic association with IPD.  This 
approach suggested that rs356165 and rs356204 are putative functional variants 
which could underlie said association. 
 
No differences in DLPFC SNCA expression were seen when comparing IPDD with 
IPDND, or when contrasting IPD against controls.  Therefore, our data do not support 
the hypothesis that there is a relationship between IPD dementia status and SNCA 
expression.  Given the contrasting results in the literature, this is perhaps 
unsurprising.  SNCA expression has been shown to be decreased, increased and 
unaltered in the IPD FC.  However, none of the relevant studies specified which parts 
of the FC were analysed (Kingsbury et al. 2004; Chiba-Falek et al. 2006; Beyer et al. 
2008).  Two reports have done so, using microarray to demonstrate that in IPD, 
SNCA is underexpressed in BA9 and unaltered in the posterior cingulate cortex (PCC) 
(Zhang et al. 2005b; Stamper et al. 2008).  Although no studies have quantified 
SNCA expression in BA46, the latter report goes some way to corroborating the 
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observed data, because this phenotype was found to be unaffected by IPD dementia 
status.  Additional support comes from a study which failed to detect an association 
between IPD dementia status and variation at the microsatellite Rep1 (De Marco et 
al. 2008), which is thought to influence SNCA expression (Chiba-Falek and 
Nussbaum 2001; Fuchs et al. 2008).  Taken together, our findings and the literature 
suggest that changes in SNCA expression are not required to maintain the IPD 
dementia phenotype.  Furthermore, SNCA was not differentially-expressed in seven 
other brain regions.  IPD SNCA expression data have not been published for the 
majority of these areas.  The lack of differential expression in the amygdala reflects 
similar results in one report (Dachsel et al. 2007).  However, our data disagree with 
two studies which showed decreased SNCA expression in the IPD putamen (Zhang et 
al. 2005b; Dachsel et al. 2007).  This disparity is likely due to differences between 
the relevant sample series, such as genetic background, disease stage, or medication 
regime.  We cannot exclude the possibility that the SNCA 126 or 98 splice forms 
exhibit differential expression in the cognitive or mapping series. 
 
Variation at rs11931074 and rs3822086 both failed to demonstrate single marker 
association with IPD.  This is contrary to the strong rs11931074 association detected 
by a recent IPD GWAS (Simon-Sanchez et al. 2009).  Simply comparing allelic 
frequencies in the two studies shows that differences in statistical power almost 
certainly explain this disparity.  Their MAFs (control = 0.07; case = 0.10) were not 
dissimilar to ours (control = 0.08; case = 0.10), however the 1713 cases and 3978 
controls analysed by Simon-Sanchez et al. afforded sufficient power to demonstrate 
association for this modest genetic effect.  This conclusion is borne out by post hoc 
calculations showing that our sample size provided 80% power to detect an effect of 
OR ≈ 1.57 with the observed control MAF at a significance of corrected p ≤ 0.05 
(disease prevalence = 0.01), which implies that this experiment lacked the necessary 
power.  The data for rs3822086 also differ from published work indicating an 
association with IPD, albeit one that didn’t survive correction for multiple testing 
(Mueller et al. 2005).  Although our two studies analysed similar numbers, Mueller et 
al. probably observed association because their control MAF (0.06) was lower than 
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ours (0.08).  This discrepancy could have arisen from ancestral differences in the 
genetic structure of these two control populations.  Due to the lack of SNCA 
differential expression (see above), it would have been redundant to undertake cis-
acting variation analyses for these polymorphisms.  This negated our ability to 
evaluate the hypothesis that SNCA locus SNP variation might influence SNCA 
expression. 
 
On the other hand, the results shown here demonstrated that the rare GT haplotype 
constructed of these two markers does significantly increase IPD risk.  Given the lack 
of single marker association for each polymorphism, this suggests that the haplotype 
is tagging one or more IPD-associated variant(s) in this population (see below).  To 
begin to explore this possibility, pairwise LD between rs3822086 and other SNCA 
locus SNPs was elucidated.  The data indicated that rs3822086, rs11931074, and 
rs3857059 are probably situated on the same haplotype block in Caucasians.  This 
finding is an important one, because it suggests that the reported associations of 
variation at rs3822086 and rs11931074 with IPD are not independent (Mueller et al. 
2005; Simon-Sanchez et al. 2009), but in fact arise from the same genetic risk factor 
i.e. these polymorphisms are tagging each other.  This conclusion might also extend 
to the published associations between variation at these two SNPs and MSA (Al-
Chalabi et al. 2009; Scholz et al. 2009), although confirmation would require 
clarifying their LD relationship in MSA cases.  Our results are broadly corroborated 
by several studies showing that haplotypes encompassing the ~93 kb intron, the 3’ 
transcribed region, and the 3’ downstream region of SNCA demonstrate significant 
association with IPD (Mueller et al. 2005; Mizuta et al. 2006; Simon-Sanchez et al. 
2009). 
 
In silico mining suggested that rs356165 and rs356204 are putative functional 
variants which might be driving the haplotypic association with IPD.  Despite their 
relatively low r2 LD with rs11931074, this conclusion is supported by the fact that 
polymorphisms both possess strong D’ LD with the latter SNP.  Due to stronger 
associations in the literature and the potential for direct influence on SNCA transcript 
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quantity, translational efficiency, or splicing, it is reasonable to infer that the 3’UTR 
variant rs356165 is the more likely candidate of the two (Mueller et al. 2005; Mizuta 
et al. 2006).  The miRBase online database was consulted for potential miRNA 
binding at this site, but unfortunately the relevant sequence is excluded (Griffiths-
Jones et al. 2008).  Nevertheless, it is quite possible that rs356204 is also involved.  
For example, this polymorphism could be situated in an as yet undefined region 
which regulates SNCA transcription and/or splicing.  It is important to mention that 
these results only suggest putative functionality for rs356165 and rs356204.  
Functional assays are still required to validate them as true functional candidates.  
Moreover, the incomplete nature of the HapMap dataset necessarily means that some 
putative functional SNPs may have been missed by this approach.  Furthermore, the 
true functional variant(s) might belong to a different class of polymorphism e.g. 
microsatellites.  Nonetheless, these data demonstrate the utility of DNA conservation 
mining for identifying putative functional variants potentially mediating genetic 
association, particularly if the relevant ROI is intronic and functional prediction is 
difficult. 
 
In conclusion, it was demonstrated that SNCA is not differentially-expressed in eight 
cortical and subcortical regions of the IPD brain, and that DLPFC SNCA expression is 
not related to IPD dementia status.  Furthermore, it was shown that a rare two-marker 
haplotype in the SNCA locus significantly increases IPD risk, and that two SNPs 
independently reported to influence susceptibility to both IPD and MSA are probably 
situated on the same haplotype block in Caucasians.  Finally, in silico mining 
successfully identified two putative functional variants which might be driving the 
observed haplotypic association with IPD. 
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Chapter 6: Discussion 
6.1. Introduction and overall experimental 
rationale 
Dementia is a regular feature of Parkinson’s disease (PD) (Aarsland et al. 2005b; 
Buter et al. 2008; Hely et al. 2008).  Parkinson’s disease dementia (PDD) is a 
progressive syndrome characterised by neuropsychological deficits affecting working 
memory (WM), attention, conceptualisation, verbal fluency, visuospatial abilities, and 
declarative memory (Girotti et al. 1988; Litvan et al. 1991; Pillon et al. 1993; Bohnen 
et al. 2006).  Studies have demonstrated that many genes harbour changes which 
cause and influence susceptibility to familial and idiopathic Parkinson’s disease 
(IPD), respectively [for example (Polymeropoulos et al. 1997; Kitada et al. 1998; 
Bonifati et al. 2003; Singleton et al. 2003; Aharon-Peretz et al. 2004; Huang et al. 
2004; Paisan-Ruiz et al. 2004; Valente et al. 2004; Healy et al. 2008; Simon-Sanchez 
et al. 2009)].  Moreover, a host of reports have shown that numerous genes exhibit 
differential expression or alternative splicing in the IPD brain [for example (Hauser et 
al. 2005; Zhang et al. 2005b; Moran et al. 2006; Cantuti-Castelvetri et al. 2007; 
Beyer et al. 2008; Tobin et al. 2008; Bossers et al. 2009; Kumaran et al. 2009; 
Simunovic et al. 2009)].  On the other hand, mutation and association analyses have 
implicated just a handful of genes in familial and idiopathic Parkinson’s disease 
dementia (IPDD) (Ohtake et al. 2004; Zarranz et al. 2004; de Lau et al. 2005; Healy 
et al. 2008; Ross et al. 2008a; Sidransky et al. 2009; Williams-Gray et al. 2009a).  
Furthermore, studies quantifying gene expression in the IPDD brain have identified 
numerous dysregulated genes, however the literature contains only two such reports 
(Bychkov et al. 2008; Stamper et al. 2008).  Despite these findings, the genetic and 
molecular factors driving IPDD aetiopathogenesis remain largely unexplored. 
 
Therefore, the principal aims of this thesis were to identify and characterise genes 
implicated in IPD dementia and/or neurodegeneration.  Quantifying and comparing 
 268 
gene expression was the first step in this methodology.  IPD is a complex dynamic 
disorder, underpinned by numerous overlapping and/or interacting processes 
mediating its initiation and progression, many of which involve dysregulated gene 
expression [reviewed in (Sulzer 2007; Ferrer 2009)].  In addition, it likely that some 
of these disease effects are linear and some are circular [reviewed in (Hirsch and 
Hunot 2009; Ferrer 2009)].  Hence, evaluating intergroup differential expression 
constituted a versatile approach with the potential to uncover genes involved at any 
point within these various pathogenic stages.  Moreover, the three group design (IPD 
dementia, IPD no dementia [IPDND], and controls) allowed us to identify genes 
implicated in either disease subtype i.e. IPD dementia or IPD neurodegeneration.  A 
very similar design was employed in a recent expression microarray study of IPDD 
(Stamper et al. 2008). 
 
Gene expression was measured using hypothesis-driven quantitative reverse 
transcriptase-polymerase chain reaction (qRT-PCR) and hypothesis-free expression 
microarray.  These complementary techniques enabled validation of observed gene 
dysregulation events.  The qRT-PCR findings were strengthened by the use of a 
standard curve on every plate, and by measuring each standard curve dilution and 
sample in triplicate.  Neuronal cell death and gliosis in IPD have the potential to 
generate artefactual expression data.  In order to control for neuronal loss and/or 
gliosis in IPD samples and for technical variation, total qRT-PCR expression data 
were normalised using a normalisation factor (NF) calculated from multiple reference 
genes.  This strategy is more effective than a single reference gene (Vandesompele et 
al. 2002; Szabo et al. 2004). 
 
As an alternative approach to control for neuronal cell death, neuronal loss-corrected 
(NLC) qRT-PCR expression data were normalised with the neuronal marker 
Neurofilament H (NEFH) acting as reference gene [for example (Fuchs et al. 2008)].  
Neuron-specific expression has been demonstrated for NEFH in the human and 
murine brain (Goldstein et al. 1983; Schulz et al. 2003; Lariviere and Julien 2004; 
Cahoy et al. 2008).  Normalisation with this marker was an alternative but most likely 
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incomplete attempt to control for neuronal loss in IPD.  It is important to note that the 
concept of NLC expression remains unverified in the post mortem qRT-PCR 
literature, and that compared to normalisation with multiple reference genes, 
normalisation with one neuronal marker probably generates data less robust to 
variation in tissue composition and experimental procedure.  Critically, the NLC data 
did not equate to neuron-specific expression.  Indeed, the use of whole tissue extracts 
meant that neither qRT-PCR nor microarray were able to scrutinise cell type-specific 
expression.  Therefore, we were unable determine the relative contributions of 
neuronal and glial expression to any observed gene dysregulation event. 
 
Subsequently, characterisation of implicated target genes was carried out.  The 
regional specificity of previous effects was gauged by employing qRT-PCR to 
evaluate differential expression in additional cortical and subcortical brain regions.  
These were chosen because of their vulnerability to Lewy pathology (LP) in IPD 
(Braak et al. 2003).  For these mapping experiments, normalisation of total 
expression was strengthened by utilising geNorm on a region-by-region basis to 
select the most stable set from four different reference genes (Vandesompele et al. 
2002).  Single nucleotide polymorphism (SNP) association and cis-acting variation 
analyses were then undertaken.  HapMap data was generally employed to select SNPs 
which captured the vast majority of SNP variation in the relevant loci.  These genetic 
experiments allowed us to determine whether target gene SNP variation plays a 
primary role in disease aetiology, and whether the relevant mechanisms involve gene 
dysregulation.  Moreover, positive results in these analyses could enrich the initial 
differential expression findings, by providing further evidence to connect target genes 
with disease.  Because the expression data failed to confirm any gene as specifically 
implicated in IPD dementia (see 3.3.3, 4.3.5, and 5.3.1), the expression mapping and 
genetic association experiments did not evaluate correlates of this IPD subtype.  In 
silico data mining of the expression microarray and other bioinformatic resources was 
carried out.  For the most part, these approaches utilised the array data to evaluate 
specific hypotheses concerning gene expression in the IPD brain.  In one instance, 
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predicted DNA conservation and IPD association data were mined to identify putative 
functional SNPs. 
 
Potential sources of bias in the genetic association analysis were minimised. About 
half of the IPD cases samples were pathologically-proven.  The influences of 
population stratification and phenotyping errors were reduced by analysing only 
Caucasian individuals and ensuring accurate diagnoses, respectively.  Hardy-
Weinberg equilibrium calculation was employed to control against genotyping errors.  
Statistical confidence was achieved by using the relatively severe Bonferroni 
approach to correct for multiple testing.  The cis-acting variation analysis had several 
weaknesses.  In order to obtain sufficient statistical power, it was necessary to analyse 
cases and controls together.  Furthermore, this approach was unable to control for 
interindividual differences in trans-acting effects caused by sample preparation, 
messenger ribonucleic acid (mRNA) quality, or the environment. 
 
In order to reduce the chance of statistical false positives, correction for multiple 
testing was employed throughout this thesis.  We mostly used the Bonferroni 
approach, although family-wise error (FWE) and the less severe false discovery rate 
(FDR) were selected for the genotypic voxel-based morphometry (VBM) and 
expression microarray analyses, respectively [reviewed in (Shaffer 1995)].  In 
addition, the in silico microarray mining results were uncorrected due to prior 
hypothesis (Rothman 1990).  The overall Bonferroni strategy was to correct within 
each experimental type on a chapter-by-chapter basis e.g. correcting across all the 
qRT-PCR statistical tests in chapter 3 (i.e. IPD cognitive expression analysis, DUSP6 
full length [FL] and 1:3 expression analysis, DUSP6 expression mapping analysis, 
DUSP6 cis-acting variation analysis) generated a correction factor of 45. 
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6.2. Principal findings 
We employed qRT-PCR and in silico mining of microarray data to demonstrate that 
Dual specificity phosphatase 6 (DUSP6) is significantly underexpressed in the IPD 
dorsolateral prefrontal cortex (DLPFC) (Brodmann area 46 [BA46]).  However, 
variation in DLPFC DUSP6 expression did not associate with IPD dementia.  
Combined qRT-PCR, in silico microarray mining, and methyl-specific polymerase 
chain reaction (MSP) analyses indicated that the observed underexpression is not an 
artefact of modulated splicing, and is unlikely to result from differential expression of 
a predicted regulatory transcription factor (TF), but may in part be caused by 
increased CpG methylation at an E Twenty-Six (ETS) family binding site upstream of 
DUSP6.  Further qRT-PCR experiments showed that DUSP6 FL is not differentially-
expressed in seven other subcortical and cortical regions of the IPD brain.  DNA 
sequencing of DUSP6 identified the +460G>C point mutation in the 5’untranslated 
region (UTR) of one familial Parkinson’s disease (FPD) patient, but we were unable 
to evaluate whether this alteration segregates with disease.  Genetic association 
analysis of 95% of common SNP variation in the DUSP6 locus indicated that the 
rs1689408 minor allele marginally lowers IPD susceptibility by trend of borderline 
significance.  Moreover, genotypic VBM demonstrated that normal rs1689408 
heterozygotes possess significantly higher grey matter density in several brain 
regions, including the subgenual anterior cingulate cortex (ACC), lateral orbitofrontal 
cortex (OFC), medial entorhinal cortex (EC), hippocampus, amygdala, insular cortex, 
DLPFC, frontal cortex (FC), and caudate.  Cis-acting variation analysis indicated that 
variation at rs1689408 does not influence DUSP6 FL expression per se, but did detect 
a trend whereby DLPFC DUSP6 FL/1:3 splice form ratios are relatively higher in 
rs1689408 heterozygotes. 
 
Microarray and qRT-PCR analyses showed that Ephrin receptor A2 (EPHA2) is 
significantly overexpressed in the IPD DLPFC (BA46).  However, association 
between variation in DLPFC EPHA2 expression and IPD dementia was not 
confirmed.  In silico microarray mining suggested that the observed effect might 
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result from constitutive activation of an EPHA2-Extraceullular-signal regulated 
kinase 1/2 (ERK1/2)-ETS-like kinase 1 (ELK1)-EPHA2 positive feedback loop.  
Additional qRT-PCR experiments demonstrated that EPHA2 is not differentially-
expressed in seven other subcortical and cortical regions of the IPD brain.  Genetic 
association analysis of 95% of common SNP variation in the EPHA2 locus indicated 
that the rs11260822 minor allele significantly increases IPD risk.  However, variation 
at this SNP did not influence DLPFC EPHA2 expression. 
 
In silico microarray mining and qRT-PCR demonstrated that α-Synuclein (SNCA) is 
not differentially-expressed in the IPD DLPFC (BA46).  Moreover, variation in 
DLPFC SNCA expression did not associate with IPD dementia.  Further qRT-PCR 
experiments showed that SNCA is not differentially-expressed in seven other 
subcortical and cortical regions of the IPD brain.  Single marker SNCA locus SNP 
association analysis indicated that variation at rs11931074 or rs3822086 does not 
associate with IPD.  However, the rare GT haplotype composed of these two SNPs 
significantly increased IPD susceptibility, suggesting that this haplotype is tagging 
one or more IPD-associated variant(s).  Elucidation of fine scale SNP linkage 
disequilibrium (LD) in the SNCA locus indicated that rs11931074, rs3822086, and 
rs3857059 are probably situated on the same haplotype block in Caucasians.  
Predicted DNA conservation and literature mining suggested that rs356165 and 
rs356204 are putative functional variants which might be driving the observed 
haplotypic association with IPD. 
 
The cognitive expression qRT-PCR study found that variation in the DLPFC (BA46) 
and angular gyrus (AG) (BA39) expression of 10 target genes does not associate with 
IPDD.  However, significant positive correlation was observed between cerebellar 
post mortem brain pH and mini mental state examination (MMSE) score in IPD 
patients.  Subsequently, we performed expression microarray to investigate DLPFC 
(BA46) differential gene expression and alternative exon splicing IPD dementia and 
neurodegeneration.  These analyses suggested that mitochondrial/metal binding, 
axonal guidance/cytoskeletal, synaptic transmission/ion transport, lipoprotein 
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metabolism, inflammation/immune response, cell adhesion/extracellular matrix, and 
transcription/splicing pathways are dysregulated in IPD dementia.  They also 
suggested that synaptic transmission/ion transport, glycosylation/protein degradation, 
inflammation/immune response, and transcription/translation pathways are 
dysregulated in IPD neurodegeneration.  However, these changes were only 
significant before correction for multiple testing.  FDR-corrected array data indicated 
an overall lack of gene dysregulation in the IPD DLPFC.  Indeed, in silico microarray 
mining suggested that variation in the DLPFC expression of genes involved in PD 
and parkinsonism-dementia is not associated with IPD neurodegeneration and 
dementia, respectively, and that the unfolded protein response (UPR) pathway is not 
chronically-activated in the IPD DLPFC. 
 
 
6.3. The role of Dual specificity phosphatase 6 in 
brain structure and idiopathic Parkinson’s 
disease pathogenesis 
Dual specificity phosphatase 6 is expressed throughout the human body, but most 
extensively in myeloid, bronchial epithelial, and lung cells.  Expression of this gene is 
approximately equivalent across different brain regions, although levels are 
moderately higher in the amygdala, occipital cortex, and cingulate cortex (Su et al. 
2004).  The DUSP6 protein (also known as Mitogen-activated protein kinase 
phosphatase 3 [MKP3]) is also broadly expressed in human tissues, but is most 
abundant in cortical neurons and bronchial epithelial cells (Berglund et al. 2008).  
Early cell culture experiments established that DUSP6 selectively inhibits ERK1/2-
mediated transcription by dephosphorylating and anchoring it in the cytoplasm (Muda 
et al. 1996; Brunet et al. 1999).  Moreover, ERK1/2-DUSP6 binding is required for 
the catalytic activation of DUSP6, and ERK1/2-mediated phosphorylation of DUSP6 
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promotes its degradation via the ubiquitin-proteasome system (UPS) (Camps et al. 
1998; Marchetti et al. 2005). 
 
In vivo studies of Xenopus, zebrafish, chicken, and mouse embryos have crystallised 
our understanding of the delicate interplay between these two proteins.  They 
demonstrated that Erk1/2 acts downstream of Fibroblast growth factor (Fgf) to induce 
Dusp6 expression, and that Dusp6 protein inhibits Erk1/2 activity, resulting in a 
negative feedback loop which regulates Erk1/2 signaling.  These data indicate that 
this pathway plays a critical role in limb and nervous tissue development, notably in 
the anterior forebrain and isthmic organising centre; the latter controls patterning of 
the neural tube into midbrain and hindbrain (Gomez et al. 2005; Tsang et al. 2004; 
Eblaghie et al. 2003; Echevarria et al. 2005; Smith et al. 2006a).  Further support for 
this conclusion has come from observations of Dusp6-/- mice, whose phenotype is 
variably penetrant dominant postnatal lethality, skeletal dwarfism, craniostynostosis 
(premature fusion of the cranial sutures), and hearing loss.  However, the incomplete 
penetrance suggests some degree of redundancy between Dusp6 and other negative 
regulators of Fgf signaling (Li et al. 2007). 
 
Pancreatic and ovarian cancer tissues exhibit DUSP6 protein underexpression, 
consistent with the well-established view that increased ERK1/2 signaling enhances 
cellular proliferation during tumourigenesis (Furukawa et al. 2003; Chan et al. 2008).  
Nevertheless, a growing body of evidence suggests that ERK1/2 can promote 
oxidative neuronal cell death in vivo.  This may be of particular relevance in 
neurodegenerative diseases characterised by increased levels of oxidative stress, such 
as IPD, where this kinase thought to be chronically-activated.  One emergent theme is 
that ERK1/2 subcellular localisation could be vitally important in mediating between 
the different outcomes of phasic versus chronic ERK1/2 activation [reviewed in 
(Colucci-D'Amato et al. 2003; Chu et al. 2004)]. 
 
Cytoplasmic aggregates of phosphorylated ERK1/2 are detected post mortem in 
autophagosomes and abnormal mitochondria in IPD and dementia with Lewy bodies 
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(DLB) substantia nigra (SN) neurons (Zhu et al. 2002; Zhu et al. 2003).  Moreover, 
neuronal cell models show that oxidative stress resulting from treatment with  
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine induces 
ERK1/2 activation and cytoplasmic aggregation concomitant with macroautophagy 
and cell death.  These downstream effects are significantly ameliorated by ERK1/2 
inhibition, and can be recapitulated in unstressed cells by overexpression of 
constitutively active ERK2 (Zhu et al. 2002; Zhu et al. 2007; Dagda et al. 2008).  
DUSP6 phosphatase activity is reversibly inhibited by oxidative stress in vitro (Seth 
and Rudolph 2006).  Glu-induced ERK1/2-dependent oxidative toxicity in primary 
cortical cells is blocked by transient overexpression of either wild type or 
catalytically inactive DUSP6, implying that activated ERK1/2 requires nuclear 
localisation to elicit cell death in this system (Levinthal and DeFranco 2005).  
Furthermore, it was recently shown that transient DUSP6 transfection reduces Glu-
induced ERK1/2-dependent apoptosis in astrocytes (Szydlowska et al. 2010).  
Interestingly, DUSP6 dysregulation has been observed in neurological illness.  This 
gene is significantly underexpressed in the DLPFC and ACC of bipolar disease 
patients compared to controls (Vawter et al. 2006).  Overall, these published findings 
indicate that DUSP6-mediated inhibition of ERK1/2 regulates neural development 
and might influence stress-induced cell death in the IPD brain. 
 
Underexpression of DUSP6 was demonstrated in the IPD DLPFC using qRT-PCR 
and validated by in silico mining of the microarray data (see figure 3.6, figure 3.9, 
and table 4.8).  Significant underexpression of total DUSP6 FL and 1:3 was shown by 
qRT-PCR in two batches of complementary DNA (cDNA) (see figure 3.9), indicating 
that this result was not an artefact caused by modulated splicing.  Similar but 
nonsignificant changes were seen when using the alternative qRT-PCR normalisation 
approach i.e. the NLC data (see figure 3.9).  The lack of significance suggests that 
neuronal cell death may partially account for the observed effect.  However, this is 
unlikely because total DUSP6 FL expression values for IPDD and IPDND were very 
similar (see figure 3.4), despite the greater atrophy of BA46 reported in IPDD 
compared to IPDND (Burton et al. 2004; Nagano-Saito et al. 2005).  Additional qRT-
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PCR experiments demonstrated that DUSP6 FL is not differentially-expressed in 
seven other subcortical and cortical regions of the IPD brain (see figure 3.10), which 
suggests that DUSP6 underexpression is restricted to the DLPFC. 
 
We employed various approaches to elucidate the mechanism driving DUSP6 
underexpression in the IPD DLPFC.  Genetic association analysis of 95% of common 
SNP variation in the DUSP6 locus suggested that variation at rs1689408 alone might 
modify IPD risk (see table 3.10) (see below).  Cis-acting variation analysis indicated 
that that variation at rs1689408 does not influence DUSP6 FL expression per se (see 
figure 3.15).  Therefore, the observed underexpression phenomenon is unlikely to 
have a primary genetic aetiology and is probably a secondary effect of IPD 
pathogenesis.  One important caveat is that variation in a different polymorphic class 
(e.g. microsatellites or copy number variation) might be responsible.  In silico 
microarray mining and qRT-PCR indicated that TFs predicted to bind the DUSP6 
putative promoter (DPP) are themselves not underexpressed in the IPD DLPFC (see 
table 4.11 and figure 4.10).  These findings suggest that DLPFC DUSP6 
underexpression does not result from differential expression of a regulatory TF.  The 
DPP was identified as the upstream region exhibiting relatively high levels of 
predicted DNA sequence conservation across 32 placental mammals, and the 
Transfac database was queried to identify predicted TF binding sites in this region.  
Obvious weaknesses were that the DPP identification approach or the incompleteness 
of Transfac may have excluded critical regulatory sequences or regulatory TFs, 
respectively.  The DPP encompasses the region found to control Fgf-induced murine 
Dusp6 expression in vivo, and the orthologous human sequence contains an ETS 
binding site which regulates reporter gene expression in cell models (Ekerot et al. 
2008; Zhang et al. 2009).  However, human DUSP6 intron 1-2 was recently shown to 
induce transcriptional activity which is sensitive to mutation of a resident ETS 
binding site (Furukawa et al. 2008).  MSP analysis showed that relative CpG 
methylation at the aforementioned DPP ETS site was marginally increased in the IPD 
DLPFC (see figure 4.12).  Because relative CpG methylation in all of the IPD cases 
was not higher than in all of the controls, this result suggests that increased CpG 
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methylation at this ETS site might account for some, but not all, of the DUSP6 
underexpression effect.  In order to fully investigate the importance of differential 
CpG methylation at the DPP ETS site, this MSP experiment would need to be 
repeated using a larger number of samples. 
 
The mechanism which mediates the observed changes in DUSP6 expression still 
remains unclear.  Nevertheless when viewed together, these findings and the 
background literature (see above) suggest that DUSP6 underexpression could 
synergise with oxidative inhibition of the DUSP6 enzyme, resulting in enhanced 
stress-induced ERK1/2 activity which might contribute to neuronal cell death in the 
IPD DLPFC.  This conclusion is supported by the recent demonstration that primary 
cortical neurons treated with the DNA-damaging agent cisplatin exhibit Dusp6 
underexpression and reduced Erk1/2 dephosphorylation (Gozdz et al. 2008).  
Moreover, increased ERK1/2 activity would be expected to induce DUSP6 
expression.  Therefore, increased CpG methylation at multiple DUSP6 regulatory 
sequences resulting in decreased TF binding represents a plausible mechanism to 
explain DUSP6 underexpression under the spectre of chronic ERK1/2 activation.  
The literature and our experimental evidence suggest that the ETS binding sites in the 
DPP and intron 1-2 could be the regulatory sequences in question. 
 
Due to the lack of available relatives, we were unable to assess segregation with FPD 
for the +460G>C point mutation identified during DUSP6 DNA sequencing (see 
table 3.8).  The overall lack of results suggests that DUSP6 mutation is unlikely to be 
a significant cause of FPD.  All identified deviations from the reference sequence 
were confirmed by a total of two sequencing reactions in both 5’ and 3’ directions.  
Nevertheless, confidence in the above conclusion would require the sequencing of 
many more FPD individuals.  Genetic association analysis of 95% of common SNP 
variation in the DUSP6 locus indicated that the rs1689408 minor allele marginally 
lowers IPD susceptibility by trend of borderline significance (see table 3.10).  
However, the findings failed to survive correction, which casts some doubt over the 
validity and strength of the observed effect, and indicates the need for replication in a 
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larger population.  Although there have been no reports of association between 
DUSP6 genetic variation and IPD, variation at the Leu114Val polymorphism 
(rs2279574) does influence the risk of bipolar disease in female Koreans (Lee et al. 
2006b). 
 
Genotypic VBM demonstrated that variation at rs1689408 has a profound effect on 
human brain structure, in that normal heterozygotes possess significantly higher grey 
matter density in several cortical and subcortical regions (see tables 3.12 and 3.13).  
These results were strengthened by the use of the relatively severe FWE correction 
approach, and the fact that several areas demonstrated association in both the region 
of interest (ROI) and global analyses.  According to HapMap, rs1689408 is in perfect 
LD with rs808820 in Caucasians.  This SNP resides just 24 bp upstream of the start 
of DUSP6 exon 2, and so might influence DUSP6 splicing.  Cis-acting variation 
analysis detected a trend whereby DLPFC DUSP6 FL/1:3 splice form ratios are 
relatively higher in rs1689408 heterozygotes (see figure 3.15).  The IPD post mortem 
qRT-PCR literature shows that relative splice form ratios have been calculated in this 
way [for example (Tobin et al. 2008)].  Moreover, the effect was seen in both the 
total and NLC data.  The weakness of these results was that they did not survive 
correction.  This suggests a relatively small effect which requires confirmation with a 
larger sample size, and importantly, that this effect is most likely distinct from the 
IPD DUSP6 underexpression described above. 
 
Collectively, these data for rs1689408 build a fascinating picture.  Compared to 
homozygotes, heterozygotes possess higher grey matter density in several regions, 
seem to have marginally lower susceptibility to IPD, and appear to exhibit a DUSP6 
splicing profile which is shifted towards the FL splice form.  It is tempting to 
speculate that a common mechanism accounts for the effects on brain structure and 
IPD risk.  Chronically-modulated DUSP6 splicing is a logical candidate, as 
alterations to this process are likely to have functional implications.  The protein 
isoform encoded by DUSP6 1:3 lacks its nuclear export sequence, and hence would 
be primarily localised in the nucleus, as well as its secondary kinase interaction motif, 
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suggesting impaired ERK1/2 binding (see figure 3.7).  This isoform also lacks three 
of the five phosphatase domains present in the FL splice form, and so would be 
predicted to possess decreased catalytic activity (see figure 3.7) (Karlsson et al. 2004; 
Zhou et al. 2001).  Thus overall, the isoform encoded by DUSP6 1:3 is expected to 
have relatively reduced abilities to dephosphorylate ERK1/2 and anchor it in the 
cytoplasm.  Therefore, a chronic increase in FL/1:3 ratio might furnish the brain with 
some degree of protection against oxidative stress-induced cell death.  Over time, the 
cumulative decrease in cell death could result in higher grey matter density and lower 
susceptibility to IPD.  This conclusion is supported by the VBM data showing that 
rs1689408 heterozygotes possess higher grey matter density in several regions that 
acquire LP during IPD pathogenesis, such as the caudate, amygdala, hippocampus, 
medial EC, and subgenual ACC (Braak et al. 2003).  In addition, this model fits 
nicely with modern thinking on neuronal cell number and the multiple hit hypothesis 
of IPD pathogenesis [reviewed in (Weidong et al. 2009)]. 
 
Dual specificity phosphatase 6 research might be pursued in several future directions.  
Laser capture microdissection (LCM) could be employed to identify the cell type(s) 
responsible for DUSP6 underexpression in the IPD DLPFC [for example (Simunovic 
et al. 2009)].  This approach would have the added advantage of being able to fully 
control for neuronal loss and/or gliosis.  However, even LCM cannot distinguish 
between primary causes and secondary and effects of pathogenesis.  Limited tissue 
availability and lack of the relevant equipment precluded the use of LCM for the 
experiments described in this thesis.  LCM would also enable the precise 
investigation of DUSP6 protein expression and ERK1/2 phosphorylation in the IPD 
brain.  We attempted protein extraction from DLPFC brain tissue followed by 
western blotting for DUSP6 and phosphorylated ERK1/2, but were unable to detect 
either molecule.  Enhanced ERK1/2 activity in this region may have upregulated 
DUSP6 ubiquitination and degradation (Marchetti et al. 2005).  Moreover, the 
relatively large tissue post mortem delays (PMDs) were likely to have significantly 
reduced protein phosphorylation and caused generalised widespread protein 
degradation (Zhu et al. 2002).  At present it is not clear if DUSP6 dysregulation is 
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specific to IPD, hence it would be interesting to perform these LCM mRNA and 
protein expression experiments in tissue obtained from other neurodegenerative 
diseases.  Furthermore, the influence of CpG methylation on DUSP6 mRNA 
expression could be thoroughly investigated in DLPFC genomic DNA (gDNA) 
obtained from a large number of individuals by cloning the entire DUSP6 locus and 
carrying out bisulphite sequencing [reviewed in (Bernstein et al. 2007)]. 
 
Genetic association between variation at rs1689408 and IPD could be replicated in a 
larger population.  In order to begin to evaluate the modulated DUSP6 splicing 
hypothesis (see above), IPD genetic association and genotypic VBM analyses could 
be performed for rs808820 variation.  If significant associations were demonstrated, 
the DUSP6 FL/1:3 cis-acting variation analysis could be repeated in much larger 
numbers of separate cases and controls, with individuals grouped by rs808820 
genotype.  Unfortunately, the lack of strong LD between these variants and any SNP 
located on the DUSP6 transcript would preclude the use of more sensitive relative 
allelic expression methods e.g. single base extension.  In addition, functional 
validation of this hypothesis could be achieved in vitro by cloning rs808820 allelic 
variants of the DUSP6 locus into minigene constructs and transfecting them into 
cultured neuronal cells [for example (Niksic et al. 1999)].  Subsequently, more 
expensive and involved experiments might be performed in vivo.  Genotypic VBM 
could be carried out in IPD neurodegeneration and/or dementia cases and compared 
against the data generated in normal controls.  Moreover, human DUSP6 FL and 1:3 
transgenes could be expressed in the forebrain of adult Dusp6-/- mice under the 
control of an inducible tissue-specific promoter [for example (Lin et al. 2009b)].  By 
activating transgene expression at several timepoints and treating with stress-inducing 
agents (e.g. epoxomicin or rotenone), this system could model the biochemical and 
neuropathological consequences of interaction between chronically-modulated 
DUSP6 splicing and oxidative stress at different stages of development.  
Furthermore, this approach might even provide evidence clarifying the circumstances 
under which chronic ERK1/2 activity is neurotoxic or neuroprotective in the IPD 
prefrontal cortex. 
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6.4. The role of Ephrin receptor A2 in idiopathic 
Parkinson’s disease pathogenesis 
Ephrin receptor A2 is expressed throughout the human body, but most extensively in 
dendritic and bronchial epithelial cells.  Its expression is approximately equivalent 
across different brain regions (Su et al. 2004).  The EPHA2 protein (also known as 
Epithelial cell kinase [ECK]) is also broadly expressed in human tissues, but is most 
abundant in cerebellum granular cells and epithelial glandular cells (Berglund et al. 
2008).  Binding of the EPHA2 receptor Tyr kinase by an Ephrin ligand initiates 
bidirectional signaling cascades known to influence a variety of cellular processes 
[reviewed in (Pasquale 2008)].  EPHA2 activation inhibits Rho family signaling, 
thereby destabilising adherens junctions and promoting cell migration (Fang et al. 
2005; Fang et al. 2008).  EPHA2 kinase activity increases cell permeability via 
phosphorylation of tight junction proteins (Tanaka et al. 2005).  These cell-cell 
repulsive effects mediate some of its physiological and pathological functions.  
During vertebrate development, EphA2 guides spinal commissural axons by ensuring 
that they do not recross the midline (Brittis et al. 2002).  EPHA2 is thought to induce 
Rho family-mediated endothelial barrier disruption and leukocyte extravasation and 
migration during inflammation [reviewed in (Ivanov and Romanovsky 2006)].  
EPHA2 protein expression is increased in many cancers.  Depending on activation 
state and cellular context, it can exhibit opposing influences on tumourigenicity via 
changes in cell adhesion and metastasis [reviewed in (Pasquale 2008)]. 
 
Several EphA2-/- mouse models have been generated.  In an early experiment, mutant 
mice developed short and kinky tails, indicating that EphA2 regulates tail notochord 
cell positioning (Naruse-Nakajima et al. 2001).  Other models confirm its divergent 
effects on carcinogenesis, and knockouts displaying both increased and decreased 
tumour progression phenotypes have been reported (Guo et al. 2006; Brantley-
Sieders et al. 2005).  The EphA2-/- mouse eye lens exhibits heat shock protein 
overexpression and progressive cataract formation, apparently via mechanisms 
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involving oxidative stress and protein aggregation (Jun et al. 2009).  Interestingly, 
EphA2 activity mediates the Erk1/2-dependent differentiation of telencephalic 
dopaminergic neuronal precursors in neurosphere cultures, and disruption of neural 
EphA receptor signaling reduces nigrostriatal dopaminergic developmental 
innervation in vivo (Aoki et al. 2004; Sieber et al. 2004).  Moreover, a meta-analysis 
of several IPD SN microarray studies was recently reported.  After correction for 
neuronal loss, Ephrin signaling was found to be the most commonly dysregulated 
pathway (Sutherland et al. 2009b).  Overall, these literature findings highlight the 
roles played by EPHA2 in neural development, cell migration, inflammation, and cell 
viability, as well as suggesting that it may be involved in IPD pathogenesis. 
 
Significant overexpression of EPHA2 was demonstrated in the IPD DLPFC using 
microarray and validated by qRT-PCR.  However, the former technique suggested 
implication in IPD dementia (see table 4.4), and the latter, implication in IPD 
neurodegeneration (see figure 4.5).  Nevertheless, the most conservative 
interpretation of IPD group spacing on the array expression plot (see figure 4.4a) and 
the qRT-PCR results (see table 4.5) is that variation in EPHA2 expression associates 
with IPD neurodegeneration.  Additional qRT-PCR experiments showed that EPHA2 
is not differentially-expressed in seven other subcortical and cortical regions of the 
IPD brain (see figure 4.6), which suggests that EPHA2 overexpression is restricted to 
the DLPFC.  Genetic association analysis of 95% of common SNP variation in the 
EPHA2 locus indicated that the rs11260822 minor allele significantly increases IPD 
risk (see table 4.7).  This finding appears relatively sound, but there is still need for 
replication in a larger population.  Variation at rs11260822 was shown not to 
influence DLPFC EPHA2 expression (see figure 4.8).  Together with the lack of 
association between IPD and the remaining common SNP variation in the EPHA2 
locus (see table 4.7), this result implies that EPHA2 overexpression is not caused by 
local genetic variation, and probably arises as a secondary effect of IPD pathogenesis. 
 
Experiments in cell models indicate the existence of an EPHA2-ERK1/2-ELK1-
EPHA2 positive feedback loop (Pratt and Kinch 2002; Pratt and Kinch 2003).  In 
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silico microarray mining suggested that EPHA2 overexpression in the IPD DLPFC 
might result from constitutive activation of this loop (see table 4.8 and figure 4.9).  
Because they are drawn from uncorrected tests, these findings possess reduced 
statistical confidence.  However, it is reasonable to infer that if maintained over time, 
even small changes in the expression of signaling cascade genes could alter cellular 
signaling patterns.  Given the relatively high number of inflammation gene 
dysregulation events observed in the array (see 4.3.3 and 4.3.4) and that EPHA2 is 
expressed in dendritic cells (Ivanov and Romanovsky 2006), the observed 
overexpression of EPHA2 might be ascribed to and/or regulate neuroinflammatory 
processes in the IPD DLPFC (see 6.7) [reviewed in (Hirsch and Hunot 2009)]. 
 
When viewed in the context of a constitutively active EPHA2-ERK1/2-ELK1-
EPHA2 loop, the changes in DUSP6 and EPHA2 expression are revealed as single 
nodes in a larger system, whose functions are as yet unknown.  One intriguing 
possibility could be to ensure chronic ERK1/2 activation in IPD.  This kinase 
constitutes a central player in signal transduction, executing a myriad of functions.  
Its activation can be neuroprotective or neurotoxic, depending on a multitude of 
factors, including duration of activity, subcellular localisation, effector choice, cell 
type, and pathological state.  Furthermore, cytoplasmic aggregates of phosphorylated 
ERK1/2 have been detected in post mortem IPD SN neurons (see 6.3) [reviewed in 
(Colucci-D'Amato et al. 2003; Chu et al. 2004)].  Given that parkinsonian brain cells 
are continuously exposed to many factors promoting cell death or survival, 
chronically active ERK1/2 could enable a rapid response to either influence, 
providing them with the means and option to initiate protective and/or repair 
processes or commit apoptosis, as necessary.  If ERK1/2 is the central node and its 
chronic activation the “purpose” of this system, DUSP6 and EPHA2 take on more 
importance, performing signal “gatekeeping” and “replenishment” functions, 
respectively. 
 
Several lines of EPHA2 research might be pursued in the future.  As before, LCM 
could be used to quantify cell-type specific EPHA2 mRNA and protein expression in 
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the IPD DLPFC and in other neurodegenerative disorders (see 6.3).  The association 
between variation at rs11260822 and IPD could be replicated in a larger population.  
Given the role played by EPHA2 in neural development (Brittis et al. 2002; Aoki et 
al. 2004; Sieber et al. 2004), genotypic VBM analysis might also be warranted for 
this variant.  The constitutive EPHA2 loop hypothesis could be evaluated by 
investigating protein phosphorylation in IPD DLPFC samples with low PMD, and 
subsequently explored, by overexpressing EPHA2 to recapitulate these signaling 
patterns in oxidatively-stressed neurons and assessing the outcome of treatments 
which preferentially activate specific pathways downstream of ERK1/2.  Finally, the 
latter experiment could be performed in adult EphA2-/- mice induced to overexpress 
forebrain-specific human EPHA2. 
 
 
6.5. Dual specificity phosphatase 6 and Ephrin 
receptor A2 connect idiopathic Parkinson’s 
disease with tumourigenesis 
Dysregulation of the mammalian cell cycle can result in apoptosis and/or 
tumourigenesis.  Although neurons are generally viewed as postmitotic, various 
stresses and genetic aberrations can cause them to reactivate the cell cycle and 
commit apoptosis.  Critically, evidence suggests that these mechanisms may 
contribute to neurodegenerative cell death [reviewed in (Staropoli 2008)].  For 
example, Parkin (PARK2) promotes the degradation of Cyclin E and protects neurons 
from excitotoxic and mitochondrial apoptosis (Staropoli et al. 2003; Darios et al. 
2003).  Interestingly, PARK2 locus deletion and underexpression is observed in 
several forms of cancer (Cesari et al. 2003), and PD patients display significantly 
altered neoplastic susceptibility.  Risk is elevated for certain cancer types (e.g. brain, 
skin, and breast), whereas for others, it is reduced (Olsen et al. 2005).  Moreover, in 
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silico analysis of expression microarray data has shown that many genes upregulated 
in the IPD SN are also associated with tumourigenesis (Moran and Graeber 2008). 
 
The results presented in this thesis suggest that DUSP6 and EPHA2 may be relevant 
in this context.  The DUSP6 locus is frequently deleted in neoplasia, and pancreatic 
and ovarian cancer tissues exhibit DUSP6 protein underexpression (Furukawa et al. 
1998; Furukawa et al. 2003; Chan et al. 2008).  Our data demonstrate that DUSP6 
underexpressed in IPD (see figure 3.9 and table 4.8).  Melanoma cell lines and breast 
cancer tissues display EPHA2 protein overexpression, and experiments in EphA2-/- 
mice suggest that EphA2 promotes tumour angiogenesis and metastatic progression 
(Easty et al. 1995; Zelinski et al. 2001; Brantley-Sieders et al. 2005).  Our results 
show that EPHA2 is overexpressed in IPD (see figures 4.4a and 4.5).  Collectively, 
these findings suggest that DUSP6 and EPHA2 could represent new examples of the 
common ground between IPD and tumourigenesis. 
 
 
6.6. The role of α-Synuclein in idiopathic 
Parkinson’s disease pathogenesis 
In silico microarray mining and qRT-PCR demonstrated that SNCA is not 
differentially-expressed in the eight regions of the IPD brain, including the DLPFC 
(BA46) (see figures 5.1 and 5.2).  Furthermore, variation in DLPFC SNCA expression 
did not associate with IPD dementia (see figure 5.1).  Significant association with 
IPD was shown for the rare GT haplotype composed of rs11931074 or rs3822086, but 
not for single marker analysis (see table 5.4), suggesting that this haplotype is tagging 
one or more IPD-associated variant(s).  There are no published reports of association 
with this haplotype.  However, the low haplotype frequencies observed in both IPD 
cases and controls casts doubt on this finding, and indicates the need for replication in 
a larger population.  Indeed, highly significant associations between IPD and 
variation at both rs11931074 and rs3857059 have been demonstrated (Simon-
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Sanchez et al. 2009; Satake et al. 2009), which suggests the haplotypic association 
may have been a statistical anomaly.  Nevertheless, these published associations 
imply that the ROI selected (see 5.3.5) for identifying putative functional variants 
(see below) was not equivocal. 
 
Elucidation of fine scale SNP LD in the SNCA locus indicated that rs11931074, 
rs3822086, and rs3857059 are probably situated on the same haplotype block in 
Caucasians (see figure 5.3).  The strength of these data was the relatively high sample 
numbers, and their weakness, the lack of control genotypes for rs3857059.  Predicted 
DNA conservation and literature mining suggested that rs356165 and rs356204 are 
putative functional variants which might be driving the observed haplotypic 
association with IPD (see table 5.5).  Although predicted DNA conservation mining 
appears useful for identifying putative functional variants, the weakness of this 
approach was the lack of functional validation. 
 
Overall, these results suggest that variation in extranigral SNCA expression does not 
associate with IPD neurodegeneration or dementia.  Our DLPFC data for IPD 
neurodegeneration are consistent with one study of the FC (Chiba-Falek et al. 2006), 
but contradict several others (Kingsbury et al. 2004; Zhang et al. 2005b; Beyer et al. 
2008).  Nevertheless, our DLPFC results for IPD dementia agree with one report 
investigating posterior cingulate cortex neurons (Stamper et al. 2008).  Increased 
SNCA ploidy appears to cause parkinsonism and dementia in FPD multiplication 
pedigrees by directly affecting SNCA expression (Farrer et al. 2004; Miller et al. 
2004; Ross et al. 2008a).  However, our data and the Stamper et al. report suggest 
that this mechanism is not relevant to the IPDD cortex i.e. that changes in SNCA 
expression are not required to maintain the IPDD phenotype.  SNCA research might 
be pursued in several future directions.  The haplotypic association with IPD could be 
replicated in a larger population.  Moreover, reporter gene assays could be carried out 
in neuronal cell models in order to evaluate whether rs356165 and rs356204 are 
putative functional variants. 
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6.7. The dorsolateral prefrontal cortex in 
idiopathic Parkinson’s disease dementia and 
neurodegeneration 
The cognitive expression qRT-PCR analysis showed that variation in the DLPFC 
(BA46) and angular gyrus (AG) (BA39) expression of 10 target genes does not 
associate with IPDD (see figures 3.4 and 3.5).  Brain regions and target genes were 
selected primarily from a neuropsychological perspective.  IPDD is characterised by 
WM deficits (Litvan et al. 1991; Bohnen et al. 2006), and the DLPFC and AG are 
both involved in WM (Petrides 2000; Gruber et al. 2001).  Furthermore, BA46 
exhibits significantly greater atrophy in demented IPD cases compared to their 
nondemented counterparts or controls (Burton et al. 2004; Nagano-Saito et al. 2005), 
and BA39 cerebral blood flow is significantly reduced in IPDD patients contrasted 
against controls (Firbank et al. 2003).  Target genes involved in working or long term 
memory were chosen based on the generalist brain hypothesis, which proposes that 
variation in a specific set of genes affects many cognitive abilities and disabilities 
(see 3.3.1) (Kovas and Plomin 2006).  The main weakness of this analysis was the 
cognitive criteria used to allocate patients to IPDD and IPDND groups.  The Brain 
Bank lacks detailed neuropsychological information, and hence this decision was 
based on carer reports backed up by MMSE scores, where available. 
 
Subsequent to these lacklustre findings, the cognitive expression microarray analysis 
was performed to investigate DLPFC (BA46) transcriptome dysregulation in IPD 
dementia and neurodegeneration.  The results suggested that several genes are 
implicated in each disease subtype (see tables 4.3 and 4.4).  Moreover, when both 
were compared to controls, much more dysregulation was seen in IPDD than in 
IPDND (see table 4.2).  However, all of these changes were only significant before 
correction.  The FDR-corrected data indicated an overall lack of gene dysregulation 
(see table 4.2), which was exemplified by the fact that most of attempts at qRT-PCR 
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validation failed (see table 4.5).  Nevertheless, two recently-published genome wide 
association studies (GWAS) indicate that only a handful of SNPs display highly 
significant association with IPD (Simon-Sanchez et al. 2009; Satake et al. 2009), 
suggesting that the remainder of its genetic aetiology is probably mediated by many 
variants each of small effect.  Therefore, as long as their reduced statistical 
confidence is kept in mind, our microarray results are useful in terms of flagging 
pathways of potential importance (see below).  Nevertheless, the low number of hits 
indicated that it was inappropriate to undertake formal statistical pathway analyses.  
The strength of microarray Affymetrix GeneChip Exon platform was its ability to 
detect both differential gene expression and alternative exon splicing.  The main 
weaknesses of this analysis were the group allocation criteria (see above) and the low 
number of samples. 
 
Expression microarray analysis suggested that several pathways are dysregulated in 
the IPD dementia DLPFC (see 4.3.4), and some of these are of particular interest.  
The first is inflammation.  There is a growing understanding of the important role that 
neuroinflammatory processes play in IPD pathogenesis.  Numerous reports indicate 
that neurodegeneration activates glia and peripheral immune cells, which cause 
oxidative stress and apoptosis thought to contribute to neuronal cell death and disease 
progression [reviewed in (Hirsch and Hunot 2009)].  Furthermore, array studies have 
demonstrated dysregulation of inflammatory genes in the IPDD cortex and the IPD 
SN (Stamper et al. 2008; Simunovic et al. 2009; Moran and Graeber 2008).  In 
addition, our data suggested that inflammation is also implicated in IPD 
neurodegeneration (see 4.3.3).  The other two interesting pathways are cell adhesion 
and the cytoskeleton.  These are best viewed in relation to the observed inflammation 
pathway changes.  Activated microglia, astrocytes, and T-cells all migrate to sites of 
brain injury [reviewed in (McGeer and McGeer 2008; Hirsch and Hunot 2009)], and 
this is mediated by changes in the surface expression of adhesion molecules and 
reorganisation of the cytoskeleton [reviewed in (Ivanov and Romanovsky 2006)].  As 
before, the IPDD cortex and IPD SN exhibit dysregulation of cell adhesion and/or 
cytoskeletal genes (Moran et al. 2006; Stamper et al. 2008; Bossers et al. 2009; 
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Simunovic et al. 2009).  Taken together, our data imply that neuroinflammation is an 
important facet of IPD dementia pathogenesis in the DLPFC, and suggest that the 
observed dysregulation events might be partially ascribed to glia and/or infiltrating 
leukocytes. 
 
In silico microarray mining suggested that variation in the DLPFC expression of 
genes involved in PD and parkinsonism-dementia is not associated with IPD 
neurodegeneration and dementia, respectively (see table 4.10), and that the UPR 
pathway is not chronically-activated in the IPD DLPFC (see table 4.9).  These 
uncorrected statistical results necessarily possessed reduced confidence.  However, 
this weakness is problematic for its potential to generate false positives, and so does 
not detract from these negative findings.  The parkinsonism-dementia result implied 
generalised molecular dissociation between these familial cognitive movement 
disorders and IPDD.  The lack of UPR pathway activation suggested that misfolded 
protein burden is relatively low in IPD DLPFC, and is in keeping with data showing 
that the forebrain is one the last areas to acquire LP (Braak et al. 2003).  Collectively, 
these results add to growing picture suggesting that gene dysregulation is relatively 
rare in the IPD DLPFC. 
 
When viewed in context of the literature, several conclusions can be drawn from the 
microarray findings and subsequent in silico analyses.  Common pathways are 
dysregulated in IPD dementia and IPD neurodegeneration, as well as in different 
regions of the disease brain, however, overall genetic dysregulation is much more 
extensive in demented compared to nondemented IPD patients (see also 4.4) (Zhang 
et al. 2005b; Moran et al. 2006; Stamper et al. 2008; Simunovic et al. 2009).  These 
observations support the hypothesis that IPD is a multisystem disease at the 
transcriptomic level (Zhang et al. 2005b; Moran et al. 2006), and imply that the same 
is true for IPDD.  Moreover, they suggest that IPDD can be viewed as an extension of 
the parkinsonian state.  This conclusion is bolstered by correlations between 
neuropathological/expression changes and cognitive dysfunction in IPD (Kovari et al. 
2003; Aarsland et al. 2005a; Stamper et al. 2008).  However, there was an overall 
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lack of differential expression in the qRT-PCR and microarray cognitive expression 
analyses, the PD and parkinsonism-dementia in silico analysis, the UPR pathway in 
silico analysis, and qRT-PCR SNCA analysis (see 6.6).  These results imply that the 
DLPFC is not critically-involved in late stage IPD dementia or neurodegeneration.  
Therefore, this brain region is not well suited for identifying genes implicated in 
IPDD.  Nevertheless, some genetic dysregulation was detected.  These limited 
changes suggest that, although it is subject to relatively low pathological burden 
(Braak et al. 2003), the DLPFC does experience neuroinflammation by late stage 
IPD.  Moreover, these effects may be marginally more pronounced in IPD dementia. 
 
In the future, several approaches might be employed to identify genes implicated in 
IPDD cognitive dysfunction.  It could be pertinent to repeat the cognitive expression 
microarray using a similar multiple group design.  However, certain critical changes 
would be needed.  Firstly, the study population should be a larger prospective cohort 
with excellent clinical, neuropathological, and neuropsychological information.  This 
would enable several distinct analyses to be carried out, each based on allocating IPD 
patients to different groups according to specific neuropsychological [e.g. semantic 
fluency, WM ability, attention, conceptualisation, or Mattis dementia rating scale 
score (Girotti et al. 1988; Litvan et al. 1991; Bohnen et al. 2006; Williams-Gray et al. 
2009a)] and/or neuropathological [e.g. cortical LP; cortical Alzheimer pathology; 
SNCA, Microtubule-associated protein tau (MAPT), and/or β-amyloid pathology in 
the ACC; SNCA and/or MAPT pathology in the EC; or SNCA and/or MAPT 
pathology in the hippocampus (Vermersch et al. 1993; Jellinger et al. 2002; Kovari et 
al. 2003; Aarsland et al. 2005a; Pletnikova et al. 2005; Kalaitzakis et al. 2009a)] 
criteria. 
 
Secondly, several different brain regions could be selected, and LCM used to enable 
specific interrogation of neuronal and/or glial expression.  Recent neuropathological 
and neuropsychological evidence suggests that the ACC, EC, perirhinal cortex, 
parahippocampal cortex, or hippocampus would be the most promising choices (see 
3.4 for details) (Pletnikova et al. 2005; Vermersch et al. 1993; Kovari et al. 2003; 
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Williams-Gray et al. 2009a; Pihlajamaki et al. 2000).  This approach could identify 
genes implicated in IPDD cognitive dysfunction and evaluate correlations in gene 
expression across different regions of the IPDD brain.  In order to implicate genes in 
IPDD aetiology, validated array hits could be subjected to SNP tagging and genetic 
association analysis using a large series of IPDD gDNA samples [for example 
(Elstner et al. 2009)].  An alternative approach might be to undertake a GWAS in the 
same series.  Furthermore, the relatively novel RNA sequencing technique could 
enable genome wide investigation of the relationship between genetic variation and 
expression and/or splicing in IPDD. 
 
 
6.8. Idiopathic Parkinson’s disease dementia 
molecular aetiopathogenesis research horizons 
Elucidating the molecular aetiopathogenesis of IPDD will require research based on a 
variety of concepts drawn from several neuroscientific disciplines.  The debate over 
the specific neuropathological and/or neurochemical determinant(s) of IPDD still 
rages on, in terms of both brain region(s) and molecular substrate(s).  Holistic models 
based on multiple interacting factors will probably best explain the various facets of 
IPD cognitive dysfunction and concomitant behavioural disturbances [reviewed in 
(Kalaitzakis and Pearce 2009)].  Nevertheless, prospective and retrospective 
clinicopathological studies suggest that SNCA accumulation is potentially of most 
importance (Kovari et al. 2003; Aarsland et al. 2005a; Braak et al. 2005; Kalaitzakis 
et al. 2009a).  This is supported by significant associations between IPDD and 
variation in genes whose encoded proteins promote SNCA accumulation in animal 
models (de Lau et al. 2005; Gallardo et al. 2008; Giasson et al. 2003; Williams-Gray 
et al. 2009a).  Given the recent association based on the largest incident cohort to 
date, MAPT may be confirmed as most pertinent in this regard (Williams-Gray et al. 
2009a).  Moreover, gene expression analyses suggest that apoptotic, inflammation, 
cell adhesion, cytoskeletal, axonal transport, mitochondrial, and splicing pathways 
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could turn out to be critical parts of the puzzle [see 6.4, 6.5, 6.7 and (Stamper et al. 
2008)].  Several of these pathways intersect at the point of glia, and future IPDD 
aetiopathogenesis research will probably focus increasingly on this often overlooked 
cellular lineage [reviewed in (McGeer and McGeer 2008; Hirsch and Hunot 2009)]. 
 
The technical approaches employed to investigate IPDD molecular aetiopathogenesis 
are likely to be just as varied.  Given that human clinicopathological studies will 
remain at the forefront, high quality patient phenotyping and material cataloguing 
will be essential.  Genome wide studies will best determine the genetic variants and 
expression phenotypes which associate with IPDD.  Integrated approaches examining 
variation in SNPs, copy number, microsatellites, gene expression, noncoding RNA 
expression, and protein expression will be most beneficial, especially if these genetic 
and/or expression data are correlated with clinicopathological and neuropsychological 
information (for example see 6.7).  These experiments will probably employ LCM to 
examine cell-type specific expression.  Furthermore, gene-environment and gene-
gene studies are likely to become more common [for example (McCulloch et al. 
2008)], as researchers seek to build conceptual syntheses of the real word interactions 
that mediate IPDD.  These might take the form of longitudinal imaging studies [for 
example (Pavese et al. 2009; Osaki et al. 2009)], such as genotype-phenotype 
correlations in presymptomatic individuals carrying IPDD susceptibility alleles, and 
genotype-treatment interactions in IPDD disease cases.  Meanwhile, promising 
genetic and environmental factors will be explored in animal models.  Only through 
concerted effort using various methodologies will we make headway in elucidating 
the molecular aetiopathogenesis of this debilitating disorder. 
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Appendix 
 
Group 
(n) 
Brain bank 
code 
Year of 
death 
GBA 
status 
PARK2 
status 
PINK1 
status 
P24/94 1994 WT WT WT 
P18/95 1995 WT WT WT 
P25/98 1998 Arg502Cys WT WT 
P36/98 1998 WT WT WT 
P62/98 1998 WT WT WT 
P30/00 2000 ND ND ND 
P54/00 2000 WT WT WT 
P59/00 2000 WT WT WT 
P05/01 2001 WT WT WT 
P18/01 2001 WT WT WT 
P01/02 2002 WT WT WT 
P23/02 2002 ND ND ND 
P25/03 2003 WT ND ND 
P18/05 2005 WT WT WT 
IPDD 
(15) 
P60/05 2005 WT ND ND 
P16/92 1992 WT WT WT 
P28/94 1994 WT WT WT 
P45/94 1994 WT WT WT 
P12/95 1995 WT WT WT 
P17/96 1996 WT WT WT 
P05/97 1997 WT WT WT 
P65/97 1997 WT WT WT 
P50/98 1998 WT WT WT 
P67/98 1998 WT WT WT 
P14/99 1999 WT WT WT 
P40/99 1999 ND ND ND 
P54/99 1999 Asn409Ser WT WT 
P55/00 2000 WT WT WT 
P75/00 2000 WT WT WT 
P24/01 2001 WT WT WT 
IPDND 
(16) 
P05/04 2004 ND ND ND 
 
Supplementary Table 1. IPD cognitive series: PD gene mutation data. 
Individual PD gene mutation data for the IPD cognitive series case samples.  Mutation investigations 
consisted of dideoxy DNA sequencing of all transcribed exons, and were previously performed by Drs. 
Patrick Abou-Sleiman and Emma Deas.  GBA = β-Glucocerebrosidase; IPD = idiopathic Parkinson’s 
disease; IPDD = idiopathic Parkinson’s disease with dementia; IPDND = idiopathic Parkinson’s 
disease no dementia; ND = not determined; PARK2 = Parkin; PD = Parkinson’s disease; PINK1 = 
Phosphatase and tensin homologue-induced putative kinase 1; WT = wild type. 
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Group 
(n) 
Brain 
bank code 
Year of 
death 
Drug regime 
P24/94 1994 1984 to death: levodopa 
P18/95 1995 1988 to death: carbidopa, DA agonist, levodopa 
P25/98 1998 1989 to death: carbidopa, levodopa 
P36/98 1998 1989 to death: levodopa, MAO inhibitor 
P62/98 1998 1991 to death: carbidopa, levodopa, MAO inhibitor 
P30/00 2000 1990 to death: levodopa; 1993 to death: MAO inhibitor 
P54/00 2000 Carbidopa, levodopa 
P59/00 2000 1995 to death: DA agonist, levodopa 
P05/01 2001 ND 
P18/01 2001 ACh antagonist, levodopa 
P01/02 2002 Carbidopa, levodopa 
P23/02 2002 DA agonist, levodopa, MAO inhibitor 
P25/03 2003 ND 
P18/05 2005 1974 to 1975: ACh antagonist; 1975 to death: levodopa 
IPDD 
(15) 
P60/05 2005 1982 to death: levodopa 
P16/92 1992 1991 to death: carbidopa, levodopa 
P28/94 1994 
1976 to death: ACh antagonist; 1976 to 1988: 
carbidopa, levodopa; 1990 to death: MAO inhibitor 
P45/94 1994 
1988 to 1992: carbidopa, levodopa; 
1992 to death: MAO inhibitor 
P12/95 1995 
1979 to 1993: carbidopa, levodopa; 
1993 to death: MAO inhibitor 
P17/96 1996 
1990 to 1992: carbidopa, levodopa; 
1992 to death: MAO inhibitor 
P05/97 1997 1977 to death: ACh antagonist, carbidopa, levodopa 
P65/97 1997 1984 to death: levodopa, MAO inhibitor 
P50/98 1998 
1980 to death: ACh antagonist, carbidopa, levodopa; 
1996 to death: DA agonist, MAO inhibitor 
P67/98 1998 ND 
P14/99 1999 1985 to death: levodopa, MAO inhibitor 
P40/99 1999 
1979 to death: ACh antagonist, carbidopa, levodopa, 
MAO inhibitor 
P54/99 1999 1989 to death: levodopa, MAO inhibitor 
P55/00 2000 
1975 to death: ACh antagonist, carbidopa, DA agonist, 
levodopa 
P75/00 2000 
1987 to death: levodopa; 
1994 to death: ACh antagonist, carbidopa, DA agonist 
P24/01 2001 ND 
IPDND 
(16) 
P05/04 2004 Levodopa 
 
Supplementary Table 3. IPD cognitive series: therapeutic drug regime data. 
Individual therapeutic drug regime data for the IPD cognitive series case samples.  Duration of 
treatment with each drug is displayed where known.  ACh = acetylcholine; DA = dopamine; IPD = 
idiopathic Parkinson’s disease; IPDD = idiopathic Parkinson’s disease with dementia; IPDND = 
idiopathic Parkinson’s disease no dementia; MAO = monoamine oxidase; ND = not determined. 
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Supplementary Figure 1. Microarray: Agilent RNA quality graphs. 
Agilent RNA quality graphs for the IPD microarray series (below and following pages).  For each 
RNA sample, the original capillary electrophoresis gel photograph and the resultant graph plot are 
shown.  The gel and graph for P62/98 were unavailable.  RNA quality graphs were generated using the 
RNA 6000 Nano LabChip Kit on an Agilent 2100 Bioanalyzer.  [FU] = fluorescence units; IPD = 
idiopathic Parkinson’s disease; RNA = ribonucleic acid; [s] = Svedberg. 
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Gene 
symbol 
Affymetrix 
transcript 
cluster ID 
Ensembl 
gene ID 
Affymetrix 
probeset ID 
Ensembl 
exon ID 
ADCYAP1 3775906 141433 NA NA 
C3orf36 2696109 221972 NA NA 
LY6K 3119213 160886 NA NA 
OR2M4 2390355 171180 NA NA 
POU4F3 2834025 091010 NA NA 
RPL35A 2660013 182899 NA NA 
C8orf79 3086774 170941 3086780 1541420 
CACNA2D3* 2624639 157445 2624642 1594725 
EXOC3L 3695450 179044 3695483 1795450 
FXYD2 3393446 137731 3393451 1130350 
IFI27 3549575 165949 3549592 1484740 
MAN1B1 3195174 177239 3195189 1815512 
OGT 3981120 147162 3981134 1958312 
QKI 2935475 112531 2935592 1894355 
RARRES2 3079005 106538 3079009 0729823 
RELB 3835966 104856 3835967 1048624 
RUSC1 2360887 160753 2360899 1885620 
TMC3 3635578 188869 3635603 1391451 
 
Supplementary Table 4. Microarray: clusters and probesets for genes implicated in IPD 
neurodegeneration. 
Affymetrix and Ensembl IDs for genes implicated in IPD neurodegeneration.  Affymetrix transcript 
cluster IDs and Ensembl gene IDs are listed for genes and exons dysregulated in the microarray.  For 
dysregulated exons, Affymetrix probeset IDs and Ensembl exon IDs are also listed.  Genes are listed 
alphabetically, with the differential expression group preceding the alternative splicing group (see table 
4.3).  See list of abbreviations for gene symbol definitions.  * = probeset binds an intronic location  
10 bp upstream of this exon (in the direction of transcription); bp = base pairs; ID = identity; IPD = 
idiopathic Parkinson’s disease; NA = not applicable. 
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Gene 
symbol 
Affymetrix 
transcript 
cluster ID 
Ensembl 
gene ID 
Affymetrix 
probeset ID 
Ensembl 
exon ID 
ALAS2 4009849 158578 NA NA 
EPHA2 2397948 142627 NA NA 
FAM83H 3157722 180921 NA NA 
FTH1 4037708 167996 NA NA 
MID1IP1 3974098 165175 NA NA 
UQCRFS1 3857691 169021 NA NA 
APOA5 3392957 110243 3392967 0747556 
BAIAP3 3643752 007516 3643788 0665665 
CCDC92 3476330 119242 3476339 0805119 
CDC45L 3936913 093009 3936942 0650790 
COL2A1 3452865 139219 3452919 1729865 
COL27A1 3185976 196739 3186068 0983778 
GRIA4 3347118 152578 3347122 1514240 
IKBKE 2376799 143466 2376840 1959016 
ITGAL 3656223 005844 3656278 1399855 
KRT9 3757138 171403 3757142 1118285 
NUP98 3359910 110713 3359948 0988546 
ODF2 3190463 136811 3190507 1667665 
PCNX 3542689 100731 3542722 1136831 
PPP1R16A 3120613 160972 3120631 1473528 
PSMB8 2950199 204264 2950201 1842282 
RARS2 2963707 146282 2963740 1937897 
RICH2 3710870 006740 3710897 1676651 
SEPW1 3837504 178980 3837520 1264160 
TEX2 3766716 136478 3766723 0947953 
TFIP11 3955875 100109 3955903 1851651 
TRPM4 3838317 130529 3838334 0896129 
ZNF407 3793888 215421 3793949 1104021 
 
Supplementary Table 5. Microarray: clusters and probesets for genes implicated in IPD 
dementia. 
Affymetrix and Ensembl IDs for genes implicated in IPD dementia.  Affymetrix transcript cluster IDs 
and Ensembl gene IDs are listed for genes and exons dysregulated in the microarray.  For dysregulated 
exons, Affymetrix probeset IDs and Ensembl exon IDs are also listed.  Genes are listed alphabetically, 
with the differential expression group preceding the alternative splicing group (see table 4.4).  See list 
of abbreviations for gene symbol definitions.  ID = identity; IPD = idiopathic Parkinson’s disease; NA 
= not applicable. 
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